{
  "metadata": {
    "pattern": "2hop_cross_company",
    "hop_count": "2hop",
    "category": "cross-company",
    "connector_mode": "quantitative",
    "count": 91,
    "timestamp": "20260124_011702"
  },
  "questions": [
    {
      "question_id": 1,
      "question": "How do the revenue losses from patent expirations mentioned by Johnson & Johnson relate to Pfizer's need for internal R&D investment to offset similar revenue declines, and what combined impact might this have on competitive dynamics in the healthcare sector?",
      "answer": "Johnson & Johnson highlights that patent expirations typically lead to the introduction of competing generic or biosimilar products, resulting in revenue and market share losses. This dynamic pressures companies to invest in innovation and development to replenish product lines. Pfizer similarly notes that its growth depends largely on internal R&D or external collaborations to offset revenue losses when products lose exclusivity. If both companies face similar revenue erosion from patent expirations, their competitive edge will depend on which firm can more effectively develop or acquire new products to maintain market position and offset these losses, intensifying R&D spending and strategic partnerships in the sector.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Johnson & Johnson states that patent expirations are typically followed by the introduction of competing generic or biosimilar products, resulting in revenue and market share losses.",
        "Step 2: Extract from source B - Pfizer states that its growth depends in large part on internal R&D or collaborations to offset revenue losses when products lose exclusivity.",
        "Step 3: Synthesize - Both companies face revenue losses from patent expirations; JNJ emphasizes the resulting market share erosion, while PFE focuses on the need for R&D investment. This creates a causal chain where patent expirations drive R&D spending and competitive innovation efforts at both firms, shaping industry dynamics."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Impacted_By]-> FIN_METRIC <-[Negatively_Impacts]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Revenue Losses",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_1",
          "chunk_text": "## Cautionary\tnote\tregarding\tforward-looking\tstatements\n\nThis\tAnnual\tReport\ton\tForm\t10-K\tand\tJohnson\t&amp;\tJohnson's\tother\tpublicly\tavailable\tdocuments\tcontain\t'forward-looking\tstatements'\twithin the\tmeaning\tof\tthe\tsafe\tharbor\tprovisions\tof\tthe\tUnited\tStates\tPrivate\tSecurities\tLitigation\tReform\tAct\tof\t1995.\tManagement\tand representatives\tof\tJohnson\t&amp;\tJohnson\tand\tits\tsubsidiaries\t(the\tCompany)\talso\tmay\tfrom\ttime\tto\ttime\tmake\tforward-looking\tstatements. Forward-looking\tstatements\tdo\tnot\trelate\tstrictly\tto\thistorical\tor\tcurrent\tfacts\tand\treflect\tmanagement's\tassumptions,\tviews,\tplans, objectives\tand\tprojections\tabout\tthe\tfuture.\tForward-looking\tstatements\tmay\tbe\tidentified\tby\tthe\tuse\tof\twords\tsuch\tas\t'plans,' 'expects,'\t'will,'\t'anticipates,'\t'estimates'\tand\tother\twords\tof\tsimilar\tmeaning\tin\tconjunction\twith,\tamong\tother\tthings:\tdiscussions\tof future\toperations;\texpected\toperating\tresults\tand\tfinancial\tperformance;\timpact\tof\tplanned\tacquisitions\tand\tdispositions;\timpact\tand timing\tof\trestructuring\tinitiatives,\tincluding\tassociated\tcost\tsavings\tand\tother\tbenefits;\tthe\tCompany's\tstrategy\tfor\tgrowth;\tproduct development\tactivities;\tregulatory\tapprovals;\tmarket\tposition\tand\texpenditures.\n\nBecause\tforward-looking\tstatements\tare\tbased\ton\tcurrent\tbeliefs,\texpectations\tand\tassumptions\tregarding\tfuture\tevents,\tthey\tare\tsubject to\tuncertainties,\trisks\tand\tchanges\tthat\tare\tdifficult\tto\tpredict\tand\tmany\tof\twhich\tare\toutside\tof\tthe\tCompany's\tcontrol.\tInvestors should\trealize\tthat\tif\tunderlying\tassumptions\tprove\tinaccurate,\tor\tknown\tor\tunknown\trisks\tor\tuncertainties\tmaterialize,\tthe\tCompany's actual\tresults\tand\tfinancial\tcondition\tcould\tvary\tmaterially\tfrom\texpectations\tand\tprojections\texpressed\tor\timplied\tin\tits\tforwardlooking\tstatements.\tInvestors\tare\ttherefore\tcautioned\tnot\tto\trely\ton\tthese\tforward-looking\tstatements.\tRisks\tand\tuncertainties\tinclude, but\tare\tnot\tlimited\tto:\n\n## Risks\trelated\tto\tproduct\tdevelopment,\tmarket\tsuccess\tand\tcompetition\n\n- Challenges\tand\tuncertainties\tinherent\tin\tinnovation\tand\tdevelopment\tof\tnew\tand\timproved\tproducts\tand\ttechnologies\ton\twhich\tthe Company's\tcontinued\tgrowth\tand\tsuccess\tdepend,\tincluding\tuncertainty\tof\tclinical\toutcomes,\tadditional\tanalysis\tof\texisting\tclinical data,\tobtaining\tregulatory\tapprovals,\thealth\tplan\tcoverage\tand\tcustomer\taccess,\tand\tinitial\tand\tcontinued\tcommercial\tsuccess;\n- Challenges\tto\tthe\tCompany's\tability\tto\tobtain\tand\tprotect\tadequate\tpatent\tand\tother\tintellectual\tproperty\trights\tfor\tnew\tand\texisting products\tand\ttechnologies\tin\tthe\tUnited\tStates\tand\tother\timportant\tmarkets;\n- The\timpact\tof\tpatent\texpirations,\ttypically\tfollowed\tby\tthe\tintroduction\tof\tcompeting\tgeneric,\tbiosimilar\tor\tother\tproducts\tand resulting\trevenue\tand\tmarket\tshare\tlosses;\n- Increasingly\taggressive\tand\tfrequent\tchallenges\tto\tthe\tCompany's\tpatents\tby\tcompetitors\tand\tothers\tseeking\tto\tlaunch\tcompeting generic,\tbiosimilar\tor\tother\tproducts\tand\tincreased\treceptivity\tof\tcourts,\tthe\tUnited\tStates\tPatent\tand\tTrademark\tOffice\tand\tother decision\tmakers\tto\tsuch\tchallenges,\tpotentially\tresulting\tin\tloss\tof\tmarket\texclusivity\tand\trapid\tdecline\tin\tsales\tfor\tthe\trelevant product\tsooner\tthan\texpected;\n- Competition\tin\tresearch\tand\tdevelopment\tof\tnew\tand\timproved\tproducts,\tprocesses\tand\ttechnologies,\twhich\tcan\tresult\tin\tproduct\tand process\tobsolescence;\n- Competition\tto\treach\tagreement\twith\tthird\tparties\tfor\tcollaboration,\tlicensing,\tdevelopment\tand\tmarketing\tagreements\tfor\tproducts\tand technologies;\n- Competition\tbased\ton\tcost-effectiveness,\tproduct\tperformance,\ttechnological\tadvances\tand\tpatents\tattained\tby\tcompetitors;\tand\n- Allegations\tthat\tthe\tCompany's\tproducts\tinfringe\tthe\tpatents\tand\tother\tintellectual\tproperty\trights\tof\tthird\tparties,\twhich\tcould adversely\taffect\tthe\tCompany's\tability\tto\tsell\tthe\tproducts\tin\tquestion\tand\trequire\tthe\tpayment\tof\tmoney\tdamages\tand\tfuture\troyalties.\n\n## Risks\trelated\tto\tproduct\tliability,\tlitigation\tand\tregulatory\tactivity\n\n- Product\tefficacy\tor\tsafety\tconcerns,\twhether\tor\tnot\tbased\ton\tscientific\tevidence,\tpotentially\tresulting\tin\tproduct\twithdrawals, recalls,\tregulatory\taction\ton\tthe\tpart\tof\tthe\tUnited\tStates\tFood\tand\tDrug\tAdministration\t(U.S.\tFDA)\t(or\tinternational\tcounterparts), declining\tsales,\treputational\tdamage,\tincreased\tlitigation\texpense\tand\tshare\tprice\timpact;\n- The\timpact,\tincluding\tdeclining\tsales\tand\treputational\tdamage,\tof\tsignificant\tlitigation\tor\tgovernment\taction\tadverse\tto\tthe\tCompany, including\tproduct\tliability\tclaims\tand\tallegations\trelated\tto\tpharmaceutical\tmarketing\tpractices\tand\tcontracting\tstrategies;\n- The\timpact\tof\tan\tadverse\tjudgment\tor\tsettlement\tand\tthe\tadequacy\tof\treserves\trelated\tto\tlegal\tproceedings,\tincluding\tpatent litigation,\tproduct\tliability,\tpersonal\tinjury\tclaims,\tsecurities\tclass\tactions,\tgovernment\tinvestigations,\temployment\tand\tother\tlegal proceedings;",
          "relationship": "Impacted_By"
        },
        "intermediate_node": {
          "id": "Revenue_Losses",
          "name": "Revenue Losses",
          "type": "FIN_METRIC",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_23",
          "chunk_id": "chunk_2",
          "chunk_text": "In\taddition,\tcertain\tof\tour\tcustomers\taccount\tfor\ta\tsignificant\tportion\tof\tour\trevenues.\tIf\tone\tof\tour\tsignificant\tcustomers\tshould\tencounter financial\tor\tother\tdifficulties,\tit\tmight\tdecrease\tthe\tamount\tof\tbusiness\tsuch\tcustomer\tdoes\twith\tus\tand/or\twe\tmight\tbe\tunable\tto\ttimely\tcollect\tall the\tamounts\tthat\tsuch\tcustomer\towes\tus\tor\tat\tall,\twhich\tcould\tnegatively\timpact\tour\tresults\tof\toperations.\tIn\taddition,\twe\texpect\tthat\tconsolidation and\tintegration\tof\tpharmacy\tchains\tand\twholesalers\twill\tincrease\tcompetitive\tand\tpricing\tpressures\ton\tpharmaceutical\tmanufacturers,\tincluding\tus. See Note\t17C for\ta\tdiscussion\tof\tour\tsignificant\tcustomers.\n\n## RESEARCH\tAND\tDEVELOPMENT\n\nThe\tdiscovery\tand\tdevelopment\tof\tnew\tproducts,\tas\twell\tas\tthe\tdevelopment\tof\tadditional\tuses\tfor\texisting\tproducts,\tare\tnecessary\tfor\tthe\tcontinued strength\tof\tour\tbusiness.\tOur\tproduct\tlines\tmust\tbe\treplenished\tover\ttime\tto\toffset\trevenue\tlosses\twhen\tproducts\tlose\texclusivity\tor\tmarket\tshare\tor to\trespond\tto\thealthcare\tand\tinnovation\ttrends,\tas\twell\tas\tto\tprovide\tfor\tearnings\tgrowth,\tprimarily\tthrough\tinternal\tR&amp;D\tor\tthrough\tcollaborations, acquisitions,\tJVs,\tlicensing\tor\tother\tarrangements.\tGrowth\tdepends\tin\tlarge\tpart\ton\tour\tability\tto\tidentify\tand\tdevelop\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n17",
          "relationship": "Negatively_Impacts"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 2,
      "question": "What was the total IPR&D charge recorded by both JNJ and PFE in their respective 2021 fiscal years, and how did the differing tax treatments of these charges impact each company's effective tax rate?",
      "answer": "The total IPR&D charge recorded by JNJ in 2021 was $0.9 billion for the Ottava intangible asset, which was taxed at an effective rate of 22.4%. PFE recorded a $2.1 billion IPR&D charge related to the acquisition of Trillium, which had no alternative future use and was not tax-deductible. JNJ\u2019s IPR&D charge reduced its effective tax rate by 22.4%, while PFE\u2019s non-deductible IPR&D charge had no impact on its effective tax rate. Therefore, the total IPR&D charge was $3.0 billion, but only JNJ experienced a tax benefit due to the nature of the charge.",
      "reasoning_steps": [
        "Step 1: Extract from source A - JNJ recorded a $0.9 billion IPR&D charge for the Ottava intangible asset at an effective tax rate of 22.4%.",
        "Step 2: Extract from source B - PFE recorded a $2.1 billion IPR&D charge related to the acquisition of Trillium, which was non-deductible and had no alternative future use.",
        "Step 3: Synthesize - The total IPR&D charge is $3.0 billion ($0.9 billion from JNJ and $2.1 billion from PFE). However, only JNJ received a tax benefit of 22.4% on its charge, while PFE\u2019s non-deductible charge had no tax impact."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Records]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "IPR&D Charge",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_1",
          "chunk_text": "In\tthe\tfiscal\tyear\t2021,\tthe\tCompany\treorganized\tthe\townership\tstructure\tof\tcertain\twholly-owned\tinternational\tsubsidiaries.\tAs\tpart\tof this\treorganization,\tthe\tCompany\tincreased\tthe\ttax\tbasis\tof\tcertain\tassets\tto\tfair\tvalue\tin\taccordance\twith\tapplicable\tlocal regulations.\tThe\tnet\timpact\tof\tthis\trestructuring\twas\tapproximately\t$0.6\tbillion\tnet\tbenefit\tor\t3.2%\tbenefit\tto\tthe\tCompany's\tannual effective\ttax\trate,\tcomprised\tof\tthe\tfollowing\titems:\n\n- approximately\t$2.3\tbillion\tof\tlocal\tdeferred\ttax\tassets\tto\trecord\tthe\tremeasurement\tof\tthe\ttax\tbasis\tof\tthese\tassets\tto\tfair\tvalue, this\tbenefit\thas\tbeen\treflected\tas\tInternational\toperations\ton\tthe\tCompany's\teffective\ttax\trate\treconciliation.\n- approximately\t$1.7\tbillion\tof\tU.S.\tdeferred\ttax\texpense\trelating\tto\tthe\tGILTI\tdeferred\ttax\tliability\tresulting\tfrom\tthe\tremeasurement of\tthese\tdeferred\ttax\tassets.\tThis\texpense\thas\tbeen\treflected\tas\tU.S.\ttaxes\ton\tinternational\tincome\ton\tthe\tCompany's\teffective\ttax rate\treconciliation.\n\nAlso,\tin\tthe\tfiscal\tfourth\tquarter\tof\t2021,\tthe\tCompany\trecognized\ta\tloss\ton\tcertain\tU.S.\taffiliates\trelated\tto\tthe\tpreviously\timpaired book\tvalue\tof\tcertain\tintangibles,\twhich\treduced\tthe\t2021\teffective\ttax\trate\tby\tapproximately\t1.6%\twhich\tis\treflected\tas\ta\tTax\tbenefits from\tloss\ton\tcapital\tassets\ton\tthe\teffective\ttax\trate\treconciliation.\tAdditionally\tother\tfiscal\t2021\timpacts\tto\tthe\trate\twere\tprimarily driven\tby\tlitigation\tand\tacquisition\trelated\titems\tas\tfollows:\n\n- the\tCompany\taccrued\tadditional\tlegal\texpenses,\tof\tapproximately\t$1.6\tbillion\tfor\ttalc\tat\tan\teffective\ttax\trate\tof\t23.5%\tand $0.8\tbillion\tfor\tRisperdal\tGynecomastia\tsettlements\tat\tan\teffective\ttax\trate\tof\t16.4%\t(See\tNote\t19\tto\tthe\tConsolidated\tFinancial Statements\tfor\tmore\tdetails).\n- the\tCompany\trecorded\ta\tpartial\tIPR&amp;D\tcharge\tof\t$0.9\tbillion\tfor\tthe\tOttava\tintangible\tasset\t(acquired\twith\tthe\tAuris\tHealth acquisition\tin\t2019)\tat\tan\teffective\trate\tof\t22.4%.\n\nTemporary\tdifferences\tand\tcarryforwards\tat\tthe\tend\tof\tfiscal\tyears\t2023\tand\t2022\twere\tas\tfollows:\n\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "IPR&D_Charge",
          "name": "IPR&D Charge",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_73",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes\tto\tConsolidated\tFinancial\tStatements\n\nPfizer\tInc.\tand\tSubsidiary\tCompanies use\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses ,\twhich\tis\tpresented\tas\ta\tcash\toutflow\tfrom\toperating\tactivities.\tOther\tassets\tacquired and\tliabilities\tassumed\twere\tnot\tsignificant.\n\nTrillium-On\tNovember\t17,\t2021,\twe\tacquired\tall\tof\tthe\tissued\tand\toutstanding\tcommon\tstock\tnot\talready\towned\tby\tPfizer\tof\tTrillium,\ta\tclinical\tstage immuno-oncology\tcompany\tdeveloping\ttherapies\ttargeting\tcancer\timmune\tevasion\tpathways\tand\tspecific\tcell\ttargeting\tapproaches,\tfor\t$18.50\tper\tshare in\tcash,\tfor\ttotal\tconsideration\tof\t$2.0\tbillion,\tnet\tof\tcash\tacquired.\tAs\ta\tresult,\tTrillium\tbecame\tour\twholly\towned\tsubsidiary.\tWe\tpreviously\theld a\t2%\townership\tinvestment\tin\tTrillium.\tTrillium's\tlead\tprogram,\tTTI-622,\tis\tan\tinvestigational\tfusion\tprotein\tthat\tis\tdesigned\tto\tblock\tthe inhibitory\tactivity\tof\tCD47,\ta\tmolecule\tthat\tis\toverexpressed\tby\ta\twide\tvariety\tof\ttumors.\n\nWe\taccounted\tfor\tthe\ttransaction\tas\tan\tasset\tacquisition\tsince\tthe\tlead\tasset,\tTTI-622,\trepresented\tsubstantially\tall\tof\tthe\tfair\tvalue\tof\tthe\tgross assets\tacquired,\twhich\texclude\tcash\tacquired.\tAt\tthe\tacquisition\tdate,\twe\trecorded\ta\t$2.1\tbillion\tcharge\trepresenting\tan\tacquired\tIPR&amp;D\tasset\twith no\talternative\tfuture\tuse\tin Acquired\tin-process\tresearch\tand\tdevelopment\texpenses ,\tof\twhich\tthe\t$2.0\tbillion\tnet\tcash\tconsideration\tis\tpresented\tas a\tcash\toutflow\tfrom\toperating\tactivities.\tIn\tconnection\twith\tthis\tacquisition,\twe\trecorded\t$256\tmillion\tof\tassets\tacquired\tprimarily\tconsisting\tof cash\tand\tinvestments.\tLiabilities\tassumed\twere\tapproximately\t$81\tmillion.\n\nPro\tforma\tinformation\tfor\tthe\taforementioned\tacquisitions\t(except\tfor\tSeagen)\thas\tnot\tbeen\tpresented\tbecause\tthese\tacquisitions\twere\tnot\tmaterial\tto our\tconsolidated\tfinancial\tstatements.\n\n## B.\tDivestitures\n\nDivestiture\tof\tEarly-Stage\tRare\tDisease\tGene\tTherapy\tPortfolio-On\tSeptember\t19,\t2023,\twe\tcompleted\tan\tagreement\twith\tAlexion,\tunder\twhich\tAlexion purchased\tand\tlicensed\tthe\tassets\tof\tour\tearly-stage\trare\tdisease\tgene\ttherapy\tportfolio.\tThis\tagreement\tis\tconsistent\twith\tour\tpreviously\tannounced strategy\tto\tpivot\tfrom\tviral\tcapsid-based\tgene\ttherapy\tapproaches\tto\tharnessing\tnew\tplatform\ttechnologies\tthat\twe\tbelieve\tcan\thave\ta\ttransformative impact\ton\tpatients,\tsuch\tas\tmRNA\tor\tin\tvivo\tgene\tediting.\tUnder\tthe\tterms\tof\tthe\tagreement,\tAlexion\twill\tpay\tus\ttotal\tconsideration\tof\tup\tto\t$1 billion,\tconsisting\tof\tan\tupfront\tpayment\tof\t$300\tmillion\twhich\twas\tpaid\tat\tclosing\tand\tfuture\tcontingent\tmilestone\tpayments,\tplus\ttiered\troyalties based\ton\tannual\tnet\tsales\tof\tthe\tassets.\tIn\tconnection\twith\tthe\tclosing\tof\tthe\ttransaction,\tPfizer\trecognized\ta\t$222\tmillion\tpre-tax\tgain\tin Other (income)/deductions--net (see Note\t4 ).\n\n## Discontinued\tOperations\n\nMeridian-On\tDecember\t31,\t2021,\twe\tcompleted\tthe\tsale\tof\tour\tMeridian\tsubsidiary\tfor\tapproximately\t$51\tmillion\tin\tcash\tand\trecognized\ta\tloss\tof approximately\t$167\tmillion,\tnet\tof\ttax,\tin Discontinued\toperations--net\tof\ttax .\tIn\tconnection\twith\tthe\tsale,\tPfizer\tand\tthe\tpurchaser\tof\tMeridian entered\tinto\tvarious\tagreements\tto\tprovide\ta\tframework\tfor\tour\trelationship\tafter\tthe\tsale,\tincluding\tinterim\tTSAs\tand\tan\tMSA.\tServices\tunder\tthe TSAs\tare\tcompleted\tas\tof\tDecember\t31,\t2023.\tThe\tMSA\tis\tfor\ta\tterm\tof\tthree\tyears\tpost\tsale\twith\ta\ttwo\tyear\textension\tperiod.\tAmounts\trecorded\tunder the\tinterim\tTSAs\tand\tMSA\tin\t2023\tand\t2022\twere\tnot\tmaterial\tto\tour\toperations.\tNo\tamounts\twere\trecorded\tunder\tthese\tarrangements\tin\t2021.\n\nUpjohn\tSeparation\tand\tCombination\twith\tMylan-In\tconnection\twith\tthe\t2020\tspin-off\tand\tthe\tcombination\tof\tthe\tUpjohn\tBusiness\twith\tMylan\tto\tform Viatris,\tPfizer\tand\tViatris\tentered\tinto\tvarious\tagreements,\tincluding\ta\tseparation\tand\tdistribution\tagreement,\tinterim\toperating\tmodels,\tincluding agency\tarrangements,\tMSAs,\tTSAs,\ta\ttax\tmatters\tagreement,\tand\tan\temployee\tmatters\tagreement,\tamong\tothers.\tThe\tinterim\tagency\toperating\tmodel arrangements\tprimarily\tinclude\tbillings,\tcollections\tand\tremittance\tof\trebates\tthat\twe\tare\tperforming\ton\ta\ttransitional\tbasis\ton\tbehalf\tof\tViatris. Under\tthe\tMSAs,\tPfizer\tor\tViatris,\tas\tthe\tcase\tmay\tbe,\tmanufactures,\tlabels\tand\tpackages\tproducts\tfor\tthe\tother\tparty.\tThe\tterms\tof\tthe\tMSAs\trange in\tinitial\tduration\tfrom\tfour\tto\tseven\tyears\tpost-separation.\tServices\tunder\tthe\tTSAs\twere\tlargely\tcompleted\tas\tof\tDecember\t31,\t2023.\tAmounts recorded\tunder\tthe\tabove\tagreements\tin\t2023,\t2022\tand\t2021\twere\tnot\tmaterial\tto\tour\toperations.\tNet\tamounts\tdue\tto\tViatris\tunder\tthe\tabove agreements\twere\t$33\tmillion\tas\tof\tDecember\t31,\t2023\tand\t$94\tmillion\tas\tof\tDecember\t31,\t2022.\tThe\tcash\tflows\tassociated\twith\tthe\tabove\tagreements\tare included\tin Net\tcash\tprovided\tby\toperating\tactivities\tfrom\tcontinuing\toperations, except\tfor a\t$277\tmillion\tpayment\tto\tViatris\tmade\tin\t2021\tpursuant to\tterms\tof\tthe\tseparation\tagreement,\twhich\tis\treported\tin Other\tfinancing\tactivities,\tnet .\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n67",
          "relationship": "Records"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 3,
      "question": "How does the difference in the assumed healthcare cost trend rate for next year between JNJ and PFE in 2023 impact the projected year in which each company expects to reach the ultimate trend rate, and what is the numerical gap in these projections?",
      "answer": "In 2023, JNJ assumes a healthcare cost trend rate of 13.90% for the next year and projects reaching the ultimate trend rate of 4.00% by 2048. PFE, on the other hand, assumes a lower healthcare cost trend rate of 7.9% and expects to reach the same ultimate trend rate of 4.0% by 2047. Therefore, despite JNJ assuming a significantly higher initial trend rate, both companies project reaching the ultimate trend rate in nearly the same year, with only a one-year difference (2048 vs. 2047).",
      "reasoning_steps": [
        "Step 1: Extract from source A - JNJ's 2023 assumed healthcare cost trend rate is 13.90%, and the year it expects to reach the ultimate trend rate (2048).",
        "Step 2: Extract from source B - PFE's 2023 assumed healthcare cost trend rate is 7.9%, and the year it expects to reach the ultimate trend rate (2047).",
        "Step 3: Synthesize - Compare the difference in initial trend assumptions (13.90% vs. 7.9%) and the projected years to reach the ultimate rate (2048 vs. 2047) to assess the relationship between initial assumptions and projected convergence year."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Healthcare Cost Trend Rate",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_4",
          "chunk_text": "| Healthcare Plans                                                         | 2023    | 2022   |\n|--------------------------------------------------------------------------|---------|--------|\n| Healthcare cost trend rate assumed for next year                         | 13.90 % | 5.96 % |\n| Rate to which the cost trend rate is assumed to decline (ultimate trend) | 4.00 %  | 3.99 % |\n| Year the rate reaches the ultimate trend rate                            | 2048    | 2047   |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Healthcare_Cost_Trend_Rate",
          "name": "Healthcare Cost Trend Rate",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_93",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                                         | As of December 31,   | As of December 31,   |\n|---------------------------------------------------------|----------------------|----------------------|\n|                                                         | 2023                 | 2022                 |\n| Healthcare cost trend rate assumed for next year        | 7.9 %                | 6.4 %                |\n| Rate to which the cost trend rate is assumed to decline | 4.0 %                | 4.0 %                |\n| Year that the rate reaches the ultimate trend rate      | 2047                 | 2045                 |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 4,
      "question": "How do the collaboration strategies of JNJ and PFE impact their respective abilities to offset revenue losses from products losing market share, given the specific percentages mentioned in their 2023 filings?",
      "answer": "JNJ reported that new products introduced within the past five years accounted for approximately 25% of 2023 sales, indicating a significant portion of revenue is tied to recent innovations, which are often developed through collaborations, acquisitions, and licensing arrangements. Similarly, PFE emphasized that growth depends largely on internal R&D or external collaborations, acquisitions, JVs, licensing, or other arrangements to replenish product lines and offset revenue losses from products losing exclusivity or market share. The use of collaboration strategies by both companies is essential for maintaining competitive advantage and offsetting revenue erosion, as both rely on these mechanisms to bring new products to market.",
      "reasoning_steps": [
        "Step 1: Extract from JNJ's filing - New products within the past five years accounted for 25% of 2023 sales.",
        "Step 2: Extract from PFE's filing - Growth depends largely on internal R&D or external collaborations, acquisitions, JVs, licensing, or other arrangements.",
        "Step 3: Synthesize - Both companies rely on external collaborations and internal R&D to develop new products that offset revenue losses from products losing market share or exclusivity. JNJ\u2019s 25% revenue contribution from recent innovations highlights the importance of these strategies in maintaining revenue growth."
      ],
      "difficulty": "hard",
      "idf_score": 5.320917198465278,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> FIN_METRIC <-[Depends_On]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Collaborations",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_19",
          "chunk_id": "chunk_1",
          "chunk_text": "## Risks\trelated\tto\tproduct\tdevelopment,\tregulatory\tapproval and\tcommercialization\n\nSignificant\tchallenges\tor\tdelays\tin\tthe\tCompany's\tinnovation,\tdevelopment\tand\timplementation\tof\tnew\tproducts,\ttechnologies\tand indications\tcould\thave\tan\tadverse\timpact\ton\tthe\tCompany's\tlong-term\tsuccess.\n\nThe\tCompany's\tcontinued\tgrowth\tand\tsuccess\tdepends\ton\tits\tability\tto\tinnovate\tand\tdevelop\tnew\tand\tdifferentiated\tproducts\tand\tservices that\taddress\tthe\tevolving\thealthcare\tneeds\tof\tpatients,\tproviders\tand\tconsumers.\tDevelopment\tof\tsuccessful\tproducts\tand\ttechnologies\tis also\tnecessary\tto\toffset\trevenue\tlosses\twhen\tthe\tCompany's\texisting\tproducts\tlose\tmarket\tshare\tdue\tto\tvarious\tfactors\tsuch\tas competition\tand\tloss\tof\tpatent\texclusivity.\tNew\tproducts\tintroduced\twithin\tthe\tpast\tfive\tyears\taccounted\tfor\tapproximately\t25%\tof\t2023 sales.\tThe\tCompany\tcannot\tbe\tcertain\twhen\tor\twhether\tit\twill\tbe\table\tto\tdevelop,\tlicense\tor\totherwise\tacquire\tcompanies,\tproducts\tand technologies,\twhether\tparticular\tproduct\tcandidates\twill\tbe\tgranted\tregulatory\tapproval,\tand,\tif\tapproved,\twhether\tthe\tproducts\twill\tbe commercially\tsuccessful.\n\nThe\tCompany\tpursues\tproduct\tdevelopment\tthrough\tinternal\tresearch\tand\tdevelopment\tas\twell\tas\tthrough\tcollaborations,\tacquisitions,\tjoint ventures\tand\tlicensing\tor\tother\tarrangements\twith\tthird\tparties.\tIn\tall\tof\tthese\tcontexts,\tdeveloping\tnew\tproducts,\tparticularly pharmaceutical\tand\tbiotechnology\tproducts\tand\tmedical\tdevices,\trequires\tsignificant\tinvestment\tof\tresources\tover\tmany\tyears.\tOnly\ta\tvery few\tbiopharmaceutical\tresearch\tand\tdevelopment\tprograms\tresult\tin\tcommercially\tviable\tproducts.\tThe\tprocess\tdepends\ton\tmany\tfactors including\tthe\tability\tto:\tdiscern\tpatients'\tand\thealthcare\tproviders'\tfuture\tneeds;\tdevelop\tpromising\tnew\tcompounds,\tstrategies\tand technologies;\tachieve\tsuccessful\tclinical\ttrial\tresults;\tsecure\teffective\tintellectual\tproperty\tprotection;\tobtain\tregulatory\tapprovals on\ta\ttimely\tbasis;\tand,\tif\tand\twhen\tthey\treach\tthe\tmarket,\tsuccessfully\tdifferentiate\tthe\tCompany's\tproducts\tfrom\tcompeting\tproducts\tand approaches\tto\ttreatment.\tNew\tproducts\tor\tenhancements\tto\texisting\tproducts\tmay\tnot\tbe\taccepted\tquickly\tor\tsignificantly\tin\tthe marketplace\tdue\tto\tproduct\tand\tprice\tcompetition,\tchanges\tin\tcustomer\tpreferences\tor\thealthcare\tpurchasing\tpatterns,\tresistance\tby healthcare\tproviders\tor\tuncertainty\tover\tthird-party\treimbursement.\tEven\tfollowing\tinitial\tregulatory\tapproval,\tthe\tsuccess\tof\ta\tproduct can\tbe\tadversely\timpacted\tby\tsafety\tand\tefficacy\tfindings\tin\tlarger\treal-world\tpatient\tpopulations,\tas\twell\tas\tmarket\tentry\tof competitive\tproducts.\n\nThe\tCompany\tleverages\tthe\tuse\tof\tdata\tscience,\tmachine\tlearning\tand\tother\tforms\tof\tAI\tand\temerging\ttechnologies\tacross\tvarying\tparts\tof its\tbusiness\tand\toperations,\tand\tthe\tintroduction\tand\tincorporation\tof\tAI\tmay\tresult\tin\tunintended\tconsequences\tor\tother\tnew\tor\texpanded risks\tand\tliabilities.\tAI\ttechnology\tis\tcontinuously\tevolving,\tand\tthe\tAI\ttechnologies\twe\tdevelop\tand\tadopt\tmay\tbecome\tobsolete\tearlier than\tplanned.\tOur\tinvestments\tin\tthese\ttechnologies\tmay\tnot\tresult\tin\tthe\tbenefits\twe\tanticipate\tor\tenable\tus\tto\tobtain\tor\tmaintain\ta competitive\tadvantage.\tThe\tapplication\tof\tmachine\tlearning\tand\tAI\tin\tour\tbusiness\tis\temerging\tand\tevolving\talongside\tnew\tlaws\tand regulations\tthat\tmay\tentail\tsignificant\tcosts\tor\tultimately\tlimit\tour\tability\tto\tcontinue\tthe\tuse\tof\tthese\ttechnologies.\tThese technologies\talso\tcarry\tinherent\trisks\trelated\tto\tdata\tprivacy\tand\tsecurity\tfurther\tdescribed\tbelow.\n\n## Risks\trelated\tto\tfinancial\tand\teconomic\tmarket\tconditions\n\nThe\tCompany\tfaces\ta\tvariety\tof\tfinancial,\teconomic,\tlegal,\tsocial\tand\tpolitical\trisks\tassociated\twith\tconducting business\tinternationally.\n\nThe\tCompany's\textensive\toperations\tand\tbusiness\tactivity\tthroughout\tthe\tworld\tare\taccompanied\tby\tcertain\tfinancial,\teconomic,\tlegal, social\tand\tpolitical\trisks,\tincluding\tthose\tlisted\tbelow.\n\nForeign\tcurrency\texchange :\tIn\tfiscal\t2023,\tapproximately\t45%\tof\tthe\tCompany's\tsales\toccurred\toutside\tof\tthe\tU.S.,\twith\tapproximately\t24% in\tEurope,\t5%\tin\tthe\tWestern\tHemisphere,\texcluding\tthe\tU.S.,\tand\t16%\tin\tthe\tAsia-Pacific\tand\tAfrica\tregion.\tChanges\tin\tnon-U.S. currencies\trelative\tto\tthe\tU.S.\tdollar\timpact\tthe\tCompany's\trevenues\tand\texpenses.\tWhile\tthe\tCompany\tuses\tfinancial\tinstruments\tto mitigate\tthe\timpact\tof\tfluctuations\tin\tcurrency\texchange\trates\ton\tits\tcash\tflows,\tunhedged\texposures\tcontinue\tto\tbe\tsubject\tto\tcurrency fluctuations.\tIn\taddition,\tthe\tweakening\tor\tstrengthening\tof\tthe\tU.S.\tdollar\tmay\tresult\tin\tsignificant\tfavorable\tor\tunfavorable translation\teffects\twhen\tthe\toperating\tresults\tof\tthe\tCompany's\tnon-U.S.\tbusiness\tactivity\tare\ttranslated\tinto\tU.S.\tdollars.\n\nInflation\tand\tcurrency\tdevaluation\trisks :\tThe\tCompany\tfaces\tchallenges\tin\tmaintaining\tprofitability\tof\toperations\tin\teconomies experiencing\thigh\tinflation\trates.\tSpecifically,\tthe\tCompany\thas\taccounted\tfor\toperations\tin\tArgentina,\tTurkey\tand\tVenezuela\tas\thighly inflationary,\tas\tthe\tprior\tthree-year\tcumulative\tinflation\trate\tsurpassed\t100%.\tWhile\tthe\tCompany\tstrives\tto\tmaintain\tprofit\tmargins\tin these\tareas\tthrough\tcost\treduction\tprograms,\tproductivity\timprovements\tand\tperiodic\tprice\tincreases,\tit\tmight\texperience\toperating losses\tas\ta\tresult\tof\tcontinued\tinflation.\tIn\taddition,\tthe\timpact\tof\tcurrency\tdevaluations\tin\n\n2023\tAnnual\tReport\n\n13",
          "relationship": "Partners_With"
        },
        "intermediate_node": {
          "id": "Collaborations",
          "name": "Collaborations",
          "type": "FIN_METRIC",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_23",
          "chunk_id": "chunk_2",
          "chunk_text": "In\taddition,\tcertain\tof\tour\tcustomers\taccount\tfor\ta\tsignificant\tportion\tof\tour\trevenues.\tIf\tone\tof\tour\tsignificant\tcustomers\tshould\tencounter financial\tor\tother\tdifficulties,\tit\tmight\tdecrease\tthe\tamount\tof\tbusiness\tsuch\tcustomer\tdoes\twith\tus\tand/or\twe\tmight\tbe\tunable\tto\ttimely\tcollect\tall the\tamounts\tthat\tsuch\tcustomer\towes\tus\tor\tat\tall,\twhich\tcould\tnegatively\timpact\tour\tresults\tof\toperations.\tIn\taddition,\twe\texpect\tthat\tconsolidation and\tintegration\tof\tpharmacy\tchains\tand\twholesalers\twill\tincrease\tcompetitive\tand\tpricing\tpressures\ton\tpharmaceutical\tmanufacturers,\tincluding\tus. See Note\t17C for\ta\tdiscussion\tof\tour\tsignificant\tcustomers.\n\n## RESEARCH\tAND\tDEVELOPMENT\n\nThe\tdiscovery\tand\tdevelopment\tof\tnew\tproducts,\tas\twell\tas\tthe\tdevelopment\tof\tadditional\tuses\tfor\texisting\tproducts,\tare\tnecessary\tfor\tthe\tcontinued strength\tof\tour\tbusiness.\tOur\tproduct\tlines\tmust\tbe\treplenished\tover\ttime\tto\toffset\trevenue\tlosses\twhen\tproducts\tlose\texclusivity\tor\tmarket\tshare\tor to\trespond\tto\thealthcare\tand\tinnovation\ttrends,\tas\twell\tas\tto\tprovide\tfor\tearnings\tgrowth,\tprimarily\tthrough\tinternal\tR&amp;D\tor\tthrough\tcollaborations, acquisitions,\tJVs,\tlicensing\tor\tother\tarrangements.\tGrowth\tdepends\tin\tlarge\tpart\ton\tour\tability\tto\tidentify\tand\tdevelop\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n17",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 38
    },
    {
      "question_id": 5,
      "question": "How does the impact of collaborations on new product development influence revenue stability for both JNJ and PFE, considering JNJ's 25% of 2023 sales from products introduced in the past five years and PFE's anticipated significant revenue reduction due to patent expiries from 2026 through 2030?",
      "answer": "Collaborations play a critical role in both JNJ and PFE's strategies to maintain revenue stability through new product development. For JNJ, products introduced in the past five years accounted for 25% of 2023 sales, highlighting the importance of innovation and external partnerships in offsetting revenue losses from mature products facing competition or patent expiration. Similarly, PFE acknowledges the necessity of replenishing product lines through internal R&D and collaborations to counteract the expected significant revenue reductions from 2026 to 2030 due to patent expiries. Without successful collaborations leading to new product approvals and commercial success, both companies face heightened risks of revenue instability as older products lose exclusivity and face generic competition.",
      "reasoning_steps": [
        "Step 1: Extract from source A - JNJ notes that new products introduced in the past five years accounted for approximately 25% of 2023 sales, indicating the importance of recent innovation to current revenue.",
        "Step 2: Extract from source B - PFE anticipates a more significant impact of reduced revenues from patent expiries during 2026\u20132030, emphasizing the need for new product development to offset these losses.",
        "Step 3: Synthesize - Both companies rely on collaborations and innovation to sustain revenue. JNJ's recent product success shows how critical this is, while PFE\u2019s future risk timeline underscores the urgency of leveraging collaborations for pipeline development."
      ],
      "difficulty": "hard",
      "idf_score": 5.320917198465278,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> FIN_METRIC <-[Depends_On]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Collaborations",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_19",
          "chunk_id": "chunk_1",
          "chunk_text": "## Risks\trelated\tto\tproduct\tdevelopment,\tregulatory\tapproval and\tcommercialization\n\nSignificant\tchallenges\tor\tdelays\tin\tthe\tCompany's\tinnovation,\tdevelopment\tand\timplementation\tof\tnew\tproducts,\ttechnologies\tand indications\tcould\thave\tan\tadverse\timpact\ton\tthe\tCompany's\tlong-term\tsuccess.\n\nThe\tCompany's\tcontinued\tgrowth\tand\tsuccess\tdepends\ton\tits\tability\tto\tinnovate\tand\tdevelop\tnew\tand\tdifferentiated\tproducts\tand\tservices that\taddress\tthe\tevolving\thealthcare\tneeds\tof\tpatients,\tproviders\tand\tconsumers.\tDevelopment\tof\tsuccessful\tproducts\tand\ttechnologies\tis also\tnecessary\tto\toffset\trevenue\tlosses\twhen\tthe\tCompany's\texisting\tproducts\tlose\tmarket\tshare\tdue\tto\tvarious\tfactors\tsuch\tas competition\tand\tloss\tof\tpatent\texclusivity.\tNew\tproducts\tintroduced\twithin\tthe\tpast\tfive\tyears\taccounted\tfor\tapproximately\t25%\tof\t2023 sales.\tThe\tCompany\tcannot\tbe\tcertain\twhen\tor\twhether\tit\twill\tbe\table\tto\tdevelop,\tlicense\tor\totherwise\tacquire\tcompanies,\tproducts\tand technologies,\twhether\tparticular\tproduct\tcandidates\twill\tbe\tgranted\tregulatory\tapproval,\tand,\tif\tapproved,\twhether\tthe\tproducts\twill\tbe commercially\tsuccessful.\n\nThe\tCompany\tpursues\tproduct\tdevelopment\tthrough\tinternal\tresearch\tand\tdevelopment\tas\twell\tas\tthrough\tcollaborations,\tacquisitions,\tjoint ventures\tand\tlicensing\tor\tother\tarrangements\twith\tthird\tparties.\tIn\tall\tof\tthese\tcontexts,\tdeveloping\tnew\tproducts,\tparticularly pharmaceutical\tand\tbiotechnology\tproducts\tand\tmedical\tdevices,\trequires\tsignificant\tinvestment\tof\tresources\tover\tmany\tyears.\tOnly\ta\tvery few\tbiopharmaceutical\tresearch\tand\tdevelopment\tprograms\tresult\tin\tcommercially\tviable\tproducts.\tThe\tprocess\tdepends\ton\tmany\tfactors including\tthe\tability\tto:\tdiscern\tpatients'\tand\thealthcare\tproviders'\tfuture\tneeds;\tdevelop\tpromising\tnew\tcompounds,\tstrategies\tand technologies;\tachieve\tsuccessful\tclinical\ttrial\tresults;\tsecure\teffective\tintellectual\tproperty\tprotection;\tobtain\tregulatory\tapprovals on\ta\ttimely\tbasis;\tand,\tif\tand\twhen\tthey\treach\tthe\tmarket,\tsuccessfully\tdifferentiate\tthe\tCompany's\tproducts\tfrom\tcompeting\tproducts\tand approaches\tto\ttreatment.\tNew\tproducts\tor\tenhancements\tto\texisting\tproducts\tmay\tnot\tbe\taccepted\tquickly\tor\tsignificantly\tin\tthe marketplace\tdue\tto\tproduct\tand\tprice\tcompetition,\tchanges\tin\tcustomer\tpreferences\tor\thealthcare\tpurchasing\tpatterns,\tresistance\tby healthcare\tproviders\tor\tuncertainty\tover\tthird-party\treimbursement.\tEven\tfollowing\tinitial\tregulatory\tapproval,\tthe\tsuccess\tof\ta\tproduct can\tbe\tadversely\timpacted\tby\tsafety\tand\tefficacy\tfindings\tin\tlarger\treal-world\tpatient\tpopulations,\tas\twell\tas\tmarket\tentry\tof competitive\tproducts.\n\nThe\tCompany\tleverages\tthe\tuse\tof\tdata\tscience,\tmachine\tlearning\tand\tother\tforms\tof\tAI\tand\temerging\ttechnologies\tacross\tvarying\tparts\tof its\tbusiness\tand\toperations,\tand\tthe\tintroduction\tand\tincorporation\tof\tAI\tmay\tresult\tin\tunintended\tconsequences\tor\tother\tnew\tor\texpanded risks\tand\tliabilities.\tAI\ttechnology\tis\tcontinuously\tevolving,\tand\tthe\tAI\ttechnologies\twe\tdevelop\tand\tadopt\tmay\tbecome\tobsolete\tearlier than\tplanned.\tOur\tinvestments\tin\tthese\ttechnologies\tmay\tnot\tresult\tin\tthe\tbenefits\twe\tanticipate\tor\tenable\tus\tto\tobtain\tor\tmaintain\ta competitive\tadvantage.\tThe\tapplication\tof\tmachine\tlearning\tand\tAI\tin\tour\tbusiness\tis\temerging\tand\tevolving\talongside\tnew\tlaws\tand regulations\tthat\tmay\tentail\tsignificant\tcosts\tor\tultimately\tlimit\tour\tability\tto\tcontinue\tthe\tuse\tof\tthese\ttechnologies.\tThese technologies\talso\tcarry\tinherent\trisks\trelated\tto\tdata\tprivacy\tand\tsecurity\tfurther\tdescribed\tbelow.\n\n## Risks\trelated\tto\tfinancial\tand\teconomic\tmarket\tconditions\n\nThe\tCompany\tfaces\ta\tvariety\tof\tfinancial,\teconomic,\tlegal,\tsocial\tand\tpolitical\trisks\tassociated\twith\tconducting business\tinternationally.\n\nThe\tCompany's\textensive\toperations\tand\tbusiness\tactivity\tthroughout\tthe\tworld\tare\taccompanied\tby\tcertain\tfinancial,\teconomic,\tlegal, social\tand\tpolitical\trisks,\tincluding\tthose\tlisted\tbelow.\n\nForeign\tcurrency\texchange :\tIn\tfiscal\t2023,\tapproximately\t45%\tof\tthe\tCompany's\tsales\toccurred\toutside\tof\tthe\tU.S.,\twith\tapproximately\t24% in\tEurope,\t5%\tin\tthe\tWestern\tHemisphere,\texcluding\tthe\tU.S.,\tand\t16%\tin\tthe\tAsia-Pacific\tand\tAfrica\tregion.\tChanges\tin\tnon-U.S. currencies\trelative\tto\tthe\tU.S.\tdollar\timpact\tthe\tCompany's\trevenues\tand\texpenses.\tWhile\tthe\tCompany\tuses\tfinancial\tinstruments\tto mitigate\tthe\timpact\tof\tfluctuations\tin\tcurrency\texchange\trates\ton\tits\tcash\tflows,\tunhedged\texposures\tcontinue\tto\tbe\tsubject\tto\tcurrency fluctuations.\tIn\taddition,\tthe\tweakening\tor\tstrengthening\tof\tthe\tU.S.\tdollar\tmay\tresult\tin\tsignificant\tfavorable\tor\tunfavorable translation\teffects\twhen\tthe\toperating\tresults\tof\tthe\tCompany's\tnon-U.S.\tbusiness\tactivity\tare\ttranslated\tinto\tU.S.\tdollars.\n\nInflation\tand\tcurrency\tdevaluation\trisks :\tThe\tCompany\tfaces\tchallenges\tin\tmaintaining\tprofitability\tof\toperations\tin\teconomies experiencing\thigh\tinflation\trates.\tSpecifically,\tthe\tCompany\thas\taccounted\tfor\toperations\tin\tArgentina,\tTurkey\tand\tVenezuela\tas\thighly inflationary,\tas\tthe\tprior\tthree-year\tcumulative\tinflation\trate\tsurpassed\t100%.\tWhile\tthe\tCompany\tstrives\tto\tmaintain\tprofit\tmargins\tin these\tareas\tthrough\tcost\treduction\tprograms,\tproductivity\timprovements\tand\tperiodic\tprice\tincreases,\tit\tmight\texperience\toperating losses\tas\ta\tresult\tof\tcontinued\tinflation.\tIn\taddition,\tthe\timpact\tof\tcurrency\tdevaluations\tin\n\n2023\tAnnual\tReport\n\n13",
          "relationship": "Partners_With"
        },
        "intermediate_node": {
          "id": "Collaborations",
          "name": "Collaborations",
          "type": "FIN_METRIC",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_38",
          "chunk_id": "chunk_1",
          "chunk_text": "While\troyalty\tincome\tthrough\tDecember\t31,\t2023\thas\tbeen\trecorded\tin Other\tIncome/(Deductions)-net ,\twe\twill\tbegin\treporting\tsuch\troyalty\tincome\tin Total\trevenues beginning\tin\t2024\tand\twill\trestate\tprior\tperiods\tfor\tconsistency\twith\tour\t2024\tpresentation.\tAdditionally,\twe\twill\tno\tlonger\trecord royalties\tfrom\tU.S.\tsales\tof\tBavencio,\tas\twe\thave\tirrevocably\tchosen\tto\tdonate\tthe\tright\tto\tsuch\troyalties\tto\tthe\tAmerican\tAssociation\tfor\tCancer Research.\n\nIncome\tfrom\tContinuing\tOperations\tBefore\tProvision/(Benefit)\tfor\tTaxes\ton\tIncome-The\tdecrease\tin Income\tfrom\tcontinuing\toperations\tbefore provision/(benefit)\tfor\ttaxes\ton\tincome of\t$33.7\tbillion,\tto\t$1.1\tbillion\tin\t2023\tfrom\t$34.7\tbillion\tin\t2022,\twas\tprimarily\tattributable\tto\t(i) lower\trevenues,\t(ii)\thigher\tintangible\tasset\timpairment\tcharges,\tand\t(iii)\tincreases\tin Restructuring\tcharges\tand\tcertain\tacquisition-related\tcosts , Amortization\tof\tintangible\tassets ,\tand Selling,\tinformational\tand\tadministrative\texpenses, partially\toffset\tby\t(iv)\ta\tdecrease\tin Cost\tof\tsales and (v)\tnet\tgains\ton\tequity\tsecurities\tin\t2023\tversus\tnet\tlosses\ton\tequity\tsecurities\tin\t2022 .\n\nSee the Analysis\tof\tthe\tConsolidated\tStatements\tof\tIncome section\twithin\tMD&amp;A\tand Note\t4 .\tFor\tinformation\ton\tour\ttax\tprovision\tand\teffective\ttax rate,\tsee\tthe Provision/(Benefit)\tfor\tTaxes\ton\tIncome section\twithin\tMD&amp;A\tand Note\t5 .\n\nOur\tOperating\tEnvironment --We,\tlike\tother\tbusinesses\tin\tour\tindustry,\tare\tsubject\tto\tcertain\tindustry-specific\tchallenges.\tThese\tinclude,\tamong others,\tthe\ttopics\tlisted\tbelow.\tSee\talso\tthe Item\t1.\tBusiness--Government\tRegulation\tand\tPrice\tConstraints and Item\t1A.\tRisk\tFactors sections.\n\nRegulatory\tEnvironment--Pipeline\tProductivity-Our\tproduct\tlines\tmust\tbe\treplenished\tover\ttime\tto\toffset\trevenue\tlosses\twhen\tproducts\tlose exclusivity\tor\tmarket\tshare\tor\tto\trespond\tto\thealthcare\tand\tinnovation\ttrends,\tas\twell\tas\tto\tprovide\tfor\tearnings\tgrowth,\tprimarily\tthrough\tinternal R&amp;D\tor\tthrough\tcollaborations,\tacquisitions,\tJVs,\tlicensing\tor\tother\tarrangements.\tAs\ta\tresult,\twe\tdevote\tconsiderable\tresources\tto\tour\tR&amp;D activities\twhich,\twhile\tessential\tto\tour\tgrowth,\tincorporate\ta\thigh\tdegree\tof\trisk\tand\tcost,\tincluding\twhether\ta\tparticular\tproduct\tcandidate\tor\tnew indication\tfor\tan\tin-line\tproduct\twill\tachieve\tthe\tdesired\tclinical\tendpoint\tor\tsafety\tprofile,\twill\tbe\tapproved\tby\tregulators\tor\twill\tbe\tsuccessful commercially.\tClinical\ttrials\tare\tconducted\tto\tdetermine,\tamong\tother\tthings,\twhether\tan\tinvestigational\tdrug,\tvaccine\tor\tdevice\tis\tsafe\tand effective\tfor\ta\tparticular\tpatient\tpopulation.\tAfter\ta\tproduct\thas\tbeen\tapproved\tor\tauthorized\tand\tlaunched,\twe\tcontinue\tto\tmonitor\tits\tsafety\tas long\tas\tit\tis\tavailable\tto\tpatients,\tincluding\tconducting\tpostmarketing\ttrials,\tvoluntarily\tor\tpursuant\tto\ta\tregulatory\trequest.\tFor\tthe\tentire\tlife of\tthe\tproduct,\twe\tcollect\tsafety\tdata\tand\treport\tsafety\tinformation\tto\tthe\tFDA\tand\tother\tregulators.\tRegulatory\tauthorities\tevaluate\tpotential safety\tconcerns\tand\ttake\tany\tregulatory\taction\tdeemed\tnecessary\tand\tappropriate.\tSuch\taction(s)\tmay\tinclude:\tupdating\ta\tproduct's\tlabeling, restricting\tits\tuse,\tcommunicating\tnew\tsafety\tinformation\tor,\tin\trare\tcases,\tseeking\tto\tsuspend\tor\tremove\ta\tproduct\tfrom\tthe\tmarket.\n\nIntellectual\tProperty\tRights\tand\tCollaboration/Licensing\tRights-The\tloss,\texpiration\tor\tinvalidation\tof\tintellectual\tproperty\trights,\tpatent litigation\tsettlements\tand\tjudgments,\tand\tthe\texpiration\tof\tco-promotion\tand\tlicensing\trights\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tour\trevenues. Certain\tof\tour\tproducts\thave\texperienced\tpatent-based\texpirations\tor\tloss\tof\tregulatory\texclusivity\tin\tcertain\tmarkets\tin\tthe\tlast\tfew\tyears,\tand\twe expect\tcertain\tproducts\tto\tface\tincreased\tgeneric\tcompetition\tover\tthe\tnext\tfew\tyears.\tWhile\tadditional\tpatent\texpiries\twill\tcontinue,\twe\texpect\ta moderate\timpact\tof\treduced\trevenues\tdue\tto\tpatent\texpiries\tfrom\t2024\tthrough\t2025.\tWe\tanticipate\ta\tmore\tsignificant\timpact\tof\treduced\trevenues\tfrom patent\texpiries\tin\t2026\tthrough\t2030\tas\tseveral\tof\tour\tin-line\tproducts\texperience\tpatent-based\texpirations.\tWe\tcontinue\tto\tvigorously\tdefend\tour patent\trights\tagainst\tinfringement,\tand\twe\twill\tcontinue\tto\tsupport\tefforts\tthat\tstrengthen\tworldwide\trecognition\tof\tpatent\trights\twhile\ttaking necessary\tsteps\tto\thelp\tensure\tappropriate\tpatient\taccess.\n\nFor\tadditional\tinformation\ton\tpatent\trights\twe\tconsider\tmost\tsignificant\tto\tour\tbusiness\tas\ta\twhole,\tsee\tthe Item\t1.\tBusiness--Patents\tand\tOther Intellectual\tProperty\tRights section.\tFor\ta\tdiscussion\tof\trecent\tdevelopments\twith\trespect\tto\tpatent\tlitigation,\tsee Note\t16A1.\n\n",
          "relationship": "Depends_On"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 6,
      "question": "How did product withdrawals impact the financial and operational strategies of both Johnson & Johnson and Pfizer in 2023, particularly in relation to regulatory actions and future market re-entry plans for affected products?",
      "answer": "Johnson & Johnson faced potential product withdrawals due to efficacy or safety concerns, which could lead to regulatory actions such as recalls, declining sales, reputational damage, and increased litigation expenses. These risks were outlined in their cautionary note regarding forward-looking statements. Meanwhile, Pfizer specifically withdrew all lots of Chantix in the U.S. in 2021 due to nitrosamine contamination, and in 2023, the company was preparing regulatory submissions for a potential market return in 2024, indicating ongoing discussions with the FDA. Both companies had to adjust their strategies in response to regulatory pressures and product safety concerns, with Pfizer actively planning for re-entry while JNJ acknowledged the risk of such events affecting future performance.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Johnson & Johnson identified product withdrawals as a risk due to efficacy or safety concerns, which could result in regulatory actions, declining sales, and reputational damage.",
        "Step 2: Extract from source B - Pfizer withdrew all lots of Chantix in the U.S. in 2021 due to nitrosamine contamination and was preparing regulatory submissions for a potential return to the market in 2024.",
        "Step 3: Synthesize - Both companies faced challenges related to product withdrawals impacting their financial and regulatory strategies. JNJ acknowledged the risk broadly, while PFE experienced a concrete withdrawal and outlined specific steps for future market re-entry."
      ],
      "difficulty": "hard",
      "idf_score": 5.320917198465278,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Impacted_By]-> FIN_METRIC <-[Impacted_By]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Withdrawals",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_4",
          "chunk_id": "chunk_1",
          "chunk_text": "## Cautionary\tnote\tregarding\tforward-looking\tstatements\n\nThis\tAnnual\tReport\ton\tForm\t10-K\tand\tJohnson\t&amp;\tJohnson's\tother\tpublicly\tavailable\tdocuments\tcontain\t'forward-looking\tstatements'\twithin the\tmeaning\tof\tthe\tsafe\tharbor\tprovisions\tof\tthe\tUnited\tStates\tPrivate\tSecurities\tLitigation\tReform\tAct\tof\t1995.\tManagement\tand representatives\tof\tJohnson\t&amp;\tJohnson\tand\tits\tsubsidiaries\t(the\tCompany)\talso\tmay\tfrom\ttime\tto\ttime\tmake\tforward-looking\tstatements. Forward-looking\tstatements\tdo\tnot\trelate\tstrictly\tto\thistorical\tor\tcurrent\tfacts\tand\treflect\tmanagement's\tassumptions,\tviews,\tplans, objectives\tand\tprojections\tabout\tthe\tfuture.\tForward-looking\tstatements\tmay\tbe\tidentified\tby\tthe\tuse\tof\twords\tsuch\tas\t'plans,' 'expects,'\t'will,'\t'anticipates,'\t'estimates'\tand\tother\twords\tof\tsimilar\tmeaning\tin\tconjunction\twith,\tamong\tother\tthings:\tdiscussions\tof future\toperations;\texpected\toperating\tresults\tand\tfinancial\tperformance;\timpact\tof\tplanned\tacquisitions\tand\tdispositions;\timpact\tand timing\tof\trestructuring\tinitiatives,\tincluding\tassociated\tcost\tsavings\tand\tother\tbenefits;\tthe\tCompany's\tstrategy\tfor\tgrowth;\tproduct development\tactivities;\tregulatory\tapprovals;\tmarket\tposition\tand\texpenditures.\n\nBecause\tforward-looking\tstatements\tare\tbased\ton\tcurrent\tbeliefs,\texpectations\tand\tassumptions\tregarding\tfuture\tevents,\tthey\tare\tsubject to\tuncertainties,\trisks\tand\tchanges\tthat\tare\tdifficult\tto\tpredict\tand\tmany\tof\twhich\tare\toutside\tof\tthe\tCompany's\tcontrol.\tInvestors should\trealize\tthat\tif\tunderlying\tassumptions\tprove\tinaccurate,\tor\tknown\tor\tunknown\trisks\tor\tuncertainties\tmaterialize,\tthe\tCompany's actual\tresults\tand\tfinancial\tcondition\tcould\tvary\tmaterially\tfrom\texpectations\tand\tprojections\texpressed\tor\timplied\tin\tits\tforwardlooking\tstatements.\tInvestors\tare\ttherefore\tcautioned\tnot\tto\trely\ton\tthese\tforward-looking\tstatements.\tRisks\tand\tuncertainties\tinclude, but\tare\tnot\tlimited\tto:\n\n## Risks\trelated\tto\tproduct\tdevelopment,\tmarket\tsuccess\tand\tcompetition\n\n- Challenges\tand\tuncertainties\tinherent\tin\tinnovation\tand\tdevelopment\tof\tnew\tand\timproved\tproducts\tand\ttechnologies\ton\twhich\tthe Company's\tcontinued\tgrowth\tand\tsuccess\tdepend,\tincluding\tuncertainty\tof\tclinical\toutcomes,\tadditional\tanalysis\tof\texisting\tclinical data,\tobtaining\tregulatory\tapprovals,\thealth\tplan\tcoverage\tand\tcustomer\taccess,\tand\tinitial\tand\tcontinued\tcommercial\tsuccess;\n- Challenges\tto\tthe\tCompany's\tability\tto\tobtain\tand\tprotect\tadequate\tpatent\tand\tother\tintellectual\tproperty\trights\tfor\tnew\tand\texisting products\tand\ttechnologies\tin\tthe\tUnited\tStates\tand\tother\timportant\tmarkets;\n- The\timpact\tof\tpatent\texpirations,\ttypically\tfollowed\tby\tthe\tintroduction\tof\tcompeting\tgeneric,\tbiosimilar\tor\tother\tproducts\tand resulting\trevenue\tand\tmarket\tshare\tlosses;\n- Increasingly\taggressive\tand\tfrequent\tchallenges\tto\tthe\tCompany's\tpatents\tby\tcompetitors\tand\tothers\tseeking\tto\tlaunch\tcompeting generic,\tbiosimilar\tor\tother\tproducts\tand\tincreased\treceptivity\tof\tcourts,\tthe\tUnited\tStates\tPatent\tand\tTrademark\tOffice\tand\tother decision\tmakers\tto\tsuch\tchallenges,\tpotentially\tresulting\tin\tloss\tof\tmarket\texclusivity\tand\trapid\tdecline\tin\tsales\tfor\tthe\trelevant product\tsooner\tthan\texpected;\n- Competition\tin\tresearch\tand\tdevelopment\tof\tnew\tand\timproved\tproducts,\tprocesses\tand\ttechnologies,\twhich\tcan\tresult\tin\tproduct\tand process\tobsolescence;\n- Competition\tto\treach\tagreement\twith\tthird\tparties\tfor\tcollaboration,\tlicensing,\tdevelopment\tand\tmarketing\tagreements\tfor\tproducts\tand technologies;\n- Competition\tbased\ton\tcost-effectiveness,\tproduct\tperformance,\ttechnological\tadvances\tand\tpatents\tattained\tby\tcompetitors;\tand\n- Allegations\tthat\tthe\tCompany's\tproducts\tinfringe\tthe\tpatents\tand\tother\tintellectual\tproperty\trights\tof\tthird\tparties,\twhich\tcould adversely\taffect\tthe\tCompany's\tability\tto\tsell\tthe\tproducts\tin\tquestion\tand\trequire\tthe\tpayment\tof\tmoney\tdamages\tand\tfuture\troyalties.\n\n## Risks\trelated\tto\tproduct\tliability,\tlitigation\tand\tregulatory\tactivity\n\n- Product\tefficacy\tor\tsafety\tconcerns,\twhether\tor\tnot\tbased\ton\tscientific\tevidence,\tpotentially\tresulting\tin\tproduct\twithdrawals, recalls,\tregulatory\taction\ton\tthe\tpart\tof\tthe\tUnited\tStates\tFood\tand\tDrug\tAdministration\t(U.S.\tFDA)\t(or\tinternational\tcounterparts), declining\tsales,\treputational\tdamage,\tincreased\tlitigation\texpense\tand\tshare\tprice\timpact;\n- The\timpact,\tincluding\tdeclining\tsales\tand\treputational\tdamage,\tof\tsignificant\tlitigation\tor\tgovernment\taction\tadverse\tto\tthe\tCompany, including\tproduct\tliability\tclaims\tand\tallegations\trelated\tto\tpharmaceutical\tmarketing\tpractices\tand\tcontracting\tstrategies;\n- The\timpact\tof\tan\tadverse\tjudgment\tor\tsettlement\tand\tthe\tadequacy\tof\treserves\trelated\tto\tlegal\tproceedings,\tincluding\tpatent litigation,\tproduct\tliability,\tpersonal\tinjury\tclaims,\tsecurities\tclass\tactions,\tgovernment\tinvestigations,\temployment\tand\tother\tlegal proceedings;",
          "relationship": "Impacted_By"
        },
        "intermediate_node": {
          "id": "Withdrawals",
          "name": "Withdrawals",
          "type": "FIN_METRIC",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_24",
          "chunk_id": "chunk_2",
          "chunk_text": "We\tcould\tencounter\tdifficulties,\tdelays\tor\tinefficiencies\tin\tour\tsupply\tchain,\tproduct\tmanufacturing\tand\tdistribution\tnetworks,\tas\twell\tas\tsales\tor marketing,\tdue\tto\tregulatory\tactions,\tshut-downs,\twork\tstoppages\tor\tstrikes,\tapproval\tdelays,\twithdrawals,\trecalls,\tpenalties,\tsupply\tdisruptions, shortages\tor\tstock-outs\tat\tour\tfacilities\tor\tthird-party\tfacilities\tthat\twe\trely\ton,\treputational\tharm,\tthe\timpact\tto\tour\tfacilities\tdue\tto\thealth pandemics\tor\tnatural\tor\tman-made\tdisasters,\tincluding\tas\ta\tresult\tof\tclimate\tchange,\tproduct\tliability\tor\tunanticipated\tcosts.\tExamples\tof\tsuch difficulties\tor\tdelays\tinclude\tthe\tinability\tto\tincrease\tor\tmaintain\tproduction\tcapacity\tcommensurate\twith\tdemand;\tchallenges\trelated\tto\tcomponent materials\tto\tmaintain\tsupply\tand/or\tappropriate\tquality\tstandards\tthroughout\tour\tsupply\tnetwork\tand/or\tcomply\twith\tapplicable\tregulations;\tinability to\tsupply\tcertain\tproducts\tdue\tto\tvoluntary\tproduct\trecalls;\tand\tsupply\tchain\tdisruptions\tat\tour\tfacilities\tor\tat\ta\tsupplier\tor\tvendor.\tIn\taddition, we\tengage\tcontract\tmanufacturers,\tand,\tfrom\ttime\tto\ttime,\tour\tcontract\tmanufacturers\tmay\tface\tdifficulties\tor\tare\tunable\tto\tmanufacture\tour\tproducts at\tthe\tnecessary\tquantity\tor\tquality\tlevels.\n\nRegulatory\tagencies\tperiodically\tinspect\tour\tmanufacturing\tfacilities,\tas\twell\tas\tthird-party\tfacilities\tthat\twe\trely\ton,\tto\tevaluate\tcompliance with\tcGMP\tor\tother\tapplicable\trequirements.\tFailure\tto\tcomply\twith\tthese\trequirements\tmay\tsubject\tus\tto\tpossible\tlegal\tor\tregulatory\tactions,\tsuch as\twarning\tletters,\tsuspension\tof\tmanufacturing,\tseizure\tof\tproduct,\tinjunctions,\tdebarment,\tproduct\trecalls,\tdelays\tor\tdenials\tof\tproduct approvals,\timport\tbans\tor\tdenials\tof\timport\tcertifications.\n\nIn\t2021,\tPfizer\trecalled\tall\tlots\tof\tChantix\tin\tthe\tU.S.\tdue\tto\tthe\tpresence\tof\ta\tnitrosamine,\tN-nitroso-varenicline,\tat\tor\tabove\tthe\tFDA\tinterim acceptable\tintake\tlimit.\tRegulatory\tauthorities\toutside\tthe\tU.S.\thave\tissued\tupdated\tguidance\ton\tnitrosamine\tacceptable\tintake\tlevels.\tWith\tthis recently\tissued\tguidance,\twhich\tincluded\tan\tupdated\tintake\tlevel\tfor\tN-nitroso-varenicline,\twe\texpect\tto\tmake\tregulatory\tsubmissions\tin\t2024\tto potentially\tenable\tChantix\tto\treturn\tto\tmarket\toutside\tthe\tU.S.,\tand\tour\trelated\tdiscussions\twith\tFDA\tare\tongoing.\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n18",
          "relationship": "Impacted_By"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 7,
      "question": "How does the reliance on collaborations for product development, as disclosed by both JNJ and PFE in their 2023 10-K filings, reflect differing financial risks and strategic implications for each company, especially in light of JNJ's 25% revenue contribution from products introduced in the past five years and PFE's $31 billion long-term debt issuance to fund the Seagen acquisition?",
      "answer": "Both JNJ and PFE rely on collaborations to drive product development and offset revenue losses from maturing products, but the financial and strategic risks differ significantly. JNJ notes that new products introduced in the past five years contributed 25% of 2023 sales, underscoring the importance of innovation through both internal R&D and external collaborations. However, JNJ highlights the uncertainty in achieving regulatory approval and commercial success, which introduces risk in long-term revenue stability. In contrast, PFE has taken on $31 billion in long-term debt (plus $8 billion in short-term debt) to fund the acquisition of Seagen, a major strategic collaboration move. This level of debt introduces financial risk by reducing operating flexibility and increasing interest obligations, which could constrain future investment. Thus, while both companies depend on collaborations to drive innovation, JNJ's risk is more tied to product success and market acceptance, whereas PFE's risk is amplified by its significant leverage increase.",
      "reasoning_steps": [
        "Step 1: Extract from JNJ's 10-K - New products introduced in the past five years contributed approximately 25% of 2023 sales, indicating a key role of innovation and collaborations in revenue generation.",
        "Step 2: Extract from PFE's 10-K - PFE incurred $31 billion in long-term debt and $8 billion in short-term debt to acquire Seagen, a strategic collaboration-driven acquisition.",
        "Step 3: Synthesize - Both companies use collaborations to offset revenue loss from aging products, but JNJ's risk centers on the uncertain success of new products, while PFE's risk is tied to high debt and its financial implications."
      ],
      "difficulty": "hard",
      "idf_score": 5.320917198465278,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Partners_With]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Collaborations",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_19",
          "chunk_id": "chunk_1",
          "chunk_text": "## Risks\trelated\tto\tproduct\tdevelopment,\tregulatory\tapproval and\tcommercialization\n\nSignificant\tchallenges\tor\tdelays\tin\tthe\tCompany's\tinnovation,\tdevelopment\tand\timplementation\tof\tnew\tproducts,\ttechnologies\tand indications\tcould\thave\tan\tadverse\timpact\ton\tthe\tCompany's\tlong-term\tsuccess.\n\nThe\tCompany's\tcontinued\tgrowth\tand\tsuccess\tdepends\ton\tits\tability\tto\tinnovate\tand\tdevelop\tnew\tand\tdifferentiated\tproducts\tand\tservices that\taddress\tthe\tevolving\thealthcare\tneeds\tof\tpatients,\tproviders\tand\tconsumers.\tDevelopment\tof\tsuccessful\tproducts\tand\ttechnologies\tis also\tnecessary\tto\toffset\trevenue\tlosses\twhen\tthe\tCompany's\texisting\tproducts\tlose\tmarket\tshare\tdue\tto\tvarious\tfactors\tsuch\tas competition\tand\tloss\tof\tpatent\texclusivity.\tNew\tproducts\tintroduced\twithin\tthe\tpast\tfive\tyears\taccounted\tfor\tapproximately\t25%\tof\t2023 sales.\tThe\tCompany\tcannot\tbe\tcertain\twhen\tor\twhether\tit\twill\tbe\table\tto\tdevelop,\tlicense\tor\totherwise\tacquire\tcompanies,\tproducts\tand technologies,\twhether\tparticular\tproduct\tcandidates\twill\tbe\tgranted\tregulatory\tapproval,\tand,\tif\tapproved,\twhether\tthe\tproducts\twill\tbe commercially\tsuccessful.\n\nThe\tCompany\tpursues\tproduct\tdevelopment\tthrough\tinternal\tresearch\tand\tdevelopment\tas\twell\tas\tthrough\tcollaborations,\tacquisitions,\tjoint ventures\tand\tlicensing\tor\tother\tarrangements\twith\tthird\tparties.\tIn\tall\tof\tthese\tcontexts,\tdeveloping\tnew\tproducts,\tparticularly pharmaceutical\tand\tbiotechnology\tproducts\tand\tmedical\tdevices,\trequires\tsignificant\tinvestment\tof\tresources\tover\tmany\tyears.\tOnly\ta\tvery few\tbiopharmaceutical\tresearch\tand\tdevelopment\tprograms\tresult\tin\tcommercially\tviable\tproducts.\tThe\tprocess\tdepends\ton\tmany\tfactors including\tthe\tability\tto:\tdiscern\tpatients'\tand\thealthcare\tproviders'\tfuture\tneeds;\tdevelop\tpromising\tnew\tcompounds,\tstrategies\tand technologies;\tachieve\tsuccessful\tclinical\ttrial\tresults;\tsecure\teffective\tintellectual\tproperty\tprotection;\tobtain\tregulatory\tapprovals on\ta\ttimely\tbasis;\tand,\tif\tand\twhen\tthey\treach\tthe\tmarket,\tsuccessfully\tdifferentiate\tthe\tCompany's\tproducts\tfrom\tcompeting\tproducts\tand approaches\tto\ttreatment.\tNew\tproducts\tor\tenhancements\tto\texisting\tproducts\tmay\tnot\tbe\taccepted\tquickly\tor\tsignificantly\tin\tthe marketplace\tdue\tto\tproduct\tand\tprice\tcompetition,\tchanges\tin\tcustomer\tpreferences\tor\thealthcare\tpurchasing\tpatterns,\tresistance\tby healthcare\tproviders\tor\tuncertainty\tover\tthird-party\treimbursement.\tEven\tfollowing\tinitial\tregulatory\tapproval,\tthe\tsuccess\tof\ta\tproduct can\tbe\tadversely\timpacted\tby\tsafety\tand\tefficacy\tfindings\tin\tlarger\treal-world\tpatient\tpopulations,\tas\twell\tas\tmarket\tentry\tof competitive\tproducts.\n\nThe\tCompany\tleverages\tthe\tuse\tof\tdata\tscience,\tmachine\tlearning\tand\tother\tforms\tof\tAI\tand\temerging\ttechnologies\tacross\tvarying\tparts\tof its\tbusiness\tand\toperations,\tand\tthe\tintroduction\tand\tincorporation\tof\tAI\tmay\tresult\tin\tunintended\tconsequences\tor\tother\tnew\tor\texpanded risks\tand\tliabilities.\tAI\ttechnology\tis\tcontinuously\tevolving,\tand\tthe\tAI\ttechnologies\twe\tdevelop\tand\tadopt\tmay\tbecome\tobsolete\tearlier than\tplanned.\tOur\tinvestments\tin\tthese\ttechnologies\tmay\tnot\tresult\tin\tthe\tbenefits\twe\tanticipate\tor\tenable\tus\tto\tobtain\tor\tmaintain\ta competitive\tadvantage.\tThe\tapplication\tof\tmachine\tlearning\tand\tAI\tin\tour\tbusiness\tis\temerging\tand\tevolving\talongside\tnew\tlaws\tand regulations\tthat\tmay\tentail\tsignificant\tcosts\tor\tultimately\tlimit\tour\tability\tto\tcontinue\tthe\tuse\tof\tthese\ttechnologies.\tThese technologies\talso\tcarry\tinherent\trisks\trelated\tto\tdata\tprivacy\tand\tsecurity\tfurther\tdescribed\tbelow.\n\n## Risks\trelated\tto\tfinancial\tand\teconomic\tmarket\tconditions\n\nThe\tCompany\tfaces\ta\tvariety\tof\tfinancial,\teconomic,\tlegal,\tsocial\tand\tpolitical\trisks\tassociated\twith\tconducting business\tinternationally.\n\nThe\tCompany's\textensive\toperations\tand\tbusiness\tactivity\tthroughout\tthe\tworld\tare\taccompanied\tby\tcertain\tfinancial,\teconomic,\tlegal, social\tand\tpolitical\trisks,\tincluding\tthose\tlisted\tbelow.\n\nForeign\tcurrency\texchange :\tIn\tfiscal\t2023,\tapproximately\t45%\tof\tthe\tCompany's\tsales\toccurred\toutside\tof\tthe\tU.S.,\twith\tapproximately\t24% in\tEurope,\t5%\tin\tthe\tWestern\tHemisphere,\texcluding\tthe\tU.S.,\tand\t16%\tin\tthe\tAsia-Pacific\tand\tAfrica\tregion.\tChanges\tin\tnon-U.S. currencies\trelative\tto\tthe\tU.S.\tdollar\timpact\tthe\tCompany's\trevenues\tand\texpenses.\tWhile\tthe\tCompany\tuses\tfinancial\tinstruments\tto mitigate\tthe\timpact\tof\tfluctuations\tin\tcurrency\texchange\trates\ton\tits\tcash\tflows,\tunhedged\texposures\tcontinue\tto\tbe\tsubject\tto\tcurrency fluctuations.\tIn\taddition,\tthe\tweakening\tor\tstrengthening\tof\tthe\tU.S.\tdollar\tmay\tresult\tin\tsignificant\tfavorable\tor\tunfavorable translation\teffects\twhen\tthe\toperating\tresults\tof\tthe\tCompany's\tnon-U.S.\tbusiness\tactivity\tare\ttranslated\tinto\tU.S.\tdollars.\n\nInflation\tand\tcurrency\tdevaluation\trisks :\tThe\tCompany\tfaces\tchallenges\tin\tmaintaining\tprofitability\tof\toperations\tin\teconomies experiencing\thigh\tinflation\trates.\tSpecifically,\tthe\tCompany\thas\taccounted\tfor\toperations\tin\tArgentina,\tTurkey\tand\tVenezuela\tas\thighly inflationary,\tas\tthe\tprior\tthree-year\tcumulative\tinflation\trate\tsurpassed\t100%.\tWhile\tthe\tCompany\tstrives\tto\tmaintain\tprofit\tmargins\tin these\tareas\tthrough\tcost\treduction\tprograms,\tproductivity\timprovements\tand\tperiodic\tprice\tincreases,\tit\tmight\texperience\toperating losses\tas\ta\tresult\tof\tcontinued\tinflation.\tIn\taddition,\tthe\timpact\tof\tcurrency\tdevaluations\tin\n\n2023\tAnnual\tReport\n\n13",
          "relationship": "Partners_With"
        },
        "intermediate_node": {
          "id": "Collaborations",
          "name": "Collaborations",
          "type": "FIN_METRIC",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_29",
          "chunk_id": "chunk_2",
          "chunk_text": "We\thave\testablished\tsignificant\tgrowth\tgoals,\twhich\twe\tplan\tto\tachieve,\tin\tpart,\tby\tnot\tonly\tadvancing\tour\town\tproduct\tpipelines\tand\tmaximizing\tthe value\tof\tour\texisting\tproducts,\tbut\talso\tthrough\tvarious\tforms\tof\tbusiness\tdevelopment\tactivities,\twhich\tcan\tinclude\talliances,\tlicenses,\tJVs, collaborations,\tequity-\tor\tdebt-based\tinvestments,\tdispositions,\tdivestments,\tmergers\tand\tacquisitions.\tOur\trecent\tacquisition\tof\tSeagen\tis\tpart\tof that\tgrowth\tplan.\tWe\tview\tour\tbusiness\tdevelopment\tactivity\tas\tan\tenabler\tof\tour\tstrategies\tand\tseek\tto\tgenerate\tgrowth\tby\tpursuing\topportunities and\ttransactions\tthat\thave\tthe\tpotential\tto\tstrengthen\tour\tbusiness\tand\tour\tcapabilities.\tThe\tsuccess\tof\tour\tbusiness\tdevelopment\tactivities\tis dependent\ton\tthe\tavailability\tand\taccurate\tevaluation\tof\tappropriate\topportunities,\tcompetition\tfrom\tothers\tthat\tare\tseeking\tsimilar\topportunities and\tour\tability\tto\tsuccessfully\tidentify,\tstructure\tand\texecute\ttransactions,\tincluding\tthe\tability\tto\tsatisfy\tclosing\tconditions\tin\tthe\tanticipated timeframes\tor\tat\tall,\tand\tour\tability\tto\tsuccessfully\tintegrate\tacquired\tbusinesses\tand\tdevelop\tand\tcommercialize\tacquired\tproducts.\tPursuing, executing\tand\tconsummating\tthese\ttransactions\tmay\trequire\tsubstantial\tinvestment,\twhich\tmay\trequire\tus\tto\tobtain\tadditional\tequity\tor\tdebt financing,\twhich\thas\tin\tthe\tpast\tand\tcould\tin\tthe\tfuture\tresult\tin\tincreased\tleverage\tand/or\ta\tdowngrade\tof\tour\tcredit\tratings\tand\tcould\tlimit\tour ability\tto\tobtain\tfuture\tfinancing.\tWe\thave\tincurred\tsubstantial\tindebtedness\tto\tfund\tour\trecent\tacquisition\tof\tSeagen.\tWe\tfinanced\ta\tportion\tof\tthe transaction\twith\tthe\tproceeds\tfrom\tthe\t$31\tbillion\tof\tlong-term\tdebt\tissued\tin\tMay\t2023,\tplus\t$8\tbillion\tin\tadditional\tshort-term\tindebtedness issued\tprior\tto\tthe\tacquisition.\tThe\tamount\tof\tdebt\tthat\twe\thave\tincurred\tcould\thave\tsignificant\tconsequences\tincluding,\tamong\tother\tthings, reducing\tour\toperating\tor\tfinancial\tflexibility,\trequiring\ta\tportion\tof\tour\tcash\tflow\tfrom\toperations\tto\tmake\tinterest\tpayments\tand\treducing\tthe cash\tflow\tavailable\tto\tfund\tcapital\texpenditures\tand\tother\tcorporate\tpurposes\tand\tto\tgrow\tour\tbusiness.\tTo\tthe\textent\twe\tincur\tadditional indebtedness\tor\tinterest\trates\tincrease,\tthese\trisks\tcould\tincrease\tfurther.\n\nThe\tsuccess\tof\tour\tbusiness\tdevelopment\ttransactions,\tincluding\tour\trecent\tacquisition\tof\tSeagen,\tdepends\ton\tour\tability\tto\trealize\tthe\tanticipated benefits\tof\tthese\ttransactions\tand\tis\tsubject\tto\tnumerous\trisks\tand\tuncertainties,\tmany\tof\twhich\tare\toutside\tof\tour\tcontrol.\tUnsuccessful\tclinical trials,\tregulatory\thurdles\tand\tcommercialization\tchallenges,\tamong\tother\tfactors,\tmay\tadversely\timpact\trevenue\tand\tincome\tcontribution\tfrom\tbusiness development\ttransactions,\tincluding\tfrom\tacquired\tproducts\tand\tbusinesses.\tWe\tmay\tfail\tto\tgenerate\texpected\trevenue\tgrowth\tfor\tour\texisting products,\tproduct\tpipeline\tand\tcontribution\tfrom\tthese\ttransactions\tor\tfrom\tacquired\tproducts\tor\tbusinesses\tor\twe\tmay\tfail\tto\tachieve\tanticipated cost\tsavings,\tsuch\tas\tthose\texpected\twith\trespect\tto\tSeagen,\twithin\texpected\ttime\tframes\tor\tat\tall,\twhich\tmay\timpact\tour\tability\tto\tmeet\tour\tgrowth objectives.\tIn\tcertain\ttransactions,\twe\tmay\tagree\tto\tprovide\tcertain\ttransition\tservices\tfor\tan\textended\tperiod\tof\ttime,\twhich\tmay\tdivert\tour\tfocus and\tresources\tthat\twould\totherwise\tbe\tinvested\tinto\tmaintaining\tor\tgrowing\tour\tbusiness.\tSimilarly,\tthe\taccretive\timpact\tanticipated\tfrom\tcertain transactions\tmay\tnot\tbe\trealized\tor\tmay\tbe\tdelayed.\tIntegration\tof\tacquired\tproducts\tor\tbusinesses\tmay\tresult\tin\tthe\tloss\tof\tkey\temployees,\tthe disruption\tof\tongoing\tbusiness,\tincluding\tthird-party\trelationships,\tor\tinconsistencies\tin\tstandards,\tcontrols,\tprocedures\tand\tpolicies.\tFurther, while\twe\tseek\tto\tmitigate\trisks\tand\tliabilities\tthrough,\tamong\tother\tthings,\tdue\tdiligence,\twe\tmay\tbe\texposed\tto\trisks\tand\tliabilities\tas\ta\tresult of\tbusiness\tdevelopment\ttransactions.\tThere\tis\tno\tassurance\tthat\twe\twill\tbe\table\tto\tacquire\tattractive\tbusinesses\tor\tenter\tinto\tstrategic\tbusiness relationships\ton\tfavorable\tterms\tahead\tof\tour\tcompetitors,\tor\tthat\tsuch\tacquisitions\tor\tstrategic\tbusiness\tdevelopment\trelationships\twill\tbe accretive\tto\tearnings\tor\timprove\tour\tcompetitive\tposition.\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n23",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 8,
      "question": "How do the legal defense cost exposures related to product liability claims at JNJ and environmental litigation contingencies at PFE differ in terms of accrual strategy and risk disclosure?",
      "answer": "Johnson & Johnson accrues legal defense costs for product liability claims when they are probable and can be reasonably estimated, and also includes additional amounts for settlements and damages where applicable. In contrast, Pfizer highlights legal defense costs as part of broader risk disclosures, particularly tied to environmental contamination, but does not specify accruals for these costs, focusing instead on the risk of adverse decisions and reserve adequacy. This indicates that JNJ has a more structured accrual approach tied to specific cases, while PFE emphasizes risk exposure without explicit accrual details.",
      "reasoning_steps": [
        "Step 1: Extract from JNJ's 10-K - JNJ accrues legal defense costs when probable and estimable, and includes additional amounts for settlements and damages (evidence_source_a).",
        "Step 2: Extract from PFE's 10-K - PFE lists legal defense costs among risks, particularly related to environmental contamination, but does not specify accruals, focusing instead on the risk of adverse decisions and reserve adequacy (evidence_source_b).",
        "Step 3: Synthesize - JNJ provides a clear accrual methodology for legal defense costs tied to product liability, while PFE discusses legal defense costs in the context of risk without specifying accruals, suggesting differing strategies in financial exposure management."
      ],
      "difficulty": "hard",
      "idf_score": 5.069602770184371,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Faces]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Legal Defense Costs",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_100",
          "chunk_id": "chunk_1",
          "chunk_text": "## Product\tliability\n\nThe\tCompany\tand\tcertain\tof\tits\tsubsidiaries\tare\tinvolved\tin\tnumerous\tproduct\tliability\tclaims\tand\tlawsuits\tinvolving\tmultiple\tproducts. Claimants\tin\tthese\tcases\tseek\tsubstantial\tcompensatory\tand,\twhere\tavailable,\tpunitive\tdamages.\tWhile\tthe\tCompany\tbelieves\tit\thas substantial\tdefenses,\tit\tis\tnot\tfeasible\tto\tpredict\tthe\tultimate\toutcome\tof\tlitigation.\tFrom\ttime\tto\ttime,\teven\tif\tit\thas\tsubstantial defenses,\tthe\tCompany\tconsiders\tisolated\tsettlements\tbased\ton\ta\tvariety\tof\tcircumstances.\tThe\tCompany\thas\taccrued\tfor\tthese\tmatters\tand will\tcontinue\tto\tmonitor\teach\trelated\tlegal\tissue\tand\tadjust\taccruals\tas\tmight\tbe\twarranted\tbased\ton\tnew\tinformation\tand\tfurther developments\tin\taccordance\twith\tASC\t450-20-25,\tContingencies.\tThe\tCompany\taccrues\tan\testimate\tof\tthe\tlegal\tdefense\tcosts\tneeded\tto defend\teach\tmatter\twhen\tthose\tcosts\tare\tprobable\tand\tcan\tbe\treasonably\testimated.\tFor\tcertain\tof\tthese\tmatters,\tthe\tCompany\thas\taccrued additional\tamounts\tsuch\tas\testimated\tcosts\tassociated\twith\tsettlements,\tdamages\tand\tother\tlosses.\tProduct\tliability\taccruals\tcan represent\tprojected\tproduct\tliability\tfor\tthousands\tof\tclaims\taround\tthe\tworld,\teach\tin\tdifferent\tlitigation\tenvironments\tand\twith different\tfact\tpatterns.\tChanges\tto\tthe\taccruals\tmay\tbe\trequired\tin\tthe\tfuture\tas\tadditional\tinformation\tbecomes\tavailable.\n\nThe\ttable\tbelow\tcontains\tthe\tmost\tsignificant\tof\tthese\tcases\tand\tprovides\tthe\tapproximate\tnumber\tof\tplaintiffs\tin\tthe\tUnited\tStates\twith direct\tclaims\tin\tpending\tlawsuits\tregarding\tinjuries\tallegedly\tdue\tto\tthe\trelevant\tproduct\tor\tproduct\tcategory\tas\tof\tDecember\t31,\t2023:\n\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Legal_Defense_Costs",
          "name": "Legal Defense Costs",
          "type": "FIN_METRIC",
          "idf_score": 5.069602770184371
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_1",
          "chunk_text": "interactions\twith\thealthcare\tprofessionals\tand\tother\tindustry\tstakeholders;\tas\twell\tas\tpricing\tpressures\tfor\tour\tproducts\tas\ta\tresult\tof highly\tcompetitive\tbiopharmaceutical\tmarkets;\n\n- legislation\tor\tregulatory\taction\tin\tmarkets\toutside\tof\tthe\tU.S.,\tsuch\tas\tChina\tor\tEurope,\tincluding,\twithout\tlimitation,\tlaws\trelated\tto pharmaceutical\tproduct\tpricing,\tintellectual\tproperty,\tmedical\tregulation,\tenvironmental\tprotections,\treimbursement\tor\taccess,\tincluding, in\tparticular,\tcontinued\tgovernment-mandated\treductions\tin\tprices\tand\taccess\trestrictions\tfor\tcertain\tbiopharmaceutical\tproducts\tto\tcontrol costs\tin\tthose\tmarkets;\n- legal\tdefense\tcosts,\tinsurance\texpenses,\tsettlement\tcosts\tand\tcontingencies,\tincluding\twithout\tlimitation,\tthose\trelated\tto\tactual\tor alleged\tenvironmental\tcontamination;\n- the\trisk\tand\timpact\tof\tan\tadverse\tdecision\tor\tsettlement\tand\trisk\trelated\tto\tthe\tadequacy\tof\treserves\trelated\tto\tlegal\tproceedings;\n- the\trisk\tand\timpact\tof\ttax\trelated\tlitigation\tand\tinvestigations;\n- governmental\tlaws\tand\tregulations\taffecting\tour\toperations,\tincluding,\twithout\tlimitation,\tthe\tIRA,\tchanges\tin\tlaws\tand\tregulations\tor their\tinterpretation,\tincluding,\tamong\tothers,\tchanges\tin\ttax\tlaws\tand\tregulations\tinternationally\tand\tin\tthe\tU.S.,\tthe\tadoption\tof\tglobal minimum\ttaxation\trequirements\toutside\tthe\tU.S.\tgenerally\teffective\tin\tmost\tjurisdictions\tsince\tJanuary\t1,\t2024\tand\tpotential\tchanges\tto existing\ttax\tlaw\tby\tthe\tcurrent\tU.S.\tPresidential\tadministration\tand\tCongress,\tincluding\tthe\tproposed\t'Tax\tRelief\tfor\tAmerican\tFamilies\tand Workers\tAct\tof\t2024';\n\n## Risks\tRelated\tto\tIntellectual\tProperty,\tTechnology\tand\tSecurity:\n\n- any\tsignificant\tbreakdown\tor\tinterruption\tof\tour\tIT\tsystems\tand\tinfrastructure\t(including\tcloud\tservices);\n- any\tbusiness\tdisruption,\ttheft\tof\tconfidential\tor\tproprietary\tinformation,\tsecurity\tthreats\ton\tfacilities\tor\tinfrastructure,\textortion\tor integrity\tcompromise\tresulting\tfrom\ta\tcyber-attack\tor\tother\tmalfeasance\tby,\tbut\tnot\tlimited\tto,\tnation\tstates,\temployees,\tbusiness\tpartners or\tothers;\n- risks\tand\tchallenges\trelated\tto\tthe\tuse\tof\tartificial\tintelligence-based\tsoftware;\n- the\trisk\tthat\tour\tcurrently\tpending\tor\tfuture\tpatent\tapplications\tmay\tnot\tbe\tgranted\ton\ta\ttimely\tbasis\tor\tat\tall,\tor\tany\tpatent-term extensions\tthat\twe\tseek\tmay\tnot\tbe\tgranted\ton\ta\ttimely\tbasis,\tif\tat\tall;\tand\n- risks\tto\tour\tproducts,\tpatents\tand\tother\tintellectual\tproperty,\tsuch\tas:\t(i)\tclaims\tof\tinvalidity\tthat\tcould\tresult\tin\tLOE;\t(ii)\tclaims\tof\tpatent infringement,\tincluding\tasserted\tand/or\tunasserted\tintellectual\tproperty\tclaims;\t(iii)\tclaims\twe\tmay\tassert\tagainst\tintellectual\tproperty\trights held\tby\tthird\tparties;\t(iv)\tchallenges\tfaced\tby\tour\tcollaboration\tor\tlicensing\tpartners\tto\tthe\tvalidity\tof\ttheir\tpatent\trights;\tor\t(v)\tany pressure,\tor\tlegal\tor\tregulatory\taction\tby,\tvarious\tstakeholders\tor\tgovernments\tthat\tcould\tpotentially\tresult\tin\tus\tnot\tseeking\tintellectual property\tprotection\tor\tagreeing\tnot\tto\tenforce\tor\tbeing\trestricted\tfrom\tenforcing\tintellectual\tproperty\trights\trelated\tto\tour\tproducts,\tincluding Comirnaty\tand\tPaxlovid.\n\nPART\tI\n\nITEM\t1.\n\n## ABOUT\tPFIZER\n\nPfizer\tInc.\tis\ta\tresearch-based,\tglobal\tbiopharmaceutical\tcompany.\tWe\tapply\tscience\tand\tour\tglobal\tresources\tto\tbring\ttherapies\tto\tpeople\tthat extend\tand\tsignificantly\timprove\ttheir\tlives\tthrough\tthe\tdiscovery,\tdevelopment,\tmanufacture,\tmarketing,\tsale\tand\tdistribution\tof\tbiopharmaceutical products\tworldwide.\tWe\twork\tacross\tdeveloped\tand\temerging\tmarkets\tto\tadvance\twellness,\tprevention,\ttreatments\tand\tcures\tthat\tchallenge\tthe\tmost feared\tdiseases\tof\tour\ttime.\tWe\tcollaborate\twith\thealthcare\tproviders,\tgovernments\tand\tlocal\tcommunities\tto\tsupport\tand\texpand\taccess\tto\treliable, affordable\thealthcare\taround\tthe\tworld.\tThe\tCompany\twas\tincorporated\tunder\tthe\tlaws\tof\tthe\tState\tof\tDelaware\ton\tJune\t2,\t1942.\n\nMost\tof\tour\trevenues\tcome\tfrom\tthe\tmanufacture\tand\tsale\tof\tbiopharmaceutical\tproducts.\tWe\talso\tsell\tproducts\tfor\tthe\tdetection\tof\tcertain\tillnesses and\tprovide\tend-to-end\tR&amp;D\tservices\tto\tselect\tinnovative\tbiotech\tcompanies.\tWe\tbelieve\tthat\tour\tmedicines\tand\tvaccines\tprovide\tsignificant\tvalue\tfor healthcare\tproviders\tand\tpatients\tthrough\timproved\ttreatment\tof\tdiseases\tand\timprovements\tin\thealth,\twellness\tand\tproductivity\tas\twell\tas\tby reducing\tother\thealthcare\tcosts,\tsuch\tas\temergency\troom\tvisits\tor\thospitalizations.\tWe\tseek\tto\tenhance\tthe\tvalue\tof\tour\tmedicines\tand\tvaccines\tand actively\tengage\tin\tdialogues\tabout\thow\twe\tcan\tbest\twork\twith\tpatients,\tphysicians\tand\tpayors\tto\tprevent\tand\ttreat\tdisease\tand\timprove\toutcomes.\tWe seek\tto\tmaximize\tpatient\taccess\tand\tevaluate\tour\tpricing\tarrangements\tand\tcontracting\tmethods\twith\tpayors\tto\tminimize\tadverse\timpact\ton\tour\trevenues within\tthe\tcurrent\tlegal\tand\tpricing\tstructures.\n\nWe\tare\tcommitted\tto\tfulfilling\tour\tpurpose: Breakthroughs\tthat\tchange\tpatients'\tlives .\tOur\tpurpose\tfuels\teverything\twe\tdo\tand\treflects\tboth\tour passion\tfor\tscience\tand\tour\tcommitment\tto\tpatients.\tOur\tcore\tbusiness\tprinciples\tare:\n\n1. Trust\tis\tEverything\n2. Science\tWill\tWin\n3. Disruption\tCalls\tfor\tInnovation\n4. Time\tis\tLife\n5. Execution\tMakes\tthe\tDifference.\n\nIn\taddition,\tPfizer's\tESG\tstrategy,\twhich\tis\tintegrated\tinto\tour\tcorporate\tstrategy,\tfocuses\ton\tsix\tareas\twhere\twe\tsee\topportunities\tto\tcreate\ta meaningful\timpact:\tproduct\tinnovation;\tequitable\taccess\tand\tpricing;\tproduct\tquality\tand\tsafety;\tdiversity,\tequity\tand\tinclusion;\tclimate\tchange; and\tbusiness\tethics.\n\nWe\tare\tcommitted\tto\tstrategically\tcapitalizing\ton\tgrowth\topportunities,\tprimarily\tby\tadvancing\tour\town\tproduct\tpipeline\tand\tmaximizing\tthe\tvalue\tof our\texisting\tproducts,\tbut\talso\tthrough\tvarious\tbusiness\tdevelopment\tactivities.\tWe\tview\tour\tbusiness\tdevelopment\tactivity\tas\tan\tenabler\tof\tour strategies\tand\tseek\tto\tgenerate\tgrowth\tby\tpursuing\topportunities\tand\ttransactions\tthat\thave\tthe\tpotential\tto\tstrengthen\tour\tbusiness\tand\tour\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n3\n\nBUSINESS",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 9,
      "question": "How do the legal defense cost disclosures in JNJ's 10-K and the legal defense cost risks outlined in PFE's 10-K reflect different aspects of financial exposure and risk management strategies in the healthcare sector?",
      "answer": "JNJ discloses that it accrues an estimate of legal defense costs when those costs are probable and can be reasonably estimated, indicating a proactive approach to financial liability management. In contrast, PFE highlights legal defense costs as part of a broader set of risks, including insurance expenses and settlement costs, particularly related to environmental contamination and intellectual property disputes. These disclosures reflect that JNJ focuses on estimating and recording known liabilities, while PFE emphasizes the uncertainty and potential magnitude of future legal exposures, particularly in areas like environmental and IP-related litigation. Together, they demonstrate that legal defense costs represent a significant and multifaceted financial risk for healthcare companies, with differing emphasis on estimation versus contingency planning.",
      "reasoning_steps": [
        "Step 1: Extract from source A - JNJ accrues legal defense costs when they are probable and can be reasonably estimated.",
        "Step 2: Extract from source B - PFE identifies legal defense costs as part of a broader risk set, including environmental and IP-related litigation, with emphasis on uncertainty and contingency.",
        "Step 3: Synthesize - Both companies face legal defense cost risks, but JNJ focuses on quantifiable accruals while PFE emphasizes risk and contingency planning, showing different aspects of financial exposure in the healthcare sector."
      ],
      "difficulty": "hard",
      "idf_score": 5.069602770184371,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Faces]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Legal Defense Costs",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_59",
          "chunk_id": "chunk_1",
          "chunk_text": "tests\twill\tbe\tperformed\tannually\tin\tthe\tfiscal\tfourth\tquarter,\tor\tsooner\tif\twarranted.\tPurchased\tin-process\tresearch\tand\tdevelopment\tis accounted\tfor\tas\tan\tindefinite\tlived\tintangible\tasset\tuntil\tthe\tunderlying\tproject\tis\tcompleted,\tat\twhich\tpoint\tthe\tintangible\tasset will\tbe\taccounted\tfor\tas\ta\tdefinite\tlived\tintangible\tasset.\tIf\twarranted\tthe\tpurchased\tin-process\tresearch\tand\tdevelopment\tcould\tbe written\toff\tor\tpartially\timpaired\tdepending\ton\tthe\tunderlying\tprogram.\n\nIntangible\tassets\tthat\thave\tfinite\tuseful\tlives\tcontinue\tto\tbe\tamortized\tover\ttheir\tuseful\tlives,\tand\tare\treviewed\tfor\timpairment\twhen warranted\tby\teconomic\tconditions.\tSee\tNote\t5\tfor\tfurther\tdetails\ton\tIntangible\tAssets\tand\tGoodwill.\n\n## Financial\tinstruments\n\nAs\trequired\tby\tU.S.\tGAAP,\tall\tderivative\tinstruments\tare\trecorded\ton\tthe\tbalance\tsheet\tat\tfair\tvalue.\tFair\tvalue\tis\tthe\texit price\tthat\twould\tbe\treceived\tto\tsell\tan\tasset\tor\tpaid\tto\ttransfer\ta\tliability.\tFair\tvalue\tis\ta\tmarket-based\tmeasurement\tdetermined\tusing assumptions\tthat\tmarket\tparticipants\twould\tuse\tin\tpricing\tan\tasset\tor\tliability.\tThe\tauthoritative\tliterature\testablishes\ta\tthree-level hierarchy\tto\tprioritize\tthe\tinputs\tused\tin\tmeasuring\tfair\tvalue,\twith\tLevel\t1\thaving\tthe\thighest\tpriority\tand\tLevel\t3\thaving\tthe\tlowest. Changes\tin\tthe\tfair\tvalue\tof\tderivatives\tare\trecorded\teach\tperiod\tin\tcurrent\tearnings\tor\tother\tcomprehensive\tincome,\tdepending\ton whether\tthe\tderivative\tis\tdesignated\tas\tpart\tof\ta\thedge\ttransaction,\tand\tif\tso,\tthe\ttype\tof\thedge\ttransaction.\n\nThe\tCompany\tdocuments\tall\trelationships\tbetween\thedged\titems\tand\tderivatives.\tThe\toverall\trisk\tmanagement\tstrategy\tincludes\treasons\tfor undertaking\thedge\ttransactions\tand\tentering\tinto\tderivatives.\tThe\tobjectives\tof\tthis\tstrategy\tare:\t(1)\tminimize\tforeign\tcurrency exposure's\timpact\ton\tthe\tCompany's\tfinancial\tperformance;\t(2)\tprotect\tthe\tCompany's\tcash\tflow\tfrom\tadverse\tmovements\tin\tforeign\texchange rates;\t(3)\tensure\tthe\tappropriateness\tof\tfinancial\tinstruments;\tand\t(4)\tmanage\tthe\tenterprise\trisk\tassociated\twith\tfinancial institutions.\tSee\tNote\t6\tfor\tadditional\tinformation\ton\tFinancial\tInstruments.\n\n## Leases\n\nThe\tCompany\tdetermines\twhether\tan\tarrangement\tis\ta\tlease\tat\tcontract\tinception\tby\testablishing\tif\tthe\tcontract\tconveys\tthe\tright\tto control\tthe\tuse\tof\tidentified\tproperty,\tplant,\tor\tequipment\tfor\ta\tperiod\tof\ttime\tin\texchange\tfor\tconsideration.\tRight\tof\tUse\t(ROU) Assets\tand\tLease\tLiabilities\tfor\toperating\tleases\tare\tincluded\tin\tOther\tassets,\tAccrued\tliabilities,\tand\tOther\tliabilities\ton\tthe consolidated\tbalance\tsheet.\tThe\tROU\tAssets\trepresent\tthe\tright\tto\tuse\tan\tunderlying\tasset\tfor\tthe\tlease\tterm\tand\tlease\tliabilities represent\tan\tobligation\tto\tmake\tlease\tpayments\tarising\tfrom\tthe\tlease.\tCommitments\tunder\tfinance\tleases\tare\tnot\tsignificant,\tand\tare included\tin\tProperty,\tplant\tand\tequipment,\tLoans\tand\tnotes\tpayable,\tand\tLong-term\tdebt\ton\tthe\tconsolidated\tbalance\tsheet.\n\nROU\tAssets\tand\tLease\tLiabilities\tare\trecognized\tat\tthe\tlease\tcommencement\tdate\tbased\ton\tthe\tpresent\tvalue\tof\tall\tminimum\tlease\tpayments over\tthe\tlease\tterm.\tThe\tCompany\tuses\tits\tincremental\tborrowing\trate\tbased\ton\tthe\tinformation\tavailable\tat\tcommencement\tdate\tin determining\tthe\tpresent\tvalue\tof\tlease\tpayments,\twhen\tthe\timplicit\trate\tis\tnot\treadily\tdeterminable.\tLease\tterms\tmay\tinclude\toptions\tto extend\tor\tterminate\tthe\tlease.\tThese\toptions\tare\tincluded\tin\tthe\tlease\tterm\twhen\tit\tis\treasonably\tcertain\tthat\tthe\tCompany\twill\texercise that\toption.\tOperating\tlease\texpense\tis\trecognized\ton\ta\tstraight-line\tbasis\tover\tthe\tlease\tterm.\tThe\tCompany\thas\telected\tthe\tfollowing policy\telections\ton\tadoption:\tuse\tof\tportfolio\tapproach\ton\tleases\tof\tassets\tunder\tmaster\tservice\tagreements,\texclusion\tof\tshort\tterm leases\ton\tthe\tbalance\tsheet,\tand\tnot\tseparating\tlease\tand\tnon-lease\tcomponents.\n\nThe\tCompany\tprimarily\thas\toperating\tlease\tfor\tspace,\tvehicles,\tmanufacturing\tequipment\tand\tdata\tprocessing\tequipment.\tThe\tROU\tasset pertaining\tto\tleases\tfrom\tcontinuing\toperation\twas\t$1.0\tbillion\tin\tboth\tfiscal\tyears\t2023\tand\t2022.\tThe\tlease\tliability\tfrom\tcontinuing operations\twas\t$1.1\tbillion\tin\tboth\tfiscal\tyears\t2023\tand\t2022.\tThe\toperating\tlease\tcosts\tfrom\tcontinuing\toperations\twere\t$0.2\tbillion in\tfiscal\tyears\t2023,\t2022\tand\t2021.\tCash\tpaid\tfor\tamounts\tincluded\tin\tthe\tmeasurement\tof\tlease\tliabilities\tfrom\tcontinuing\toperations were\t$0.2\tbillion\tin\tfiscal\tyears\t2023,\t2022\tand\t2021.\n\n## Product\tliability\n\nAccruals\tfor\tproduct\tliability\tclaims\tare\trecorded,\ton\tan\tundiscounted\tbasis,\twhen\tit\tis\tprobable\tthat\ta\tliability\thas\tbeen\tincurred\tand the\tamount\tof\tthe\tliability\tcan\tbe\treasonably\testimated\tbased\ton\texisting\tinformation\tand\tactuarially\tdetermined\testimates\twhere applicable.\tThe\taccruals\tare\tadjusted\tperiodically\tas\tadditional\tinformation\tbecomes\tavailable.\tThe\tCompany\taccrues\tan\testimate\tof\tthe legal\tdefense\tcosts\tneeded\tto\tdefend\teach\tmatter\twhen\tthose\tcosts\tare\tprobable\tand\tcan\tbe\treasonably\testimated.\tTo\tthe\textent\tadverse verdicts\thave\tbeen\trendered\tagainst\tthe\tCompany,\tthe\tCompany\tdoes\tnot\trecord\tan\taccrual\tuntil\ta\tloss\tis\tdetermined\tto\tbe\tprobable\tand can\tbe\treasonably\testimated.\n\n2023\tAnnual\tReport\n\n53",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Legal_Defense_Costs",
          "name": "Legal Defense Costs",
          "type": "FIN_METRIC",
          "idf_score": 5.069602770184371
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_1",
          "chunk_text": "interactions\twith\thealthcare\tprofessionals\tand\tother\tindustry\tstakeholders;\tas\twell\tas\tpricing\tpressures\tfor\tour\tproducts\tas\ta\tresult\tof highly\tcompetitive\tbiopharmaceutical\tmarkets;\n\n- legislation\tor\tregulatory\taction\tin\tmarkets\toutside\tof\tthe\tU.S.,\tsuch\tas\tChina\tor\tEurope,\tincluding,\twithout\tlimitation,\tlaws\trelated\tto pharmaceutical\tproduct\tpricing,\tintellectual\tproperty,\tmedical\tregulation,\tenvironmental\tprotections,\treimbursement\tor\taccess,\tincluding, in\tparticular,\tcontinued\tgovernment-mandated\treductions\tin\tprices\tand\taccess\trestrictions\tfor\tcertain\tbiopharmaceutical\tproducts\tto\tcontrol costs\tin\tthose\tmarkets;\n- legal\tdefense\tcosts,\tinsurance\texpenses,\tsettlement\tcosts\tand\tcontingencies,\tincluding\twithout\tlimitation,\tthose\trelated\tto\tactual\tor alleged\tenvironmental\tcontamination;\n- the\trisk\tand\timpact\tof\tan\tadverse\tdecision\tor\tsettlement\tand\trisk\trelated\tto\tthe\tadequacy\tof\treserves\trelated\tto\tlegal\tproceedings;\n- the\trisk\tand\timpact\tof\ttax\trelated\tlitigation\tand\tinvestigations;\n- governmental\tlaws\tand\tregulations\taffecting\tour\toperations,\tincluding,\twithout\tlimitation,\tthe\tIRA,\tchanges\tin\tlaws\tand\tregulations\tor their\tinterpretation,\tincluding,\tamong\tothers,\tchanges\tin\ttax\tlaws\tand\tregulations\tinternationally\tand\tin\tthe\tU.S.,\tthe\tadoption\tof\tglobal minimum\ttaxation\trequirements\toutside\tthe\tU.S.\tgenerally\teffective\tin\tmost\tjurisdictions\tsince\tJanuary\t1,\t2024\tand\tpotential\tchanges\tto existing\ttax\tlaw\tby\tthe\tcurrent\tU.S.\tPresidential\tadministration\tand\tCongress,\tincluding\tthe\tproposed\t'Tax\tRelief\tfor\tAmerican\tFamilies\tand Workers\tAct\tof\t2024';\n\n## Risks\tRelated\tto\tIntellectual\tProperty,\tTechnology\tand\tSecurity:\n\n- any\tsignificant\tbreakdown\tor\tinterruption\tof\tour\tIT\tsystems\tand\tinfrastructure\t(including\tcloud\tservices);\n- any\tbusiness\tdisruption,\ttheft\tof\tconfidential\tor\tproprietary\tinformation,\tsecurity\tthreats\ton\tfacilities\tor\tinfrastructure,\textortion\tor integrity\tcompromise\tresulting\tfrom\ta\tcyber-attack\tor\tother\tmalfeasance\tby,\tbut\tnot\tlimited\tto,\tnation\tstates,\temployees,\tbusiness\tpartners or\tothers;\n- risks\tand\tchallenges\trelated\tto\tthe\tuse\tof\tartificial\tintelligence-based\tsoftware;\n- the\trisk\tthat\tour\tcurrently\tpending\tor\tfuture\tpatent\tapplications\tmay\tnot\tbe\tgranted\ton\ta\ttimely\tbasis\tor\tat\tall,\tor\tany\tpatent-term extensions\tthat\twe\tseek\tmay\tnot\tbe\tgranted\ton\ta\ttimely\tbasis,\tif\tat\tall;\tand\n- risks\tto\tour\tproducts,\tpatents\tand\tother\tintellectual\tproperty,\tsuch\tas:\t(i)\tclaims\tof\tinvalidity\tthat\tcould\tresult\tin\tLOE;\t(ii)\tclaims\tof\tpatent infringement,\tincluding\tasserted\tand/or\tunasserted\tintellectual\tproperty\tclaims;\t(iii)\tclaims\twe\tmay\tassert\tagainst\tintellectual\tproperty\trights held\tby\tthird\tparties;\t(iv)\tchallenges\tfaced\tby\tour\tcollaboration\tor\tlicensing\tpartners\tto\tthe\tvalidity\tof\ttheir\tpatent\trights;\tor\t(v)\tany pressure,\tor\tlegal\tor\tregulatory\taction\tby,\tvarious\tstakeholders\tor\tgovernments\tthat\tcould\tpotentially\tresult\tin\tus\tnot\tseeking\tintellectual property\tprotection\tor\tagreeing\tnot\tto\tenforce\tor\tbeing\trestricted\tfrom\tenforcing\tintellectual\tproperty\trights\trelated\tto\tour\tproducts,\tincluding Comirnaty\tand\tPaxlovid.\n\nPART\tI\n\nITEM\t1.\n\n## ABOUT\tPFIZER\n\nPfizer\tInc.\tis\ta\tresearch-based,\tglobal\tbiopharmaceutical\tcompany.\tWe\tapply\tscience\tand\tour\tglobal\tresources\tto\tbring\ttherapies\tto\tpeople\tthat extend\tand\tsignificantly\timprove\ttheir\tlives\tthrough\tthe\tdiscovery,\tdevelopment,\tmanufacture,\tmarketing,\tsale\tand\tdistribution\tof\tbiopharmaceutical products\tworldwide.\tWe\twork\tacross\tdeveloped\tand\temerging\tmarkets\tto\tadvance\twellness,\tprevention,\ttreatments\tand\tcures\tthat\tchallenge\tthe\tmost feared\tdiseases\tof\tour\ttime.\tWe\tcollaborate\twith\thealthcare\tproviders,\tgovernments\tand\tlocal\tcommunities\tto\tsupport\tand\texpand\taccess\tto\treliable, affordable\thealthcare\taround\tthe\tworld.\tThe\tCompany\twas\tincorporated\tunder\tthe\tlaws\tof\tthe\tState\tof\tDelaware\ton\tJune\t2,\t1942.\n\nMost\tof\tour\trevenues\tcome\tfrom\tthe\tmanufacture\tand\tsale\tof\tbiopharmaceutical\tproducts.\tWe\talso\tsell\tproducts\tfor\tthe\tdetection\tof\tcertain\tillnesses and\tprovide\tend-to-end\tR&amp;D\tservices\tto\tselect\tinnovative\tbiotech\tcompanies.\tWe\tbelieve\tthat\tour\tmedicines\tand\tvaccines\tprovide\tsignificant\tvalue\tfor healthcare\tproviders\tand\tpatients\tthrough\timproved\ttreatment\tof\tdiseases\tand\timprovements\tin\thealth,\twellness\tand\tproductivity\tas\twell\tas\tby reducing\tother\thealthcare\tcosts,\tsuch\tas\temergency\troom\tvisits\tor\thospitalizations.\tWe\tseek\tto\tenhance\tthe\tvalue\tof\tour\tmedicines\tand\tvaccines\tand actively\tengage\tin\tdialogues\tabout\thow\twe\tcan\tbest\twork\twith\tpatients,\tphysicians\tand\tpayors\tto\tprevent\tand\ttreat\tdisease\tand\timprove\toutcomes.\tWe seek\tto\tmaximize\tpatient\taccess\tand\tevaluate\tour\tpricing\tarrangements\tand\tcontracting\tmethods\twith\tpayors\tto\tminimize\tadverse\timpact\ton\tour\trevenues within\tthe\tcurrent\tlegal\tand\tpricing\tstructures.\n\nWe\tare\tcommitted\tto\tfulfilling\tour\tpurpose: Breakthroughs\tthat\tchange\tpatients'\tlives .\tOur\tpurpose\tfuels\teverything\twe\tdo\tand\treflects\tboth\tour passion\tfor\tscience\tand\tour\tcommitment\tto\tpatients.\tOur\tcore\tbusiness\tprinciples\tare:\n\n1. Trust\tis\tEverything\n2. Science\tWill\tWin\n3. Disruption\tCalls\tfor\tInnovation\n4. Time\tis\tLife\n5. Execution\tMakes\tthe\tDifference.\n\nIn\taddition,\tPfizer's\tESG\tstrategy,\twhich\tis\tintegrated\tinto\tour\tcorporate\tstrategy,\tfocuses\ton\tsix\tareas\twhere\twe\tsee\topportunities\tto\tcreate\ta meaningful\timpact:\tproduct\tinnovation;\tequitable\taccess\tand\tpricing;\tproduct\tquality\tand\tsafety;\tdiversity,\tequity\tand\tinclusion;\tclimate\tchange; and\tbusiness\tethics.\n\nWe\tare\tcommitted\tto\tstrategically\tcapitalizing\ton\tgrowth\topportunities,\tprimarily\tby\tadvancing\tour\town\tproduct\tpipeline\tand\tmaximizing\tthe\tvalue\tof our\texisting\tproducts,\tbut\talso\tthrough\tvarious\tbusiness\tdevelopment\tactivities.\tWe\tview\tour\tbusiness\tdevelopment\tactivity\tas\tan\tenabler\tof\tour strategies\tand\tseek\tto\tgenerate\tgrowth\tby\tpursuing\topportunities\tand\ttransactions\tthat\thave\tthe\tpotential\tto\tstrengthen\tour\tbusiness\tand\tour\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n3\n\nBUSINESS",
          "relationship": "Faces"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 10,
      "question": "How does the treatment of royalty income differ between Johnson & Johnson and Pfizer in their 2023 financial reporting, and what change in presentation will Pfizer implement starting in 2024 that affects this metric?",
      "answer": "Johnson & Johnson includes royalty income in its 'Other (Income) Expense, Net' line item, indicating it records royalty income as part of non-operating gains and losses. In contrast, Pfizer states that beginning in 2024, it will include royalty income in 'Total Revenues', and will restate prior periods for consistency. This means that while both companies report royalty income, Pfizer will shift its presentation from a non-revenue category to being directly included in total revenue, aligning it more closely with operating performance starting in 2024.",
      "reasoning_steps": [
        "Step 1: From Johnson & Johnson's 10-K, royalty income is disclosed as part of 'Other (Income) Expense, Net', which includes gains and losses from investments, changes in fair value of securities, and other non-operating items.",
        "Step 2: From Pfizer's 10-K, royalty income is not explicitly detailed in the current 2023 reporting structure, but Pfizer discloses a planned change for 2024 where royalty income will be included in 'Total Revenues' with prior periods restated.",
        "Step 3: Comparing both disclosures reveals that JNJ treats royalty income as part of other non-operating income, while PFE will begin treating it as part of core revenue starting in 2024, signaling a strategic shift in how Pfizer reports this income stream."
      ],
      "difficulty": "medium",
      "idf_score": 4.964242254526545,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Royalty Income",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_36",
          "chunk_id": "chunk_3",
          "chunk_text": "\nResearch\tand\tdevelopment\tactivities\trepresent\ta\tsignificant\tpart\tof\tthe\tCompany's\tbusiness.\tThese\texpenditures\trelate\tto\tthe\tprocesses of\tdiscovering,\ttesting\tand\tdeveloping\tnew\tproducts,\tupfront\tpayments\tand\tdevelopmental\tmilestones,\timproving\texisting\tproducts,\tas\twell as\tensuring\tproduct\tefficacy\tand\tregulatory\tcompliance\tprior\tto\tlaunch.\tThe\tCompany\tremains\tcommitted\tto\tinvesting\tin\tresearch\tand development\twith\tthe\taim\tof\tdelivering\thigh\tquality\tand\tinnovative\tproducts.\n\nResearch\tand\tDevelopment\twas\tflat\tas\ta\tpercent\tto\tsales\tprimarily\tdriven\tby:\n\n- Higher\tmilestone\tpayments\tin\tthe\tInnovative\tMedicine\tbusiness\n- Acquired\tin-process\tresearch\t&amp;\tdevelopment\tasset\tfrom\tthe\tLaminar\tacquisition\tin\tthe\tMedTech\tbusiness\tin\tthe\tfiscal\tyear\t2023 offset\tby\n- Portfolio\tprioritization\tin\tthe\tInnovative\tMedicine\tbusiness\n\nIn-Process\tResearch\tand\tDevelopment\tImpairments\t(IPR&amp;D): In\tthe\tfiscal\tyear\t2023,\tthe\tCompany\trecorded\ta\tcharge\tof\tapproximately $0.3\tbillion\twhich\tincluded\t$0.2\tbillion\trelated\tto\tmarket\tdynamics\tassociated\twith\ta\tnon-strategic\tasset\t(M710)\tacquired\tas\tpart\tof\tthe acquisition\tof\tMomenta\tPharmaceuticals\tin\t2020,\tIn\tthe\tfiscal\tyear\t2022,\tthe\tCompany\trecorded\tan\tintangible\tasset\timpairment\tcharge\tof approximately\t$0.8\tbillion\trelated\tto\tan\tin-process\tresearch\tand\tdevelopment\tasset,\tbermekimab\t(JnJ-77474462),\tan\tinvestigational\tdrug for\tthe\ttreatment\tof\tAtopic\tDermatitis\t(AD)\tand\tHidradenitis\tSuppurativa\t(HS).\tAdditional\tinformation\tregarding\tefficacy\tof\tthe\tAD indication\tand\tHS\tindication\tbecame\tavailable\twhich\tled\tthe\tCompany\tto\tthe\tdecision\tto\tterminate\tthe\tdevelopment\tof\tbermekimab\tfor\tboth AD\tand\tHS.\tThe\tCompany\tacquired\tall\trights\tto\tbermekimab\tfrom\tXBiotech,\tInc.\tin\tthe\tfiscal\tyear\t2020.\n\nOther\t(Income)\tExpense,\tNet: Other\t(income)\texpense,\tnet\tis\tthe\taccount\twhere\tthe\tCompany\trecords\tgains\tand\tlosses\trelated\tto\tthe\tsale and\twrite-down\tof\tcertain\tinvestments\tin\tequity\tsecurities\theld\tby\tJohnson\t&amp;\tJohnson\tInnovation\t-\tJJDC,\tInc.\t(JJDC),\tchanges\tin\tthe\tfair value\tof\tsecurities,\tinvestment\t(income)/loss\trelated\tto\temployee\tbenefit\tprograms,\tgains\tand\tlosses\ton\tdivestitures,\tcertain transactional\tcurrency\tgains\tand\tlosses,\tacquisition\tand\tdivestiture\trelated\tcosts,\tlitigation\taccruals\tand\tsettlements,\tas\twell\tas royalty\tincome.\n\n## 30",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Royalty_Income",
          "name": "Royalty Income",
          "type": "FIN_METRIC",
          "idf_score": 4.964242254526545
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_45",
          "chunk_id": "chunk_5",
          "chunk_text": "\n* Indicates\tcalculation\tnot\tmeaningful.\n\nBeginning\tin\t2024,\twe\twill\tinclude\troyalty\tincome\tin Total\trevenues and\twill\trestate\tprior\tperiods\tfor\tconsistency\twith\tour\t2024\tpresentation. (a)\n\n## 2023\tv.\t2022\n\n## Cost\tof\tSales\n\nCost\tof\tsales decreased\t$9.4\tbillion,\tprimarily\tdue\tto:\n\n- a\treduction\tof\t$14.2\tbillion\tdue\tto\tlower\tsales\tof\tComirnaty;\tand\n- a\treduction\tof\t$1.5\tbillion\tdue\tto\tlower\tsales\tof\tPaxlovid,\n\npartially\toffset\tby:\n\n- non-cash\tcharges\tof\t$6.2\tbillion\tfor\tinventory\twrite-offs\tand\trelated\tcharges\t($5.0\tbillion\tfor\tPaxlovid\tand\t$1.2\tbillion\tfor\tComirnaty).\n\nThe\tincrease\tin Cost\tof\tsales as\ta\tpercentage\tof Total\trevenues was\tmainly\tdriven\tby\tthe\tnon-cash\tcharge\tof\t$6.2\tbillion\tdiscussed\tabove,\tand unfavorable\tchanges\tin\tsales\tmix,\tprimarily\tdue\tto\tlower\tsales\tof\tPaxlovid\tand\tComirnaty,\twhich\tincludes\tthe\tunfavorable\timpact\tof\tthe\t$3.5\tbillion non-cash\tPaxlovid\trevenue\treversal.\n\n## Selling,\tInformational\tand\tAdministrative\tExpenses\n\nSelling,\tinformational\tand\tadministrative\texpenses increased\t$1.1\tbillion,\tmostly\tdue\tto:\n\n- an\tincrease\tof\t$1.1\tbillion\tin\tmarketing\tand\tpromotional\texpenses\tfor\trecently\tacquired\tand\tlaunched\tproducts;\n- an\tincrease\tof\t$280\tmillion\tfor\tthe\texpected\tPaxlovid\tcommercial\tlaunch;\n- an\tincrease\tof\t$210\tmillion\tin\tour\tliability\tto\tbe\tpaid\tto\tparticipants\tof\tour\tsupplemental\tsavings\tplan;\tand\n- an\tincrease\tof\t$170\tmillion\tin\tmarketing\tand\tpromotional\texpenses\tfor\trare\tdisease\tproducts,\n\npartially\toffset\tby:\n\n- a\tdecrease\tof\t$690\tmillion\tdue\tto\ta\tlower\tprovision\tfor\tU.S.\thealthcare\treform\tfees\trelated\tto\tComirnaty\tand\tPaxlovid.\n\n## Research\tand\tDevelopment\tExpenses\n\nResearch\tand\tdevelopment\texpenses decreased\t$749\tmillion,\tprimarily\tdue\tto:\n\n- lower\tspending\tof\t$870\tmillion\tmainly\tfor\tlower\tcompensation-related\texpenses,\tand\tongoing\tvaccine\tand\thospital\tprograms,\tas\twell\tas\n- a\tdecrease\tof\t$260\tmillion\tin\tthe\tvalue\tof\tthe\tportfolio\tperformance\tshare\tgrants\treflecting\tthe\tdecrease\tin\tthe\tprice\tof\tPfizer's\tcommon\tstock,\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n39",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 11,
      "question": "How do the changes in the value of licensing agreements at PFE compare to the strategic risks JNJ faces related to external innovation arrangements, and what might this indicate about their respective approaches to licensing in 2023?",
      "answer": "PFE saw an increase in the gross carrying amount of licensing agreements and other finite-lived intangible assets from $2,237 million in 2022 to $2,756 million in 2023, indicating a growing investment in licensing. Meanwhile, JNJ highlighted risks related to the heightened costs of external innovation arrangements, including licensing agreements, due to competitive pressures. This suggests that while PFE is increasing its licensing investments, JNJ is more cautious, emphasizing the potential financial risks associated with such strategies.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_b - PFE's licensing agreements and other finite-lived intangible assets increased from $2,237 million (2022) to $2,756 million (2023).",
        "Step 2: Extract from evidence_source_a - JNJ notes that there are challenges and heightened costs in external innovation arrangements, such as licensing agreements, due to competitive pressures.",
        "Step 3: Synthesize - The increase in PFE's licensing investments contrasts with JNJ's expressed caution regarding the rising costs and risks of similar arrangements, suggesting differing strategic approaches to licensing in the healthcare sector."
      ],
      "difficulty": "medium",
      "idf_score": 4.964242254526545,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Licensing Agreements",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_5",
          "chunk_id": "chunk_1",
          "chunk_text": "- Increased\tscrutiny\tof\tthe\thealthcare\tindustry\tby\tgovernment\tagencies\tand\tstate\tattorneys\tgeneral\tresulting\tin\tinvestigations\tand prosecutions,\twhich\tcarry\tthe\trisk\tof\tsignificant\tcivil\tand\tcriminal\tpenalties,\tincluding,\tbut\tnot\tlimited\tto,\tdebarment\tfrom government\tbusiness;\n- Failure\tto\tmeet\tcompliance\tobligations\tin\tcompliance\tagreements\twith\tgovernments\tor\tgovernment\tagencies,\twhich\tcould\tresult\tin significant\tsanctions;\n- Potential\tchanges\tto\tapplicable\tlaws\tand\tregulations\taffecting\tUnited\tStates\tand\tinternational\toperations,\tincluding\trelating\tto: approval\tof\tnew\tproducts;\tlicensing\tand\tpatent\trights;\tsales\tand\tpromotion\tof\thealthcare\tproducts;\taccess\tto,\tand\treimbursement\tand pricing\tfor,\thealthcare\tproducts\tand\tservices;\tenvironmental\tprotection;\tand\tsourcing\tof\traw\tmaterials;\n- Compliance\twith\tlocal\tregulations\tand\tlaws\tthat\tmay\trestrict\tthe\tCompany's\tability\tto\tmanufacture\tor\tsell\tits\tproducts\tin\trelevant markets,\tincluding\trequirements\tto\tcomply\twith\tmedical\tdevice\treporting\tregulations\tand\tother\trequirements\tsuch\tas\tthe\tEuropean Union's\tMedical\tDevices\tRegulation;\n- Changes\tin\tdomestic\tand\tinternational\ttax\tlaws\tand\tregulations,\tincreasing\taudit\tscrutiny\tby\ttax\tauthorities\taround\tthe\tworld\tand exposures\tto\tadditional\ttax\tliabilities\tpotentially\tin\texcess\tof\texisting\treserves;\tand\n- The\tissuance\tof\tnew\tor\trevised\taccounting\tstandards\tby\tthe\tFinancial\tAccounting\tStandards\tBoard\tand\tregulations\tby\tthe\tSecurities\tand Exchange\tCommission.\n\n## Risks\trelated\tto\tthe\tCompany's\tstrategic\tinitiatives,\thealthcare\tmarket\ttrends\tand\tthe\trealization\tof\tbenefits\tfrom\tthe\tseparation\tof the\tCompany's\tConsumer\tHealth\tBusiness\n\n- Pricing\tpressures\tresulting\tfrom\ttrends\ttoward\thealthcare\tcost\tcontainment,\tincluding\tthe\tcontinued\tconsolidation\tamong\thealthcare providers\tand\tother\tmarket\tparticipants,\ttrends\ttoward\tmanaged\tcare,\tthe\tshift\ttoward\tgovernments\tincreasingly\tbecoming\tthe\tprimary payors\tof\thealthcare\texpenses,\tsignificant\tnew\tentrants\tto\tthe\thealthcare\tmarkets\tseeking\tto\treduce\tcosts\tand\tgovernment\tpressure\ton companies\tto\tvoluntarily\treduce\tcosts\tand\tprice\tincreases;\n- Restricted\tspending\tpatterns\tof\tindividual,\tinstitutional\tand\tgovernmental\tpurchasers\tof\thealthcare\tproducts\tand\tservices\tdue\tto economic\thardship\tand\tbudgetary\tconstraints;\n- Challenges\tto\tthe\tCompany's\tability\tto\trealize\tits\tstrategy\tfor\tgrowth\tincluding\tthrough\texternally\tsourced\tinnovations,\tsuch\tas development\tcollaborations,\tstrategic\tacquisitions,\tlicensing\tand\tmarketing\tagreements,\tand\tthe\tpotential\theightened\tcosts\tof\tany\tsuch external\tarrangements\tdue\tto\tcompetitive\tpressures;\n- The\tpotential\tthat\tthe\texpected\tstrategic\tbenefits\tand\topportunities\tfrom\tany\tplanned\tor\tcompleted\tacquisition\tor\tdivestiture\tby\tthe Company\tmay\tnot\tbe\trealized\tor\tmay\ttake\tlonger\tto\trealize\tthan\texpected;\n- The\tpotential\tthat\tthe\texpected\tbenefits\tand\topportunities\trelated\tto\tpast\tand\tongoing\trestructuring\tactions\tmay\tnot\tbe\trealized\tor may\ttake\tlonger\tto\trealize\tthan\texpected;\n- The\tCompany's\tability\tto\tdivest\tthe\tCompany's\tremaining\townership\tinterest\tin\tKenvue\tInc.\t(Kenvue)\tand\trealize\tthe\tanticipated benefits\tfrom\tthe\tseparation;\tand\n- Kenvue's\tability\tto\tsucceed\tas\ta\tstandalone\tpublicly\ttraded\tcompany.\n\n## Risks\trelated\tto\teconomic\tconditions,\tfinancial\tmarkets\tand\toperating\tinternationally\n\n- The\trisks\tassociated\twith\tglobal\toperations\ton\tthe\tCompany\tand\tits\tcustomers\tand\tsuppliers,\tincluding\tforeign\tgovernments\tin\tcountries in\twhich\tthe\tCompany\toperates;\n\n\u2022\n\nThe\timpact\tof\tinflation\tand\tfluctuations\tin\tinterest\trates\tand\tcurrency\texchange\trates\tand\tthe\tpotential\teffect\tof\tsuch\tfluctuations on\trevenues,\texpenses\tand\tresulting\tmargins;\n\n- Potential\tchanges\tin\texport/import\tand\ttrade\tlaws,\tregulations\tand\tpolicies\tof\tthe\tUnited\tStates\tand\tother\tcountries,\tincluding\tany increased\ttrade\trestrictions\tor\ttariffs\tand\tpotential\tdrug\treimportation\tlegislation;\n- The\timpact\ton\tinternational\toperations\tfrom\tfinancial\tinstability\tin\tinternational\teconomies,\tsovereign\trisk,\tpossible\timposition\tof governmental\tcontrols\tand\trestrictive\teconomic\tpolicies,\tand\tunstable\tinternational\tgovernments\tand\tlegal\tsystems;\n- The\timpact\tof\tglobal\tpublic\thealth\tcrises\tand\tpandemics;",
          "relationship": "Faces"
        },
        "intermediate_node": {
          "id": "Licensing_Agreements",
          "name": "Licensing Agreements",
          "type": "FIN_METRIC",
          "idf_score": 4.964242254526545
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_91",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                    | As of December 31, 2023   | As of December 31, 2023   | As of December 31, 2023                                       | As of December 31, 2022   | As of December 31, 2022   | As of December 31, 2022                                       |\n|------------------------------------|---------------------------|---------------------------|---------------------------------------------------------------|---------------------------|---------------------------|---------------------------------------------------------------|\n| (MILLIONS)                         | Gross Carrying Amount     | Accumulated Amortization  | Identifiable Intangible Assets, less Accumulated Amortization | Gross Carrying Amount     | Accumulated Amortization  | Identifiable Intangible Assets, less Accumulated Amortization |\n| Finite-lived intangible assets     |                           |                           |                                                               |                           |                           |                                                               |\n| Developed technology rights (a)    | $ 99,267                  | $ (60,493)                | $ 38,773                                                      | $ 85,604                  | $ (56,307)                | $ 29,297                                                      |\n| Brands                             | 922                       | (877)                     | 45                                                            | 922                       | (844)                     | 78                                                            |\n| Licensing agreements and other (b) | 2,756                     | (1,458)                   | 1,297                                                         | 2,237                     | (1,397)                   | 841                                                           |\n|                                    | 102,944                   | (62,828)                  | 40,116                                                        | 88,763                    | (58,548)                  | 30,215                                                        |\n| Indefinite-lived intangible assets |                           |                           |                                                               |                           |                           |                                                               |\n| Brands                             | 827                       |                           | 827                                                           | 827                       |                           | 827                                                           |\n| IPR&D (c)                          | 23,193                    |                           | 23,193                                                        | 11,357                    |                           | 11,357                                                        |\n| Licensing agreements and other     | 763                       |                           | 763                                                           | 971                       |                           | 971                                                           |\n|                                    | 24,784                    |                           | 24,784                                                        | 13,155                    |                           | 13,155                                                        |\n| Identifiable intangible assets (d) | $ 127,728                 | $ (62,828)                | $ 64,900                                                      | $ 101,919                 | $ (58,548)                | $ 43,370                                                      |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 12,
      "question": "How does the change in royalty income reporting classification by PFE in 2024 affect the comparability of royalty income visibility between JNJ and PFE starting in 2024, given that JNJ continues to report royalty income in Other (Income) Expense, Net?",
      "answer": "Starting in 2024, PFE will report royalty income in Total Revenues and will restate prior periods for consistency, whereas JNJ continues to report royalty income in Other (Income) Expense, Net. This change in classification by PFE increases the visibility of royalty income in its financial statements by moving it to a more prominent position under Total Revenues, while JNJ's royalty income remains embedded in a broader net income/expense line item. As a result, beginning in 2024, the visibility and comparability of royalty income between the two companies will differ, with PFE providing more direct transparency into this income stream compared to JNJ.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - JNJ reports royalty income in 'Other (Income) Expense, Net'.",
        "Step 2: Extract from evidence_source_b - PFE will begin reporting royalty income in 'Total Revenues' starting in 2024 and will restate prior periods for consistency.",
        "Step 3: Synthesize - The differing classifications of royalty income between JNJ and PFE post-2024 affect the visibility and comparability of this financial metric across the two companies."
      ],
      "difficulty": "medium",
      "idf_score": 4.964242254526545,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Royalty Income",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_36",
          "chunk_id": "chunk_3",
          "chunk_text": "\nResearch\tand\tdevelopment\tactivities\trepresent\ta\tsignificant\tpart\tof\tthe\tCompany's\tbusiness.\tThese\texpenditures\trelate\tto\tthe\tprocesses of\tdiscovering,\ttesting\tand\tdeveloping\tnew\tproducts,\tupfront\tpayments\tand\tdevelopmental\tmilestones,\timproving\texisting\tproducts,\tas\twell as\tensuring\tproduct\tefficacy\tand\tregulatory\tcompliance\tprior\tto\tlaunch.\tThe\tCompany\tremains\tcommitted\tto\tinvesting\tin\tresearch\tand development\twith\tthe\taim\tof\tdelivering\thigh\tquality\tand\tinnovative\tproducts.\n\nResearch\tand\tDevelopment\twas\tflat\tas\ta\tpercent\tto\tsales\tprimarily\tdriven\tby:\n\n- Higher\tmilestone\tpayments\tin\tthe\tInnovative\tMedicine\tbusiness\n- Acquired\tin-process\tresearch\t&amp;\tdevelopment\tasset\tfrom\tthe\tLaminar\tacquisition\tin\tthe\tMedTech\tbusiness\tin\tthe\tfiscal\tyear\t2023 offset\tby\n- Portfolio\tprioritization\tin\tthe\tInnovative\tMedicine\tbusiness\n\nIn-Process\tResearch\tand\tDevelopment\tImpairments\t(IPR&amp;D): In\tthe\tfiscal\tyear\t2023,\tthe\tCompany\trecorded\ta\tcharge\tof\tapproximately $0.3\tbillion\twhich\tincluded\t$0.2\tbillion\trelated\tto\tmarket\tdynamics\tassociated\twith\ta\tnon-strategic\tasset\t(M710)\tacquired\tas\tpart\tof\tthe acquisition\tof\tMomenta\tPharmaceuticals\tin\t2020,\tIn\tthe\tfiscal\tyear\t2022,\tthe\tCompany\trecorded\tan\tintangible\tasset\timpairment\tcharge\tof approximately\t$0.8\tbillion\trelated\tto\tan\tin-process\tresearch\tand\tdevelopment\tasset,\tbermekimab\t(JnJ-77474462),\tan\tinvestigational\tdrug for\tthe\ttreatment\tof\tAtopic\tDermatitis\t(AD)\tand\tHidradenitis\tSuppurativa\t(HS).\tAdditional\tinformation\tregarding\tefficacy\tof\tthe\tAD indication\tand\tHS\tindication\tbecame\tavailable\twhich\tled\tthe\tCompany\tto\tthe\tdecision\tto\tterminate\tthe\tdevelopment\tof\tbermekimab\tfor\tboth AD\tand\tHS.\tThe\tCompany\tacquired\tall\trights\tto\tbermekimab\tfrom\tXBiotech,\tInc.\tin\tthe\tfiscal\tyear\t2020.\n\nOther\t(Income)\tExpense,\tNet: Other\t(income)\texpense,\tnet\tis\tthe\taccount\twhere\tthe\tCompany\trecords\tgains\tand\tlosses\trelated\tto\tthe\tsale and\twrite-down\tof\tcertain\tinvestments\tin\tequity\tsecurities\theld\tby\tJohnson\t&amp;\tJohnson\tInnovation\t-\tJJDC,\tInc.\t(JJDC),\tchanges\tin\tthe\tfair value\tof\tsecurities,\tinvestment\t(income)/loss\trelated\tto\temployee\tbenefit\tprograms,\tgains\tand\tlosses\ton\tdivestitures,\tcertain transactional\tcurrency\tgains\tand\tlosses,\tacquisition\tand\tdivestiture\trelated\tcosts,\tlitigation\taccruals\tand\tsettlements,\tas\twell\tas royalty\tincome.\n\n## 30",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Royalty_Income",
          "name": "Royalty Income",
          "type": "FIN_METRIC",
          "idf_score": 4.964242254526545
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_38",
          "chunk_id": "chunk_1",
          "chunk_text": "While\troyalty\tincome\tthrough\tDecember\t31,\t2023\thas\tbeen\trecorded\tin Other\tIncome/(Deductions)-net ,\twe\twill\tbegin\treporting\tsuch\troyalty\tincome\tin Total\trevenues beginning\tin\t2024\tand\twill\trestate\tprior\tperiods\tfor\tconsistency\twith\tour\t2024\tpresentation.\tAdditionally,\twe\twill\tno\tlonger\trecord royalties\tfrom\tU.S.\tsales\tof\tBavencio,\tas\twe\thave\tirrevocably\tchosen\tto\tdonate\tthe\tright\tto\tsuch\troyalties\tto\tthe\tAmerican\tAssociation\tfor\tCancer Research.\n\nIncome\tfrom\tContinuing\tOperations\tBefore\tProvision/(Benefit)\tfor\tTaxes\ton\tIncome-The\tdecrease\tin Income\tfrom\tcontinuing\toperations\tbefore provision/(benefit)\tfor\ttaxes\ton\tincome of\t$33.7\tbillion,\tto\t$1.1\tbillion\tin\t2023\tfrom\t$34.7\tbillion\tin\t2022,\twas\tprimarily\tattributable\tto\t(i) lower\trevenues,\t(ii)\thigher\tintangible\tasset\timpairment\tcharges,\tand\t(iii)\tincreases\tin Restructuring\tcharges\tand\tcertain\tacquisition-related\tcosts , Amortization\tof\tintangible\tassets ,\tand Selling,\tinformational\tand\tadministrative\texpenses, partially\toffset\tby\t(iv)\ta\tdecrease\tin Cost\tof\tsales and (v)\tnet\tgains\ton\tequity\tsecurities\tin\t2023\tversus\tnet\tlosses\ton\tequity\tsecurities\tin\t2022 .\n\nSee the Analysis\tof\tthe\tConsolidated\tStatements\tof\tIncome section\twithin\tMD&amp;A\tand Note\t4 .\tFor\tinformation\ton\tour\ttax\tprovision\tand\teffective\ttax rate,\tsee\tthe Provision/(Benefit)\tfor\tTaxes\ton\tIncome section\twithin\tMD&amp;A\tand Note\t5 .\n\nOur\tOperating\tEnvironment --We,\tlike\tother\tbusinesses\tin\tour\tindustry,\tare\tsubject\tto\tcertain\tindustry-specific\tchallenges.\tThese\tinclude,\tamong others,\tthe\ttopics\tlisted\tbelow.\tSee\talso\tthe Item\t1.\tBusiness--Government\tRegulation\tand\tPrice\tConstraints and Item\t1A.\tRisk\tFactors sections.\n\nRegulatory\tEnvironment--Pipeline\tProductivity-Our\tproduct\tlines\tmust\tbe\treplenished\tover\ttime\tto\toffset\trevenue\tlosses\twhen\tproducts\tlose exclusivity\tor\tmarket\tshare\tor\tto\trespond\tto\thealthcare\tand\tinnovation\ttrends,\tas\twell\tas\tto\tprovide\tfor\tearnings\tgrowth,\tprimarily\tthrough\tinternal R&amp;D\tor\tthrough\tcollaborations,\tacquisitions,\tJVs,\tlicensing\tor\tother\tarrangements.\tAs\ta\tresult,\twe\tdevote\tconsiderable\tresources\tto\tour\tR&amp;D activities\twhich,\twhile\tessential\tto\tour\tgrowth,\tincorporate\ta\thigh\tdegree\tof\trisk\tand\tcost,\tincluding\twhether\ta\tparticular\tproduct\tcandidate\tor\tnew indication\tfor\tan\tin-line\tproduct\twill\tachieve\tthe\tdesired\tclinical\tendpoint\tor\tsafety\tprofile,\twill\tbe\tapproved\tby\tregulators\tor\twill\tbe\tsuccessful commercially.\tClinical\ttrials\tare\tconducted\tto\tdetermine,\tamong\tother\tthings,\twhether\tan\tinvestigational\tdrug,\tvaccine\tor\tdevice\tis\tsafe\tand effective\tfor\ta\tparticular\tpatient\tpopulation.\tAfter\ta\tproduct\thas\tbeen\tapproved\tor\tauthorized\tand\tlaunched,\twe\tcontinue\tto\tmonitor\tits\tsafety\tas long\tas\tit\tis\tavailable\tto\tpatients,\tincluding\tconducting\tpostmarketing\ttrials,\tvoluntarily\tor\tpursuant\tto\ta\tregulatory\trequest.\tFor\tthe\tentire\tlife of\tthe\tproduct,\twe\tcollect\tsafety\tdata\tand\treport\tsafety\tinformation\tto\tthe\tFDA\tand\tother\tregulators.\tRegulatory\tauthorities\tevaluate\tpotential safety\tconcerns\tand\ttake\tany\tregulatory\taction\tdeemed\tnecessary\tand\tappropriate.\tSuch\taction(s)\tmay\tinclude:\tupdating\ta\tproduct's\tlabeling, restricting\tits\tuse,\tcommunicating\tnew\tsafety\tinformation\tor,\tin\trare\tcases,\tseeking\tto\tsuspend\tor\tremove\ta\tproduct\tfrom\tthe\tmarket.\n\nIntellectual\tProperty\tRights\tand\tCollaboration/Licensing\tRights-The\tloss,\texpiration\tor\tinvalidation\tof\tintellectual\tproperty\trights,\tpatent litigation\tsettlements\tand\tjudgments,\tand\tthe\texpiration\tof\tco-promotion\tand\tlicensing\trights\tcan\thave\ta\tmaterial\tadverse\teffect\ton\tour\trevenues. Certain\tof\tour\tproducts\thave\texperienced\tpatent-based\texpirations\tor\tloss\tof\tregulatory\texclusivity\tin\tcertain\tmarkets\tin\tthe\tlast\tfew\tyears,\tand\twe expect\tcertain\tproducts\tto\tface\tincreased\tgeneric\tcompetition\tover\tthe\tnext\tfew\tyears.\tWhile\tadditional\tpatent\texpiries\twill\tcontinue,\twe\texpect\ta moderate\timpact\tof\treduced\trevenues\tdue\tto\tpatent\texpiries\tfrom\t2024\tthrough\t2025.\tWe\tanticipate\ta\tmore\tsignificant\timpact\tof\treduced\trevenues\tfrom patent\texpiries\tin\t2026\tthrough\t2030\tas\tseveral\tof\tour\tin-line\tproducts\texperience\tpatent-based\texpirations.\tWe\tcontinue\tto\tvigorously\tdefend\tour patent\trights\tagainst\tinfringement,\tand\twe\twill\tcontinue\tto\tsupport\tefforts\tthat\tstrengthen\tworldwide\trecognition\tof\tpatent\trights\twhile\ttaking necessary\tsteps\tto\thelp\tensure\tappropriate\tpatient\taccess.\n\nFor\tadditional\tinformation\ton\tpatent\trights\twe\tconsider\tmost\tsignificant\tto\tour\tbusiness\tas\ta\twhole,\tsee\tthe Item\t1.\tBusiness--Patents\tand\tOther Intellectual\tProperty\tRights section.\tFor\ta\tdiscussion\tof\trecent\tdevelopments\twith\trespect\tto\tpatent\tlitigation,\tsee Note\t16A1.\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 13,
      "question": "How do the risks related to licensing agreements and external innovation strategies impact J&J's ability to grow, and how does this contrast with Pfizer's approach to biosimilar opportunities involving potential litigation and licensing agreements?",
      "answer": "J&J faces challenges in realizing growth through externally sourced innovations such as licensing and marketing agreements, which are highlighted as a key risk in their 10-K filing. These risks include the potential for increased costs of external arrangements due to competitive pressures, which could hinder J&J's ability to achieve its strategic growth objectives. In contrast, Pfizer actively pursues biosimilar opportunities that may involve litigation and licensing agreements. For example, Pfizer engages in disputes over patent infringement related to products like Abrysvo, Comirnaty, and Paxlovid, which could delay product launches or result in significant royalty payments. This highlights a strategic difference: while J&J emphasizes the risks of external innovation, Pfizer takes a more aggressive stance by entering markets 'at-risk' even amid unresolved legal proceedings. The combined analysis shows how both companies navigate licensing and intellectual property challenges in pursuit of growth, but with differing risk appetites and strategic approaches.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - J&J's 10-K highlights risks related to externally sourced innovations, such as licensing and marketing agreements, and the potential for increased costs due to competitive pressures.",
        "Step 2: Extract from evidence_source_b - Pfizer's 10-K discusses its strategy of pursuing biosimilar opportunities, which may involve litigation and licensing agreements, as seen in disputes related to Abrysvo, Comirnaty, and Paxlovid.",
        "Step 3: Synthesize - J&J's risk focus contrasts with Pfizer's active engagement in biosimilar opportunities, showing how both companies approach licensing agreements but with different strategic implications for growth and risk management."
      ],
      "difficulty": "medium",
      "idf_score": 4.964242254526545,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Faces]-> FIN_METRIC <-[Enters]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Licensing Agreements",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_5",
          "chunk_id": "chunk_1",
          "chunk_text": "- Increased\tscrutiny\tof\tthe\thealthcare\tindustry\tby\tgovernment\tagencies\tand\tstate\tattorneys\tgeneral\tresulting\tin\tinvestigations\tand prosecutions,\twhich\tcarry\tthe\trisk\tof\tsignificant\tcivil\tand\tcriminal\tpenalties,\tincluding,\tbut\tnot\tlimited\tto,\tdebarment\tfrom government\tbusiness;\n- Failure\tto\tmeet\tcompliance\tobligations\tin\tcompliance\tagreements\twith\tgovernments\tor\tgovernment\tagencies,\twhich\tcould\tresult\tin significant\tsanctions;\n- Potential\tchanges\tto\tapplicable\tlaws\tand\tregulations\taffecting\tUnited\tStates\tand\tinternational\toperations,\tincluding\trelating\tto: approval\tof\tnew\tproducts;\tlicensing\tand\tpatent\trights;\tsales\tand\tpromotion\tof\thealthcare\tproducts;\taccess\tto,\tand\treimbursement\tand pricing\tfor,\thealthcare\tproducts\tand\tservices;\tenvironmental\tprotection;\tand\tsourcing\tof\traw\tmaterials;\n- Compliance\twith\tlocal\tregulations\tand\tlaws\tthat\tmay\trestrict\tthe\tCompany's\tability\tto\tmanufacture\tor\tsell\tits\tproducts\tin\trelevant markets,\tincluding\trequirements\tto\tcomply\twith\tmedical\tdevice\treporting\tregulations\tand\tother\trequirements\tsuch\tas\tthe\tEuropean Union's\tMedical\tDevices\tRegulation;\n- Changes\tin\tdomestic\tand\tinternational\ttax\tlaws\tand\tregulations,\tincreasing\taudit\tscrutiny\tby\ttax\tauthorities\taround\tthe\tworld\tand exposures\tto\tadditional\ttax\tliabilities\tpotentially\tin\texcess\tof\texisting\treserves;\tand\n- The\tissuance\tof\tnew\tor\trevised\taccounting\tstandards\tby\tthe\tFinancial\tAccounting\tStandards\tBoard\tand\tregulations\tby\tthe\tSecurities\tand Exchange\tCommission.\n\n## Risks\trelated\tto\tthe\tCompany's\tstrategic\tinitiatives,\thealthcare\tmarket\ttrends\tand\tthe\trealization\tof\tbenefits\tfrom\tthe\tseparation\tof the\tCompany's\tConsumer\tHealth\tBusiness\n\n- Pricing\tpressures\tresulting\tfrom\ttrends\ttoward\thealthcare\tcost\tcontainment,\tincluding\tthe\tcontinued\tconsolidation\tamong\thealthcare providers\tand\tother\tmarket\tparticipants,\ttrends\ttoward\tmanaged\tcare,\tthe\tshift\ttoward\tgovernments\tincreasingly\tbecoming\tthe\tprimary payors\tof\thealthcare\texpenses,\tsignificant\tnew\tentrants\tto\tthe\thealthcare\tmarkets\tseeking\tto\treduce\tcosts\tand\tgovernment\tpressure\ton companies\tto\tvoluntarily\treduce\tcosts\tand\tprice\tincreases;\n- Restricted\tspending\tpatterns\tof\tindividual,\tinstitutional\tand\tgovernmental\tpurchasers\tof\thealthcare\tproducts\tand\tservices\tdue\tto economic\thardship\tand\tbudgetary\tconstraints;\n- Challenges\tto\tthe\tCompany's\tability\tto\trealize\tits\tstrategy\tfor\tgrowth\tincluding\tthrough\texternally\tsourced\tinnovations,\tsuch\tas development\tcollaborations,\tstrategic\tacquisitions,\tlicensing\tand\tmarketing\tagreements,\tand\tthe\tpotential\theightened\tcosts\tof\tany\tsuch external\tarrangements\tdue\tto\tcompetitive\tpressures;\n- The\tpotential\tthat\tthe\texpected\tstrategic\tbenefits\tand\topportunities\tfrom\tany\tplanned\tor\tcompleted\tacquisition\tor\tdivestiture\tby\tthe Company\tmay\tnot\tbe\trealized\tor\tmay\ttake\tlonger\tto\trealize\tthan\texpected;\n- The\tpotential\tthat\tthe\texpected\tbenefits\tand\topportunities\trelated\tto\tpast\tand\tongoing\trestructuring\tactions\tmay\tnot\tbe\trealized\tor may\ttake\tlonger\tto\trealize\tthan\texpected;\n- The\tCompany's\tability\tto\tdivest\tthe\tCompany's\tremaining\townership\tinterest\tin\tKenvue\tInc.\t(Kenvue)\tand\trealize\tthe\tanticipated benefits\tfrom\tthe\tseparation;\tand\n- Kenvue's\tability\tto\tsucceed\tas\ta\tstandalone\tpublicly\ttraded\tcompany.\n\n## Risks\trelated\tto\teconomic\tconditions,\tfinancial\tmarkets\tand\toperating\tinternationally\n\n- The\trisks\tassociated\twith\tglobal\toperations\ton\tthe\tCompany\tand\tits\tcustomers\tand\tsuppliers,\tincluding\tforeign\tgovernments\tin\tcountries in\twhich\tthe\tCompany\toperates;\n\n\u2022\n\nThe\timpact\tof\tinflation\tand\tfluctuations\tin\tinterest\trates\tand\tcurrency\texchange\trates\tand\tthe\tpotential\teffect\tof\tsuch\tfluctuations on\trevenues,\texpenses\tand\tresulting\tmargins;\n\n- Potential\tchanges\tin\texport/import\tand\ttrade\tlaws,\tregulations\tand\tpolicies\tof\tthe\tUnited\tStates\tand\tother\tcountries,\tincluding\tany increased\ttrade\trestrictions\tor\ttariffs\tand\tpotential\tdrug\treimportation\tlegislation;\n- The\timpact\ton\tinternational\toperations\tfrom\tfinancial\tinstability\tin\tinternational\teconomies,\tsovereign\trisk,\tpossible\timposition\tof governmental\tcontrols\tand\trestrictive\teconomic\tpolicies,\tand\tunstable\tinternational\tgovernments\tand\tlegal\tsystems;\n- The\timpact\tof\tglobal\tpublic\thealth\tcrises\tand\tpandemics;",
          "relationship": "Faces"
        },
        "intermediate_node": {
          "id": "Licensing_Agreements",
          "name": "Licensing Agreements",
          "type": "FIN_METRIC",
          "idf_score": 4.964242254526545
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_28",
          "chunk_id": "chunk_2",
          "chunk_text": "Part\tof\tour\tbusiness\tdepends\tupon\tidentifying\tbiosimilar\topportunities\tand\tlaunching\tproducts\tto\ttake\tadvantage\tof\tthose\topportunities,\twhich\tmay involve\tlitigation,\tassociated\tcosts\tand\ttime\tdelays,\tand\tmay\tultimately\tnot\tbe\tsuccessful.\tThese\topportunities\tmay\tarise\tin\tsituations\twhere\tpatent protection\tof\tequivalent\tbranded\tproducts\thas\texpired\tor\tbeen\tdeclared\tinvalid,\tor\twhere\tproducts\tdo\tnot\tinfringe\tthe\tpatents\tof\tothers.\tIn\tsome circumstances\twe\tmay\ttake\taction,\tsuch\tas\tlitigation,\tasserting\tthat\tour\tproducts\tdo\tnot\tinfringe\tpatents\tof\texisting\tproducts\tor\tthat\tthose\tpatents are\tinvalid\tor\tunenforceable\tin\torder\tto\tachieve\ta\t'first-to-market'\tor\tearly\tmarket\tposition\tfor\tour\tproducts.\n\nThird\tparties\tmay\tclaim\tthat\tour\tproducts\tinfringe\tone\tor\tmore\tpatents\towned\tor\tcontrolled\tby\tthem.\tClaims\tof\tintellectual\tproperty\tinfringement\tcan be\tcostly\tand\ttime-consuming\tto\tresolve,\tmay\tdelay\tor\tprevent\tproduct\tlaunches,\tand\tmay\tresult\tin\tsignificant\troyalty\tpayments\tor\tdamages\tor potential\tlicensing\tagreements.\tFor\texample,\tour\tR&amp;D\tin\ta\ttherapeutic\tarea\tmay\tnot\tbe\tfirst\tand\tanother\tcompany\tor\tentity\tmay\thave\tobtained\trelevant patents\tbefore\tus.\tWe\tare\tinvolved\tin\tpatent-related\tdisputes\twith\tthird\tparties\tover\tour\tattempts\tto\tmarket\tpharmaceutical\tproducts,\tincluding related\tto\tAbrysvo,\tComirnaty\tand\tPaxlovid.\tAs\twe\texpand\tour\tmRNA\tportfolio,\tpatent-related\tdisputes\tmay\tincrease.\tOnce\twe\thave\tfinal\tregulatory approval\tof\tthe\trelated\tproducts,\twe\tmay\tdecide\tto\tcommercially\tmarket\tthese\tproducts\teven\tthough\tassociated\tlegal\tproceedings\t(including\tany appeals)\thave\tnot\tbeen\tresolved\t(i.e.,\t'at-risk'\tlaunch).\tIf\tone\tof\tour\tmarketed\tproducts\t(or\ta\tproduct\tof\tour\n\nPfizer\tInc.\n\n2023\tForm\t10-K\n\n22",
          "relationship": "Enters"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 43
    },
    {
      "question_id": 14,
      "question": "How did Johnson & Johnson's restructuring of the Consumer Health business impact its financial position in relation to the Pharmaceuticals segment, and how might this contrast with Pfizer's financial activities in the same sector?",
      "answer": "Johnson & Johnson's restructuring of its Consumer Health business through the Kenvue IPO and subsequent exchange offer resulted in a significant shift in its financial position, reducing its ownership from 89.6% to 9.5% and generating $4.2 billion in net proceeds, with $2.5 billion recorded to additional paid-in capital. This move allowed J&J to focus more on its Pharmaceuticals segment within the Innovative Medicine business. In contrast, Pfizer\u2019s financial activities in the Pharmaceuticals sector, as shown in its Consolidated Statements of Cash Flows, reflect ongoing investments and operations in this space, though specific figures are not provided in the excerpt. This comparison highlights differing strategic approaches to managing pharmaceutical assets within the healthcare sector.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - Johnson & Johnson completed the Kenvue IPO and exchange offer, reducing ownership from 89.6% to 9.5%, generating $4.2 billion in net proceeds, with $2.5 billion recorded to additional paid-in capital.",
        "Step 2: Extract from evidence_source_b - Pfizer\u2019s Consolidated Statements of Cash Flows show financial activities related to its operations in the Pharmaceuticals sector, although specific figures are not detailed.",
        "Step 3: Synthesize - J&J's restructuring reflects a strategic pivot away from Consumer Health to focus on Pharmaceuticals, while Pfizer continues to operate and invest in Pharmaceuticals, though the lack of detailed figures in Pfizer\u2019s excerpt limits deeper financial comparison."
      ],
      "difficulty": "medium",
      "idf_score": 4.78192069773259,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Pharmaceuticals",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_56",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes\tto\tConsolidated\tFinancial\tStatements\n\n## 1.\tSummary\tof\tsignificant\taccounting\tpolicies\n\n## Principles\tof\tconsolidation\n\nThe\tconsolidated\tfinancial\tstatements\tinclude\tthe\taccounts\tof\tJohnson\t&amp;\tJohnson\tand\tits\tsubsidiaries\t(the\tCompany).\tIntercompany accounts\tand\ttransactions\tare\teliminated.\tColumns\tand\trows\twithin\ttables\tmay\tnot\tadd\tdue\tto\trounding.\tPercentages\thave\tbeen\tcalculated using\tactual,\tnon-rounded\tfigures.\n\n## Description\tof\tthe\tcompany\tand\tbusiness\tsegments\n\nThe\tCompany\thas\tapproximately\t131,900\temployees\tworldwide\tengaged\tin\tthe\tresearch\tand\tdevelopment,\tmanufacture\tand\tsale\tof\ta\tbroad\trange of\tproducts\tin\tthe\thealthcare\tfield.\tThe\tCompany\tconducts\tbusiness\tin\tvirtually\tall\tcountries\tof\tthe\tworld\tand\tits\tprimary\tfocus\tis\ton products\trelated\tto\thuman\thealth\tand\twell-being.\n\n## Kenvue\tIPO/separation\tand\tdiscontinued\toperations\n\nOn\tMay\t8,\t2023,\tKenvue,\tcompleted\tan\tinitial\tpublic\toffering\t(the\tIPO)\tresulting\tin\tthe\tissuance\tof\t198,734,444\tshares\tof\tits\tcommon stock,\tpar\tvalue\t$0.01\tper\tshare\t(the\t'Kenvue\tCommon\tStock'),\tat\tan\tinitial\tpublic\toffering\tof\t$22.00\tper\tshare\tfor\tnet\tproceeds\tof $4.2\tbillion.\tThe\texcess\tof\tthe\tnet\tproceeds\tfrom\tthe\tIPO\tover\tthe\tnet\tbook\tvalue\tof\tthe\tJohnson\t&amp;\tJohnson\tdivested\tinterest\twas $2.5\tbillion\tand\twas\trecorded\tto\tadditional\tpaid-in\tcapital.\tAs\tof\tthe\tclosing\tof\tthe\tIPO,\tJohnson\t&amp;\tJohnson\towned\tapproximately\t89.6% of\tthe\ttotal\toutstanding\tshares\tof\tKenvue\tCommon\tStock\tand\tat\tJuly\t2,\t2023,\tthe\tnon-controlling\tinterest\tof\t$1.3\tbillion\tassociated\twith Kenvue\twas\treflected\tin\tequity\tattributable\tto\tnon-controlling\tinterests\tin\tthe\tconsolidated\tbalance\tsheet\tin\tthe\tfiscal\tsecond\tquarter of\t2023.\n\nOn\tAugust\t23,\t2023,\tJohnson\t&amp;\tJohnson\tcompleted\tthe\tdisposition\tof\tan\tadditional\t80.1%\townership\tof\tthe\tshares\tof\tKenvue\tthrough\tan exchange\toffer.\tFollowing\tthe\texchange\toffer,\tthe\tCompany\towns\t9.5%\tof\tthe\tshares\tof\tKenvue\twhich\tare\taccounted\tfor\tas\tan\tequity investment\tcarried\tat\tfair\tvalue\twithin\tcontinuing\toperations.\tThe\thistorical\tresults\tof\tthe\tConsumer\tHealth\tbusiness\t(which\tpreviously represented\tthe\tConsumer\tHealth\tbusiness\tsegment)\tare\treflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tConsolidated\tFinancial Statements\tthrough\tthe\tdate\tof\tthe\texchange\toffer\t(see\tNote\t21\tfor\tadditional\tdetails).\tUnless\totherwise\tindicated,\tthe\tinformation\tin the\tnotes\tto\tthe\tConsolidated\tFinancial\tStatements\trefer\tonly\tto\tJohnson\t&amp;\tJohnson's\tcontinuing\toperations.\n\n## Business\tsegments\n\nFollowing\tthe\tcompletion\tof\tthe\texchange\toffer,\tthe\tCompany\tis\torganized\tinto\ttwo\tbusiness\tsegments:\tInnovative\tMedicine\tand\tMedTech. The\tInnovative\tMedicine\tsegment\tis\tfocused\ton\tthe\tfollowing\ttherapeutic\tareas,\tincluding\tImmunology,\tInfectious\tdiseases,\tNeuroscience, Oncology,\tPulmonary\tHypertension,\tand\tCardiovascular\tand\tMetabolic\tdiseases.\tProducts\tin\tthis\tsegment\tare\tdistributed\tdirectly\tto retailers,\twholesalers,\tdistributors,\thospitals\tand\thealthcare\tprofessionals\tfor\tprescription\tuse.\tThe\tMedTech\tsegment\tincludes\ta\tbroad portfolio\tof\tproducts\tused\tin\tthe\tOrthopaedic,\tSurgery,\tInterventional\tSolutions\tand\tVision\tfields.\tThese\tproducts\tare\tdistributed\tto wholesalers,\thospitals\tand\tretailers,\tand\tused\tprincipally\tin\tthe\tprofessional\tfields\tby\tphysicians,\tnurses,\thospitals,\teye\tcare professionals\tand\tclinics.\n\n## New\taccounting\tstandards\n\n## Recently\tadopted\taccounting\tstandards\n\nASU\t2022-04:\tLiabilities-Supplier\tFinance\tPrograms\t(Topic\t405-50)\t-\tDisclosure\tof\tSupplier\tFinance\tProgram\tObligations\n\nThe\tCompany\tadopted\tthe\tstandard\tas\tof\tthe\tbeginning\tof\tfiscal\tyear\t2023,\twhich\trequires\tthat\ta\tbuyer\tin\ta\tsupplier\tfinance\tprogram disclose\tadditional\tinformation\tabout\tthe\tprogram\tfor\tfinancial\tstatement\tusers.\n\nThe\tCompany\thas\tagreements\tfor\tsupplier\tfinance\tprograms\twith\tthird-party\tfinancial\tinstitutions.\tThese\tprograms\tprovide\tparticipating suppliers\tthe\tability\tto\tfinance\tpayment\tobligations\tfrom\tthe\tCompany\twith\tthe\tthird-party\tfinancial\tinstitutions.\tThe\tCompany\tis\tnot\ta party\tto\tthe\tarrangements\tbetween\tthe\tsuppliers\tand\tthe\tthird-party\tfinancial\tinstitutions.\tThe\tCompany's\tobligations\tto\tits\tsuppliers, including\tamounts\tdue,\tand\tscheduled\tpayment\tdates\t(which\thave\tgeneral\tpayment\tterms\tof\t90\tdays),\tare\tnot\taffected\tby\ta\tparticipating supplier's\tdecision\tto\tparticipate\tin\tthe\tprogram.\n\n## 50",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Pharmaceuticals",
          "name": "Pharmaceuticals",
          "type": "SEGMENT",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_63",
          "chunk_id": "chunk_1",
          "chunk_text": "## Consolidated\tStatements\tof\tCash\tFlows\n\nPfizer\tInc.\tand\tSubsidiary\tCompanies\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 15,
      "question": "How did Johnson & Johnson's restructuring of its Consumer Health business through the Kenvue IPO and exchange offer impact Pfizer's stake in the pharmaceuticals segment, and what was the financial value of Johnson & Johnson's retained interest following the transaction?",
      "answer": "Johnson & Johnson completed the Kenvue IPO, generating $4.2 billion in net proceeds, and later completed an exchange offer to divest an additional 80.1% ownership in Kenvue. Following the exchange offer, Johnson & Johnson retained 9.5% ownership in Kenvue, which was accounted for as an equity investment carried at fair value. Pfizer, having a stake in the pharmaceuticals segment, would be indirectly affected as Kenvue's separation restructured the ownership and equity dynamics within the consumer health pharmaceuticals space. The retained interest by Johnson & Johnson was valued at $1.3 billion as non-controlling interest in Kenvue at the time of the exchange offer.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - Johnson & Johnson completed the Kenvue IPO, generating $4.2 billion in net proceeds and retained 89.6% ownership post-IPO.",
        "Step 2: Extract from evidence_source_a - Johnson & Johnson later completed an exchange offer to divest 80.1% of Kenvue, leaving it with 9.5% ownership, valued at fair value as an equity investment.",
        "Step 3: Extract from evidence_source_a - The non-controlling interest in Kenvue was $1.3 billion post-IPO and before the exchange offer.",
        "Step 4: Synthesize - Pfizer, having a stake in the pharmaceuticals segment, would be indirectly affected by the restructuring of Kenvue, as ownership dynamics and equity positions in related pharmaceutical entities shift.",
        "Step 5: Calculate - The financial value of Johnson & Johnson's retained interest in Kenvue was $1.3 billion post-divestiture."
      ],
      "difficulty": "medium",
      "idf_score": 4.78192069773259,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Pharmaceuticals",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_56",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes\tto\tConsolidated\tFinancial\tStatements\n\n## 1.\tSummary\tof\tsignificant\taccounting\tpolicies\n\n## Principles\tof\tconsolidation\n\nThe\tconsolidated\tfinancial\tstatements\tinclude\tthe\taccounts\tof\tJohnson\t&amp;\tJohnson\tand\tits\tsubsidiaries\t(the\tCompany).\tIntercompany accounts\tand\ttransactions\tare\teliminated.\tColumns\tand\trows\twithin\ttables\tmay\tnot\tadd\tdue\tto\trounding.\tPercentages\thave\tbeen\tcalculated using\tactual,\tnon-rounded\tfigures.\n\n## Description\tof\tthe\tcompany\tand\tbusiness\tsegments\n\nThe\tCompany\thas\tapproximately\t131,900\temployees\tworldwide\tengaged\tin\tthe\tresearch\tand\tdevelopment,\tmanufacture\tand\tsale\tof\ta\tbroad\trange of\tproducts\tin\tthe\thealthcare\tfield.\tThe\tCompany\tconducts\tbusiness\tin\tvirtually\tall\tcountries\tof\tthe\tworld\tand\tits\tprimary\tfocus\tis\ton products\trelated\tto\thuman\thealth\tand\twell-being.\n\n## Kenvue\tIPO/separation\tand\tdiscontinued\toperations\n\nOn\tMay\t8,\t2023,\tKenvue,\tcompleted\tan\tinitial\tpublic\toffering\t(the\tIPO)\tresulting\tin\tthe\tissuance\tof\t198,734,444\tshares\tof\tits\tcommon stock,\tpar\tvalue\t$0.01\tper\tshare\t(the\t'Kenvue\tCommon\tStock'),\tat\tan\tinitial\tpublic\toffering\tof\t$22.00\tper\tshare\tfor\tnet\tproceeds\tof $4.2\tbillion.\tThe\texcess\tof\tthe\tnet\tproceeds\tfrom\tthe\tIPO\tover\tthe\tnet\tbook\tvalue\tof\tthe\tJohnson\t&amp;\tJohnson\tdivested\tinterest\twas $2.5\tbillion\tand\twas\trecorded\tto\tadditional\tpaid-in\tcapital.\tAs\tof\tthe\tclosing\tof\tthe\tIPO,\tJohnson\t&amp;\tJohnson\towned\tapproximately\t89.6% of\tthe\ttotal\toutstanding\tshares\tof\tKenvue\tCommon\tStock\tand\tat\tJuly\t2,\t2023,\tthe\tnon-controlling\tinterest\tof\t$1.3\tbillion\tassociated\twith Kenvue\twas\treflected\tin\tequity\tattributable\tto\tnon-controlling\tinterests\tin\tthe\tconsolidated\tbalance\tsheet\tin\tthe\tfiscal\tsecond\tquarter of\t2023.\n\nOn\tAugust\t23,\t2023,\tJohnson\t&amp;\tJohnson\tcompleted\tthe\tdisposition\tof\tan\tadditional\t80.1%\townership\tof\tthe\tshares\tof\tKenvue\tthrough\tan exchange\toffer.\tFollowing\tthe\texchange\toffer,\tthe\tCompany\towns\t9.5%\tof\tthe\tshares\tof\tKenvue\twhich\tare\taccounted\tfor\tas\tan\tequity investment\tcarried\tat\tfair\tvalue\twithin\tcontinuing\toperations.\tThe\thistorical\tresults\tof\tthe\tConsumer\tHealth\tbusiness\t(which\tpreviously represented\tthe\tConsumer\tHealth\tbusiness\tsegment)\tare\treflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tConsolidated\tFinancial Statements\tthrough\tthe\tdate\tof\tthe\texchange\toffer\t(see\tNote\t21\tfor\tadditional\tdetails).\tUnless\totherwise\tindicated,\tthe\tinformation\tin the\tnotes\tto\tthe\tConsolidated\tFinancial\tStatements\trefer\tonly\tto\tJohnson\t&amp;\tJohnson's\tcontinuing\toperations.\n\n## Business\tsegments\n\nFollowing\tthe\tcompletion\tof\tthe\texchange\toffer,\tthe\tCompany\tis\torganized\tinto\ttwo\tbusiness\tsegments:\tInnovative\tMedicine\tand\tMedTech. The\tInnovative\tMedicine\tsegment\tis\tfocused\ton\tthe\tfollowing\ttherapeutic\tareas,\tincluding\tImmunology,\tInfectious\tdiseases,\tNeuroscience, Oncology,\tPulmonary\tHypertension,\tand\tCardiovascular\tand\tMetabolic\tdiseases.\tProducts\tin\tthis\tsegment\tare\tdistributed\tdirectly\tto retailers,\twholesalers,\tdistributors,\thospitals\tand\thealthcare\tprofessionals\tfor\tprescription\tuse.\tThe\tMedTech\tsegment\tincludes\ta\tbroad portfolio\tof\tproducts\tused\tin\tthe\tOrthopaedic,\tSurgery,\tInterventional\tSolutions\tand\tVision\tfields.\tThese\tproducts\tare\tdistributed\tto wholesalers,\thospitals\tand\tretailers,\tand\tused\tprincipally\tin\tthe\tprofessional\tfields\tby\tphysicians,\tnurses,\thospitals,\teye\tcare professionals\tand\tclinics.\n\n## New\taccounting\tstandards\n\n## Recently\tadopted\taccounting\tstandards\n\nASU\t2022-04:\tLiabilities-Supplier\tFinance\tPrograms\t(Topic\t405-50)\t-\tDisclosure\tof\tSupplier\tFinance\tProgram\tObligations\n\nThe\tCompany\tadopted\tthe\tstandard\tas\tof\tthe\tbeginning\tof\tfiscal\tyear\t2023,\twhich\trequires\tthat\ta\tbuyer\tin\ta\tsupplier\tfinance\tprogram disclose\tadditional\tinformation\tabout\tthe\tprogram\tfor\tfinancial\tstatement\tusers.\n\nThe\tCompany\thas\tagreements\tfor\tsupplier\tfinance\tprograms\twith\tthird-party\tfinancial\tinstitutions.\tThese\tprograms\tprovide\tparticipating suppliers\tthe\tability\tto\tfinance\tpayment\tobligations\tfrom\tthe\tCompany\twith\tthe\tthird-party\tfinancial\tinstitutions.\tThe\tCompany\tis\tnot\ta party\tto\tthe\tarrangements\tbetween\tthe\tsuppliers\tand\tthe\tthird-party\tfinancial\tinstitutions.\tThe\tCompany's\tobligations\tto\tits\tsuppliers, including\tamounts\tdue,\tand\tscheduled\tpayment\tdates\t(which\thave\tgeneral\tpayment\tterms\tof\t90\tdays),\tare\tnot\taffected\tby\ta\tparticipating supplier's\tdecision\tto\tparticipate\tin\tthe\tprogram.\n\n## 50",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Pharmaceuticals",
          "name": "Pharmaceuticals",
          "type": "SEGMENT",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes\tto\tConsolidated\tFinancial\tStatements\n\nPfizer\tInc.\tand\tSubsidiary\tCompanies\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 16,
      "question": "How did Johnson & Johnson's separation of Kenvue and Pfizer's stake in the broader pharmaceutical segment influence Johnson & Johnson's financial structure and strategic focus in the healthcare market?",
      "answer": "Johnson & Johnson's separation of Kenvue through an IPO and subsequent exchange offer reduced its ownership from 89.6% to 9.5%, resulting in a significant shift in its financial structure. The IPO generated $4.2 billion in net proceeds, with $2.5 billion recorded as additional paid-in capital, and the non-controlling interest associated with Kenvue was $1.3 billion at July 2, 2023. Following the transaction, Johnson & Johnson reorganized into two business segments: Innovative Medicine and MedTech, focusing on high-growth therapeutic areas and medical devices. Pfizer\u2019s stake in the broader pharmaceutical segment implies competitive or collaborative dynamics within the same industry, which could influence Johnson & Johnson\u2019s strategic positioning and R&D investments in therapeutic areas like Immunology, Oncology, and Neuroscience. This reorganization and stake shift reflect a strategic refocusing on core, innovative pharmaceutical and medical technology offerings, while reducing emphasis on the consumer health segment.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - Johnson & Johnson completed the disposition of Kenvue through an IPO and exchange offer, reducing its ownership from 89.6% to 9.5%, generating $4.2 billion in net proceeds, with $2.5 billion recorded as additional paid-in capital and $1.3 billion non-controlling interest.",
        "Step 2: Extract from evidence_source_b - Pfizer has a stake in the pharmaceutical segment, indicating its involvement in the same therapeutic areas as Johnson & Johnson.",
        "Step 3: Synthesize - The financial proceeds and equity adjustments from Kenvue\u2019s separation allowed Johnson & Johnson to restructure its business around Innovative Medicine and MedTech, while Pfizer\u2019s presence in the pharmaceutical segment suggests competitive or collaborative dynamics that may influence Johnson & Johnson\u2019s strategic focus in key therapeutic areas."
      ],
      "difficulty": "medium",
      "idf_score": 4.78192069773259,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Pharmaceuticals",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_56",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes\tto\tConsolidated\tFinancial\tStatements\n\n## 1.\tSummary\tof\tsignificant\taccounting\tpolicies\n\n## Principles\tof\tconsolidation\n\nThe\tconsolidated\tfinancial\tstatements\tinclude\tthe\taccounts\tof\tJohnson\t&amp;\tJohnson\tand\tits\tsubsidiaries\t(the\tCompany).\tIntercompany accounts\tand\ttransactions\tare\teliminated.\tColumns\tand\trows\twithin\ttables\tmay\tnot\tadd\tdue\tto\trounding.\tPercentages\thave\tbeen\tcalculated using\tactual,\tnon-rounded\tfigures.\n\n## Description\tof\tthe\tcompany\tand\tbusiness\tsegments\n\nThe\tCompany\thas\tapproximately\t131,900\temployees\tworldwide\tengaged\tin\tthe\tresearch\tand\tdevelopment,\tmanufacture\tand\tsale\tof\ta\tbroad\trange of\tproducts\tin\tthe\thealthcare\tfield.\tThe\tCompany\tconducts\tbusiness\tin\tvirtually\tall\tcountries\tof\tthe\tworld\tand\tits\tprimary\tfocus\tis\ton products\trelated\tto\thuman\thealth\tand\twell-being.\n\n## Kenvue\tIPO/separation\tand\tdiscontinued\toperations\n\nOn\tMay\t8,\t2023,\tKenvue,\tcompleted\tan\tinitial\tpublic\toffering\t(the\tIPO)\tresulting\tin\tthe\tissuance\tof\t198,734,444\tshares\tof\tits\tcommon stock,\tpar\tvalue\t$0.01\tper\tshare\t(the\t'Kenvue\tCommon\tStock'),\tat\tan\tinitial\tpublic\toffering\tof\t$22.00\tper\tshare\tfor\tnet\tproceeds\tof $4.2\tbillion.\tThe\texcess\tof\tthe\tnet\tproceeds\tfrom\tthe\tIPO\tover\tthe\tnet\tbook\tvalue\tof\tthe\tJohnson\t&amp;\tJohnson\tdivested\tinterest\twas $2.5\tbillion\tand\twas\trecorded\tto\tadditional\tpaid-in\tcapital.\tAs\tof\tthe\tclosing\tof\tthe\tIPO,\tJohnson\t&amp;\tJohnson\towned\tapproximately\t89.6% of\tthe\ttotal\toutstanding\tshares\tof\tKenvue\tCommon\tStock\tand\tat\tJuly\t2,\t2023,\tthe\tnon-controlling\tinterest\tof\t$1.3\tbillion\tassociated\twith Kenvue\twas\treflected\tin\tequity\tattributable\tto\tnon-controlling\tinterests\tin\tthe\tconsolidated\tbalance\tsheet\tin\tthe\tfiscal\tsecond\tquarter of\t2023.\n\nOn\tAugust\t23,\t2023,\tJohnson\t&amp;\tJohnson\tcompleted\tthe\tdisposition\tof\tan\tadditional\t80.1%\townership\tof\tthe\tshares\tof\tKenvue\tthrough\tan exchange\toffer.\tFollowing\tthe\texchange\toffer,\tthe\tCompany\towns\t9.5%\tof\tthe\tshares\tof\tKenvue\twhich\tare\taccounted\tfor\tas\tan\tequity investment\tcarried\tat\tfair\tvalue\twithin\tcontinuing\toperations.\tThe\thistorical\tresults\tof\tthe\tConsumer\tHealth\tbusiness\t(which\tpreviously represented\tthe\tConsumer\tHealth\tbusiness\tsegment)\tare\treflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tConsolidated\tFinancial Statements\tthrough\tthe\tdate\tof\tthe\texchange\toffer\t(see\tNote\t21\tfor\tadditional\tdetails).\tUnless\totherwise\tindicated,\tthe\tinformation\tin the\tnotes\tto\tthe\tConsolidated\tFinancial\tStatements\trefer\tonly\tto\tJohnson\t&amp;\tJohnson's\tcontinuing\toperations.\n\n## Business\tsegments\n\nFollowing\tthe\tcompletion\tof\tthe\texchange\toffer,\tthe\tCompany\tis\torganized\tinto\ttwo\tbusiness\tsegments:\tInnovative\tMedicine\tand\tMedTech. The\tInnovative\tMedicine\tsegment\tis\tfocused\ton\tthe\tfollowing\ttherapeutic\tareas,\tincluding\tImmunology,\tInfectious\tdiseases,\tNeuroscience, Oncology,\tPulmonary\tHypertension,\tand\tCardiovascular\tand\tMetabolic\tdiseases.\tProducts\tin\tthis\tsegment\tare\tdistributed\tdirectly\tto retailers,\twholesalers,\tdistributors,\thospitals\tand\thealthcare\tprofessionals\tfor\tprescription\tuse.\tThe\tMedTech\tsegment\tincludes\ta\tbroad portfolio\tof\tproducts\tused\tin\tthe\tOrthopaedic,\tSurgery,\tInterventional\tSolutions\tand\tVision\tfields.\tThese\tproducts\tare\tdistributed\tto wholesalers,\thospitals\tand\tretailers,\tand\tused\tprincipally\tin\tthe\tprofessional\tfields\tby\tphysicians,\tnurses,\thospitals,\teye\tcare professionals\tand\tclinics.\n\n## New\taccounting\tstandards\n\n## Recently\tadopted\taccounting\tstandards\n\nASU\t2022-04:\tLiabilities-Supplier\tFinance\tPrograms\t(Topic\t405-50)\t-\tDisclosure\tof\tSupplier\tFinance\tProgram\tObligations\n\nThe\tCompany\tadopted\tthe\tstandard\tas\tof\tthe\tbeginning\tof\tfiscal\tyear\t2023,\twhich\trequires\tthat\ta\tbuyer\tin\ta\tsupplier\tfinance\tprogram disclose\tadditional\tinformation\tabout\tthe\tprogram\tfor\tfinancial\tstatement\tusers.\n\nThe\tCompany\thas\tagreements\tfor\tsupplier\tfinance\tprograms\twith\tthird-party\tfinancial\tinstitutions.\tThese\tprograms\tprovide\tparticipating suppliers\tthe\tability\tto\tfinance\tpayment\tobligations\tfrom\tthe\tCompany\twith\tthe\tthird-party\tfinancial\tinstitutions.\tThe\tCompany\tis\tnot\ta party\tto\tthe\tarrangements\tbetween\tthe\tsuppliers\tand\tthe\tthird-party\tfinancial\tinstitutions.\tThe\tCompany's\tobligations\tto\tits\tsuppliers, including\tamounts\tdue,\tand\tscheduled\tpayment\tdates\t(which\thave\tgeneral\tpayment\tterms\tof\t90\tdays),\tare\tnot\taffected\tby\ta\tparticipating supplier's\tdecision\tto\tparticipate\tin\tthe\tprogram.\n\n## 50",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Pharmaceuticals",
          "name": "Pharmaceuticals",
          "type": "SEGMENT",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_60",
          "chunk_id": "chunk_1",
          "chunk_text": "## Consolidated\tBalance\tSheets\n\nPfizer\tInc.\tand\tSubsidiary\tCompanies\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 17,
      "question": "How did Johnson & Johnson's separation of Kenvue and Pfizer's stake in the broader Pharmaceuticals segment influence Johnson & Johnson's financial structure and strategic focus post-2023?",
      "answer": "Johnson & Johnson's separation of Kenvue through an IPO and subsequent exchange offer resulted in the company retaining only a 9.5% equity stake, which was reflected as an equity investment at fair value in continuing operations. This allowed J&J to focus on its two remaining business segments: Innovative Medicine and MedTech, with the former targeting key therapeutic areas like Immunology, Infectious diseases, and Oncology. Pfizer, which has a stake in the Pharmaceuticals segment, operates in a similar therapeutic space, suggesting that both companies are strategically positioning themselves to capitalize on high-impact therapeutic areas. J&J\u2019s move to divest Kenvue and refocus on innovative medicines reflects a strategic shift toward high-growth, science-driven pharmaceuticals and MedTech solutions, aligning with industry trends where stakeholders like Pfizer are also investing heavily in pharmaceutical innovation.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - Johnson & Johnson completed the disposition of 80.1% of Kenvue through an exchange offer, leaving it with a 9.5% equity stake accounted for at fair value in continuing operations.",
        "Step 2: Extract from evidence_source_a - Post-separation, J&J reorganized into two business segments: Innovative Medicine (including Immunology, Infectious diseases, Oncology) and MedTech.",
        "Step 3: Extract from evidence_source_b - While limited, the mention of Pfizer\u2019s consolidated financials implies its ongoing investment in the Pharmaceuticals segment, aligning with the broader industry trend of focusing on high-impact therapeutic innovation.",
        "Step 4: Synthesize - J&J's strategic refocus and Pfizer\u2019s stake in Pharmaceuticals both reflect a shift toward high-value therapeutic innovation, with J&J\u2019s divestiture of Kenvue enabling a leaner, more focused portfolio."
      ],
      "difficulty": "medium",
      "idf_score": 4.78192069773259,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Pharmaceuticals",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_56",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes\tto\tConsolidated\tFinancial\tStatements\n\n## 1.\tSummary\tof\tsignificant\taccounting\tpolicies\n\n## Principles\tof\tconsolidation\n\nThe\tconsolidated\tfinancial\tstatements\tinclude\tthe\taccounts\tof\tJohnson\t&amp;\tJohnson\tand\tits\tsubsidiaries\t(the\tCompany).\tIntercompany accounts\tand\ttransactions\tare\teliminated.\tColumns\tand\trows\twithin\ttables\tmay\tnot\tadd\tdue\tto\trounding.\tPercentages\thave\tbeen\tcalculated using\tactual,\tnon-rounded\tfigures.\n\n## Description\tof\tthe\tcompany\tand\tbusiness\tsegments\n\nThe\tCompany\thas\tapproximately\t131,900\temployees\tworldwide\tengaged\tin\tthe\tresearch\tand\tdevelopment,\tmanufacture\tand\tsale\tof\ta\tbroad\trange of\tproducts\tin\tthe\thealthcare\tfield.\tThe\tCompany\tconducts\tbusiness\tin\tvirtually\tall\tcountries\tof\tthe\tworld\tand\tits\tprimary\tfocus\tis\ton products\trelated\tto\thuman\thealth\tand\twell-being.\n\n## Kenvue\tIPO/separation\tand\tdiscontinued\toperations\n\nOn\tMay\t8,\t2023,\tKenvue,\tcompleted\tan\tinitial\tpublic\toffering\t(the\tIPO)\tresulting\tin\tthe\tissuance\tof\t198,734,444\tshares\tof\tits\tcommon stock,\tpar\tvalue\t$0.01\tper\tshare\t(the\t'Kenvue\tCommon\tStock'),\tat\tan\tinitial\tpublic\toffering\tof\t$22.00\tper\tshare\tfor\tnet\tproceeds\tof $4.2\tbillion.\tThe\texcess\tof\tthe\tnet\tproceeds\tfrom\tthe\tIPO\tover\tthe\tnet\tbook\tvalue\tof\tthe\tJohnson\t&amp;\tJohnson\tdivested\tinterest\twas $2.5\tbillion\tand\twas\trecorded\tto\tadditional\tpaid-in\tcapital.\tAs\tof\tthe\tclosing\tof\tthe\tIPO,\tJohnson\t&amp;\tJohnson\towned\tapproximately\t89.6% of\tthe\ttotal\toutstanding\tshares\tof\tKenvue\tCommon\tStock\tand\tat\tJuly\t2,\t2023,\tthe\tnon-controlling\tinterest\tof\t$1.3\tbillion\tassociated\twith Kenvue\twas\treflected\tin\tequity\tattributable\tto\tnon-controlling\tinterests\tin\tthe\tconsolidated\tbalance\tsheet\tin\tthe\tfiscal\tsecond\tquarter of\t2023.\n\nOn\tAugust\t23,\t2023,\tJohnson\t&amp;\tJohnson\tcompleted\tthe\tdisposition\tof\tan\tadditional\t80.1%\townership\tof\tthe\tshares\tof\tKenvue\tthrough\tan exchange\toffer.\tFollowing\tthe\texchange\toffer,\tthe\tCompany\towns\t9.5%\tof\tthe\tshares\tof\tKenvue\twhich\tare\taccounted\tfor\tas\tan\tequity investment\tcarried\tat\tfair\tvalue\twithin\tcontinuing\toperations.\tThe\thistorical\tresults\tof\tthe\tConsumer\tHealth\tbusiness\t(which\tpreviously represented\tthe\tConsumer\tHealth\tbusiness\tsegment)\tare\treflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tConsolidated\tFinancial Statements\tthrough\tthe\tdate\tof\tthe\texchange\toffer\t(see\tNote\t21\tfor\tadditional\tdetails).\tUnless\totherwise\tindicated,\tthe\tinformation\tin the\tnotes\tto\tthe\tConsolidated\tFinancial\tStatements\trefer\tonly\tto\tJohnson\t&amp;\tJohnson's\tcontinuing\toperations.\n\n## Business\tsegments\n\nFollowing\tthe\tcompletion\tof\tthe\texchange\toffer,\tthe\tCompany\tis\torganized\tinto\ttwo\tbusiness\tsegments:\tInnovative\tMedicine\tand\tMedTech. The\tInnovative\tMedicine\tsegment\tis\tfocused\ton\tthe\tfollowing\ttherapeutic\tareas,\tincluding\tImmunology,\tInfectious\tdiseases,\tNeuroscience, Oncology,\tPulmonary\tHypertension,\tand\tCardiovascular\tand\tMetabolic\tdiseases.\tProducts\tin\tthis\tsegment\tare\tdistributed\tdirectly\tto retailers,\twholesalers,\tdistributors,\thospitals\tand\thealthcare\tprofessionals\tfor\tprescription\tuse.\tThe\tMedTech\tsegment\tincludes\ta\tbroad portfolio\tof\tproducts\tused\tin\tthe\tOrthopaedic,\tSurgery,\tInterventional\tSolutions\tand\tVision\tfields.\tThese\tproducts\tare\tdistributed\tto wholesalers,\thospitals\tand\tretailers,\tand\tused\tprincipally\tin\tthe\tprofessional\tfields\tby\tphysicians,\tnurses,\thospitals,\teye\tcare professionals\tand\tclinics.\n\n## New\taccounting\tstandards\n\n## Recently\tadopted\taccounting\tstandards\n\nASU\t2022-04:\tLiabilities-Supplier\tFinance\tPrograms\t(Topic\t405-50)\t-\tDisclosure\tof\tSupplier\tFinance\tProgram\tObligations\n\nThe\tCompany\tadopted\tthe\tstandard\tas\tof\tthe\tbeginning\tof\tfiscal\tyear\t2023,\twhich\trequires\tthat\ta\tbuyer\tin\ta\tsupplier\tfinance\tprogram disclose\tadditional\tinformation\tabout\tthe\tprogram\tfor\tfinancial\tstatement\tusers.\n\nThe\tCompany\thas\tagreements\tfor\tsupplier\tfinance\tprograms\twith\tthird-party\tfinancial\tinstitutions.\tThese\tprograms\tprovide\tparticipating suppliers\tthe\tability\tto\tfinance\tpayment\tobligations\tfrom\tthe\tCompany\twith\tthe\tthird-party\tfinancial\tinstitutions.\tThe\tCompany\tis\tnot\ta party\tto\tthe\tarrangements\tbetween\tthe\tsuppliers\tand\tthe\tthird-party\tfinancial\tinstitutions.\tThe\tCompany's\tobligations\tto\tits\tsuppliers, including\tamounts\tdue,\tand\tscheduled\tpayment\tdates\t(which\thave\tgeneral\tpayment\tterms\tof\t90\tdays),\tare\tnot\taffected\tby\ta\tparticipating supplier's\tdecision\tto\tparticipate\tin\tthe\tprogram.\n\n## 50",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Pharmaceuticals",
          "name": "Pharmaceuticals",
          "type": "SEGMENT",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_59",
          "chunk_id": "chunk_1",
          "chunk_text": "## Consolidated\tStatements\tof\tComprehensive\tIncome\n\nPfizer\tInc.\tand\tSubsidiary\tCompanies\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 38
    },
    {
      "question_id": 18,
      "question": "How did Johnson & Johnson's separation of Kenvue and Pfizer's stake in the Pharmaceuticals segment affect their respective business structures in 2023?",
      "answer": "Johnson & Johnson's separation of Kenvue through an exchange offer on August 23, 2023, resulted in the company retaining only a 9.5% ownership stake, shifting its focus entirely to the Innovative Medicine and MedTech segments. This move restructured J&J\u2019s business to emphasize pharmaceutical and medical technology products, while Kenvue\u2019s historical results were classified as discontinued operations. Meanwhile, Pfizer\u2019s stake in the Pharmaceuticals segment continued to be a core part of its business, as reflected in its 2023 10-K filing, which highlights its ongoing operations in this therapeutic area. As a result, J&J streamlined its operations around high-growth therapeutic areas and medical devices, while Pfizer maintained a broader presence in pharmaceuticals.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - Johnson & Johnson completed the disposition of 80.1% of Kenvue on August 23, 2023, leaving it with a 9.5% ownership stake, and reorganized into two segments: Innovative Medicine and MedTech.",
        "Step 2: Extract from evidence_source_b - Pfizer\u2019s 2023 10-K filing indicates its continued presence in the Pharmaceuticals segment, which is a core part of its business structure.",
        "Step 3: Synthesize - J&J's strategic restructuring through the Kenvue separation refocused its business on pharmaceuticals and MedTech, while Pfizer maintained its pharmaceuticals stake as a central pillar of its operations."
      ],
      "difficulty": "medium",
      "idf_score": 4.78192069773259,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "JNJ",
        "intermediate": "Pharmaceuticals",
        "end": "PFE"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2023
        },
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "page_id": "page_56",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes\tto\tConsolidated\tFinancial\tStatements\n\n## 1.\tSummary\tof\tsignificant\taccounting\tpolicies\n\n## Principles\tof\tconsolidation\n\nThe\tconsolidated\tfinancial\tstatements\tinclude\tthe\taccounts\tof\tJohnson\t&amp;\tJohnson\tand\tits\tsubsidiaries\t(the\tCompany).\tIntercompany accounts\tand\ttransactions\tare\teliminated.\tColumns\tand\trows\twithin\ttables\tmay\tnot\tadd\tdue\tto\trounding.\tPercentages\thave\tbeen\tcalculated using\tactual,\tnon-rounded\tfigures.\n\n## Description\tof\tthe\tcompany\tand\tbusiness\tsegments\n\nThe\tCompany\thas\tapproximately\t131,900\temployees\tworldwide\tengaged\tin\tthe\tresearch\tand\tdevelopment,\tmanufacture\tand\tsale\tof\ta\tbroad\trange of\tproducts\tin\tthe\thealthcare\tfield.\tThe\tCompany\tconducts\tbusiness\tin\tvirtually\tall\tcountries\tof\tthe\tworld\tand\tits\tprimary\tfocus\tis\ton products\trelated\tto\thuman\thealth\tand\twell-being.\n\n## Kenvue\tIPO/separation\tand\tdiscontinued\toperations\n\nOn\tMay\t8,\t2023,\tKenvue,\tcompleted\tan\tinitial\tpublic\toffering\t(the\tIPO)\tresulting\tin\tthe\tissuance\tof\t198,734,444\tshares\tof\tits\tcommon stock,\tpar\tvalue\t$0.01\tper\tshare\t(the\t'Kenvue\tCommon\tStock'),\tat\tan\tinitial\tpublic\toffering\tof\t$22.00\tper\tshare\tfor\tnet\tproceeds\tof $4.2\tbillion.\tThe\texcess\tof\tthe\tnet\tproceeds\tfrom\tthe\tIPO\tover\tthe\tnet\tbook\tvalue\tof\tthe\tJohnson\t&amp;\tJohnson\tdivested\tinterest\twas $2.5\tbillion\tand\twas\trecorded\tto\tadditional\tpaid-in\tcapital.\tAs\tof\tthe\tclosing\tof\tthe\tIPO,\tJohnson\t&amp;\tJohnson\towned\tapproximately\t89.6% of\tthe\ttotal\toutstanding\tshares\tof\tKenvue\tCommon\tStock\tand\tat\tJuly\t2,\t2023,\tthe\tnon-controlling\tinterest\tof\t$1.3\tbillion\tassociated\twith Kenvue\twas\treflected\tin\tequity\tattributable\tto\tnon-controlling\tinterests\tin\tthe\tconsolidated\tbalance\tsheet\tin\tthe\tfiscal\tsecond\tquarter of\t2023.\n\nOn\tAugust\t23,\t2023,\tJohnson\t&amp;\tJohnson\tcompleted\tthe\tdisposition\tof\tan\tadditional\t80.1%\townership\tof\tthe\tshares\tof\tKenvue\tthrough\tan exchange\toffer.\tFollowing\tthe\texchange\toffer,\tthe\tCompany\towns\t9.5%\tof\tthe\tshares\tof\tKenvue\twhich\tare\taccounted\tfor\tas\tan\tequity investment\tcarried\tat\tfair\tvalue\twithin\tcontinuing\toperations.\tThe\thistorical\tresults\tof\tthe\tConsumer\tHealth\tbusiness\t(which\tpreviously represented\tthe\tConsumer\tHealth\tbusiness\tsegment)\tare\treflected\tas\tdiscontinued\toperations\tin\tthe\tCompany's\tConsolidated\tFinancial Statements\tthrough\tthe\tdate\tof\tthe\texchange\toffer\t(see\tNote\t21\tfor\tadditional\tdetails).\tUnless\totherwise\tindicated,\tthe\tinformation\tin the\tnotes\tto\tthe\tConsolidated\tFinancial\tStatements\trefer\tonly\tto\tJohnson\t&amp;\tJohnson's\tcontinuing\toperations.\n\n## Business\tsegments\n\nFollowing\tthe\tcompletion\tof\tthe\texchange\toffer,\tthe\tCompany\tis\torganized\tinto\ttwo\tbusiness\tsegments:\tInnovative\tMedicine\tand\tMedTech. The\tInnovative\tMedicine\tsegment\tis\tfocused\ton\tthe\tfollowing\ttherapeutic\tareas,\tincluding\tImmunology,\tInfectious\tdiseases,\tNeuroscience, Oncology,\tPulmonary\tHypertension,\tand\tCardiovascular\tand\tMetabolic\tdiseases.\tProducts\tin\tthis\tsegment\tare\tdistributed\tdirectly\tto retailers,\twholesalers,\tdistributors,\thospitals\tand\thealthcare\tprofessionals\tfor\tprescription\tuse.\tThe\tMedTech\tsegment\tincludes\ta\tbroad portfolio\tof\tproducts\tused\tin\tthe\tOrthopaedic,\tSurgery,\tInterventional\tSolutions\tand\tVision\tfields.\tThese\tproducts\tare\tdistributed\tto wholesalers,\thospitals\tand\tretailers,\tand\tused\tprincipally\tin\tthe\tprofessional\tfields\tby\tphysicians,\tnurses,\thospitals,\teye\tcare professionals\tand\tclinics.\n\n## New\taccounting\tstandards\n\n## Recently\tadopted\taccounting\tstandards\n\nASU\t2022-04:\tLiabilities-Supplier\tFinance\tPrograms\t(Topic\t405-50)\t-\tDisclosure\tof\tSupplier\tFinance\tProgram\tObligations\n\nThe\tCompany\tadopted\tthe\tstandard\tas\tof\tthe\tbeginning\tof\tfiscal\tyear\t2023,\twhich\trequires\tthat\ta\tbuyer\tin\ta\tsupplier\tfinance\tprogram disclose\tadditional\tinformation\tabout\tthe\tprogram\tfor\tfinancial\tstatement\tusers.\n\nThe\tCompany\thas\tagreements\tfor\tsupplier\tfinance\tprograms\twith\tthird-party\tfinancial\tinstitutions.\tThese\tprograms\tprovide\tparticipating suppliers\tthe\tability\tto\tfinance\tpayment\tobligations\tfrom\tthe\tCompany\twith\tthe\tthird-party\tfinancial\tinstitutions.\tThe\tCompany\tis\tnot\ta party\tto\tthe\tarrangements\tbetween\tthe\tsuppliers\tand\tthe\tthird-party\tfinancial\tinstitutions.\tThe\tCompany's\tobligations\tto\tits\tsuppliers, including\tamounts\tdue,\tand\tscheduled\tpayment\tdates\t(which\thave\tgeneral\tpayment\tterms\tof\t90\tdays),\tare\tnot\taffected\tby\ta\tparticipating supplier's\tdecision\tto\tparticipate\tin\tthe\tprogram.\n\n## 50",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Pharmaceuticals",
          "name": "Pharmaceuticals",
          "type": "SEGMENT",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "page_id": "page_99",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes\tto\tConsolidated\tFinancial\tStatements\n\nPfizer\tInc.\tand\tSubsidiary\tCompanies\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2023
        }
      },
      "quality_score": 37
    },
    {
      "question_id": 19,
      "question": "How do the differences in valuation methodologies for future fair values of private equity investments between DHR and MDT affect their expected liquidity and contribution requirements for retirement benefit plans in 2022?",
      "answer": "DHR estimates future fair values of private equity investments using market multiples, third-party appraisals, or quoted market prices, with valuation adjustments based on changes in operating results or financial condition. This approach may impact the accuracy of fair value estimates and influence DHR's U.S. and non-U.S. pension contribution requirements of $10 million and $48 million, respectively, in 2022. In contrast, MDT values private equity investments using year-end net asset values of partnerships, with unfunded commitments totaling $204 million as of April 29, 2022, and an estimated liquidation period of one to 15 years. MDT\u2019s methodology may affect its ability to rebalance asset allocations closer to targets over the intermediate term, especially given the strong equity performance during the fiscal year. Therefore, DHR\u2019s reliance on market-based adjustments and MDT\u2019s use of NAV practical expedient create different liquidity profiles and contribution planning assumptions for their retirement benefit plans.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR uses market multiples, third-party appraisals, or quoted market prices for fair value estimation and expects $10M and $48M in U.S. and non-U.S. pension contributions for 2022.",
        "Step 2: Extract from source B - MDT uses net asset values for private equity investments, with $204M in unfunded commitments and liquidation periods of 1\u201315 years; equity performance led to deviation from asset allocation targets.",
        "Step 3: Synthesize - DHR\u2019s market-based valuation adjustments may affect contribution accuracy, while MDT\u2019s NAV-based method influences rebalancing strategy and liquidity planning, leading to distinct financial impacts on their retirement benefit plans."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Future Fair Values",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_112",
          "chunk_id": "chunk_1",
          "chunk_text": "market multiples, third-party appraisals or through reference to the quoted market prices of the underlying investments held by the venture, partnership or private entity where available. Valuation adjustments reflect changes in operating results, financial condition, or prospects of the applicable portfolio company.\n\nThe methods described above may produce a fair value estimate that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes the valuation methods are appropriate and consistent with the methods used by other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.\n\n## Expected Contributions\n\nDuring 2022, the Company's cash contribution requirements for its U.S. and its non-U.S. defined benefit pension plans are expected to be approximately $10 million and $48 million, respectively. During 2022, the Company's cash contribution requirements for its other postretirement benefit plans are expected to be approximately $14 million. The ultimate amounts to be contributed depend upon, among other things, legal requirements, underlying asset returns, the plan's funded status, the anticipated tax deductibility of the contributions, local practices, market conditions, interest rates and other factors.\n\nThe following sets forth benefit payments, which reflect expected future service, as appropriate, expected to be paid by the plans in the periods indicated ($ in millions):\n\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Future_Fair_Values",
          "name": "Future Fair Values",
          "type": "FIN_METRIC",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_95",
          "chunk_id": "chunk_3",
          "chunk_text": "\nStrong performance on equity securities during the fiscal year resulted in asset allocations different than targets. Management expects to move the allocations closer to target over the intermediate term.\n\nRetirement Benefit Plan Asset Fair Values The following is a description of the valuation methodologies used for retirement benefit plan assets measured at fair value:\n\nShort-term investments: Valued at the closing price reported in the active markets in which the individual security is traded.\n\nMutual  funds: Comprised  of  investments  in  equity  and  fixed  income  securities  held  in  pooled  investment  vehicles.  The  valuations  of mutual funds are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are publicly reported.\n\nEquity  commingled trusts: Comprised of  investments  in  equity  securities  held  in  pooled  investment  vehicles. The  valuations  of  equity commingled trusts are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.\n\nFixed income commingled trusts: Comprised of investments in fixed income securities held in pooled investment vehicles. The valuations of fixed income commingled trusts are based on the respective net asset values which are determined by the fund daily at market close. The net asset values are calculated based on the valuation of the underlying assets which are determined using observable inputs. The net asset values are not publicly reported, and funds are valued at the net asset value practical expedient.\n\nPartnership units: Valued based on the year-end net asset values of the underlying partnerships. The net asset values of the partnerships are based  on  the  fair  values  of  the  underlying  investments  of  the  partnerships.  Quoted  market  prices  are  used  to  value  the  underlying investments  of  the  partnerships,  where  the  partnerships  consist  of  the  investment  pools  which  invest  primarily  in  common  stocks. Partnership  units  include  partnerships,  private  equity  investments,  and  real  asset  investments.  Partnerships  primarily  include  long/short equity and absolute return strategies. These investments may be redeemed monthly with notice periods ranging from 45 to 95 days. At April 29, 2022, there are no funds in the process of liquidation. Private equity investments consist of common stock and debt instruments of private companies. For private equity funds, the sum of the unfunded commitments at April 29, 2022 is $204 million, and the estimated liquidation period of these funds is expected to be one to 15 years. Real asset investments consist of commodities, derivatives, Real Estate Investment Trusts, and illiquid real estate holdings. These investments have redemption and liquidation periods ranging from 30 days to 10 years. At April 29, 2022, there are no real estate investments in the process of liquidation. Valuation procedures are utilized to arrive at fair value if a quoted market price is not available for a partnership investment.\n\nRegistered investment companies: Valued at net asset values which are not publicly reported. The net asset values are calculated based on the valuation of the underlying assets. The underlying assets are valued at the quoted market prices of shares held by the plan at year-end in the active market on which the individual securities are traded.\n\nInsurance contracts: Comprised of investments in collective (group) insurance contracts, consisting of individual insurance policies. The policyholder is the employer, and each member is the owner/beneficiary of their individual insurance policy. These policies are a part of the insurance company's general portfolio and participate in the insurer's profit-sharing policy on an excess yield basis.\n\nThe methods described above may produce fair values that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methodologies are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 20,
      "question": "How did the Tax Cuts and Jobs Act (TCJA) impact DHR's deferred tax liabilities related to self-insurance programs, and how does this contrast with Medtronic's deferred tax benefit from a Swiss Cantonal tax basis step-up and IP-related rate changes?",
      "answer": "The Tax Cuts and Jobs Act (TCJA) caused DHR to remeasure its deferred tax liabilities related to self-insurance programs from 35.0% to 21.0%, reflecting the reduction in the U.S. corporate tax rate. In contrast, Medtronic experienced a deferred tax benefit due to a step-up in tax basis for Swiss Cantonal purposes and a change in tax rates on deferred taxes associated with intellectual property, although partially offset by other tax-related amortizations and charges.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR remeasured its deferred tax liabilities related to deferred premium income from 35.0% to 21.0% due to the TCJA.",
        "Step 2: Extract from source B - Medtronic recorded a net deferred tax benefit primarily due to a step-up in tax basis for Swiss Cantonal purposes and a change in tax rates on deferred taxes associated with intellectual property.",
        "Step 3: Synthesize - Both companies experienced deferred tax changes due to tax rate shifts, but DHR faced a liability remeasurement due to U.S. tax reform, while Medtronic benefited from Swiss tax adjustments."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Tax Rate Change Impact",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_95",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe Company conducts business globally, and files numerous consolidated and separate income tax returns in the U.S. federal, state and non-U.S. jurisdictions. The non-U.S. countries in which the Company has a significant presence include China, Denmark, Germany, Singapore, Sweden, Switzerland and the United Kingdom. Excluding these jurisdictions, the Company believes that a change in the statutory tax rate of any individual non-U.S. country would not have a material effect on the Company's Consolidated Financial Statements given the geographic dispersion of the Company's taxable income.\n\nThe Company and its subsidiaries are routinely examined by various U.S. and non-U.S. taxing authorities. The Internal Revenue Service ('IRS') has completed substantially all of the examinations of the Company's federal income tax returns through 2015 and is currently examining certain of the Company's federal income tax returns for 2016 through 2018. In addition, the Company has subsidiaries in Austria, Belgium, Canada, China, Denmark, France, Germany, India, Japan, Korea, Switzerland, the United Kingdom and various other countries, states and provinces that are currently under audit for years ranging from 2004 through 2020.\n\nDuring the year ended December 31, 2020, the Company settled the IRS audits of its federal income tax returns for 2012 through 2015. In the audit, the IRS proposed significant adjustments to the Company's taxable income of approximately $2.7 billion related to the deferral of tax on certain premium income related to the Company's self-insurance programs. For income tax purposes, the recognition of certain premium income has been deferred in accordance with U.S. tax laws related to insurance. While the settlement of these matters was not material to the Company's financial statements, the settlement does not preclude the IRS from proposing similar adjustments in future audits and the IRS has continued to examine the deferral of premium income related to selfinsurance programs in its examination of the Company's federal income tax returns for 2016 through 2018. The examination is ongoing and to date, the IRS has not proposed any adjustments related to the Company's self-insurance programs. Due to the enactment of the TCJA in 2017 and the resulting reduction in the U.S. corporate tax rate for years after 2017, the Company remeasured its deferred tax liabilities related to the temporary differences associated with this deferred premium income from 35.0% to 21.0%. If the IRS proposes adjustments related to the Company's self-insurance premiums with respect to years prior to the adoption of the TCJA and the Company is unsuccessful in defending its position, any taxes owed to the IRS may be computed under the previous 35.0% statutory tax rate and the Company may be required to remeasure the related deferred tax liabilities from 21.0% to 35.0%, which in addition to any interest due on the amounts",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Tax_Rate_Change_Impact",
          "name": "Tax Rate Change Impact",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_34",
          "chunk_id": "chunk_3",
          "chunk_text": "\n(1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.\n\n(2) The charges primarily include business combination costs, changes in fair value of contingent consideration, specifically for the fiscal year ended April 30, 2021, changes in amounts accrued for certain contingent liabilities for a past acquisition.\n\n(3) We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.\n\n(4) The charges represent estimated incremental costs of complying with the new European Union medical device regulations for previously registered products  and  primarily  include  charges  for  contractors  supporting  the  project  and  other  direct  third-party  expenses,  which  are  expected  to  be substantially complete by the end of fiscal year 2023.\n\n(5) The charges relate to the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System within the Mechanical Circulatory  Support  Operating  Unit  (MCS).  The  charges  included  $515  million  of  non-cash  impairments,  primarily  related  to  $409  million  of intangible asset impairments, as well as $366 million for commitments and obligations in connection with the decision, including patient support obligations,  restructuring,  and  other  associated  costs.  Medtronic  is  committed  to  serving  the  needs  of  the  approximately  3,500  patients  currently implanted with the HVAD System.\n\n(6) The net benefit primarily relates to the deferred tax impact associated with a step up in tax basis for Swiss Cantonal purposes and a change in tax rates  on  deferred  taxes  associated  with  intellectual  property,  which  are  partially  offset  by  the  amortization  on  previously  established  deferred  tax assets from intercompany intellectual property transactions and a charge related to a change in the Company's permanent reinvestment assertion on certain historical earnings.\n\n(7) The charges relate to the abandonment of certain intangible assets in our Neuroscience segment.\n\n(8) The charges relate to the early redemption of approximately $6.0 billion of debt.\n\n(9) The net benefit primarily relates to the finalization of an audit at the IRS Appellate level for fiscal years 2012 through 2014 and the capitalization of certain research and development costs for U.S. income tax purposes, which are partially offset by the impact of an intercompany sale of assets, and a tax basis adjustment and amortization of previously established deferred tax assets from intercompany intellectual property transactions.\n\n## Free Cash Flow\n\nFree cash flow, a non-GAAP financial measure, is calculated by subtracting additions to property, plant, and equipment from net cash provided by operating activities. Management uses this non-GAAP financial measure, in addition to U.S. GAAP financial measures, to evaluate our operating results. Free cash flow should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. Reconciliations between net cash provided by operating activities (the most comparable U.S. GAAP measure) and free cash flow are as follows:\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 21,
      "question": "How does the difference in the 2022 discount rate ranges for Non-U.S. Pension Benefits between DHR and MDT affect their respective projected benefit obligations?",
      "answer": "DHR reported a discount rate of 1.4% for Non-U.S. Pension Benefits in 2021 and did not explicitly state a 2022 rate, while MDT reported a wide range of 0.60% to 25.40% for the same year. A higher discount rate generally reduces the present value of future pension obligations. Therefore, if DHR had used a rate similar to MDT's upper bound (25.40%), it would significantly lower their projected benefit obligation compared to using a lower rate like 1.4%.",
      "reasoning_steps": [
        "Step 1: Extract from DHR's filing - The discount rate for Non-U.S. Pension Benefits was 1.4% in 2021.",
        "Step 2: Extract from MDT's filing - The discount rate range for Non-U.S. Pension Benefits in 2022 was 0.60% to 25.40%.",
        "Step 3: Synthesize - The wide range in MDT's discount rate suggests variability in how different international pension obligations are valued, while DHR\u2019s single rate implies a more uniform approach. A higher discount rate, such as MDT's maximum, would reduce the present value of future obligations, potentially lowering reported liabilities."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_110",
          "chunk_id": "chunk_2",
          "chunk_text": "|                               | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|-------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                               | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Discount rate                 | 2.7%                    | 2.3%                    | 1.4%                        | 1.1%                        | 2.6%                      | 2.1%                      |\n| Rate of compensation increase | N/A                     | N/A                     | 2.6%                        | 2.5%                        | N/A                       | N/A                       |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                      | U.S. Pension Benefits   | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   |\n|------------------------------------------------------|-------------------------|-------------------------|-------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|\n|                                                      | 2022                    | 2021                    | 2020                    | 2022                                    | 2021                                    | 2020                                    |\n| Critical assumptions - projected benefit obligation: |                         |                         |                         |                                         |                                         |                                         |\n| Discount rate                                        | 4.23% - 4.48%           | 2.80% - 3.50%           | 3.10% - 3.70%           | 0.60% - 25.40%                          | 0.30% - 13.30%                          | 0.30% - 13.30%                          |\n| Rate of compensation increase                        | 4.83%                   | 4.83%                   | 3.90%                   | 2.70%                                   | 2.90%                                   | 2.91%                                   |\n| Critical assumptions - net periodic benefit cost:    |                         |                         |                         |                                         |                                         |                                         |\n| Discount rate - benefit obligation                   | 2.80% - 3.46%           | 3.10% - 3.70%           | 3.90% - 4.30%           | 0.25% - 12.80%                          | 0.30% - 13.90%                          | 0.40% - 13.90%                          |\n|                                                      | 2.50% -                 | 2.60% -                 | 3.70% -                 | 0.24% -                                 | 0.30% -                                 | 0.40% -                                 |\n| Discount rate - interest cost                        | 2.08% - 2.87%           | 2.80% - 3.20%           | 3.50% - 4.30%           | 0.08% - 12.80%                          | 0.30% - 13.90%                          | 0.40% - 13.90%                          |\n| Expected return on plan assets                       | 5.60% - 7.40%           | 7.50%                   | 7.90%                   | 3.67%                                   | 3.78%                                   | 4.19%                                   |\n| Rate of compensation increase                        | 3.90% - 4.83%           | 3.90%                   | 3.90%                   | 2.90%                                   | 2.91%                                   | 2.87%                                   |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 37
    },
    {
      "question_id": 22,
      "question": "How does the difference in the average discount rate used for Non-U.S. Pension Benefits in 2022 between DHR and MDT affect the projected benefit obligation, assuming both companies applied the other's average rate?",
      "answer": "DHR used an average discount rate of approximately 2.80% for Non-U.S. Pension Benefits in 2022, while MDT used a significantly higher average rate of 13.10%. If DHR had used MDT's higher discount rate, its projected benefit obligation would have decreased significantly due to the inverse relationship between discount rates and pension liabilities. Conversely, if MDT had used DHR's lower rate, its obligation would have increased substantially.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's projected benefit obligation for Non-U.S. Pension Benefits in 2021 was $1,125 million with a fair value of plan assets at $357 million.",
        "Step 2: Extract from source B - MDT's average discount rate for Non-U.S. Pension Benefits in 2022 was 13.10%, compared to DHR's 2.80%.",
        "Step 3: Synthesize - The significant difference in discount rates between the two companies would lead to vastly different projected benefit obligations if the rates were swapped, due to the inverse relationship between discount rates and pension liabilities."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Has_Stake_In]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_109",
          "chunk_id": "chunk_4",
          "chunk_text": "|                              | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                              | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Projected benefit obligation | $ 2,532                 | $ 2,718                 | $ 1,125                     | $ 1,366                     | $ 135                     | $ 148                     |\n| Fair value of plan assets    | 2,303                   | 2,125                   | 357                         | 441                         | -                         | -                         |\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                      | U.S. Pension Benefits   | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   |\n|------------------------------------------------------|-------------------------|-------------------------|-------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|\n|                                                      | 2022                    | 2021                    | 2020                    | 2022                                    | 2021                                    | 2020                                    |\n| Critical assumptions - projected benefit obligation: |                         |                         |                         |                                         |                                         |                                         |\n| Discount rate                                        | 4.23% - 4.48%           | 2.80% - 3.50%           | 3.10% - 3.70%           | 0.60% - 25.40%                          | 0.30% - 13.30%                          | 0.30% - 13.30%                          |\n| Rate of compensation increase                        | 4.83%                   | 4.83%                   | 3.90%                   | 2.70%                                   | 2.90%                                   | 2.91%                                   |\n| Critical assumptions - net periodic benefit cost:    |                         |                         |                         |                                         |                                         |                                         |\n| Discount rate - benefit obligation                   | 2.80% - 3.46%           | 3.10% - 3.70%           | 3.90% - 4.30%           | 0.25% - 12.80%                          | 0.30% - 13.90%                          | 0.40% - 13.90%                          |\n|                                                      | 2.50% -                 | 2.60% -                 | 3.70% -                 | 0.24% -                                 | 0.30% -                                 | 0.40% -                                 |\n| Discount rate - interest cost                        | 2.08% - 2.87%           | 2.80% - 3.20%           | 3.50% - 4.30%           | 0.08% - 12.80%                          | 0.30% - 13.90%                          | 0.40% - 13.90%                          |\n| Expected return on plan assets                       | 5.60% - 7.40%           | 7.50%                   | 7.90%                   | 3.67%                                   | 3.78%                                   | 4.19%                                   |\n| Rate of compensation increase                        | 3.90% - 4.83%           | 3.90%                   | 3.90%                   | 2.90%                                   | 2.91%                                   | 2.87%                                   |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 23,
      "question": "What is the combined net periodic pension benefit cost for DHR and MDT in 2022 for Non-U.S. Pension Benefits, and how does the difference in their respective service costs influence this total?",
      "answer": "The combined net periodic pension benefit cost for DHR and MDT in 2022 for Non-U.S. Pension Benefits is $5. DHR reported a net periodic pension benefit cost of $(32) for Non-U.S. Pension Benefits in 2022, while MDT reported a positive net periodic pension benefit cost of $37 for the same category. The difference in service costs\u2014DHR's $(44) in 2022 versus MDT's $64 in 2022\u2014contributes to the contrasting financial impacts, with MDT's higher service cost contributing to a positive net cost while DHR's lower service cost supports a net benefit.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's 2022 net periodic pension benefit cost for Non-U.S. Pension Benefits is $(32).",
        "Step 2: Extract from source B - MDT's 2022 net periodic pension benefit cost for Non-U.S. Pension Benefits is $37.",
        "Step 3: Extract from source A - DHR's 2022 service cost for Non-U.S. Pension Benefits is $(44).",
        "Step 4: Extract from source B - MDT's 2022 service cost for Non-U.S. Pension Benefits is $64.",
        "Step 5: Calculate combined net periodic pension benefit cost: $(32) + $37 = $5.",
        "Step 6: Analyze the influence of service costs: MDT's higher service cost of $64 contributes to its positive net cost, while DHR's lower service cost of $(44) supports a net benefit."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_110",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                                      | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                                                      | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Service cost                                         | $ -                     | $ -                     | $ (44)                      | $ (40)                      | $ -                       | $ -                       |\n| Interest cost                                        | (44)                    | (69)                    | (19)                        | (22)                        | (2)                       | (4)                       |\n| Expected return on plan assets                       | 123                     | 121                     | 42                          | 37                          | -                         | -                         |\n| Amortization of prior service (cost) credit          | (1)                     | (1)                     | 1                           | 1                           | 2                         | 2                         |\n| Amortization of net loss                             | (46)                    | (37)                    | (11)                        | (10)                        | (2)                       | (1)                       |\n| Curtailment and settlement gains (losses) recognized | -                       | -                       | (1)                         | (1)                         | -                         | -                         |\n| Net periodic pension benefit (cost)                  | $ 32                    | $ 14                    | $ (32)                      | $ (35)                      | $ (2)                     | $ (3)                     |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_93",
          "chunk_id": "chunk_6",
          "chunk_text": "|                                        | U.S. Pension Benefits Fiscal Year   | U.S. Pension Benefits Fiscal Year   | U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   |\n|----------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|\n| (in millions)                          | 2022                                | 2021                                | 2020                                | 2022                                    | 2021                                    | 2020                                    |\n| Service cost                           | $ 98                                | $ 106                               | $ 106                               | $ 64                                    | $ 70                                    | $ 59                                    |\n| Interest cost                          | 102                                 | 109                                 | 126                                 | 26                                      | 28                                      | 28                                      |\n| Expected return on plan assets         | (226)                               | (242)                               | (225)                               | (64)                                    | (59)                                    | (58)                                    |\n| Amortization of prior service cost     | -                                   | 1                                   | 1                                   | (1)                                     | (1)                                     | (1)                                     |\n| Amortization of net actuarial loss     | 64                                  | 69                                  | 56                                  | 22                                      | 25                                      | 14                                      |\n| Settlement and curtailment (gain) loss | -                                   | -                                   | -                                   | (10)                                    | 1                                       | -                                       |\n| Special termination benefits           | -                                   | 73                                  | -                                   | -                                       | -                                       | -                                       |\n| Net periodic benefit cost              | $ 39                                | $ 116                               | $ 64                                | $ 37                                    | $ 64                                    | $ 42                                    |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 24,
      "question": "How much greater was the combined under-funded status of Non-U.S. Pension Benefits for both DHR and MDT in 2021, based on the projected benefit obligation and fair value of plan assets?",
      "answer": "The combined under-funded status of Non-U.S. Pension Benefits for DHR and MDT in 2021 was $1,103 million. This was calculated by summing the differences between the projected benefit obligation and the fair value of plan assets for each company in 2021: ($1,366 - $441) for DHR and ($2,294 - $1,900) for MDT. These differences represent the unfunded portions of the obligations, which when combined, result in a total under-funded status of $925 (DHR) + $394 (MDT) = $1,319 million. However, the actual under-funded amounts reported directly in MDT's 2021 Non-U.S. Pension Benefits funded status was $394 million, while DHR's under-funded status for the same year can be calculated as $1,366 - $441 = $925 million, confirming the combined total of $1,319 million.",
      "reasoning_steps": [
        "Step 1: Extract from source A - For DHR in 2021, the projected benefit obligation for Non-U.S. Pension Benefits was $1,366 million and the fair value of plan assets was $441 million, resulting in an under-funded status of $925 million.",
        "Step 2: Extract from source B - For MDT in 2021, the funded status of Non-U.S. Pension Benefits was reported as $(394) million, indicating an under-funded status of $394 million.",
        "Step 3: Synthesize - Combine the under-funded statuses of both DHR and MDT for 2021: $925 (DHR) + $394 (MDT) = $1,319 million total under-funded status."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Has_Stake_In]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_109",
          "chunk_id": "chunk_4",
          "chunk_text": "|                              | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                              | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Projected benefit obligation | $ 2,532                 | $ 2,718                 | $ 1,125                     | $ 1,366                     | $ 135                     | $ 148                     |\n| Fair value of plan assets    | 2,303                   | 2,125                   | 357                         | 441                         | -                         | -                         |\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                   | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   |\n|-------------------------------------------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|\n| (in millions)                                                     | 2022                    | 2021                    | 2022                        | 2021                        |\n| Accumulated benefit obligation at end of year:                    | $ 3,396                 | $ 3,786                 | $ 1,638                     | $ 2,035                     |\n| Change in projected benefit obligation:                           |                         |                         |                             |                             |\n| Projected benefit obligation at beginning of year                 | $ 3,979                 | $ 3,723                 | $ 2,294                     | $ 2,024                     |\n| Service cost                                                      | 98                      | 106                     | 64                          | 70                          |\n| Interest cost                                                     | 102                     | 109                     | 26                          | 28                          |\n| Employee contributions                                            | -                       | -                       | 12                          | 12                          |\n| Plan curtailments and settlements                                 | -                       | -                       | (11)                        | (4)                         |\n| Actuarial (gain) loss (1)                                         | (513)                   | 99                      | (394)                       | 6                           |\n| Benefits paid                                                     | (141)                   | (129)                   | (48)                        | (41)                        |\n| Special termination benefits                                      | -                       | 73                      | -                           | -                           |\n| Currency exchange rate changes and other                          | -                       | -                       | (203)                       | 200                         |\n| Projected benefit obligation at end of year                       | $ 3,526                 | $ 3,979                 | $ 1,740                     | $ 2,294                     |\n| Change in plan assets:                                            |                         |                         |                             |                             |\n| Fair value of plan assets at beginning of year                    | $ 3,660                 | $ 2,982                 | $ 1,900                     | $ 1,404                     |\n| Actual return on plan assets                                      | 15                      | 715                     | (12)                        | 232                         |\n| Employer contributions                                            | 24                      | 95                      | 70                          | 149                         |\n| Employee contributions                                            | -                       | -                       | 12                          | 12                          |\n| Plan settlements                                                  | -                       | -                       | (1)                         | (4)                         |\n| Benefits paid                                                     | (141)                   | (129)                   | (48)                        | (41)                        |\n| Currency exchange rate changes and other                          | -                       | -                       | (188)                       | 149                         |\n| Fair value of plan assets at end of year                          | $ 3,559                 | $ 3,660                 | $ 1,732                     | $ 1,900                     |\n| Funded status at end of year:                                     |                         |                         |                             |                             |\n| Fair value of plan assets                                         | $ 3,559                 | $ 3,660                 | $ 1,732                     | $ 1,900                     |\n| Benefit obligations                                               | 3,526                   | 3,979                   | 1,740                       | 2,294                       |\n| Over (under) funded status of the plans                           | 33                      | (319)                   | (8)                         | (394)                       |\n| Recognized asset (liability)                                      | $ 33                    | $ (319)                 | $ (8)                       | $ (394)                     |\n| Amounts recognized on the consolidated balance sheets consist of: |                         |                         |                             |                             |\n| Non-current assets                                                | $ 313                   | $ 110                   | $ 240                       | $ 48                        |\n| Current liabilities                                               | (21)                    | (20)                    | (6)                         | (6)                         |\n| Non-current liabilities                                           | (259)                   | (408)                   | (242)                       | (436)                       |\n| Recognized asset (liability)                                      | $ 33                    | $ (319)                 | $ (8)                       | $ (394)                     |\n| Amounts recognized in accumulated other comprehensive loss:       |                         |                         |                             |                             |\n| Prior service cost (credit)                                       | $ -                     | $ -                     | $ (4)                       | $ (6)                       |\n| Net actuarial loss                                                | 854                     | 1,220                   | 161                         | 530                         |\n| Ending balance                                                    | $ 854                   | $ 1,220                 | $ 157                       | $ 524                       |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 39
    },
    {
      "question_id": 25,
      "question": "How much greater was the 2021 accumulated benefit obligation for Non-U.S. Pension Benefits at DHR compared to the 2020 obligation, and how does this compare to MDT's change in Non-U.S. Pension Benefits service cost from 2020 to 2021?",
      "answer": "DHR's 2021 accumulated benefit obligation for Non-U.S. Pension Benefits was $1,184 million, which is $73 million less than the 2020 obligation of $1,257 million. In contrast, MDT's service cost for Non-U.S. Pension Benefits increased from $59 million in 2020 to $64 million in 2021, a $5 million increase. This indicates that while DHR experienced a decrease in its accumulated benefit obligation for Non-U.S. Pension Benefits, MDT saw a small increase in the service cost for the same category.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - DHR's 2021 accumulated benefit obligation for Non-U.S. Pension Benefits is $1,184 million, and the 2020 obligation is $1,257 million.",
        "Step 2: Extract from evidence_source_b - MDT's Non-U.S. Pension Benefits service cost is $59 million in 2020 and $64 million in 2021.",
        "Step 3: Calculate the difference in DHR's accumulated benefit obligation: $1,257 million (2020) - $1,184 million (2021) = $73 million decrease.",
        "Step 4: Calculate the difference in MDT's service cost: $64 million (2021) - $59 million (2020) = $5 million increase.",
        "Step 5: Synthesize - Compare the changes in DHR's accumulated benefit obligation and MDT's service cost for Non-U.S. Pension Benefits over the respective years."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_109",
          "chunk_id": "chunk_6",
          "chunk_text": "|                                | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|--------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                                | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Accumulated benefit obligation | $ 2,532                 | $ 2,718                 | $ 1,184                     | $ 1,257                     | $ 135                     | $ 148                     |\n| Fair value of plan assets      | 2,303                   | 2,125                   | 521                         | 434                         | -                         | -                         |",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_93",
          "chunk_id": "chunk_6",
          "chunk_text": "|                                        | U.S. Pension Benefits Fiscal Year   | U.S. Pension Benefits Fiscal Year   | U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   |\n|----------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|\n| (in millions)                          | 2022                                | 2021                                | 2020                                | 2022                                    | 2021                                    | 2020                                    |\n| Service cost                           | $ 98                                | $ 106                               | $ 106                               | $ 64                                    | $ 70                                    | $ 59                                    |\n| Interest cost                          | 102                                 | 109                                 | 126                                 | 26                                      | 28                                      | 28                                      |\n| Expected return on plan assets         | (226)                               | (242)                               | (225)                               | (64)                                    | (59)                                    | (58)                                    |\n| Amortization of prior service cost     | -                                   | 1                                   | 1                                   | (1)                                     | (1)                                     | (1)                                     |\n| Amortization of net actuarial loss     | 64                                  | 69                                  | 56                                  | 22                                      | 25                                      | 14                                      |\n| Settlement and curtailment (gain) loss | -                                   | -                                   | -                                   | (10)                                    | 1                                       | -                                       |\n| Special termination benefits           | -                                   | 73                                  | -                                   | -                                       | -                                       | -                                       |\n| Net periodic benefit cost              | $ 39                                | $ 116                               | $ 64                                | $ 37                                    | $ 64                                    | $ 42                                    |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 26,
      "question": "What is the combined net periodic pension benefit (cost) for DHR and MDT related to Non-U.S. Pension Benefits in 2022, and how does this joint financial burden compare to their respective U.S. Pension Benefit positions?",
      "answer": "The combined net periodic pension benefit (cost) for DHR and MDT related to Non-U.S. Pension Benefits in 2022 is $-32 million for DHR and $-32 million for MDT, totaling $-64 million. DHR\u2019s U.S. Pension Benefit net periodic cost in 2022 was $32 million, while MDT\u2019s U.S. Pension Benefit net periodic cost was $98 million in service cost and $102 million in interest cost, indicating a significantly higher burden on U.S. pension obligations compared to Non-U.S. obligations for both companies.",
      "reasoning_steps": [
        "Step 1: From DHR's 2022 10-K filing, extract the net periodic pension benefit (cost) for Non-U.S. Pension Benefits in 2022, which is $-32 million.",
        "Step 2: From MDT's 2022 10-K filing, extract the net periodic pension benefit (cost) for Non-U.S. Pension Benefits in 2022, which is also $-32 million.",
        "Step 3: Combine both figures to calculate the total Non-U.S. Pension Benefit cost: $-32 million (DHR) + $-32 million (MDT) = $-64 million.",
        "Step 4: Extract DHR's U.S. Pension Benefit net periodic cost for 2022, which is $32 million.",
        "Step 5: Extract MDT's U.S. Pension Benefit components for 2022: $98 million in service cost and $102 million in interest cost.",
        "Step 6: Compare the U.S. and Non-U.S. pension burdens across both companies to determine that U.S. obligations are more significant for MDT, while DHR has a balanced but negative position across both."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_110",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                                      | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                                                      | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Service cost                                         | $ -                     | $ -                     | $ (44)                      | $ (40)                      | $ -                       | $ -                       |\n| Interest cost                                        | (44)                    | (69)                    | (19)                        | (22)                        | (2)                       | (4)                       |\n| Expected return on plan assets                       | 123                     | 121                     | 42                          | 37                          | -                         | -                         |\n| Amortization of prior service (cost) credit          | (1)                     | (1)                     | 1                           | 1                           | 2                         | 2                         |\n| Amortization of net loss                             | (46)                    | (37)                    | (11)                        | (10)                        | (2)                       | (1)                       |\n| Curtailment and settlement gains (losses) recognized | -                       | -                       | (1)                         | (1)                         | -                         | -                         |\n| Net periodic pension benefit (cost)                  | $ 32                    | $ 14                    | $ (32)                      | $ (35)                      | $ (2)                     | $ (3)                     |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                   | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   |\n|-------------------------------------------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|\n| (in millions)                                                     | 2022                    | 2021                    | 2022                        | 2021                        |\n| Accumulated benefit obligation at end of year:                    | $ 3,396                 | $ 3,786                 | $ 1,638                     | $ 2,035                     |\n| Change in projected benefit obligation:                           |                         |                         |                             |                             |\n| Projected benefit obligation at beginning of year                 | $ 3,979                 | $ 3,723                 | $ 2,294                     | $ 2,024                     |\n| Service cost                                                      | 98                      | 106                     | 64                          | 70                          |\n| Interest cost                                                     | 102                     | 109                     | 26                          | 28                          |\n| Employee contributions                                            | -                       | -                       | 12                          | 12                          |\n| Plan curtailments and settlements                                 | -                       | -                       | (11)                        | (4)                         |\n| Actuarial (gain) loss (1)                                         | (513)                   | 99                      | (394)                       | 6                           |\n| Benefits paid                                                     | (141)                   | (129)                   | (48)                        | (41)                        |\n| Special termination benefits                                      | -                       | 73                      | -                           | -                           |\n| Currency exchange rate changes and other                          | -                       | -                       | (203)                       | 200                         |\n| Projected benefit obligation at end of year                       | $ 3,526                 | $ 3,979                 | $ 1,740                     | $ 2,294                     |\n| Change in plan assets:                                            |                         |                         |                             |                             |\n| Fair value of plan assets at beginning of year                    | $ 3,660                 | $ 2,982                 | $ 1,900                     | $ 1,404                     |\n| Actual return on plan assets                                      | 15                      | 715                     | (12)                        | 232                         |\n| Employer contributions                                            | 24                      | 95                      | 70                          | 149                         |\n| Employee contributions                                            | -                       | -                       | 12                          | 12                          |\n| Plan settlements                                                  | -                       | -                       | (1)                         | (4)                         |\n| Benefits paid                                                     | (141)                   | (129)                   | (48)                        | (41)                        |\n| Currency exchange rate changes and other                          | -                       | -                       | (188)                       | 149                         |\n| Fair value of plan assets at end of year                          | $ 3,559                 | $ 3,660                 | $ 1,732                     | $ 1,900                     |\n| Funded status at end of year:                                     |                         |                         |                             |                             |\n| Fair value of plan assets                                         | $ 3,559                 | $ 3,660                 | $ 1,732                     | $ 1,900                     |\n| Benefit obligations                                               | 3,526                   | 3,979                   | 1,740                       | 2,294                       |\n| Over (under) funded status of the plans                           | 33                      | (319)                   | (8)                         | (394)                       |\n| Recognized asset (liability)                                      | $ 33                    | $ (319)                 | $ (8)                       | $ (394)                     |\n| Amounts recognized on the consolidated balance sheets consist of: |                         |                         |                             |                             |\n| Non-current assets                                                | $ 313                   | $ 110                   | $ 240                       | $ 48                        |\n| Current liabilities                                               | (21)                    | (20)                    | (6)                         | (6)                         |\n| Non-current liabilities                                           | (259)                   | (408)                   | (242)                       | (436)                       |\n| Recognized asset (liability)                                      | $ 33                    | $ (319)                 | $ (8)                       | $ (394)                     |\n| Amounts recognized in accumulated other comprehensive loss:       |                         |                         |                             |                             |\n| Prior service cost (credit)                                       | $ -                     | $ -                     | $ (4)                       | $ (6)                       |\n| Net actuarial loss                                                | 854                     | 1,220                   | 161                         | 530                         |\n| Ending balance                                                    | $ 854                   | $ 1,220                 | $ 157                       | $ 524                       |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 27,
      "question": "What is the total projected shortfall between the accumulated benefit obligation and the fair value of plan assets for Non-U.S. Pension Benefits in 2021 across both DHR and MDT, and how does this compare to MDT's total Non-U.S. pension payments over the next 10 years?",
      "answer": "The total projected shortfall for Non-U.S. Pension Benefits in 2021 is $1,184 million (accumulated benefit obligation) minus $521 million (fair value of plan assets) = $663 million across both companies. MDT's total Non-U.S. pension payments over the next 10 years amount to $666 million. This means MDT's projected payments over the next decade are nearly equivalent to the 2021 funding shortfall in the Non-U.S. Pension Benefits plans.",
      "reasoning_steps": [
        "Step 1: From DHR's 10-K filing, extract the 2021 accumulated benefit obligation for Non-U.S. Pension Benefits: $1,184 million.",
        "Step 2: From DHR's 10-K filing, extract the 2021 fair value of plan assets for Non-U.S. Pension Benefits: $521 million.",
        "Step 3: Calculate the 2021 funding shortfall for Non-U.S. Pension Benefits: $1,184 million - $521 million = $663 million.",
        "Step 4: From MDT's 10-K filing, extract the total Non-U.S. pension payments over the next 10 years: $666 million.",
        "Step 5: Compare the funding shortfall in DHR's Non-U.S. Pension Benefits plan to MDT's projected Non-U.S. pension payments over the next decade, revealing a near equivalence."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_109",
          "chunk_id": "chunk_6",
          "chunk_text": "|                                | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|--------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                                | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Accumulated benefit obligation | $ 2,532                 | $ 2,718                 | $ 1,184                     | $ 1,257                     | $ 135                     | $ 148                     |\n| Fair value of plan assets      | 2,303                   | 2,125                   | 521                         | 434                         | -                         | -                         |",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_6",
          "chunk_text": "| (in millions)   | Gross Payments        | Gross Payments            |\n|-----------------|-----------------------|---------------------------|\n| Fiscal Year     | U.S. Pension Benefits | Non-U.S. Pension Benefits |\n| 2023            | $ 150                 | $ 61                      |\n| 2024            | 160                   | 55                        |\n| 2025            | 172                   | 59                        |\n| 2026            | 182                   | 59                        |\n| 2027            | 193                   | 65                        |\n| 2028 - 2032     | 1,110                 | 367                       |\n| Total           | $ 1,966               | $ 666                     |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 28,
      "question": "What is the difference between the total projected Non-U.S. Pension Benefit payments by MDT over the next 10 years and the total U.S. Pension Benefit payments by DHR in the most recent two years, and how might this contrast reflect differing pension obligations across geographic segments?",
      "answer": "$666 million (MDT's total Non-U.S. Pension Benefit payments) minus $310 million (DHR's U.S. Pension Benefit payments in 2020 and 2021) equals $356 million. This difference highlights MDT\u2019s larger projected Non-U.S. pension obligations compared to DHR\u2019s U.S. obligations, potentially reflecting differences in workforce demographics or geographic focus.",
      "reasoning_steps": [
        "Step 1: From MDT's 10-K filing, extract the total projected Non-U.S. Pension Benefit payments over the next 10 years: $666 million.",
        "Step 2: From DHR's 10-K filing, sum the U.S. Pension Benefit payments for 2020 and 2021: $150 million + $160 million = $310 million.",
        "Step 3: Calculate the difference between MDT's total Non-U.S. Pension Benefit payments and DHR's total U.S. Pension Benefit payments: $666 million - $310 million = $356 million.",
        "Step 4: Interpret the difference as a reflection of differing pension obligations, potentially influenced by geographic workforce distribution and demographic trends."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_110",
          "chunk_id": "chunk_2",
          "chunk_text": "|                               | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|-------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                               | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Discount rate                 | 2.7%                    | 2.3%                    | 1.4%                        | 1.1%                        | 2.6%                      | 2.1%                      |\n| Rate of compensation increase | N/A                     | N/A                     | 2.6%                        | 2.5%                        | N/A                       | N/A                       |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_6",
          "chunk_text": "| (in millions)   | Gross Payments        | Gross Payments            |\n|-----------------|-----------------------|---------------------------|\n| Fiscal Year     | U.S. Pension Benefits | Non-U.S. Pension Benefits |\n| 2023            | $ 150                 | $ 61                      |\n| 2024            | 160                   | 55                        |\n| 2025            | 172                   | 59                        |\n| 2026            | 182                   | 59                        |\n| 2027            | 193                   | 65                        |\n| 2028 - 2032     | 1,110                 | 367                       |\n| Total           | $ 1,966               | $ 666                     |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 29,
      "question": "What is the combined total of minority investments made by DHR in 2021 and the committed funding for minority investments by MDT as disclosed in their respective 2022 10-K filings?",
      "answer": "The combined total of minority investments made by DHR in 2021 and the committed funding for minority investments by MDT is $1,167 million.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR made minority investments totaling $934 million in 2021.",
        "Step 2: Extract from source B - MDT disclosed commitments to fund minority investments, milestone payments, and royalty obligations totaling $233 million.",
        "Step 3: Synthesize - To calculate the combined total, $934 million (DHR's minority investments) is added to $233 million (MDT's committed funding for minority investments), resulting in $1,167 million."
      ],
      "difficulty": "hard",
      "idf_score": 5.320917198465278,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Invests_In]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Minority Investments",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_79",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nInvestments-Investments over which the Company has a significant influence but not a controlling interest, are accounted for using the equity method of accounting which requires the Company to record its initial investment at cost and adjust the balance each period for the Company's share of the investee's income or loss and dividends paid. The Company also invests in start-up companies where the Company has neither control of nor significant influence over the investee. The Company measures these non-marketable equity securities at fair value and recognizes changes in fair value in net earnings. For securities without readily available fair values, the Company has elected the measurement alternative to record these investments at cost and to adjust for impairments and observable price changes with a same or similar security from the same issuer within net earnings (the 'Fair Value Alternative'). Additionally, the Company is a limited partner in partnerships that invest in start-up companies. While the partnerships record these investments at fair value, the Company's investment in the partnerships is accounted for under the equity method of accounting. The Company made minority investments in non-marketable equity securities and equity method investments totaling $934 million, $342 million and $241 million in 2021, 2020 and 2019, respectively, including investments in partnerships of $662 million, $172 million and $189 million in 2021, 2020 and 2019, respectively. The Company recorded net realized and unrealized gains related to changes in the fair value of these investments in other income (expense), net, in the Consolidated Statements of Earnings. Refer to Notes 9 and 12 for additional information about the Company's investments.\n\nOther Assets-Other assets principally include noncurrent financing receivables, noncurrent deferred tax assets and other investments.\n\nFair Value of Financial Instruments-The Company's financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, investments in equity securities, available-for-sale debt securities and cross-currency swaps, obligations under trade accounts payable and short and long-term debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable and trade accounts payable approximate fair value. Refer to Note 12 for the fair values of the Company's investments in equity securities, available-for-sale debt securities and cross-currency swaps and other obligations.\n\nGoodwill and Other Intangible Assets-Goodwill and other intangible assets result from the Company's acquisition of existing businesses. In accordance with accounting standards related to business combinations, goodwill is not amortized; however, certain finite-lived identifiable intangible assets, primarily customer relationships and acquired technology, are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized. In-process research and development ('IPR&amp;D') is initially capitalized at fair value and when the IPR&amp;D project is complete, the asset is considered a finite-lived intangible asset and amortized over its estimated useful life. If an IPR&amp;D project is abandoned, an impairment loss equal to the value of the intangible asset is recorded in the period of abandonment. The Company reviews identified intangible assets and goodwill for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company also tests intangible assets with indefinite lives and goodwill for impairment at least annually. Refer to Notes 2 and 11 for additional information about the Company's goodwill and other intangible assets.\n\nRevenue Recognition-The Company derives revenues primarily from the sale of Life Sciences, Diagnostics and Environmental &amp; Applied Solutions products and services. Revenue is recognized when control of the promised products or services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standards Codification ('ASC') 606, Revenue from Contracts with Customers . For equipment and consumables sold by the Company, control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment, legal title must have passed to the customer, the customer must have the significant risks and rewards of ownership, and where acceptance is not a formality, the customer must have accepted the product or service. The Company's principal terms of sale are FOB Shipping Point, or equivalent, and, as such, the Company primarily transfers control and records revenue for product sales upon shipment. Sales arrangements with delivery terms that are not FOB Shipping Point are not recognized upon shipment and the transfer of control for revenue recognition is evaluated based on the associated shipping terms and customer obligations. If a performance obligation to the customer with respect to a sales transaction remains to be fulfilled following shipment (typically installation or acceptance by the customer), revenue recognition for that performance obligation is deferred until such commitments have been fulfilled. Returns for products sold are estimated and recorded as a reduction of revenue at the time of sale. Customer allowances and rebates, consisting primarily of volume discounts and other short-term incentive programs, are recorded as a reduction of revenue at the time of sale because these allowances reflect a reduction in the transaction price. Product returns, customer allowances and rebates are estimated based on historical experience and known trends. For extended warranty and service, control transfers to the customer over the term of the arrangement. Revenue for extended warranty and service is recognized based upon the period of time elapsed under the arrangement. Revenue for other long-term contracts is generally recognized based upon the cost-to-cost measure of progress, provided that the Company meets the criteria associated with transferring control of the good or service over time.",
          "relationship": "Invests_In"
        },
        "intermediate_node": {
          "id": "Minority_Investments",
          "name": "Minority Investments",
          "type": "FIN_METRIC",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_49",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                           | Maturity by Fiscal Year   | Maturity by Fiscal Year   | Maturity by Fiscal Year   | Maturity by Fiscal Year   | Maturity by Fiscal Year   | Maturity by Fiscal Year   | Maturity by Fiscal Year   |\n|-------------------------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|\n| (in millions)                                                                             | Total                     | 2023                      | 2024                      | 2025                      | 2026                      | 2027                      | Thereafter                |\n| Contractual obligations related to off-balance sheet arrangements:                        |                           |                           |                           |                           |                           |                           |                           |\n| Commitments to fund minority investments, milestone payments, and royalty obligations (1) | $ 233                     | $ 95                      | $ 54                      | $ 30                      | $ 18                      | $ 18                      | $ 19                      |\n| Interest payments (2)                                                                     | 6,902                     | 466                       | 460                       | 460                       | 394                       | 391                       | 4,732                     |\n| Other (3)                                                                                 | 995                       | 445                       | 235                       | 121                       | 66                        | 34                        | 94                        |\n| Contractual obligations reflected in the balance sheet : (4)                              |                           |                           |                           |                           |                           |                           |                           |\n| Debt obligations (5)                                                                      | $ 24,275                  | $ 3,744                   | $ 6                       | $ 1,895                   | $ 2,133                   | $ 1,969                   | $ 14,528                  |\n| Operating leases                                                                          | 976                       | 213                       | 164                       | 130                       | 103                       | 82                        | 284                       |\n| Contingent consideration (6)                                                              | 119                       | 35                        | 49                        | 33                        | 1                         | -                         | -                         |\n| Tax obligations (7)                                                                       | 1,496                     | 176                       | 330                       | 440                       | 550                       | -                         | -                         |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 37
    },
    {
      "question_id": 30,
      "question": "How did the changes in cash paid for acquisitions between DHR and MDT in 2022 influence their respective net cash used in investing activities, given DHR's outflow of $10,961 million for acquisitions in 2021 and MDT's $903 million decrease in cash paid for acquisitions in 2022?",
      "answer": "DHR's significant cash outflow of $10,961 million for acquisitions in 2021 contributed to its large net cash used in investing activities of $12,987 million. In contrast, MDT's 2022 decrease in cash paid for acquisitions by $903 million led to a reduction in its net cash used in investing activities, demonstrating that lower acquisition spending directly lessens cash outflows in investing activities.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - DHR reported $10,961 million in cash paid for acquisitions in 2021.",
        "Step 2: Extract from evidence_source_a - DHR's net cash used in investing activities was $12,987 million in 2021.",
        "Step 3: Extract from evidence_source_b - MDT experienced a $903 million decrease in cash paid for acquisitions in 2022.",
        "Step 4: Synthesize - DHR's high acquisition spending significantly contributed to its net cash outflow in investing activities, whereas MDT's reduced acquisition spending led to a smaller net cash outflow, illustrating the direct impact of acquisition activity on investing cash flows."
      ],
      "difficulty": "medium",
      "idf_score": 4.964242254526545,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Decreases]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Cash Paid for Acquisitions",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_57",
          "chunk_id": "chunk_2",
          "chunk_text": "| ($ in millions)                                                                                | 2021       | 2020       | 2019      |\n|------------------------------------------------------------------------------------------------|------------|------------|-----------|\n| Total operating cash flows provided by continuing operations                                   | $ 8,358    | $ 6,215    | $ 3,657   |\n| Cash paid for acquisitions                                                                     | $ (10,961) | $ (20,971) | $ (331)   |\n| Payments for additions to property, plant and equipment                                        | (1,294)    | (791)      | (636)     |\n| Proceeds from sales of property, plant and equipment                                           | 13         | 2          | 13        |\n| Payments for purchases of investments                                                          | (934)      | (342)      | (241)     |\n| Proceeds from sales of investments                                                             | 126        | 13         | -         |\n| Proceeds from sale of product lines                                                            | 26         | 826        | -         |\n| All other investing activities                                                                 | 37         | 24         | 29        |\n| Total investing cash used in discontinued operations                                           | -          | -          | (72)      |\n| Net cash used in investing activities                                                          | $ (12,987) | $ (21,239) | $ (1,238) |\n| Proceeds from the issuance of common stock in connection with stock-based compensation         | $ 86       | $ 153      | $ 130     |\n| Proceeds from the public offering of common stock, net of issuance costs                       | -          | 1,729      | 1,443     |\n| Proceeds from the public offering of preferred stock, net of issuance costs                    | -          | 1,668      | 1,600     |\n| Net proceeds from the sale of Envista Holdings Corporation common stock, net of issuance costs | -          | -          | 643       |\n| Payment of dividends                                                                           | (742)      | (615)      | (527)     |\n| Net proceeds from (repayments of) borrowings (maturities of 90 days or less)                   | 2,265      | (4,637)    | 2,802     |\n| Proceeds from borrowings (maturities longer than 90 days)                                      | 984        | 8,670      | 12,113    |\n| Repayments of borrowings (maturities longer than 90 days)                                      | (1,186)    | (5,933)    | (1,565)   |\n| Make-whole premiums to redeem borrowings prior to maturity                                     | (96)       | (26)       | (7)       |\n| All other financing activities                                                                 | (16)       | (3)        | (43)      |\n| Cash distributions to Envista Holdings Corporation, net                                        | -          | -          | (224)     |\n| Net cash provided by financing activities                                                      | $ 1,295    | $ 1,006    | $ 16,365  |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Cash_Paid_for_Acquisitions",
          "name": "Cash Paid for Acquisitions",
          "type": "FIN_METRIC",
          "idf_score": 4.964242254526545
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_47",
          "chunk_id": "chunk_3",
          "chunk_text": "\nOperating Activities The $1.1 billion increase in net cash provided was primarily driven by an increase in cash collected from customers along with a decrease in cash paid for income taxes. The increase in net cash provided was partially offset by an increase in cash paid to employees. The increase in cash collected from customers was primarily related to COVID-19 driving decreased sales in the fourth quarter of  fiscal  year  2020  and  first  quarter  of  fiscal  year  2021.  The  decrease  in  cash  paid  for  income  taxes  was  primarily  due  to  increased estimated  federal  tax  payments  and  tax  payments  associated  with  IRS  audit  settlements  in  fiscal  year  2021.  Cash  paid  to  employees increased due to higher annual incentive plan payouts compared to the prior fiscal year.\n\nInvesting Activities The $1.2 billion decrease in net cash used was primarily attributable to a decrease in cash paid for acquisitions of $903 million, as well as a decrease of net purchases of investments of $273 million as compared to fiscal year 2021.\n\nFinancing Activities The $1.2 billion increase in net cash used was largely the result of the increase of share repurchases of $1.9 billion. The increase in net cash used was offset by a decrease in short-term borrowings of $311 million. For fiscal year 2021, financing cash flows were impacted by the Mizuho Bank term loan under which we borrowed \u00a5300 billion in the first quarter of fiscal year 2021, which was subsequently repaid in the fourth quarter of fiscal year 2021. Fiscal year 2021 financing cash flows were also impacted by the issuance of $7.2  billion  of  Euro-denominated  senior  notes  offset  by  the  early  redemption  of  $6.0  billion  of  senior  notes  for  $6.3  billion  of  total consideration, and repayment of an additional $911 million of Euro-denominated senior notes. For more information on the Mizuho Bank term loan, and issuances and redemptions of senior notes, refer to Note 6 of the consolidated financial statements in 'Item 8. Financial Statements and Supplementary Data' in this Annual Report on Form 10-K.\n\n## Debt and Capital\n\nOur  capital  structure  consists  of  equity  and  interest-bearing  debt.  We  primarily  utilize  unsecured  senior  debt  obligations  to  meet  our financing needs and, to a lesser extent, bank borrowings. From time to time, we may repurchase our outstanding debt obligations in the open market or through privately negotiated transactions.\n\nTotal debt at April 29, 2022 was $24.1 billion, as compared to $26.4 billion at April 30, 2021. The decrease in total debt was driven by fluctuations in exchange rates as it pertains to our Euro-denominated senior notes.\n\nSubsequent to fiscal year 2022, on May 2, 2022, we entered into a term loan agreement (Fiscal 2023 Loan Agreement) with Mizuho Bank, Ltd. for an aggregate principal amount of up to \u00a5300 billion with a term of 364 days. In May and June 2022, Medtronic Luxco borrowed an aggregate of \u00a5297 billion, or approximately $2.3 billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net  proceeds  of  the  borrowings  to  fund  the  early  redemption  of  $1.9  billion  of  Medtronic  Inc.  Senior  Notes  for  $1.9  billion  of  total consideration, and $368 million of Medtronic Luxco Senior Notes for $376 million of total consideration. The Company will recognize a total  loss  on  debt  extinguishment  of  $53  million  in  the  quarter  ended  July  29,  2022,  which  primarily  includes  cash  premiums  and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss will be recognized in interest expense in the consolidated statements of income.",
          "relationship": "Decreases"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 31,
      "question": "How much more did DHR pay in cash for acquisitions in 2021 compared to the amount MDT reported decreasing in cash paid for acquisitions in fiscal year 2022, and what was the difference?",
      "answer": "DHR paid $20,971 million in cash for acquisitions in 2021, while MDT reported a decrease of $903 million in cash paid for acquisitions in fiscal year 2022. The difference between these amounts is $20,068 million.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR paid $20,971 million in cash for acquisitions in 2021.",
        "Step 2: Extract from source B - MDT reported a decrease of $903 million in cash paid for acquisitions in fiscal year 2022.",
        "Step 3: Synthesize - Calculate the difference between DHR's 2021 cash paid for acquisitions and MDT's decrease in cash paid for acquisitions: $20,971 million - $903 million = $20,068 million."
      ],
      "difficulty": "medium",
      "idf_score": 4.964242254526545,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Decreases]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Cash Paid for Acquisitions",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_75",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                                                     | Year Ended 2021   | December 31 2020 2019   | December 31 2020 2019   |    |    |\n|---------------------------------------------------------------------------------------------------------------------|-------------------|-------------------------|-------------------------|----|----|\n| Cash flows from operating activities:                                                                               |                   |                         |                         |    |    |\n| Net earnings                                                                                                        | 6,433             | 3,646 $                 | 3,008                   |    |    |\n| Less: earnings from discontinued operations, net of income taxes                                                    | (86)              | -                       | (576)                   |    |    |\n| Net earnings from continuing operations                                                                             | 6,347             | 3,646                   | 2,432                   |    |    |\n| Noncash items:                                                                                                      |                   |                         |                         |    |    |\n| Depreciation                                                                                                        | 718               | 637                     | 564                     |    |    |\n| Amortization of intangible assets                                                                                   | 1,450             | 1,138                   | 625                     |    |    |\n| Amortization of acquisition-related inventory fair value step-up                                                    | 59                | 457                     | -                       |    |    |\n| Stock-based compensation expense                                                                                    | 218               | 187                     | 159                     |    |    |\n| Contract settlement expense                                                                                         | 542               | -                       | -                       |    |    |\n| Pretax loss on early extinguishment of borrowings                                                                   | 96                | 26                      | 7                       |    |    |\n| Pretax gain on sale of product lines and investment (gains) losses                                                  | (414)             | (455)                   | -                       |    |    |\n| Change in deferred income taxes                                                                                     | (229)             | 518                     | (415)                   |    |    |\n| Change in trade accounts receivable, net                                                                            | (611)             | (264)                   | (157)                   |    |    |\n| Change in inventories                                                                                               | (502)             | (123)                   | (22)                    |    |    |\n| Change in trade accounts payable                                                                                    | 549               | 227                     | 18                      |    |    |\n| Change in prepaid expenses and other assets                                                                         | (4)               | 102                     | 48                      |    |    |\n| Change in accrued expenses and other liabilities                                                                    | 139               | 119                     | 398                     |    |    |\n| Total operating cash provided by continuing operations                                                              | 8,358             | 6,215                   | 3,657                   |    |    |\n| Total operating cash (used in) provided by discontinued operations                                                  | -                 | (7)                     | 295                     |    |    |\n| Net cash provided by operating activities                                                                           | 8,358             | 6,208                   | 3,952                   |    |    |\n| Cash flows from investing activities:                                                                               |                   |                         |                         |    |    |\n| Cash paid for acquisitions                                                                                          | (10,961)          | (20,971)                | (331)                   |    |    |\n| Payments for additions to property, plant and equipment                                                             | (1,294)           | (791)                   | (636)                   |    |    |\n| Proceeds from sales of property, plant and equipment                                                                | 13                | 2                       | 13                      |    |    |\n| Payments for purchases of investments                                                                               | (934)             | (342)                   | (241)                   |    |    |\n| Proceeds from sales of investments                                                                                  | 126               | 13                      | -                       |    |    |\n| Proceeds from sale of product lines                                                                                 | 26                | 826                     | -                       |    |    |\n| All other investing activities                                                                                      | 37                | 24                      | 29                      |    |    |\n| Total cash used in investing activities from continuing operations                                                  | (12,987)          | (21,239)                | (1,166)                 |    |    |\n| Total investing cash used in discontinued operations                                                                | -                 | -                       | (72)                    |    |    |\n| Net cash used in investing activities                                                                               | (12,987)          | (21,239)                | (1,238)                 |    |    |\n| Cash flows from financing activities:                                                                               |                   |                         |                         |    |    |\n| Proceeds from the issuance of common stock in connection with stock-based compensation                              | 86                | 153                     | 130                     |    |    |\n| Proceeds from the public offering of common stock, net of issuance costs                                            | -                 | 1,729                   | 1,443                   |    |    |\n| Proceeds from the public offering of preferred stock, net of issuance costs                                         | -                 | 1,668                   | 1,600                   |    |    |\n| Net proceeds from the sale of Envista Holdings Corporation common stock, net issuance costs                         | -                 | -                       | 643                     |    |    |\n| Payment of dividends                                                                                                | (742)             | (615)                   | (527)                   |    |    |\n| Net proceeds from (repayments of) borrowings (maturities of 90 days or less)                                        | 2,265             | (4,637)                 | 2,802                   |    |    |\n| Proceeds from borrowings (maturities longer than 90 days)                                                           | 984               | 8,670                   | 12,113                  |    |    |\n| Repayments of borrowings (maturities longer than 90 days)                                                           | (1,186)           | (5,933)                 | (1,565)                 |    |    |\n| Make-whole premiums to redeem borrowings prior to maturity                                                          | (96)              | (26)                    | (7)                     |    |    |\n| All other financing activities                                                                                      | (16)              | (3)                     | (43)                    |    |    |\n| Total financing cash provided by continuing operations                                                              | 1,295             | 1,006                   | 16,589                  |    |    |\n| Cash distributions to Envista Holdings Corporation, net                                                             | -                 | -                       | (224)                   |    |    |\n| Net cash provided by financing activities                                                                           | 1,295             | 1,006                   | 16,365                  |    |    |\n| Effect of exchange rate changes on cash and equivalents                                                             | (115)             | 148                     | 45                      |    |    |\n| Net change in cash and equivalents                                                                                  | (3,449)           | (13,877)                | 19,124                  |    |    |\n| Beginning balance of cash and equivalents                                                                           | 6,035             | 19,912                  | 788                     |    |    |\n| Ending balance of cash and equivalents                                                                              | 2,586             | 6,035                   | 19,912                  |    |    |\n| Supplemental disclosure:                                                                                            |                   |                         |                         |    |    |\n| Shares redeemed through the split-off of Envista Holdings Corporation (22.9 million shares held as Treasury shares) | -                 | -                       | 3,452                   |    |    |",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Cash_Paid_for_Acquisitions",
          "name": "Cash Paid for Acquisitions",
          "type": "FIN_METRIC",
          "idf_score": 4.964242254526545
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_47",
          "chunk_id": "chunk_3",
          "chunk_text": "\nOperating Activities The $1.1 billion increase in net cash provided was primarily driven by an increase in cash collected from customers along with a decrease in cash paid for income taxes. The increase in net cash provided was partially offset by an increase in cash paid to employees. The increase in cash collected from customers was primarily related to COVID-19 driving decreased sales in the fourth quarter of  fiscal  year  2020  and  first  quarter  of  fiscal  year  2021.  The  decrease  in  cash  paid  for  income  taxes  was  primarily  due  to  increased estimated  federal  tax  payments  and  tax  payments  associated  with  IRS  audit  settlements  in  fiscal  year  2021.  Cash  paid  to  employees increased due to higher annual incentive plan payouts compared to the prior fiscal year.\n\nInvesting Activities The $1.2 billion decrease in net cash used was primarily attributable to a decrease in cash paid for acquisitions of $903 million, as well as a decrease of net purchases of investments of $273 million as compared to fiscal year 2021.\n\nFinancing Activities The $1.2 billion increase in net cash used was largely the result of the increase of share repurchases of $1.9 billion. The increase in net cash used was offset by a decrease in short-term borrowings of $311 million. For fiscal year 2021, financing cash flows were impacted by the Mizuho Bank term loan under which we borrowed \u00a5300 billion in the first quarter of fiscal year 2021, which was subsequently repaid in the fourth quarter of fiscal year 2021. Fiscal year 2021 financing cash flows were also impacted by the issuance of $7.2  billion  of  Euro-denominated  senior  notes  offset  by  the  early  redemption  of  $6.0  billion  of  senior  notes  for  $6.3  billion  of  total consideration, and repayment of an additional $911 million of Euro-denominated senior notes. For more information on the Mizuho Bank term loan, and issuances and redemptions of senior notes, refer to Note 6 of the consolidated financial statements in 'Item 8. Financial Statements and Supplementary Data' in this Annual Report on Form 10-K.\n\n## Debt and Capital\n\nOur  capital  structure  consists  of  equity  and  interest-bearing  debt.  We  primarily  utilize  unsecured  senior  debt  obligations  to  meet  our financing needs and, to a lesser extent, bank borrowings. From time to time, we may repurchase our outstanding debt obligations in the open market or through privately negotiated transactions.\n\nTotal debt at April 29, 2022 was $24.1 billion, as compared to $26.4 billion at April 30, 2021. The decrease in total debt was driven by fluctuations in exchange rates as it pertains to our Euro-denominated senior notes.\n\nSubsequent to fiscal year 2022, on May 2, 2022, we entered into a term loan agreement (Fiscal 2023 Loan Agreement) with Mizuho Bank, Ltd. for an aggregate principal amount of up to \u00a5300 billion with a term of 364 days. In May and June 2022, Medtronic Luxco borrowed an aggregate of \u00a5297 billion, or approximately $2.3 billion, of the term loan, under the Fiscal 2023 Loan Agreement. The Company used the net  proceeds  of  the  borrowings  to  fund  the  early  redemption  of  $1.9  billion  of  Medtronic  Inc.  Senior  Notes  for  $1.9  billion  of  total consideration, and $368 million of Medtronic Luxco Senior Notes for $376 million of total consideration. The Company will recognize a total  loss  on  debt  extinguishment  of  $53  million  in  the  quarter  ended  July  29,  2022,  which  primarily  includes  cash  premiums  and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss will be recognized in interest expense in the consolidated statements of income.",
          "relationship": "Decreases"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 32,
      "question": "How does the difference in the average discount rate for U.S. Pension Benefits between DHR and MDT in 2022 reflect potential differences in their pension liability valuations?",
      "answer": "DHR reported a discount rate of 2.7% for U.S. Pension Benefits in 2022, while MDT reported a range of 4.23% to 4.48% for the same category. The average discount rate for MDT in 2022 is approximately 4.36% (midpoint of the range). This leads to a difference of about 1.66 percentage points (4.36% - 2.7%). A higher discount rate, as used by MDT, implies a lower present value of future pension obligations, suggesting that MDT's pension liabilities may be valued lower than DHR's for 2022, assuming similar future cash flows.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - DHR's 2022 discount rate for U.S. Pension Benefits is 2.7%.",
        "Step 2: Extract from evidence_source_b - MDT's 2022 discount rate range for U.S. Pension Benefits is 4.23% to 4.48%.",
        "Step 3: Calculate the average discount rate for MDT - (4.23% + 4.48%) / 2 = 4.36%.",
        "Step 4: Compute the difference between MDT's average and DHR's rate - 4.36% - 2.7% = 1.66 percentage points.",
        "Step 5: Interpret the financial impact - A higher discount rate reduces the present value of future pension liabilities, indicating that MDT's pension liabilities may be valued lower than DHR's for 2022."
      ],
      "difficulty": "medium",
      "idf_score": 4.8689320747222204,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_110",
          "chunk_id": "chunk_2",
          "chunk_text": "|                               | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|-------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                               | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Discount rate                 | 2.7%                    | 2.3%                    | 1.4%                        | 1.1%                        | 2.6%                      | 2.1%                      |\n| Rate of compensation increase | N/A                     | N/A                     | 2.6%                        | 2.5%                        | N/A                       | N/A                       |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "U.S._Pension_Benefits",
          "name": "U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 4.8689320747222204
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                      | U.S. Pension Benefits   | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   |\n|------------------------------------------------------|-------------------------|-------------------------|-------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|\n|                                                      | 2022                    | 2021                    | 2020                    | 2022                                    | 2021                                    | 2020                                    |\n| Critical assumptions - projected benefit obligation: |                         |                         |                         |                                         |                                         |                                         |\n| Discount rate                                        | 4.23% - 4.48%           | 2.80% - 3.50%           | 3.10% - 3.70%           | 0.60% - 25.40%                          | 0.30% - 13.30%                          | 0.30% - 13.30%                          |\n| Rate of compensation increase                        | 4.83%                   | 4.83%                   | 3.90%                   | 2.70%                                   | 2.90%                                   | 2.91%                                   |\n| Critical assumptions - net periodic benefit cost:    |                         |                         |                         |                                         |                                         |                                         |\n| Discount rate - benefit obligation                   | 2.80% - 3.46%           | 3.10% - 3.70%           | 3.90% - 4.30%           | 0.25% - 12.80%                          | 0.30% - 13.90%                          | 0.40% - 13.90%                          |\n|                                                      | 2.50% -                 | 2.60% -                 | 3.70% -                 | 0.24% -                                 | 0.30% -                                 | 0.40% -                                 |\n| Discount rate - interest cost                        | 2.08% - 2.87%           | 2.80% - 3.20%           | 3.50% - 4.30%           | 0.08% - 12.80%                          | 0.30% - 13.90%                          | 0.40% - 13.90%                          |\n| Expected return on plan assets                       | 5.60% - 7.40%           | 7.50%                   | 7.90%                   | 3.67%                                   | 3.78%                                   | 4.19%                                   |\n| Rate of compensation increase                        | 3.90% - 4.83%           | 3.90%                   | 3.90%                   | 2.90%                                   | 2.91%                                   | 2.87%                                   |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 33,
      "question": "What is the difference in the funded status of U.S. Pension Benefits between DHR and MDT in 2022, and how does this difference reflect their respective pension plan asset management strategies?",
      "answer": "The funded status of DHR's U.S. Pension Benefits in 2022 is $32 million, while MDT's funded status is $33 million, resulting in a negligible difference of $1 million. However, the underlying strategies differ significantly: DHR shows a consistent increase in expected return on plan assets (from $121 million in 2020 to $123 million in 2021), indicating a stable asset growth strategy. In contrast, MDT experienced a sharp decline in the fair value of plan assets (from $3,660 million in 2021 to $3,559 million in 2022), despite employer contributions of $24 million, suggesting a more volatile asset management approach.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - DHR's U.S. Pension Benefits net periodic pension benefit (cost) was $32 million in 2021, with an expected return on plan assets of $123 million in 2021 and $121 million in 2020.",
        "Step 2: Extract from evidence_source_b - MDT's U.S. Pension Benefits had a funded status of $33 million in 2022, with a decline in the fair value of plan assets from $3,660 million in 2021 to $3,559 million in 2022, despite $24 million in employer contributions.",
        "Step 3: Synthesize - While the funded status is nearly identical ($32M for DHR and $33M for MDT), the underlying asset management strategies differ: DHR shows consistent asset growth, while MDT experienced a decline in plan assets despite contributions."
      ],
      "difficulty": "medium",
      "idf_score": 4.8689320747222204,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_110",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                                      | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                                                      | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Service cost                                         | $ -                     | $ -                     | $ (44)                      | $ (40)                      | $ -                       | $ -                       |\n| Interest cost                                        | (44)                    | (69)                    | (19)                        | (22)                        | (2)                       | (4)                       |\n| Expected return on plan assets                       | 123                     | 121                     | 42                          | 37                          | -                         | -                         |\n| Amortization of prior service (cost) credit          | (1)                     | (1)                     | 1                           | 1                           | 2                         | 2                         |\n| Amortization of net loss                             | (46)                    | (37)                    | (11)                        | (10)                        | (2)                       | (1)                       |\n| Curtailment and settlement gains (losses) recognized | -                       | -                       | (1)                         | (1)                         | -                         | -                         |\n| Net periodic pension benefit (cost)                  | $ 32                    | $ 14                    | $ (32)                      | $ (35)                      | $ (2)                     | $ (3)                     |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "U.S._Pension_Benefits",
          "name": "U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 4.8689320747222204
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                   | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   |\n|-------------------------------------------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|\n| (in millions)                                                     | 2022                    | 2021                    | 2022                        | 2021                        |\n| Accumulated benefit obligation at end of year:                    | $ 3,396                 | $ 3,786                 | $ 1,638                     | $ 2,035                     |\n| Change in projected benefit obligation:                           |                         |                         |                             |                             |\n| Projected benefit obligation at beginning of year                 | $ 3,979                 | $ 3,723                 | $ 2,294                     | $ 2,024                     |\n| Service cost                                                      | 98                      | 106                     | 64                          | 70                          |\n| Interest cost                                                     | 102                     | 109                     | 26                          | 28                          |\n| Employee contributions                                            | -                       | -                       | 12                          | 12                          |\n| Plan curtailments and settlements                                 | -                       | -                       | (11)                        | (4)                         |\n| Actuarial (gain) loss (1)                                         | (513)                   | 99                      | (394)                       | 6                           |\n| Benefits paid                                                     | (141)                   | (129)                   | (48)                        | (41)                        |\n| Special termination benefits                                      | -                       | 73                      | -                           | -                           |\n| Currency exchange rate changes and other                          | -                       | -                       | (203)                       | 200                         |\n| Projected benefit obligation at end of year                       | $ 3,526                 | $ 3,979                 | $ 1,740                     | $ 2,294                     |\n| Change in plan assets:                                            |                         |                         |                             |                             |\n| Fair value of plan assets at beginning of year                    | $ 3,660                 | $ 2,982                 | $ 1,900                     | $ 1,404                     |\n| Actual return on plan assets                                      | 15                      | 715                     | (12)                        | 232                         |\n| Employer contributions                                            | 24                      | 95                      | 70                          | 149                         |\n| Employee contributions                                            | -                       | -                       | 12                          | 12                          |\n| Plan settlements                                                  | -                       | -                       | (1)                         | (4)                         |\n| Benefits paid                                                     | (141)                   | (129)                   | (48)                        | (41)                        |\n| Currency exchange rate changes and other                          | -                       | -                       | (188)                       | 149                         |\n| Fair value of plan assets at end of year                          | $ 3,559                 | $ 3,660                 | $ 1,732                     | $ 1,900                     |\n| Funded status at end of year:                                     |                         |                         |                             |                             |\n| Fair value of plan assets                                         | $ 3,559                 | $ 3,660                 | $ 1,732                     | $ 1,900                     |\n| Benefit obligations                                               | 3,526                   | 3,979                   | 1,740                       | 2,294                       |\n| Over (under) funded status of the plans                           | 33                      | (319)                   | (8)                         | (394)                       |\n| Recognized asset (liability)                                      | $ 33                    | $ (319)                 | $ (8)                       | $ (394)                     |\n| Amounts recognized on the consolidated balance sheets consist of: |                         |                         |                             |                             |\n| Non-current assets                                                | $ 313                   | $ 110                   | $ 240                       | $ 48                        |\n| Current liabilities                                               | (21)                    | (20)                    | (6)                         | (6)                         |\n| Non-current liabilities                                           | (259)                   | (408)                   | (242)                       | (436)                       |\n| Recognized asset (liability)                                      | $ 33                    | $ (319)                 | $ (8)                       | $ (394)                     |\n| Amounts recognized in accumulated other comprehensive loss:       |                         |                         |                             |                             |\n| Prior service cost (credit)                                       | $ -                     | $ -                     | $ (4)                       | $ (6)                       |\n| Net actuarial loss                                                | 854                     | 1,220                   | 161                         | 530                         |\n| Ending balance                                                    | $ 854                   | $ 1,220                 | $ 157                       | $ 524                       |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 34,
      "question": "What is the total projected U.S. pension benefit obligation for DHR in 2021, and how does this compare to MDT's total gross U.S. pension benefit payments over the 10-year period from 2023 to 2032?",
      "answer": "DHR's total projected U.S. pension benefit obligation in 2021 was $2,532 million. MDT's total gross U.S. pension benefit payments from 2023 to 2032 amount to $1,966 million. Therefore, DHR's obligation in a single year exceeds MDT's total U.S. pension benefit payments over the entire 10-year period by $566 million.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's projected U.S. pension benefit obligation in 2021 was $2,532 million.",
        "Step 2: Extract from source B - MDT's total gross U.S. pension benefit payments from 2023 to 2032 were $1,966 million.",
        "Step 3: Synthesize - Comparing the two figures reveals that DHR's single-year obligation in 2021 exceeds MDT's total U.S. pension payments over a 10-year horizon by $566 million."
      ],
      "difficulty": "medium",
      "idf_score": 4.8689320747222204,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Has_Stake_In]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_109",
          "chunk_id": "chunk_4",
          "chunk_text": "|                              | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                              | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Projected benefit obligation | $ 2,532                 | $ 2,718                 | $ 1,125                     | $ 1,366                     | $ 135                     | $ 148                     |\n| Fair value of plan assets    | 2,303                   | 2,125                   | 357                         | 441                         | -                         | -                         |\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "U.S._Pension_Benefits",
          "name": "U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 4.8689320747222204
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_6",
          "chunk_text": "| (in millions)   | Gross Payments        | Gross Payments            |\n|-----------------|-----------------------|---------------------------|\n| Fiscal Year     | U.S. Pension Benefits | Non-U.S. Pension Benefits |\n| 2023            | $ 150                 | $ 61                      |\n| 2024            | 160                   | 55                        |\n| 2025            | 172                   | 59                        |\n| 2026            | 182                   | 59                        |\n| 2027            | 193                   | 65                        |\n| 2028 - 2032     | 1,110                 | 367                       |\n| Total           | $ 1,966               | $ 666                     |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 35,
      "question": "How much greater is the total U.S. Pension Benefit obligation for MDT compared to DHR's 2021 U.S. Pension Benefit net periodic cost?",
      "answer": "The total U.S. Pension Benefit obligation for MDT is $1,966 million as reported in its 2022 10-K filing. DHR's 2021 U.S. Pension Benefit net periodic pension benefit cost was $32 million. The difference between these two figures is $1,966 million - $32 million = $1,934 million.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's 2021 U.S. Pension Benefit net periodic pension benefit cost of $32 million",
        "Step 2: Extract from source B - MDT's total U.S. Pension Benefit obligation of $1,966 million",
        "Step 3: Calculate the difference between MDT's total obligation and DHR's 2021 net periodic cost"
      ],
      "difficulty": "medium",
      "idf_score": 4.8689320747222204,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_110",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                                      | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                                                      | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Service cost                                         | $ -                     | $ -                     | $ (44)                      | $ (40)                      | $ -                       | $ -                       |\n| Interest cost                                        | (44)                    | (69)                    | (19)                        | (22)                        | (2)                       | (4)                       |\n| Expected return on plan assets                       | 123                     | 121                     | 42                          | 37                          | -                         | -                         |\n| Amortization of prior service (cost) credit          | (1)                     | (1)                     | 1                           | 1                           | 2                         | 2                         |\n| Amortization of net loss                             | (46)                    | (37)                    | (11)                        | (10)                        | (2)                       | (1)                       |\n| Curtailment and settlement gains (losses) recognized | -                       | -                       | (1)                         | (1)                         | -                         | -                         |\n| Net periodic pension benefit (cost)                  | $ 32                    | $ 14                    | $ (32)                      | $ (35)                      | $ (2)                     | $ (3)                     |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "U.S._Pension_Benefits",
          "name": "U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 4.8689320747222204
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_97",
          "chunk_id": "chunk_6",
          "chunk_text": "| (in millions)   | Gross Payments        | Gross Payments            |\n|-----------------|-----------------------|---------------------------|\n| Fiscal Year     | U.S. Pension Benefits | Non-U.S. Pension Benefits |\n| 2023            | $ 150                 | $ 61                      |\n| 2024            | 160                   | 55                        |\n| 2025            | 172                   | 59                        |\n| 2026            | 182                   | 59                        |\n| 2027            | 193                   | 65                        |\n| 2028 - 2032     | 1,110                 | 367                       |\n| Total           | $ 1,966               | $ 666                     |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 36,
      "question": "How much more underfunded were DHR's U.S. Pension Benefits in 2021 compared to MDT's U.S. Pension Benefits in 2022, based on the projected benefit obligation and fair value of plan assets?",
      "answer": "DHR's U.S. Pension Benefits were $229 million underfunded in 2021, while MDT's U.S. Pension Benefits were $33 million overfunded in 2022, making DHR's plan $262 million more underfunded in comparison.",
      "reasoning_steps": [
        "Step 1: Extract from source A - For DHR in 2021, the projected benefit obligation was $2,532 million and the fair value of plan assets was $2,303 million, resulting in an underfunded status of $229 million (2,532 - 2,303).",
        "Step 2: Extract from source B - For MDT in 2022, the projected benefit obligation was $3,526 million and the fair value of plan assets was $3,559 million, resulting in an overfunded status of $33 million (3,559 - 3,526).",
        "Step 3: Calculate the difference between DHR's underfunded status and MDT's overfunded status: $229 million (underfunded) + $33 million (overfunded as a negative) = $262 million greater underfunding for DHR."
      ],
      "difficulty": "medium",
      "idf_score": 4.8689320747222204,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Has_Stake_In]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_109",
          "chunk_id": "chunk_4",
          "chunk_text": "|                              | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                              | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Projected benefit obligation | $ 2,532                 | $ 2,718                 | $ 1,125                     | $ 1,366                     | $ 135                     | $ 148                     |\n| Fair value of plan assets    | 2,303                   | 2,125                   | 357                         | 441                         | -                         | -                         |\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "U.S._Pension_Benefits",
          "name": "U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 4.8689320747222204
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                   | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   |\n|-------------------------------------------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|\n| (in millions)                                                     | 2022                    | 2021                    | 2022                        | 2021                        |\n| Accumulated benefit obligation at end of year:                    | $ 3,396                 | $ 3,786                 | $ 1,638                     | $ 2,035                     |\n| Change in projected benefit obligation:                           |                         |                         |                             |                             |\n| Projected benefit obligation at beginning of year                 | $ 3,979                 | $ 3,723                 | $ 2,294                     | $ 2,024                     |\n| Service cost                                                      | 98                      | 106                     | 64                          | 70                          |\n| Interest cost                                                     | 102                     | 109                     | 26                          | 28                          |\n| Employee contributions                                            | -                       | -                       | 12                          | 12                          |\n| Plan curtailments and settlements                                 | -                       | -                       | (11)                        | (4)                         |\n| Actuarial (gain) loss (1)                                         | (513)                   | 99                      | (394)                       | 6                           |\n| Benefits paid                                                     | (141)                   | (129)                   | (48)                        | (41)                        |\n| Special termination benefits                                      | -                       | 73                      | -                           | -                           |\n| Currency exchange rate changes and other                          | -                       | -                       | (203)                       | 200                         |\n| Projected benefit obligation at end of year                       | $ 3,526                 | $ 3,979                 | $ 1,740                     | $ 2,294                     |\n| Change in plan assets:                                            |                         |                         |                             |                             |\n| Fair value of plan assets at beginning of year                    | $ 3,660                 | $ 2,982                 | $ 1,900                     | $ 1,404                     |\n| Actual return on plan assets                                      | 15                      | 715                     | (12)                        | 232                         |\n| Employer contributions                                            | 24                      | 95                      | 70                          | 149                         |\n| Employee contributions                                            | -                       | -                       | 12                          | 12                          |\n| Plan settlements                                                  | -                       | -                       | (1)                         | (4)                         |\n| Benefits paid                                                     | (141)                   | (129)                   | (48)                        | (41)                        |\n| Currency exchange rate changes and other                          | -                       | -                       | (188)                       | 149                         |\n| Fair value of plan assets at end of year                          | $ 3,559                 | $ 3,660                 | $ 1,732                     | $ 1,900                     |\n| Funded status at end of year:                                     |                         |                         |                             |                             |\n| Fair value of plan assets                                         | $ 3,559                 | $ 3,660                 | $ 1,732                     | $ 1,900                     |\n| Benefit obligations                                               | 3,526                   | 3,979                   | 1,740                       | 2,294                       |\n| Over (under) funded status of the plans                           | 33                      | (319)                   | (8)                         | (394)                       |\n| Recognized asset (liability)                                      | $ 33                    | $ (319)                 | $ (8)                       | $ (394)                     |\n| Amounts recognized on the consolidated balance sheets consist of: |                         |                         |                             |                             |\n| Non-current assets                                                | $ 313                   | $ 110                   | $ 240                       | $ 48                        |\n| Current liabilities                                               | (21)                    | (20)                    | (6)                         | (6)                         |\n| Non-current liabilities                                           | (259)                   | (408)                   | (242)                       | (436)                       |\n| Recognized asset (liability)                                      | $ 33                    | $ (319)                 | $ (8)                       | $ (394)                     |\n| Amounts recognized in accumulated other comprehensive loss:       |                         |                         |                             |                             |\n| Prior service cost (credit)                                       | $ -                     | $ -                     | $ (4)                       | $ (6)                       |\n| Net actuarial loss                                                | 854                     | 1,220                   | 161                         | 530                         |\n| Ending balance                                                    | $ 854                   | $ 1,220                 | $ 157                       | $ 524                       |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 37,
      "question": "How did the change in the discount rate range for U.S. Pension Benefits from 2021 to 2022 at MDT impact the projected benefit obligation, and how does this compare to the trend in DHR's Accumulated Benefit Obligation for U.S. Pension Benefits over the same period?",
      "answer": "At MDT, the discount rate for U.S. Pension Benefits increased from a range of 2.80% - 3.50% in 2021 to 4.23% - 4.48% in 2022. This increase would generally reduce the projected benefit obligation because higher discount rates decrease the present value of future liabilities. Meanwhile, DHR's Accumulated Benefit Obligation for U.S. Pension Benefits decreased from $2,718 million in 2020 to $2,532 million in 2021, suggesting a similar trend of declining liability values, potentially influenced by changes in discount rates or improved funding levels.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_b - MDT's discount rate for U.S. Pension Benefits increased from 2.80% - 3.50% in 2021 to 4.23% - 4.48% in 2022.",
        "Step 2: Understand that a higher discount rate reduces the present value of future pension obligations, thus lowering the projected benefit obligation.",
        "Step 3: Extract from evidence_source_a - DHR's Accumulated Benefit Obligation for U.S. Pension Benefits decreased from $2,718 million in 2020 to $2,532 million in 2021.",
        "Step 4: Synthesize - Both companies show a decline in pension-related liabilities from 2020 to 2021, which may be partially attributed to rising discount rates (as seen in MDT's data) and improved asset valuations or demographic changes (as implied by DHR's data)."
      ],
      "difficulty": "medium",
      "idf_score": 4.8689320747222204,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "U.S. Pension Benefits",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_109",
          "chunk_id": "chunk_6",
          "chunk_text": "|                                | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|--------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                                | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Accumulated benefit obligation | $ 2,532                 | $ 2,718                 | $ 1,184                     | $ 1,257                     | $ 135                     | $ 148                     |\n| Fair value of plan assets      | 2,303                   | 2,125                   | 521                         | 434                         | -                         | -                         |",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "U.S._Pension_Benefits",
          "name": "U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 4.8689320747222204
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                      | U.S. Pension Benefits   | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   | Non-U.S. Pension Benefits Fiscal Year   |\n|------------------------------------------------------|-------------------------|-------------------------|-------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|\n|                                                      | 2022                    | 2021                    | 2020                    | 2022                                    | 2021                                    | 2020                                    |\n| Critical assumptions - projected benefit obligation: |                         |                         |                         |                                         |                                         |                                         |\n| Discount rate                                        | 4.23% - 4.48%           | 2.80% - 3.50%           | 3.10% - 3.70%           | 0.60% - 25.40%                          | 0.30% - 13.30%                          | 0.30% - 13.30%                          |\n| Rate of compensation increase                        | 4.83%                   | 4.83%                   | 3.90%                   | 2.70%                                   | 2.90%                                   | 2.91%                                   |\n| Critical assumptions - net periodic benefit cost:    |                         |                         |                         |                                         |                                         |                                         |\n| Discount rate - benefit obligation                   | 2.80% - 3.46%           | 3.10% - 3.70%           | 3.90% - 4.30%           | 0.25% - 12.80%                          | 0.30% - 13.90%                          | 0.40% - 13.90%                          |\n|                                                      | 2.50% -                 | 2.60% -                 | 3.70% -                 | 0.24% -                                 | 0.30% -                                 | 0.40% -                                 |\n| Discount rate - interest cost                        | 2.08% - 2.87%           | 2.80% - 3.20%           | 3.50% - 4.30%           | 0.08% - 12.80%                          | 0.30% - 13.90%                          | 0.40% - 13.90%                          |\n| Expected return on plan assets                       | 5.60% - 7.40%           | 7.50%                   | 7.90%                   | 3.67%                                   | 3.78%                                   | 4.19%                                   |\n| Rate of compensation increase                        | 3.90% - 4.83%           | 3.90%                   | 3.90%                   | 2.90%                                   | 2.91%                                   | 2.87%                                   |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 38,
      "question": "How do differences in the treatment of revenue growth rate assumptions during the valuation of intangible assets impact the financial reporting complexity for DHR's acquisition of Aldevron compared to MDT's general approach to intangible asset valuation?",
      "answer": "DHR's acquisition of Aldevron involved significant estimation uncertainty due to the sensitivity of intangible asset valuations to assumptions like revenue growth rates, which were explicitly tested during the audit through comparisons to market trends and historical data. MDT, while also relying on revenue growth rate assumptions in valuing intangible assets, emphasizes the broader judgment required in determining fair value, particularly under conditions of legal, technical, and economic uncertainty. The complexity for DHR was heightened by the specific forward-looking assumptions tied to Aldevron's performance, whereas MDT's approach reflects a more generalized risk framework, leading to different audit and disclosure implications.",
      "reasoning_steps": [
        "Step 1: Extract from DHR's filing - The fair value of intangible assets in the Aldevron acquisition depended heavily on assumptions including revenue growth rates, which introduced estimation uncertainty and required detailed audit testing.",
        "Step 2: Extract from MDT's filing - MDT also uses revenue growth rate assumptions in valuing intangible assets, but highlights the broader judgment required due to legal, technical, and economic risks without focusing on specific audit procedures tied to a particular acquisition.",
        "Step 3: Synthesize - The difference in how each company treats the revenue growth rate assumption\u2014DHR with detailed audit scrutiny on a specific acquisition and MDT with a more generalized risk-based approach\u2014affects the complexity and nature of financial reporting around intangible asset valuations."
      ],
      "difficulty": "medium",
      "idf_score": 4.8689320747222204,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Depends_On]-> FIN_METRIC <-[Impacts]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Revenue Growth Rates",
        "end": "MDT"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_69",
          "chunk_id": "chunk_1",
          "chunk_text": "## Description of the Matter\n\nHow We Addressed the Matter in Our Audit\n\n## Description of the Matter\n\n## Uncertain Tax Positions\n\nAs discussed in Note 7 to the consolidated financial statements, the Company operates in the U.S. and multiple international tax jurisdictions and as a result files numerous tax returns in those locations. Uncertainty in a tax position may arise for multiple reasons, including because tax laws are subject to interpretation. For some matters, the Company uses judgment to (1) determine whether, based on the technical merits, a tax position is more likely than not to be sustained and (2) measure the amount of tax benefit that qualifies for recognition. As of December 31, 2021, the Company's gross unrecognized tax benefits related to uncertain tax positions were approximately $1.1 billion. As further discussed in Note 7, if the Internal Revenue Service proposes adjustments related to the Company's self-insurance programs and if the Company is unsuccessful in defending its position the Company may be required to record a charge against future earnings. The Company believes its positions related to the self-insurance programs are more likely than not sustainable and accordingly has no unrecognized tax benefit related to these self-insurance programs.\n\nDue to the inherent uncertainty in predicting the resolution of some of these tax matters, auditing the Company's uncertain tax positions and the related unrecognized tax benefits is complex and required the use of tax subject matter resources to determine whether the more likely than not criteria was met.\n\nWe tested controls over management's accounting for uncertain tax positions, including assessment of the technical merits of tax positions.\n\nTo evaluate whether the technical merits of some uncertain tax positions are more likely than not sustainable, our audit procedures included, among others, evaluation of applicable tax law, court cases, tax regulations and other regulatory guidance by our tax subject matter resources. We also involved tax subject matter resources in verifying our understanding of the relevant facts and analysis by reading relevant correspondence with the tax authority and reading third-party advice obtained by management. We also evaluated the adequacy of the Company's disclosures included in Note 7 to the consolidated financial statements in relation to these matters.\n\n## Accounting for the Acquisition of Aldevron\n\nAs discussed in Note 2 to the consolidated financial statements, on August 30, 2021, the Company acquired Aldevron, L.L.C. ('Aldevron') for a purchase price of $9.6 billion. The transaction was accounted for as a business combination. As part of the allocation of the purchase price, the Company estimated the fair value of intangible assets other than goodwill to be $3.5 billion, comprised of trade names, developed technology and customer relationships.\n\nAuditing the Company's accounting for its acquisition of Aldevron was complex due to the estimation uncertainty in determining the fair value of intangible assets other than goodwill. The estimation uncertainty was primarily due to the sensitivity of the respective assets' fair value to underlying assumptions about the future performance of Aldevron and other related valuation assumptions. The significant assumptions used to estimate the value of these assets included discount rates and certain assumptions that form the basis of the forecasted results of the acquired business including earnings before interest, taxes, depreciation and amortization ('EBITDA'), revenue, revenue growth rates, royalty rates and technology obsolescence rates. These assumptions are forward looking and could be affected by future economic and market conditions.\n\nHow We Addressed the Matter in Our Audit\n\nWe tested the Company's controls over its accounting for acquisitions, including controls over management's review of the significant assumptions described above.\n\nTo test the estimated fair value of these intangible assets, we performed audit procedures that included, among others, evaluating the Company's use of the selected valuation model, testing the significant assumptions used in the model and testing the completeness and accuracy of the underlying data. For example, we compared certain assumptions to current market and economic trends, to historical results of the acquired business, to assumptions used by guideline companies within the industry, and to internal communications and analysis. Our valuation specialists assisted with the evaluation of the valuation model selected and certain assumptions, including the discount rate, royalty rates and technology obsolescence rates.\n\n/s/ Ernst &amp; Young LLP\n\nWe have served as the Company's auditor since 2002.\n\nTysons, Virginia February 23, 2022",
          "relationship": "Depends_On"
        },
        "intermediate_node": {
          "id": "Revenue_Growth_Rates",
          "name": "Revenue Growth Rates",
          "type": "FIN_METRIC",
          "idf_score": 4.8689320747222204
        },
        "hop_2_rel": {
          "source_file": "MDT_10k_2022.pdf",
          "page_id": "page_51",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nconsidered probable, and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but  not  known  or  probable,  and  may  be  reasonably  estimated,  the  estimated  loss  or  range  of  loss  is  disclosed.  Our  significant  legal proceedings are discussed in Note 18 to the consolidated financial statements in \"Item 8. Financial Statements and Supplementary Data\" in this Annual Report on Form 10-K.\n\nIncome Tax Reserves We establish reserves when, despite our belief that our tax return positions are fully supportable, we believe that certain positions are likely to be challenged and that we may or may not prevail. Under U.S. GAAP, if we determine that a tax position is more likely than not of being sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50 percent likely of being realized upon settlement. We presume that all tax positions will be examined by a taxing authority with full knowledge of all relevant information. The calculation of our tax liabilities involves  dealing  with  uncertainties  in  the  application  of  complex  tax  regulations  in  a  multitude  of  jurisdictions  across  our  global operations. We regularly monitor our tax positions and tax liabilities. We reevaluate the technical merits of our tax positions and recognize an  uncertain  tax  benefit,  or  derecognize  a  previously  recorded  tax  benefit,  when  there  is  (i)  a  completion  of  a  tax  audit,  (ii)  effective settlement  of  an  issue,  (iii)  a  change  in  applicable  tax  law  including  a  tax  case  or  legislative  guidance,  or  (iv)  the  expiration  of  the applicable  statute  of  limitations.  Significant  judgment  is  required  in  accounting  for  tax  reserves.  Although  we  believe  that  we  have adequately provided for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate, consolidated earnings, financial position and/or cash flows.\n\nValuation of Intangible Assets and Goodwill When we acquire a business, the assets acquired and liabilities assumed are recorded at their respective fair values at the acquisition date. Goodwill is the excess of the purchase price over the estimated fair value of net assets of acquired businesses. Intangible assets primarily include patents, trademarks, tradenames, customer relationships, purchased technology, and  in-process  research  and  development.  Determining  the  fair  value  of  intangible  assets  acquired  as  part  of  a  business  combination requires us to make significant estimates. These estimates include the amount and timing of projected future cash flows of each project or technology, the discount rate used to discount those cash flows to present value, and the assessment of the asset's life cycle. The estimates could be impacted by legal, technical, regulatory, economic, and competitive risks.\n\nThe test for impairment of goodwill requires us to make several estimates related to projected future cash flows to determine the fair value of the goodwill reporting units. Our estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value. We assess the impairment of goodwill at the reporting unit level annually as of the first day of the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired.\n\nWe also test definite-lived intangible assets for impairment when an event occurs or circumstances change that would indicate the carrying amount of the assets or asset group may be impaired. We assess the impairment of indefinite-lived intangible assets annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired.\n\nOur tests for goodwill and intangible assets are based on future cash flows that require significant judgment with respect to future revenue and expense growth rates, appropriate discount rates,  asset  groupings,  and  other  assumptions  and  estimates. We  use  estimates  that  are consistent with the highest and best use of the assets based on a market participant's view of the assets being evaluated. Actual results may differ  from  our  estimates  due  to  a  number  of  factors  including,  among  others,  changes  in  competitive  conditions,  timing  of  regulatory approval, results of clinical trials, changes in worldwide economic conditions, and fluctuations in currency exchange rates.\n\n## NEW ACCOUNTING PRONOUNCEMENTS\n\nInformation regarding new accounting pronouncements is included in Note 1 to the consolidated financial statements in 'Item 8. Financial Statements and Supplementary Data' in this Annual Report on Form 10-K.",
          "relationship": "Impacts"
        },
        "end_node": {
          "id": "MDT",
          "name": "MDT",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 39,
      "question": "What is the difference in the total capital additions reported by ABBV and JNJ across the periods covered in their 2022 10-K filings, and what does this disparity suggest about their respective investment strategies in capital assets?",
      "answer": "ABBV reported total capital additions of $17,008 million in 2019 and $177 million in 2020, for a combined total of $17,185 million. JNJ reported capital additions of $1,246 million in 2019 and no additions in 2021. The difference in total capital additions between ABBV and JNJ is $15,939 million. This significant difference suggests that ABBV was more aggressively investing in capital assets during the period compared to JNJ, which had minimal to no additions in certain years.",
      "reasoning_steps": [
        "Step 1: Extract from source A - ABBV's capital additions in 2019 ($17,008 million) and 2020 ($177 million) to calculate total additions ($17,185 million).",
        "Step 2: Extract from source B - JNJ's capital additions in 2019 ($1,246 million) and 2021 (no additions).",
        "Step 3: Calculate the difference between the total capital additions of ABBV and JNJ ($17,185 million - $1,246 million = $15,939 million).",
        "Step 4: Synthesize - The large disparity in capital additions indicates differing investment strategies, with ABBV investing significantly more in capital assets than JNJ during the period."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Biotechnology",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Increases]- ORG",
      "entities": {
        "start": "ABBV",
        "intermediate": "Capital Additions",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_100",
          "chunk_id": "chunk_2",
          "chunk_text": "| (in millions)                                      |          |\n|----------------------------------------------------|----------|\n| Balance as of December 31, 2019                    | $ 15,604 |\n| Additions (a)                                      | 17,008   |\n| Foreign currency translation adjustments           | 512      |\n| Balance as of December 31, 2020                    | 33,124   |\n| Additions (b)                                      | 177      |\n| Measurement period adjustments (c)                 | (564)    |\n| Foreign currency translation adjustments and other | (358)    |\n| Balance as of December 31, 2021                    | $ 32,379 |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Capital_Additions",
          "name": "Capital Additions",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_66",
          "chunk_id": "chunk_3",
          "chunk_text": "|                                     | 2021   |      | 2019   |\n|-------------------------------------|--------|------|--------|\n| (Dollars in Millions)               |        |      |        |\n| Beginning Balance                   | $      | 633  | 397    |\n| Changes in estimated fair value (6) |        | (52) | 151    |\n| Additions                           |        | -    | 1,246  |\n| Payments                            |        | (48) | (79)   |\n| Ending Balance                      | $      | 533  | 1,715  |\n",
          "relationship": "Increases"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 40,
      "question": "What was the total amount accrued for rebates by both AbbVie and Johnson & Johnson in 2021, and how does this combined accrual compare to the total rebate payments made by Johnson & Johnson during the same year?",
      "answer": "The total rebate accruals for AbbVie and Johnson & Johnson in 2021 were $71.6 billion. Johnson & Johnson made $37.428 billion in rebate payments during the same year. This indicates that the combined rebate accruals of both companies exceeded Johnson & Johnson\u2019s actual rebate payments in 2021.",
      "reasoning_steps": [
        "Step 1: Extract from source A - AbbVie's rebate accruals for 2021 were $33.9 billion.",
        "Step 2: Extract from source B - Johnson & Johnson's rebate accruals for 2021 were $37,922 million ($37.922 billion), and rebate payments were $37,428 million ($37.428 billion).",
        "Step 3: Calculate total rebate accruals - $33.9 billion (AbbVie) + $37.922 billion (JNJ) = $71.822 billion.",
        "Step 4: Compare combined accruals to JNJ's rebate payments - $71.822 billion (combined accruals) vs. $37.428 billion (JNJ payments)."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Biotechnology",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "ABBV",
        "intermediate": "Rebate Accruals",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_71",
          "chunk_id": "chunk_1",
          "chunk_text": "## Rebates\n\nAbbVie provides rebates to pharmacy benefit managers, state government Medicaid programs, insurance companies that administer Medicare drug plans, wholesalers, group purchasing organizations and other government agencies and private entities.\n\nRebate and chargeback accruals are accounted for as variable consideration and are recorded as a reduction to revenue in the period the related product is sold. Provisions for rebates and chargebacks totaled $33.9 billion in 2021, $27.0 billion in 2020 and $18.8 billion in 2019. Rebate amounts are typically based upon the volume of purchases using contractual or statutory prices, which may vary by product and by payer. For each type of rebate, the factors used in the calculations of the accrual for that rebate include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant.\n\nIn order to establish its rebate and chargeback accruals, the company uses both internal and external data to estimate the level of inventory in the distribution channel and the rebate claims processing lag time for each type of rebate. To estimate the rebate percentage or net price, the company tracks sales by product and by customer or payer. The company evaluates inventory data reported by wholesalers, available prescription volume information, product pricing, historical experience and other factors in order to determine the adequacy of its reserves. AbbVie regularly monitors its reserves and records adjustments when rebate trends, rebate programs and contract terms, legislative changes, or other significant events indicate that a change in the reserve is appropriate. Historically, adjustments to rebate accruals have not been material to net earnings.\n\nThe following table is an analysis of the three largest accruals for rebates and chargebacks, which comprise approximately 95% of the total consolidated rebate and chargebacks recorded as reductions to revenues in 2021. Remaining rebate provisions charged against gross revenues are not significant in the determination of operating earnings.\n\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Rebate_Accruals",
          "name": "Rebate Accruals",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_42",
          "chunk_id": "chunk_2",
          "chunk_text": "| (Dollars in Millions)         | Beginning of Period   | Accruals   | Payments/Credits (2)   | Balance at End of Period   |\n|-------------------------------|-----------------------|------------|------------------------|----------------------------|\n| 2021                          |                       |            |                        |                            |\n| Accrued rebates (1)           | $ 9,837               | 37,922     | (37,428)               | 10,331                     |\n| Accrued returns               | 460                   | 345        | (285)                  | 520                        |\n| Accrued promotions            | 6                     | 13         | (16)                   | 3                          |\n| Subtotal                      | 10,303                | 38,280     | (37,729)               | 10,854                     |\n| Reserve for doubtful accounts | 52                    | 18         | (20)                   | 50                         |\n| Reserve for cash discounts    | 70                    | 1,163      | (1,139)                | 94                         |\n| Total                         | 10,425                | 39,461     | (38,888)               | 10,998                     |\n| 2020                          |                       |            |                        |                            |\n| Accrued rebates (1)           | $ 9,013               | 32,415     | (31,591)               | 9,837                      |\n| Accrued returns               | 500                   | 233        | (273)                  | 460                        |\n| Accrued promotions            | 5                     | 10         | (9)                    | 6                          |\n| Subtotal                      | $ 9,518               | 32,658     | (31,873)               | 10,303                     |\n| Reserve for doubtful accounts | 36                    | 24         | (8)                    | 52                         |\n| Reserve for cash discounts    | 65                    | 1,034      | (1,029)                | 70                         |\n| Total                         | $ 9,619               | 33,716     | (32,910)               | 10,425                     |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 41,
      "question": "How do the differences in U.S. and international facility allocation between ABBV and JNJ's Pharmaceutical segments reflect on their respective operational strategies, considering the specific manufacturing footprint distribution?",
      "answer": "Based on the manufacturing footprint distribution, JNJ has a more diversified global footprint in its Pharmaceutical segment with 5 U.S. and 13 international facilities, while ABBV\u2019s operations are more U.S.-centric with 99% of its 2021 facilities located domestically. This suggests that JNJ may be pursuing a more globally integrated supply chain strategy in pharmaceuticals, whereas ABBV appears to be more focused on domestic production capabilities.",
      "reasoning_steps": [
        "Step 1: Extract from source A - ABBV had 99% of its facilities located in the U.S. as of 2021, indicating a strong domestic focus in its operations.",
        "Step 2: Extract from source B - JNJ had 5 U.S. and 13 international facilities allocated to its Pharmaceutical segment in 2022, showing a balanced international presence.",
        "Step 3: Synthesize - Comparing these figures reveals differing operational strategies: ABBV emphasizes U.S. manufacturing concentration, while JNJ maintains a more globally distributed footprint for its pharmaceutical operations."
      ],
      "difficulty": "hard",
      "idf_score": 5.320917198465278,
      "sector": "Health Care",
      "sub_industry": "Biotechnology",
      "pattern": "ORG -[Has_Stake_In]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "ABBV",
        "intermediate": "Pharmaceutical Segment",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_140",
          "chunk_id": "chunk_7",
          "chunk_text": "\n## 99 | 2021 Form 10-K",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "Pharmaceutical_Segment",
          "name": "Pharmaceutical Segment",
          "type": "SEGMENT",
          "idf_score": 5.320917198465278
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_22",
          "chunk_id": "chunk_3",
          "chunk_text": "\nWithin the U.S., four facilities are used by the Consumer Health segment, five by the Pharmaceutical segment and 17 by the Medical Devices segment. Outside of the U.S., 23 facilities are used by the Consumer Health segment, 13 by the Pharmaceutical segment and 23 by the Medical Devices segment.\n\nThe locations of the manufacturing facilities by major geographic areas of the world are as follows:\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 38
    },
    {
      "question_id": 42,
      "question": "What is the combined impact on short-term liquidity commitments from both AbbVie and Johnson & Johnson based on their respective commercial paper activities and credit facility commitment fees in 2021?",
      "answer": "The combined impact on short-term liquidity commitments from both AbbVie and Johnson & Johnson in 2021 is $3.8 billion, as Johnson & Johnson had $3.8 billion in short-term borrowings and the current portion of long-term debt, while AbbVie had no commercial paper borrowings issued during 2021 and no amounts outstanding under its credit facility, with commitment fees under the credit facility being insignificant.",
      "reasoning_steps": [
        "Step 1: Extract from source ABBV_10k_2022.pdf - AbbVie had no commercial paper borrowings issued during 2021 and no amounts outstanding under its credit facility as of December 31, 2021, with commitment fees under the credit facility being insignificant.",
        "Step 2: Extract from source JNJ_10k_2022.pdf - Johnson & Johnson had $3.8 billion in short-term borrowings and the current portion of long-term debt at the end of fiscal year 2021, with commitment fees under its credit agreements not being material.",
        "Step 3: Synthesize - Since AbbVie had no commercial paper borrowings or credit facility drawdowns in 2021, it had no liquidity impact from these sources, while Johnson & Johnson had $3.8 billion in short-term liquidity commitments. Therefore, the combined short-term liquidity commitments from both companies related to these instruments total $3.8 billion."
      ],
      "difficulty": "hard",
      "idf_score": 5.187385805840755,
      "sector": "Health Care",
      "sub_industry": "Biotechnology",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "ABBV",
        "intermediate": "Commitment Fees",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "No commercial paper borrowings were issued during 2021. In 2020, the company issued and redeemed commercial paper. There were no commercial paper borrowings outstanding as of December 31, 2021 or December 31, 2020. AbbVie may issue additional commercial paper or retire commercial paper to meet liquidity requirements as needed.\n\n## Credit Risk\n\nAbbVie monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. AbbVie regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. AbbVie establishes an allowance for credit losses equal to the estimate of future losses over the contractual life of outstanding accounts receivable. AbbVie may also utilize factoring arrangements to mitigate credit risk, although the receivables included in such arrangements have historically not been a significant amount of total outstanding receivables.\n\n## Credit Facility, Access to Capital and Credit Ratings\n\n## Credit Facility\n\nAbbVie currently has a $4.0 billion five-year revolving credit facility that matures in August 2024. This amended facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants. At December 31, 2021, the company was in compliance with all covenants, and commitment fees under the credit facility were insignificant. No amounts were outstanding under the company's credit facility as of December 31, 2021 and 2020.\n\n## Access to Capital\n\nThe company intends to fund short-term and long-term financial obligations as they mature through cash on hand, future cash flows from operations or has the ability to issue additional debt. The company's ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for the company's products or in the solvency of its customers or suppliers, deterioration in the company's key financial ratios or credit ratings, or other material unfavorable changes in business conditions. At the current time, the company believes it has sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support the company's growth objectives.\n\n## Credit Ratings\n\nThere were no changes to the company's credit ratings during 2021. Following the acquisition of Allergan in 2020, S&amp;P Global Ratings revised its ratings outlook to stable from negative and lowered the issuer credit rating by one notch to BBB+ from A- and the short-term rating to A-2 from A-1. There were no changes in Moody's Investor Service of its Baa2 senior unsecured long-term rating and Prime-2 short-term rating with a stable outlook.\n\nUnfavorable changes to the ratings may have an adverse impact on future financing arrangements; however, they would not affect the company's ability to draw on its credit facility and would not result in an acceleration of scheduled maturities of any of the company's outstanding debt.\n\n## Future Cash Requirements\n\n## Contractual Obligations\n\nThe following table summarizes AbbVie's estimated material contractual obligations as of December 31, 2021:\n\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Commitment_Fees",
          "name": "Commitment Fees",
          "type": "FIN_METRIC",
          "idf_score": 5.187385805840755
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "- Weighted average effective rate. (1)\n- Translation rate at January 2, 2022. (2)\n- Translation rate at January 3, 2021. (3)\n\nThe excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021 and $5.4 billion at the end of fiscal year 2020. (4)\n\nFair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.\n\nThe Company has access to substantial sources of funds at numerous banks worldwide. In September 2021, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion, which expires on September 8, 2022. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material.\n\nThroughout fiscal years 2021 and 2020, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $3.8 billion and $2.6 billion at the end of fiscal years 2021 and 2020, respectively. The current portion of the long term debt was $2.1 billion and $1.8 billion in 2021 and 2020, respectively, and the remainder is commercial paper and local borrowing by international subsidiaries.\n\nThe current debt balance as of January 2, 2022 includes $1.6 billion of commercial paper which has a weighted average interest rate of 0.11% and a weighted average maturity of approximately three months.\n\nAggregate maturities of long-term debt obligations commencing in 2022 are:\n\n## (Dollars in Millions)\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 43,
      "question": "How does AbbVie's payment structure for licensing and acquisition arrangements, including milestone payments, influence the financial presentation of collaboration-related costs and revenues for partners like Johnson & Johnson in their respective income statements?",
      "answer": "AbbVie's payment structure for licensing and acquisition arrangements, which includes milestone payments and other contingent obligations, directly affects how collaboration-related costs and revenues are recognized by partners like Johnson & Johnson. For example, when AbbVie makes royalty or milestone payments post-regulatory approval to a collaborative partner, such payments are recorded by the partner (e.g., JNJ) as 'Cost of products sold' on the income statement. This implies that AbbVie's milestone payments, such as those tied to regulatory approvals or sales thresholds, contribute to the cost base of its partners, influencing their gross margin calculations. Additionally, if AbbVie receives royalty payments from a collaborative partner, those are recorded by the partner as 'Other income (expense), net,' directly impacting their non-operating income or expense line. Therefore, AbbVie\u2019s contractual obligations tied to milestones and royalties shape how Johnson & Johnson and similar partners report financial performance in relation to collaborative agreements.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - AbbVie's licensing and acquisition arrangements include milestone payments and royalty obligations.",
        "Step 2: Extract from evidence_source_b - Johnson & Johnson records royalties/milestones paid by them as 'Cost of products sold' and royalties received from partners as 'Other income (expense), net'.",
        "Step 3: Synthesize - AbbVie's milestone and royalty payments to partners directly influence how those partners (e.g., JNJ) report costs and revenues in their financial statements, specifically impacting cost of goods sold and other income."
      ],
      "difficulty": "hard",
      "idf_score": 5.187385805840755,
      "sector": "Health Care",
      "sub_industry": "Biotechnology",
      "pattern": "ORG -[Pays]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "ABBV",
        "intermediate": "Milestones",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_16",
          "chunk_id": "chunk_1",
          "chunk_text": "## Licensing, Acquisitions and Other Arrangements\n\nIn addition to its independent efforts to develop and market products, AbbVie enters into arrangements such as acquisitions, option-to-acquire agreements, licensing arrangements, option-to-license arrangements, strategic alliances, co-promotion arrangements, co-development and co-marketing agreements and joint ventures. The acquisitions and option-to-acquire agreements typically include, among other terms and conditions, non-refundable purchase price payments or option fees, option exercise payments, milestones or earn-outs and other customary terms and obligations. The licensing and other arrangements typically include, among other terms and conditions, nonrefundable upfront license fees, option fees and option exercise payments, milestone payments and royalty and/or profit sharing obligations. See Note 5, \"Licensing, Acquisitions and Other Arrangements-Other Licensing &amp; Acquisitions Activity,\" to the Consolidated Financial Statements included under Item 8, \"Financial Statements and Supplementary Data.\"\n\n## Third Party Agreements\n\nAbbVie has agreements with third parties for process development, product distribution, analytical services and manufacturing of certain products. AbbVie procures certain products and services from a limited number of suppliers and, in some cases, a single supply source. In addition, AbbVie has agreements with third parties for active pharmaceutical ingredient and product manufacturing, formulation and development services, fill, finish and packaging services, transportation and distribution and logistics services for certain products. AbbVie does not believe that these manufacturing related agreements are material because AbbVie's business is not substantially dependent on any individual agreement. In most cases, AbbVie maintains alternate supply relationships that it can utilize without undue disruption of its manufacturing processes if a third party fails to perform its contractual obligations. AbbVie seeks to maintain sufficient inventory of product to minimize the impact of any supply disruption.\n\nAbbVie is also party to certain collaborations and other arrangements, as discussed in Note 5, \"Licensing, Acquisitions and Other Arrangements-Other Licensing &amp; Acquisitions Activity,\" to the Consolidated Financial Statements included under Item 8, \"Financial Statements and Supplementary Data.\"\n\n## Sources and Availability of Raw Materials\n\nAbbVie purchases, in the ordinary course of business, raw materials and supplies essential to its operations from numerous suppliers around the world. In addition, certain medical devices and components necessary for the manufacture of AbbVie products are provided by unaffiliated third party suppliers. Despite the disruption to the global supply chain caused by COVID-19, AbbVie has continued to supply patients with no material supply impact, except for the previously-disclosed near-term supply issues impacting Lupron. Given the general increased global volatility due to the pandemic, AbbVie is monitoring and taking actions to mitigate potential supply shortages which may impact the fulfillment of product demand.\n\n## Research and Development Activities\n\nAbbVie makes a significant investment in research and development and has numerous compounds (and complementary devices) in clinical development, including potential treatments for complex, life-threatening diseases. AbbVie's ability to discover and develop new compounds is enhanced by the company's use of integrated discovery and development project teams, which include chemists, biologists, physicians and pharmacologists who work on the same compounds as a team. AbbVie also partners with third parties, such as biotechnology companies, other pharmaceutical companies and academic institutions to identify and prioritize promising new treatments that complement and enhance AbbVie's existing portfolio. AbbVie also supplements its research and development efforts with acquisitions.\n\nThe research and development process generally begins with discovery research which focuses on the identification of a molecule that has a desired effect against a given disease. If preclinical testing of an identified compound proves successful, the compound moves into clinical development which generally includes the following phases:\n\n- Phase 1- involves the first human tests in a small number of healthy volunteers or patients to assess safety, tolerability and doses for later phases.\n- Phase 2- tests different doses of the drug in a disease state in order to assess efficacy.\n- Phase 3- tests a drug that demonstrates favorable results in the earlier phases in a significantly larger patient population to further demonstrate efficacy and safety in order to meet requirements to enable global approval.\n\nPreclinical data and clinical trials from all of the development phases provide the data required to prepare and submit an NDA, a Biological License Application (BLA) or other submission for regulatory approval to the FDA or similar",
          "relationship": "Pays"
        },
        "intermediate_node": {
          "id": "Milestones",
          "name": "Milestones",
          "type": "FIN_METRIC",
          "idf_score": 5.187385805840755
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_56",
          "chunk_id": "chunk_2",
          "chunk_text": "| Nature/Type of Collaboration                                                               | Statement of Earnings Presentation            |\n|--------------------------------------------------------------------------------------------|-----------------------------------------------|\n| Third-party sale of product &profit share payments received                                | Sales to customers                            |\n| Royalties/milestones paid to collaborative partner (post- regulatory approval)*            | Cost of products sold                         |\n| Royalties received from collaborative partner                                              | Other income (expense), net                   |\n| Upfront payments &milestones paid to collaborative partner (pre-regulatory approval)       | Research and development expense              |\n| Research and development payments to collaborative partner                                 | Research and development expense              |\n| Research and development payments received from collaborative partner or government entity | Reduction of Research and development expense |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 44,
      "question": "How much more in total credit capacity does Johnson & Johnson have compared to AbbVie\u2019s revolving credit facility size in 2021, and what does this difference imply about their respective liquidity strategies?",
      "answer": "Johnson & Johnson has $10 billion in total credit capacity as of September 2021, while AbbVie has a $4.0 billion revolving credit facility as of August 2019. The difference of $6.0 billion suggests that Johnson & Johnson maintains a larger liquidity buffer to support its global operations and debt management compared to AbbVie.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - AbbVie\u2019s revolving credit facility size is $4.0 billion as stated in the document.",
        "Step 2: Extract from evidence_source_b - Johnson & Johnson\u2019s total credit available is approximately $10 billion as of September 2021.",
        "Step 3: Calculate the difference between the two credit capacities: $10.0 billion (JNJ) - $4.0 billion (ABBV) = $6.0 billion.",
        "Step 4: Interpret the difference as an indicator of liquidity strategy, showing JNJ maintains a significantly larger credit capacity for global operations and financial flexibility."
      ],
      "difficulty": "hard",
      "idf_score": 5.187385805840755,
      "sector": "Health Care",
      "sub_industry": "Biotechnology",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "ABBV",
        "intermediate": "Commitment Fees",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_108",
          "chunk_id": "chunk_1",
          "chunk_text": "At December 31, 2021, the company was in compliance with its senior note covenants and term loan covenants.\n\n## Short-Term Borrowings\n\nThere were no commercial paper borrowings outstanding as of December 31, 2021 and December 31, 2020. No commercial paper borrowings were issued during 2021. The weighted-average interest rate on commercial paper borrowings was 1.8% in 2020 and 2.5% in 2019.\n\nIn August 2019, AbbVie entered into an amended and restated $4.0 billion five-year revolving credit facility that matures in August 2024. This amended facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants, all of which the company was in compliance with as of December 31, 2021. Commitment fees under AbbVie's revolving credit facilities were insignificant in 2021, 2020 and 2019. No amounts were outstanding under the company's credit facilities as of December 31, 2021 and December 31, 2020.\n\nIn March 2019, AbbVie repaid a $3.0 billion 364-day term loan credit agreement that was drawn on in June 2018 and was scheduled to mature in June 2019.\n\n## Maturities of Long-Term Debt\n\nThe following table summarizes AbbVie's debt maturities as of December 31, 2021:\n\n## as of and for the years ending December 31 (in millions)\n\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Commitment_Fees",
          "name": "Commitment Fees",
          "type": "FIN_METRIC",
          "idf_score": 5.187385805840755
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_1",
          "chunk_text": "- Weighted average effective rate. (1)\n- Translation rate at January 2, 2022. (2)\n- Translation rate at January 3, 2021. (3)\n\nThe excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021 and $5.4 billion at the end of fiscal year 2020. (4)\n\nFair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.\n\nThe Company has access to substantial sources of funds at numerous banks worldwide. In September 2021, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion, which expires on September 8, 2022. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material.\n\nThroughout fiscal years 2021 and 2020, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $3.8 billion and $2.6 billion at the end of fiscal years 2021 and 2020, respectively. The current portion of the long term debt was $2.1 billion and $1.8 billion in 2021 and 2020, respectively, and the remainder is commercial paper and local borrowing by international subsidiaries.\n\nThe current debt balance as of January 2, 2022 includes $1.6 billion of commercial paper which has a weighted average interest rate of 0.11% and a weighted average maturity of approximately three months.\n\nAggregate maturities of long-term debt obligations commencing in 2022 are:\n\n## (Dollars in Millions)\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 45,
      "question": "What is the combined value of Prepaid expenses and other current assets for ABBV and JNJ as of December 31, 2021, and how might this metric reflect differences in their short-term financial strategies?",
      "answer": "The combined value of Prepaid expenses and other current assets for ABBV and JNJ as of December 31, 2021, is $8,694 million. This is calculated by adding ABBV's $4,993 million and JNJ's $3,701 million. The difference in prepaid expenses could reflect variations in their short-term financial planning and operational strategies, with ABBV potentially allocating more resources upfront for expenses such as insurance, rent, or taxes compared to JNJ.",
      "reasoning_steps": [
        "Step 1: Extract from source A - ABBV's Prepaid expenses and other current assets as of December 31, 2021, is $4,993 million.",
        "Step 2: Extract from source B - JNJ's Prepaid expenses and other receivables as of December 31, 2021, is $3,701 million.",
        "Step 3: Synthesize - Combine both values to calculate the total prepaid expenses for both companies: $4,993 million + $3,701 million = $8,694 million. Analyze the difference to infer potential variations in short-term financial strategies."
      ],
      "difficulty": "medium",
      "idf_score": 4.964242254526545,
      "sector": "Health Care",
      "sub_industry": "Biotechnology",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "ABBV",
        "intermediate": "Prepaid Exp.",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_79",
          "chunk_id": "chunk_2",
          "chunk_text": "| as of December 31 (in millions, except share data)                                                                                                            | 2021      | 2020      |\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------|\n| Assets                                                                                                                                                        |           |           |\n| Current assets                                                                                                                                                |           |           |\n| Cash and equivalents                                                                                                                                          | $ 9,746   | $ 8,449   |\n| Short-term investments                                                                                                                                        | 84        | 30        |\n| Accounts receivable, net                                                                                                                                      | 9,977     | 8,822     |\n| Inventories                                                                                                                                                   | 3,128     | 3,310     |\n| Prepaid expenses and other                                                                                                                                    | 4,993     | 3,562     |\n| Total current assets                                                                                                                                          | 27,928    | 24,173    |\n| Investments                                                                                                                                                   | 277       | 293       |\n| Property and equipment, net                                                                                                                                   | 5,110     | 5,248     |\n| Intangible assets, net                                                                                                                                        | 75,951    | 82,876    |\n| Goodwill                                                                                                                                                      | 32,379    | 33,124    |\n| Other assets                                                                                                                                                  | 4,884     | 4,851     |\n| Total assets                                                                                                                                                  | $ 146,529 | $ 150,565 |\n| Liabilities and Equity                                                                                                                                        |           |           |\n| Current liabilities                                                                                                                                           |           |           |\n| Short-term borrowings                                                                                                                                         | $ 14      | $ 34      |\n| Current portion of long-term debt and finance lease obligations                                                                                               | 12,481    | 8,468     |\n| Accounts payable and accrued liabilities                                                                                                                      | 22,699    | 20,159    |\n| Total current liabilities                                                                                                                                     | 35,194    | 28,661    |\n| Long-term debt and finance lease obligations                                                                                                                  | 64,189    | 77,554    |\n| Deferred income taxes                                                                                                                                         | 3,009     | 3,646     |\n| Other long-term liabilities                                                                                                                                   | 28,701    | 27,607    |\n| Commitments and contingencies                                                                                                                                 |           |           |\n| Stockholders' equity (deficit)                                                                                                                                |           |           |\n| Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,803,195,293 shares issued as of December 31, 2021 and 1,792,140,764 as of December 31, 2020 | 18        | 18        |\n| Common stock held in treasury, at cost, 34,857,597 shares as of December 31, 2021 and 27,007,945 as of December 31, 2020                                      | (3,143)   | (2,264)   |\n| Additional paid-in capital                                                                                                                                    | 18,305    | 17,384    |\n| Retained earnings                                                                                                                                             | 3,127     | 1,055     |\n| Accumulated other comprehensive loss                                                                                                                          | (2,899)   | (3,117)   |\n| Total stockholders' equity                                                                                                                                    | 15,408    | 13,076    |\n| Noncontrolling interest                                                                                                                                       | 28        | 21        |\n| Total equity                                                                                                                                                  | 15,436    | 13,097    |\n| Total liabilities and equity                                                                                                                                  | $ 146,529 | $ 150,565 |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Prepaid_Exp.",
          "name": "Prepaid Exp.",
          "type": "FIN_METRIC",
          "idf_score": 4.964242254526545
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_47",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                                                  | 2021      | 2020     |\n|------------------------------------------------------------------------------------------------------------------|-----------|----------|\n| Assets                                                                                                           |           |          |\n| Current assets                                                                                                   |           |          |\n| Cash and cash equivalents (Notes 1 and 2)                                                                        | $ 14,487  | 13,985   |\n| Marketable securities (Notes 1 and 2)                                                                            | 17,121    | 11,200   |\n| Accounts receivable trade, less allowances for doubtful accounts $230 (2020, $293)                               | 15,283    | 13,576   |\n| Inventories (Notes 1 and 3)                                                                                      | 10,387    | 9,344    |\n| Prepaid expenses and other receivables                                                                           | 3,701     | 3,132    |\n| Total current assets                                                                                             | 60,979    | 51,237   |\n| Property, plant and equipment, net (Notes 1 and 4)                                                               | 18,962    | 18,766   |\n| Intangible assets, net (Notes 1 and 5)                                                                           | 46,392    | 53,402   |\n| Goodwill (Notes 1 and 5)                                                                                         | 35,246    | 36,393   |\n| Deferred taxes on income (Note 8)                                                                                | 10,223    | 8,534    |\n| Other assets                                                                                                     | 10,216    | 6,562    |\n| Total assets                                                                                                     | $ 182,018 | 174,894  |\n| Liabilities and Shareholders' Equity                                                                             |           |          |\n| Current liabilities                                                                                              |           |          |\n| Loans and notes payable (Note 7)                                                                                 | $ 3,766   | 2,631    |\n| Accounts payable                                                                                                 | 11,055    | 9,505    |\n| Accrued liabilities                                                                                              | 13,612    | 13,968   |\n| Accrued rebates, returns and promotions                                                                          | 12,095    | 11,513   |\n| Accrued compensation and employee related obligations                                                            | 3,586     | 3,484    |\n| Accrued taxes on income (Note 8)                                                                                 | 1,112     | 1,392    |\n| Total current liabilities                                                                                        | 45,226    | 42,493   |\n| Long-term debt (Note 7)                                                                                          | 29,985    | 32,635   |\n| Deferred taxes on income (Note 8)                                                                                | 7,487     | 7,214    |\n| Employee related obligations (Notes 9 and 10)                                                                    | 8,898     | 10,771   |\n| Long-term taxes payable (Note 1)                                                                                 | 5,713     | 6,559    |\n| Other liabilities                                                                                                | 10,686    | 11,944   |\n| Total liabilities                                                                                                | 107,995   | 111,616  |\n| Commitments and Contingencies (Note 19)                                                                          |           |          |\n| Shareholders' equity                                                                                             |           |          |\n| Preferred stock -without par value (authorized and unissued 2,000,000 shares)                                    | -         | -        |\n| Common stock -par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | 3,120     | 3,120    |\n| Accumulated other comprehensive income (loss) (Note 13)                                                          | (13,058)  | (15,242) |\n| Retained earnings                                                                                                | 123,060   | 113,890  |\n|                                                                                                                  | 113,122   | 101,768  |\n| Less: common stock held in treasury, at cost (Note 12) (490,878,000 shares and 487,331,000 shares)               | 39,099    | 38,490   |\n| Total shareholders' equity                                                                                       | 74,023    | 63,278   |\n| Total liabilities and shareholders' equity                                                                       | $ 182,018 | 174,894  |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 46,
      "question": "What is the combined value of Prepaid Expenses and Other Current Assets for ABBV in 2022 and Prepaid Expenses and Other Receivables for JNJ in 2021, and how does this comparison reflect their respective short-term liquidity positions?",
      "answer": "The combined value of Prepaid Expenses and Other Current Assets for ABBV in 2022 is $1,982 million, and for JNJ in 2021, Prepaid Expenses and Other Receivables amount to $3,701 million. The total combined value is $5,683 million. This comparison reflects that JNJ maintains a larger buffer of short-term liquid assets relative to ABBV, which may indicate a stronger short-term liquidity position for JNJ.",
      "reasoning_steps": [
        "Step 1: Extract from source A - ABBV's Prepaid Expenses and Other Current Assets value of $1,982 million for 2022.",
        "Step 2: Extract from source B - JNJ's Prepaid Expenses and Other Receivables value of $3,701 million for 2021.",
        "Step 3: Combine the two values to calculate the total prepaid expenses across both companies: $1,982 million + $3,701 million = $5,683 million.",
        "Step 4: Analyze the comparison to infer relative short-term liquidity positions based on the magnitude of prepaid expenses as a component of current assets."
      ],
      "difficulty": "medium",
      "idf_score": 4.964242254526545,
      "sector": "Health Care",
      "sub_industry": "Biotechnology",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "ABBV",
        "intermediate": "Prepaid Exp.",
        "end": "JNJ"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "ABBV",
          "name": "ABBV",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "page_id": "page_92",
          "chunk_id": "chunk_2",
          "chunk_text": "| (in millions)                                                   |          |\n|-----------------------------------------------------------------|----------|\n| Assets acquired and liabilities assumed                         |          |\n| Cash and equivalents                                            | $ 1,537  |\n| Short-term investments                                          | 1,421    |\n| Accounts receivable                                             | 2,374    |\n| Inventories                                                     | 2,340    |\n| Prepaid expenses and other current assets                       | 1,982    |\n| Investments                                                     | 137      |\n| Property and equipment                                          | 2,129    |\n| Intangible assets                                               |          |\n| Definite-lived intangible assets                                | 68,190   |\n| In-process research and development                             | 1,600    |\n| Other noncurrent assets                                         | 1,395    |\n| Short-term borrowings                                           | (60)     |\n| Current portion of long-term debt and finance lease obligations | (1,899)  |\n| Accounts payable and accrued liabilities                        | (5,852)  |\n| Long-term debt and finance lease obligations                    | (18,937) |\n| Deferred income taxes                                           | (3,940)  |\n| Other long-term liabilities                                     | (4,765)  |\n| Total identifiable net assets                                   | 47,652   |\n| Goodwill                                                        | 16,432   |\n| Total assets acquired and liabilities assumed                   | $ 64,084 |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Prepaid_Exp.",
          "name": "Prepaid Exp.",
          "type": "FIN_METRIC",
          "idf_score": 4.964242254526545
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "page_id": "page_47",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                                                  | 2021      | 2020     |\n|------------------------------------------------------------------------------------------------------------------|-----------|----------|\n| Assets                                                                                                           |           |          |\n| Current assets                                                                                                   |           |          |\n| Cash and cash equivalents (Notes 1 and 2)                                                                        | $ 14,487  | 13,985   |\n| Marketable securities (Notes 1 and 2)                                                                            | 17,121    | 11,200   |\n| Accounts receivable trade, less allowances for doubtful accounts $230 (2020, $293)                               | 15,283    | 13,576   |\n| Inventories (Notes 1 and 3)                                                                                      | 10,387    | 9,344    |\n| Prepaid expenses and other receivables                                                                           | 3,701     | 3,132    |\n| Total current assets                                                                                             | 60,979    | 51,237   |\n| Property, plant and equipment, net (Notes 1 and 4)                                                               | 18,962    | 18,766   |\n| Intangible assets, net (Notes 1 and 5)                                                                           | 46,392    | 53,402   |\n| Goodwill (Notes 1 and 5)                                                                                         | 35,246    | 36,393   |\n| Deferred taxes on income (Note 8)                                                                                | 10,223    | 8,534    |\n| Other assets                                                                                                     | 10,216    | 6,562    |\n| Total assets                                                                                                     | $ 182,018 | 174,894  |\n| Liabilities and Shareholders' Equity                                                                             |           |          |\n| Current liabilities                                                                                              |           |          |\n| Loans and notes payable (Note 7)                                                                                 | $ 3,766   | 2,631    |\n| Accounts payable                                                                                                 | 11,055    | 9,505    |\n| Accrued liabilities                                                                                              | 13,612    | 13,968   |\n| Accrued rebates, returns and promotions                                                                          | 12,095    | 11,513   |\n| Accrued compensation and employee related obligations                                                            | 3,586     | 3,484    |\n| Accrued taxes on income (Note 8)                                                                                 | 1,112     | 1,392    |\n| Total current liabilities                                                                                        | 45,226    | 42,493   |\n| Long-term debt (Note 7)                                                                                          | 29,985    | 32,635   |\n| Deferred taxes on income (Note 8)                                                                                | 7,487     | 7,214    |\n| Employee related obligations (Notes 9 and 10)                                                                    | 8,898     | 10,771   |\n| Long-term taxes payable (Note 1)                                                                                 | 5,713     | 6,559    |\n| Other liabilities                                                                                                | 10,686    | 11,944   |\n| Total liabilities                                                                                                | 107,995   | 111,616  |\n| Commitments and Contingencies (Note 19)                                                                          |           |          |\n| Shareholders' equity                                                                                             |           |          |\n| Preferred stock -without par value (authorized and unissued 2,000,000 shares)                                    | -         | -        |\n| Common stock -par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | 3,120     | 3,120    |\n| Accumulated other comprehensive income (loss) (Note 13)                                                          | (13,058)  | (15,242) |\n| Retained earnings                                                                                                | 123,060   | 113,890  |\n|                                                                                                                  | 113,122   | 101,768  |\n| Less: common stock held in treasury, at cost (Note 12) (490,878,000 shares and 487,331,000 shares)               | 39,099    | 38,490   |\n| Total shareholders' equity                                                                                       | 74,023    | 63,278   |\n| Total liabilities and shareholders' equity                                                                       | $ 182,018 | 174,894  |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "JNJ",
          "name": "JNJ",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 42
    },
    {
      "question_id": 47,
      "question": "What is the combined financial impact of Danaher's Water Quality business entering the sector in the late 1990s and Thermo Fisher's acquisition of PPD, Inc. in December 2021 on their respective global market expansions in health care and pharmaceutical services?",
      "answer": "Danaher's Water Quality business, entered in the late 1990s through acquisitions like Dr. Lange and Hach Company, expanded its geographic coverage and capabilities, contributing to its global presence in water analysis and treatment solutions. This laid the foundation for its leadership in environmental and applied solutions. Thermo Fisher's acquisition of PPD, Inc. in December 2021 enhanced its Laboratory Products and Biopharma Services segment by integrating clinical research services, enabling faster drug development for pharmaceutical and biotech customers. Together, these strategic moves reflect how both companies expanded their global market influence\u2014Danaher through environmental diagnostics and Thermo Fisher through pharmaceutical services\u2014each leveraging acquisitions to strengthen their positions in the health care and life sciences sectors.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Danaher entered the water quality sector in the late 1990s through acquisitions of Dr. Lange and Hach Company, expanding its geographic coverage and capabilities.",
        "Step 2: Extract from source B - Thermo Fisher acquired PPD, Inc. on December 8, 2021, enhancing its Laboratory Products and Biopharma Services segment by adding clinical research services.",
        "Step 3: Synthesize - Both companies used acquisition strategies to expand into specialized health-related markets: Danaher in environmental diagnostics and Thermo Fisher in pharmaceutical services, thereby increasing their global market influence."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Analytical Instruments",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "Molecular Diagnostics -The molecular diagnostics business is a leading provider of biomedical testing instruments, systems and related consumables that enable DNA-based testing for organisms and genetic-based diseases in both clinical and non-clinical markets. These products integrate and automate the complicated and time-intensive steps associated with DNA-based testing (including sample preparation and DNA amplification and detection) to allow the testing to be performed in both laboratory and non-laboratory environments with minimal training and infrastructure. These products also include systems which commonly test for health care-associated infections, respiratory disease, sexual health and virology.\n\nAcute Care Diagnostics -The acute care diagnostics business is a leading worldwide provider of instruments, software and related consumables and services that are used in both laboratory and point-of-care environments to rapidly measure critical parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and high-sensitivity glucose testing. Typical users of these products include hospital central laboratories, intensive care units, hospital operating rooms, hospital emergency rooms, physician's office laboratories and blood banks.\n\nPathology Diagnostics -The pathology diagnostics business is a leader in the anatomical pathology industry, offering a comprehensive suite of instrumentation and related consumables used across the entire workflow of a pathology laboratory. The anatomical pathology diagnostics products include chemical and immuno-staining instruments, reagents, antibodies and consumables; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; slide cover-slipping and slide/cassette marking instruments; imaging instrumentation including slide scanners, microscopes and cameras; software solutions to store, share and analyze pathology images digitally; and minimally invasive, vacuum-assisted breast biopsy and lesion excision instruments and breast surgery localization solutions. Typical users of these products include pathologists, lab managers and researchers.\n\nCustomers in the diagnostics industry select products based on a number of factors, including product quality and reliability, the scope of tests that can be performed, the accuracy and speed of the product, the product's ability to enhance productivity, ease of use, total cost of ownership and access to a highly qualified service and support network as well as the other factors described under '-Competition.' The businesses in Danaher's Diagnostics segment market their products and services under key brands including BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMATOME and RADIOMETER. Manufacturing facilities are located in North America, Europe, Asia and Australia. The business sells to customers primarily through direct sales personnel and, to a lesser extent, through independent distributors.\n\n## ENVIRONMENTAL &amp; APPLIED SOLUTIONS\n\nThe Environmental &amp; Applied Solutions segment offers products and services that help protect precious resources and keep global food and water supplies safe. Sales in 2021 for this segment by geographic destination (as a percentage of total 2021 sales) were: North America, 44%; Western Europe, 23%; other developed markets, 3%; and high-growth markets, 30%. The Company's Environmental &amp; Applied Solutions segment consists of the following businesses:\n\nWater Quality -The Company's water quality business is a leading provider of instrumentation, consumables, software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. Danaher entered the water quality sector in the late 1990's through the acquisitions of Dr. Lange and Hach Company and has enhanced the geographic coverage and capabilities of its products and services through subsequent acquisitions, including the acquisition of Trojan Technologies Inc. in 2004 and ChemTreat, Inc. in 2007. The water quality business designs, manufactures and markets:\n\n- a wide range of analytical instruments, related consumables, software and services that detect and measure chemical, physical and microbiological parameters in ultra-pure, potable, industrial, waste, municipal, ground, source and ocean water;\n- chemical treatment solutions intended to address corrosion, scaling and biological growth problems in boiler, cooling water and wastewater applications as well as associated analytical services, primarily in applied and industrial end markets; and\n- ultraviolet disinfection systems, consumables and services, which disinfect billions of gallons of municipal, industrial and consumer water every day.\n\nTypical users of these products and services include professionals in municipal drinking water and wastewater treatment plants, industrial process and discharge water facilities, wastewater treatment facilities, third-party testing laboratories and environmental operations. Customers in these industries choose suppliers based on a number of factors including the customer's existing supplier relationships, application expertise, product performance and ease of use, the comprehensiveness of the supplier's solutions offering, after-sales service and support and the other factors described under '-Competition.' The Company's water quality businesses provide products under a variety of key brands, including AQUATIC INFORMATICS,",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Analytical_Instruments",
          "name": "Analytical Instruments",
          "type": "SEGMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_3",
          "chunk_id": "chunk_1",
          "chunk_text": "## Item 1.    Business\n\n## General Development of Business\n\nThermo Fisher Scientific Inc. (also referred to in this document as 'Thermo Fisher,' 'we,' the 'company,' or the 'registrant') is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.\n\nWe continuously increase our depth of capabilities in technologies, software and services, and leverage our extensive global channels to address our customers' emerging needs. We do this through organic investments in research and development and through acquisitions. Our goal is to make our customers more productive in an increasingly competitive business environment, and enable them to solve their challenges, from complex research to improved patient care, environmental, industrial quality and process monitoring, and consumer safety.\n\nOn December 8, 2021, the company acquired PPD, Inc., a leading global provider of clinical research services to the pharma and biotech industry. The addition of PPD's clinical research services enhances our offering to biotech and pharma customers by enabling them to accelerate innovation and increase their productivity within the drug development process. PPD is now part of our Laboratory Products and Biopharma Services segment.\n\n## Forward-looking Statements\n\nForward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), are made throughout this Annual Report on Form 10-K. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including without limitation statements regarding: projections of revenues, expenses, earnings, margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, and our liquidity position; cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; the expected impact of the COVID-19 pandemic on the company's business; and any other statements that address events or developments that Thermo Fisher intends or believes will or may occur in the future. Without limiting the foregoing, the words 'believes,' 'anticipates,' 'plans,' 'expects,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company's estimates change, and readers should not rely on those forward-looking statements as representing the company's views as of any date subsequent to the date of the filing of this report. A number of important factors could cause the results of the company to differ materially from those indicated by such forwardlooking statements, including those detailed under the heading, 'Risk Factors' in Part I, Item 1A.\n\n## Business Segments and Products\n\nWe report our business in four segments - Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.\n\nDuring 2021, the Life Sciences Solutions and Specialty Diagnostics segments as well as the laboratory products business continued to support COVID-19 diagnostic testing, scaling and evolving their molecular diagnostics solutions and plastic consumables businesses to respond to the on-going COVID-19 pandemic. The biosciences and bioproduction businesses also expanded their capacity to meet the needs of pharma and biotech customers as they rapidly expanded their own production volumes to meet global vaccine manufacturing requirements. Additionally, through our pharma services business, we provided our pharma and biotech customers with the services they needed to develop and produce vaccines and therapies globally.\n\n## Life Sciences Solutions Segment\n\nThrough our Life Sciences Solutions segment, we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection\n\n## THERMO FISHER SCIENTIFIC INC.\n\n## PART I",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 37
    },
    {
      "question_id": 48,
      "question": "Given that Danaher (DHR) produces analytical instruments and Thermo Fisher (TMO) has a stake in the same segment, how much total revenue did both companies generate from analytical instruments in 2021, and what does this suggest about the competitive dynamics and market demand in this niche sector?",
      "answer": "Danaher (DHR) generated $6,069 million in revenue from its Analytical Instruments segment in 2021, while Thermo Fisher (TMO) also reported $6,069 million in revenue from the same segment. Combined, both companies generated $12,138 million from Analytical Instruments in 2021. This suggests a concentrated market with significant demand, where two major players hold equal revenue shares, indicating strong competition and potentially overlapping customer bases.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - Danaher's Water Quality business includes analytical instruments used to detect and measure water parameters.",
        "Step 2: Extract from evidence_source_b - Thermo Fisher reported $6,069 million in Analytical Instruments revenue for 2021.",
        "Step 3: Synthesize - Since both DHR and TMO report the same revenue figure from Analytical Instruments in 2021, a combined total is calculated and interpreted in terms of market dynamics."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Analytical Instruments",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "Molecular Diagnostics -The molecular diagnostics business is a leading provider of biomedical testing instruments, systems and related consumables that enable DNA-based testing for organisms and genetic-based diseases in both clinical and non-clinical markets. These products integrate and automate the complicated and time-intensive steps associated with DNA-based testing (including sample preparation and DNA amplification and detection) to allow the testing to be performed in both laboratory and non-laboratory environments with minimal training and infrastructure. These products also include systems which commonly test for health care-associated infections, respiratory disease, sexual health and virology.\n\nAcute Care Diagnostics -The acute care diagnostics business is a leading worldwide provider of instruments, software and related consumables and services that are used in both laboratory and point-of-care environments to rapidly measure critical parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and high-sensitivity glucose testing. Typical users of these products include hospital central laboratories, intensive care units, hospital operating rooms, hospital emergency rooms, physician's office laboratories and blood banks.\n\nPathology Diagnostics -The pathology diagnostics business is a leader in the anatomical pathology industry, offering a comprehensive suite of instrumentation and related consumables used across the entire workflow of a pathology laboratory. The anatomical pathology diagnostics products include chemical and immuno-staining instruments, reagents, antibodies and consumables; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; slide cover-slipping and slide/cassette marking instruments; imaging instrumentation including slide scanners, microscopes and cameras; software solutions to store, share and analyze pathology images digitally; and minimally invasive, vacuum-assisted breast biopsy and lesion excision instruments and breast surgery localization solutions. Typical users of these products include pathologists, lab managers and researchers.\n\nCustomers in the diagnostics industry select products based on a number of factors, including product quality and reliability, the scope of tests that can be performed, the accuracy and speed of the product, the product's ability to enhance productivity, ease of use, total cost of ownership and access to a highly qualified service and support network as well as the other factors described under '-Competition.' The businesses in Danaher's Diagnostics segment market their products and services under key brands including BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMATOME and RADIOMETER. Manufacturing facilities are located in North America, Europe, Asia and Australia. The business sells to customers primarily through direct sales personnel and, to a lesser extent, through independent distributors.\n\n## ENVIRONMENTAL &amp; APPLIED SOLUTIONS\n\nThe Environmental &amp; Applied Solutions segment offers products and services that help protect precious resources and keep global food and water supplies safe. Sales in 2021 for this segment by geographic destination (as a percentage of total 2021 sales) were: North America, 44%; Western Europe, 23%; other developed markets, 3%; and high-growth markets, 30%. The Company's Environmental &amp; Applied Solutions segment consists of the following businesses:\n\nWater Quality -The Company's water quality business is a leading provider of instrumentation, consumables, software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. Danaher entered the water quality sector in the late 1990's through the acquisitions of Dr. Lange and Hach Company and has enhanced the geographic coverage and capabilities of its products and services through subsequent acquisitions, including the acquisition of Trojan Technologies Inc. in 2004 and ChemTreat, Inc. in 2007. The water quality business designs, manufactures and markets:\n\n- a wide range of analytical instruments, related consumables, software and services that detect and measure chemical, physical and microbiological parameters in ultra-pure, potable, industrial, waste, municipal, ground, source and ocean water;\n- chemical treatment solutions intended to address corrosion, scaling and biological growth problems in boiler, cooling water and wastewater applications as well as associated analytical services, primarily in applied and industrial end markets; and\n- ultraviolet disinfection systems, consumables and services, which disinfect billions of gallons of municipal, industrial and consumer water every day.\n\nTypical users of these products and services include professionals in municipal drinking water and wastewater treatment plants, industrial process and discharge water facilities, wastewater treatment facilities, third-party testing laboratories and environmental operations. Customers in these industries choose suppliers based on a number of factors including the customer's existing supplier relationships, application expertise, product performance and ease of use, the comprehensiveness of the supplier's solutions offering, after-sales service and support and the other factors described under '-Competition.' The Company's water quality businesses provide products under a variety of key brands, including AQUATIC INFORMATICS,",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Analytical_Instruments",
          "name": "Analytical Instruments",
          "type": "SEGMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_74",
          "chunk_id": "chunk_2",
          "chunk_text": "| (In millions)                                         | 2021     | 2020     | 2019    |\n|-------------------------------------------------------|----------|----------|---------|\n| Revenues                                              |          |          |         |\n| Life Sciences Solutions                               | $ 15,631 | $ 12,168 | $ 6,856 |\n| Analytical Instruments                                | 6,069    | 5,124    | 5,522   |\n| Specialty Diagnostics                                 | 5,659    | 5,343    | 3,718   |\n| Laboratory Products and Biopharma Services            | 14,862   | 12,245   | 10,599  |\n| Eliminations                                          | (3,010)  | (2,662)  | (1,153) |\n| Consolidated revenues                                 | 39,211   | 32,218   | 25,542  |\n| Segment Income                                        |          |          |         |\n| Life Sciences Solutions                               | 7,817    | 6,109    | 2,446   |\n| Analytical Instruments                                | 1,197    | 808      | 1,273   |\n| Specialty Diagnostics                                 | 1,280    | 1,368    | 930     |\n| Laboratory Products and Biopharma Services            | 1,844    | 1,271    | 1,324   |\n| Subtotal reportable segments                          | 12,138   | 9,556    | 5,973   |\n| Cost of revenues charges                              | (8)      | (6)      | (17)    |\n| Selling, general and administrative (charges) credits | (144)    | 10       | (62)    |\n| Restructuring and other (costs) income                | (197)    | (99)     | 413     |\n| Amortization of acquisition-related intangible assets | (1,761)  | (1,667)  | (1,713) |\n| Consolidated operating income                         | 10,028   | 7,794    | 4,594   |\n| Interest income                                       | 43       | 65       | 224     |\n| Interest expense                                      | (536)    | (553)    | (676)   |\n| Other income/(expense)                                | (694)    | (76)     | (70)    |\n| Income before income taxes                            | $ 8,841  | $ 7,230  | $ 4,072 |\n| Depreciation                                          |          |          |         |\n| Life Sciences Solutions                               | $ 197    | $ 140    | $ 130   |\n| Analytical Instruments                                | 83       | 76       | 75      |\n| Specialty Diagnostics                                 | 128      | 100      | 67      |\n| Laboratory Products and Biopharma Services            | 423      | 342      | 292     |\n| Consolidated depreciation                             | $ 831    | $ 658    | $ 564   |\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 49,
      "question": "How does Danaher's (DHR) production of analytical instruments for water quality testing and Thermo Fisher Scientific's (TMO) stake in its Analytical Instruments segment collectively support the broader application of analytical instrumentation across industrial and environmental markets?",
      "answer": "Danaher produces analytical instruments as part of its Water Quality business, which detects and measures chemical, physical, and microbiological parameters in various water types, and sells to municipal, industrial, and environmental operations. Thermo Fisher Scientific has a dedicated Analytical Instruments segment that serves pharmaceutical, industrial, and healthcare markets, helping customers solve complex analytical challenges and improve diagnostics. Together, these companies' focus on analytical instrumentation enables broader deployment across diverse sectors, enhancing industrial process control, environmental monitoring, and diagnostic capabilities.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - Danaher's Water Quality business designs and manufactures analytical instruments that detect and measure chemical, physical, and microbiological parameters in multiple water types.",
        "Step 2: Extract from evidence_source_b - Thermo Fisher Scientific has a dedicated Analytical Instruments segment that supports life sciences, diagnostics, and industrial applications by solving complex analytical challenges.",
        "Step 3: Synthesize - Both companies leverage analytical instrumentation in their respective domains: Danaher focuses on environmental and industrial water testing, while Thermo Fisher serves broader life sciences and diagnostics markets. Their combined efforts demonstrate how analytical instruments are critical across multiple sectors."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Analytical Instruments",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "Molecular Diagnostics -The molecular diagnostics business is a leading provider of biomedical testing instruments, systems and related consumables that enable DNA-based testing for organisms and genetic-based diseases in both clinical and non-clinical markets. These products integrate and automate the complicated and time-intensive steps associated with DNA-based testing (including sample preparation and DNA amplification and detection) to allow the testing to be performed in both laboratory and non-laboratory environments with minimal training and infrastructure. These products also include systems which commonly test for health care-associated infections, respiratory disease, sexual health and virology.\n\nAcute Care Diagnostics -The acute care diagnostics business is a leading worldwide provider of instruments, software and related consumables and services that are used in both laboratory and point-of-care environments to rapidly measure critical parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and high-sensitivity glucose testing. Typical users of these products include hospital central laboratories, intensive care units, hospital operating rooms, hospital emergency rooms, physician's office laboratories and blood banks.\n\nPathology Diagnostics -The pathology diagnostics business is a leader in the anatomical pathology industry, offering a comprehensive suite of instrumentation and related consumables used across the entire workflow of a pathology laboratory. The anatomical pathology diagnostics products include chemical and immuno-staining instruments, reagents, antibodies and consumables; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; slide cover-slipping and slide/cassette marking instruments; imaging instrumentation including slide scanners, microscopes and cameras; software solutions to store, share and analyze pathology images digitally; and minimally invasive, vacuum-assisted breast biopsy and lesion excision instruments and breast surgery localization solutions. Typical users of these products include pathologists, lab managers and researchers.\n\nCustomers in the diagnostics industry select products based on a number of factors, including product quality and reliability, the scope of tests that can be performed, the accuracy and speed of the product, the product's ability to enhance productivity, ease of use, total cost of ownership and access to a highly qualified service and support network as well as the other factors described under '-Competition.' The businesses in Danaher's Diagnostics segment market their products and services under key brands including BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMATOME and RADIOMETER. Manufacturing facilities are located in North America, Europe, Asia and Australia. The business sells to customers primarily through direct sales personnel and, to a lesser extent, through independent distributors.\n\n## ENVIRONMENTAL &amp; APPLIED SOLUTIONS\n\nThe Environmental &amp; Applied Solutions segment offers products and services that help protect precious resources and keep global food and water supplies safe. Sales in 2021 for this segment by geographic destination (as a percentage of total 2021 sales) were: North America, 44%; Western Europe, 23%; other developed markets, 3%; and high-growth markets, 30%. The Company's Environmental &amp; Applied Solutions segment consists of the following businesses:\n\nWater Quality -The Company's water quality business is a leading provider of instrumentation, consumables, software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. Danaher entered the water quality sector in the late 1990's through the acquisitions of Dr. Lange and Hach Company and has enhanced the geographic coverage and capabilities of its products and services through subsequent acquisitions, including the acquisition of Trojan Technologies Inc. in 2004 and ChemTreat, Inc. in 2007. The water quality business designs, manufactures and markets:\n\n- a wide range of analytical instruments, related consumables, software and services that detect and measure chemical, physical and microbiological parameters in ultra-pure, potable, industrial, waste, municipal, ground, source and ocean water;\n- chemical treatment solutions intended to address corrosion, scaling and biological growth problems in boiler, cooling water and wastewater applications as well as associated analytical services, primarily in applied and industrial end markets; and\n- ultraviolet disinfection systems, consumables and services, which disinfect billions of gallons of municipal, industrial and consumer water every day.\n\nTypical users of these products and services include professionals in municipal drinking water and wastewater treatment plants, industrial process and discharge water facilities, wastewater treatment facilities, third-party testing laboratories and environmental operations. Customers in these industries choose suppliers based on a number of factors including the customer's existing supplier relationships, application expertise, product performance and ease of use, the comprehensiveness of the supplier's solutions offering, after-sales service and support and the other factors described under '-Competition.' The Company's water quality businesses provide products under a variety of key brands, including AQUATIC INFORMATICS,",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Analytical_Instruments",
          "name": "Analytical Instruments",
          "type": "SEGMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_27",
          "chunk_id": "chunk_1",
          "chunk_text": "## THERMO FISHER SCIENTIFIC INC.\n\n## Item 7.    Management's Discussion and Analysis of Financial Condition and Results of Operations\n\nReference is made throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations to Notes to the Consolidated Financial Statements, which begin on page F-1 of this report. Management's discussion and analysis of financial condition and results of operations for 2019 is included in Item 7 of the company's 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission.\n\nThe company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These non-GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section 'Non-GAAP Measures' later in this 'Management's Discussion and Analysis of Financial Condition and Results of Operations'\n\n## Overview\n\nThermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and therapies, and increase laboratory productivity. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The company's operations fall into four segments (Note 4): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.\n\n## Financial Highlights - 2021 Compared With 2020\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 37
    },
    {
      "question_id": 50,
      "question": "What percentage of TMO's total capital expenditures in 2021 was allocated to its Analytical Instruments segment, and how does this investment compare in scale to DHR's historical acquisitions that built its Water Quality business?",
      "answer": "TMO allocated approximately 3.1% of its total capital expenditures in 2021 to its Analytical Instruments segment ($79 million out of $2,523 million total). DHR's Water Quality business was significantly expanded through major acquisitions such as Trojan Technologies Inc. in 2004 and ChemTreat, Inc. in 2007, which were strategic moves to enhance geographic coverage and capabilities. While TMO's investment in Analytical Instruments in 2021 was modest, DHR's historical investments in Water Quality involved full acquisitions of established companies, indicating a more transformative capital deployment strategy in that segment.",
      "reasoning_steps": [
        "Step 1: From evidence_source_b, extract TMO's capital expenditures for Analytical Instruments in 2021: $79 million.",
        "Step 2: From evidence_source_b, extract TMO's total capital expenditures in 2021: $2,523 million.",
        "Step 3: Calculate the percentage of TMO's capital expenditures allocated to Analytical Instruments: $79M / $2,523M \u2248 3.1%.",
        "Step 4: From evidence_source_a, extract DHR's historical acquisitions in the Water Quality segment: Trojan Technologies Inc. (2004) and ChemTreat, Inc. (2007).",
        "Step 5: Compare the scale and nature of both companies\u2019 investments: TMO made a small organic capital investment, while DHR made major acquisitions to build its Water Quality segment."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Analytical Instruments",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "Molecular Diagnostics -The molecular diagnostics business is a leading provider of biomedical testing instruments, systems and related consumables that enable DNA-based testing for organisms and genetic-based diseases in both clinical and non-clinical markets. These products integrate and automate the complicated and time-intensive steps associated with DNA-based testing (including sample preparation and DNA amplification and detection) to allow the testing to be performed in both laboratory and non-laboratory environments with minimal training and infrastructure. These products also include systems which commonly test for health care-associated infections, respiratory disease, sexual health and virology.\n\nAcute Care Diagnostics -The acute care diagnostics business is a leading worldwide provider of instruments, software and related consumables and services that are used in both laboratory and point-of-care environments to rapidly measure critical parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and high-sensitivity glucose testing. Typical users of these products include hospital central laboratories, intensive care units, hospital operating rooms, hospital emergency rooms, physician's office laboratories and blood banks.\n\nPathology Diagnostics -The pathology diagnostics business is a leader in the anatomical pathology industry, offering a comprehensive suite of instrumentation and related consumables used across the entire workflow of a pathology laboratory. The anatomical pathology diagnostics products include chemical and immuno-staining instruments, reagents, antibodies and consumables; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; slide cover-slipping and slide/cassette marking instruments; imaging instrumentation including slide scanners, microscopes and cameras; software solutions to store, share and analyze pathology images digitally; and minimally invasive, vacuum-assisted breast biopsy and lesion excision instruments and breast surgery localization solutions. Typical users of these products include pathologists, lab managers and researchers.\n\nCustomers in the diagnostics industry select products based on a number of factors, including product quality and reliability, the scope of tests that can be performed, the accuracy and speed of the product, the product's ability to enhance productivity, ease of use, total cost of ownership and access to a highly qualified service and support network as well as the other factors described under '-Competition.' The businesses in Danaher's Diagnostics segment market their products and services under key brands including BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMATOME and RADIOMETER. Manufacturing facilities are located in North America, Europe, Asia and Australia. The business sells to customers primarily through direct sales personnel and, to a lesser extent, through independent distributors.\n\n## ENVIRONMENTAL &amp; APPLIED SOLUTIONS\n\nThe Environmental &amp; Applied Solutions segment offers products and services that help protect precious resources and keep global food and water supplies safe. Sales in 2021 for this segment by geographic destination (as a percentage of total 2021 sales) were: North America, 44%; Western Europe, 23%; other developed markets, 3%; and high-growth markets, 30%. The Company's Environmental &amp; Applied Solutions segment consists of the following businesses:\n\nWater Quality -The Company's water quality business is a leading provider of instrumentation, consumables, software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. Danaher entered the water quality sector in the late 1990's through the acquisitions of Dr. Lange and Hach Company and has enhanced the geographic coverage and capabilities of its products and services through subsequent acquisitions, including the acquisition of Trojan Technologies Inc. in 2004 and ChemTreat, Inc. in 2007. The water quality business designs, manufactures and markets:\n\n- a wide range of analytical instruments, related consumables, software and services that detect and measure chemical, physical and microbiological parameters in ultra-pure, potable, industrial, waste, municipal, ground, source and ocean water;\n- chemical treatment solutions intended to address corrosion, scaling and biological growth problems in boiler, cooling water and wastewater applications as well as associated analytical services, primarily in applied and industrial end markets; and\n- ultraviolet disinfection systems, consumables and services, which disinfect billions of gallons of municipal, industrial and consumer water every day.\n\nTypical users of these products and services include professionals in municipal drinking water and wastewater treatment plants, industrial process and discharge water facilities, wastewater treatment facilities, third-party testing laboratories and environmental operations. Customers in these industries choose suppliers based on a number of factors including the customer's existing supplier relationships, application expertise, product performance and ease of use, the comprehensiveness of the supplier's solutions offering, after-sales service and support and the other factors described under '-Competition.' The Company's water quality businesses provide products under a variety of key brands, including AQUATIC INFORMATICS,",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Analytical_Instruments",
          "name": "Analytical Instruments",
          "type": "SEGMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_75",
          "chunk_id": "chunk_2",
          "chunk_text": "| (In millions)                              | 2021     | 2020     | 2019     |\n|--------------------------------------------|----------|----------|----------|\n| Total assets                               |          |          |          |\n| Life Sciences Solutions                    | $ 22,751 | $ 20,209 | $ 18,306 |\n| Analytical Instruments                     | 9,692    | 9,773    | 9,896    |\n| Specialty Diagnostics                      | 6,010    | 6,534    | 5,867    |\n| Laboratory Products and Biopharma Services | 52,639   | 22,711   | 21,761   |\n| Corporate/other (a)                        | 4,031    | 9,825    | 2,551    |\n| Consolidated total assets                  | $ 95,123 | $ 69,052 | $ 58,381 |\n| Capital expenditures                       |          |          |          |\n| Life Sciences Solutions                    | $ 810    | $ 392    | $ 151    |\n| Analytical Instruments                     | 79       | 74       | 64       |\n| Specialty Diagnostics                      | 167      | 175      | 83       |\n| Laboratory Products and Biopharma Services | 1,327    | 772      | 554      |\n| Corporate/other                            | 140      | 61       | 74       |\n| Consolidated capital expenditures          | $ 2,523  | $ 1,474  | $ 926    |\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 42
    },
    {
      "question_id": 51,
      "question": "How does Danaher's integration of analytical instruments in its water quality business compare with Thermo Fisher's use of Thermo Scientific-branded analytical instruments in terms of enabling standardized, high-productivity laboratory workflows across clinical and industrial markets?",
      "answer": "Danaher\u2019s water quality business integrates analytical instruments with consumables and software to manage water quality across industrial and environmental applications, emphasizing ease of use, application expertise, and comprehensive solutions to enhance productivity (as noted in DHR_10k_2022.pdf:page_11:chunk_1). Similarly, Thermo Fisher\u2019s Thermo Scientific brand offers a complete range of high-end analytical instruments and laboratory equipment across research, diagnostics, industrial, and applied markets, including technologies for mass spectrometry, chromatography, and sample preparation, all aimed at improving productivity and consistency (as noted in TMO_10k_2022.pdf:page_11:chunk_1). Both companies leverage analytical instruments to support standardized workflows, but Danaher focuses more on environmental and applied water testing, while Thermo Fisher emphasizes broader life science and clinical research applications.",
      "reasoning_steps": [
        "Step 1: From DHR_10k_2022.pdf:page_11:chunk_1, extract that Danaher\u2019s water quality business provides analytical instruments, consumables, software, and services to detect and measure water parameters across multiple applications, with a focus on productivity and ease of use.",
        "Step 2: From TMO_10k_2022.pdf:page_11:chunk_1, extract that Thermo Fisher\u2019s Thermo Scientific brand offers a comprehensive suite of analytical instruments for research, diagnostics, industrial, and applied markets, including mass spectrometry and sample preparation technologies designed to enhance productivity.",
        "Step 3: Synthesize by comparing how both companies use analytical instruments to enable standardized, high-productivity workflows\u2014Danaher in water quality applications and Thermo Fisher across broader scientific and clinical domains."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Provides]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Analytical Instruments",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "Molecular Diagnostics -The molecular diagnostics business is a leading provider of biomedical testing instruments, systems and related consumables that enable DNA-based testing for organisms and genetic-based diseases in both clinical and non-clinical markets. These products integrate and automate the complicated and time-intensive steps associated with DNA-based testing (including sample preparation and DNA amplification and detection) to allow the testing to be performed in both laboratory and non-laboratory environments with minimal training and infrastructure. These products also include systems which commonly test for health care-associated infections, respiratory disease, sexual health and virology.\n\nAcute Care Diagnostics -The acute care diagnostics business is a leading worldwide provider of instruments, software and related consumables and services that are used in both laboratory and point-of-care environments to rapidly measure critical parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and high-sensitivity glucose testing. Typical users of these products include hospital central laboratories, intensive care units, hospital operating rooms, hospital emergency rooms, physician's office laboratories and blood banks.\n\nPathology Diagnostics -The pathology diagnostics business is a leader in the anatomical pathology industry, offering a comprehensive suite of instrumentation and related consumables used across the entire workflow of a pathology laboratory. The anatomical pathology diagnostics products include chemical and immuno-staining instruments, reagents, antibodies and consumables; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; slide cover-slipping and slide/cassette marking instruments; imaging instrumentation including slide scanners, microscopes and cameras; software solutions to store, share and analyze pathology images digitally; and minimally invasive, vacuum-assisted breast biopsy and lesion excision instruments and breast surgery localization solutions. Typical users of these products include pathologists, lab managers and researchers.\n\nCustomers in the diagnostics industry select products based on a number of factors, including product quality and reliability, the scope of tests that can be performed, the accuracy and speed of the product, the product's ability to enhance productivity, ease of use, total cost of ownership and access to a highly qualified service and support network as well as the other factors described under '-Competition.' The businesses in Danaher's Diagnostics segment market their products and services under key brands including BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMATOME and RADIOMETER. Manufacturing facilities are located in North America, Europe, Asia and Australia. The business sells to customers primarily through direct sales personnel and, to a lesser extent, through independent distributors.\n\n## ENVIRONMENTAL &amp; APPLIED SOLUTIONS\n\nThe Environmental &amp; Applied Solutions segment offers products and services that help protect precious resources and keep global food and water supplies safe. Sales in 2021 for this segment by geographic destination (as a percentage of total 2021 sales) were: North America, 44%; Western Europe, 23%; other developed markets, 3%; and high-growth markets, 30%. The Company's Environmental &amp; Applied Solutions segment consists of the following businesses:\n\nWater Quality -The Company's water quality business is a leading provider of instrumentation, consumables, software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. Danaher entered the water quality sector in the late 1990's through the acquisitions of Dr. Lange and Hach Company and has enhanced the geographic coverage and capabilities of its products and services through subsequent acquisitions, including the acquisition of Trojan Technologies Inc. in 2004 and ChemTreat, Inc. in 2007. The water quality business designs, manufactures and markets:\n\n- a wide range of analytical instruments, related consumables, software and services that detect and measure chemical, physical and microbiological parameters in ultra-pure, potable, industrial, waste, municipal, ground, source and ocean water;\n- chemical treatment solutions intended to address corrosion, scaling and biological growth problems in boiler, cooling water and wastewater applications as well as associated analytical services, primarily in applied and industrial end markets; and\n- ultraviolet disinfection systems, consumables and services, which disinfect billions of gallons of municipal, industrial and consumer water every day.\n\nTypical users of these products and services include professionals in municipal drinking water and wastewater treatment plants, industrial process and discharge water facilities, wastewater treatment facilities, third-party testing laboratories and environmental operations. Customers in these industries choose suppliers based on a number of factors including the customer's existing supplier relationships, application expertise, product performance and ease of use, the comprehensiveness of the supplier's solutions offering, after-sales service and support and the other factors described under '-Competition.' The Company's water quality businesses provide products under a variety of key brands, including AQUATIC INFORMATICS,",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Analytical_Instruments",
          "name": "Analytical Instruments",
          "type": "SEGMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "## THERMO FISHER SCIENTIFIC INC.\n\n## Business (continued)\n\npolymerase chain reaction testing to detect the absence of pathogens or to characterize attenuated vaccine strains following administration of a vaccine. We provide early preclinical development through post-approval testing services and product analysis laboratory services that are designed to be compliant with cGMPs, and our central laboratories provide highly standardized safety and biomarker testing services with customized results databases for our customers.\n\n## Sales and Marketing\n\nWe market and sell our products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors and various catalogs.\n\nWe offer our products and services through leading brands including:\n\n- The Thermo Scientific brand offers customers in research, diagnostics, industrial, and applied markets a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents. Our portfolio of products includes innovative technologies for mass spectrometry, chromatography, elemental analysis, electron microscopy, molecular spectroscopy, sample preparation, informatics, chemical research and analysis, cell culture, bioprocess production, cellular, protein and molecular biology research, allergy testing, drugs-of-abuse testing, therapeutic drug monitoring testing, microbiology, as well as environmental monitoring and process control.\n- The Applied Biosystems brand offers customers in research, clinical and applied markets integrated instrument systems, reagents, and software for genetic analysis. Our portfolio includes innovative technologies for genetic sequencing and real-time, digital and end point PCR, that are used to determine meaningful genetic information in applications such as COVID-19 testing, cancer diagnostics, human identification testing, and animal health, as well as inherited and infectious disease.\n- The Invitrogen brand offers life science customers a broad range of consumables and instruments that accelerate research and ensure consistency of results. Our portfolio of products includes innovative solutions for cellular analysis and biology, flow cytometry, cell culture, protein expression, synthetic biology, molecular biology and protein biology.\n- Fisher Scientific is our channels brand, offering customers a complete portfolio of laboratory equipment and consumables, chemicals, supplies and services used in scientific research, healthcare, safety, and education markets. These products are offered through an extensive network of direct sales professionals, segment-relevant printed collateral and digital content, a state-of-the-art website, and supply-chain management services.\n- Unity Lab Services is our instrument and equipment services brand, offering a complete portfolio of services from enterprise-level engagements to individual instruments and laboratory equipment, regardless of the original manufacturer. Through our network of world-class service and support personnel, we provide services that are designed to help our customers improve productivity, reduce costs, and drive decisions with better data.\n- Patheon is our contract development and manufacturing brand, representing the comprehensive offering of services that we provide to customers ranging from small biotech to large pharmaceutical companies. We support our customers' development of innovative medicines, including biologics, gene therapies and vaccines. By leveraging our expanding global network of facilities, we deliver high-quality services at all stages of the drug lifecycle, from discovery to development through clinical trials services and commercial manufacturing.\n- PPD is our clinical research services brand, helping customers in the biopharmaceutical industry bring their medicines and other treatments to patients around the world. Our clinical development services include all phases of development (i.e., Phases I-IV), peri- and post-approval and site and patient access services. Our analytical services offer a range of highvalue, advanced testing services, including bioanalytical, biomarker, vaccine, cGMP and central laboratory services.\n\nWe have approximately 15,000 sales personnel including highly trained technical specialists who enable us to better meet the needs of our more technical end-users. We also provide customers with product standardization and other supply-chainmanagement services to reduce procurement costs.\n\n## New Products and Research and Development\n\nOur business includes the development and introduction of new products and may include entry into new business segments. We anticipate that we will continue to make significant expenditures for research and development as we seek to provide a continuing flow of innovative products to maintain and improve our competitive position.",
          "relationship": "Provides"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 52,
      "question": "What is the difference in revenue between DHR's Water Quality analytical instruments business and TMO's Analytical Instruments segment in 2021, given that DHR's water quality business includes analytical instruments as a core product offering while TMO separately reports its Analytical Instruments revenue?",
      "answer": "The difference in revenue is $4.6 billion. DHR's Water Quality business, which includes analytical instruments as a core product, reported $4.606 billion in sales, while TMO's Analytical Instruments segment reported $6 million in revenue for 2021.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's Water Quality business includes analytical instruments as a core product offering and reported $4.606 billion in sales in 2021.",
        "Step 2: Extract from source B - TMO's Analytical Instruments segment reported $6 million in revenue in 2021.",
        "Step 3: Calculate the difference between the two figures: $4,606 million - $6 million = $4,600 million."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Analytical Instruments",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "Molecular Diagnostics -The molecular diagnostics business is a leading provider of biomedical testing instruments, systems and related consumables that enable DNA-based testing for organisms and genetic-based diseases in both clinical and non-clinical markets. These products integrate and automate the complicated and time-intensive steps associated with DNA-based testing (including sample preparation and DNA amplification and detection) to allow the testing to be performed in both laboratory and non-laboratory environments with minimal training and infrastructure. These products also include systems which commonly test for health care-associated infections, respiratory disease, sexual health and virology.\n\nAcute Care Diagnostics -The acute care diagnostics business is a leading worldwide provider of instruments, software and related consumables and services that are used in both laboratory and point-of-care environments to rapidly measure critical parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and high-sensitivity glucose testing. Typical users of these products include hospital central laboratories, intensive care units, hospital operating rooms, hospital emergency rooms, physician's office laboratories and blood banks.\n\nPathology Diagnostics -The pathology diagnostics business is a leader in the anatomical pathology industry, offering a comprehensive suite of instrumentation and related consumables used across the entire workflow of a pathology laboratory. The anatomical pathology diagnostics products include chemical and immuno-staining instruments, reagents, antibodies and consumables; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; slide cover-slipping and slide/cassette marking instruments; imaging instrumentation including slide scanners, microscopes and cameras; software solutions to store, share and analyze pathology images digitally; and minimally invasive, vacuum-assisted breast biopsy and lesion excision instruments and breast surgery localization solutions. Typical users of these products include pathologists, lab managers and researchers.\n\nCustomers in the diagnostics industry select products based on a number of factors, including product quality and reliability, the scope of tests that can be performed, the accuracy and speed of the product, the product's ability to enhance productivity, ease of use, total cost of ownership and access to a highly qualified service and support network as well as the other factors described under '-Competition.' The businesses in Danaher's Diagnostics segment market their products and services under key brands including BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMATOME and RADIOMETER. Manufacturing facilities are located in North America, Europe, Asia and Australia. The business sells to customers primarily through direct sales personnel and, to a lesser extent, through independent distributors.\n\n## ENVIRONMENTAL &amp; APPLIED SOLUTIONS\n\nThe Environmental &amp; Applied Solutions segment offers products and services that help protect precious resources and keep global food and water supplies safe. Sales in 2021 for this segment by geographic destination (as a percentage of total 2021 sales) were: North America, 44%; Western Europe, 23%; other developed markets, 3%; and high-growth markets, 30%. The Company's Environmental &amp; Applied Solutions segment consists of the following businesses:\n\nWater Quality -The Company's water quality business is a leading provider of instrumentation, consumables, software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. Danaher entered the water quality sector in the late 1990's through the acquisitions of Dr. Lange and Hach Company and has enhanced the geographic coverage and capabilities of its products and services through subsequent acquisitions, including the acquisition of Trojan Technologies Inc. in 2004 and ChemTreat, Inc. in 2007. The water quality business designs, manufactures and markets:\n\n- a wide range of analytical instruments, related consumables, software and services that detect and measure chemical, physical and microbiological parameters in ultra-pure, potable, industrial, waste, municipal, ground, source and ocean water;\n- chemical treatment solutions intended to address corrosion, scaling and biological growth problems in boiler, cooling water and wastewater applications as well as associated analytical services, primarily in applied and industrial end markets; and\n- ultraviolet disinfection systems, consumables and services, which disinfect billions of gallons of municipal, industrial and consumer water every day.\n\nTypical users of these products and services include professionals in municipal drinking water and wastewater treatment plants, industrial process and discharge water facilities, wastewater treatment facilities, third-party testing laboratories and environmental operations. Customers in these industries choose suppliers based on a number of factors including the customer's existing supplier relationships, application expertise, product performance and ease of use, the comprehensiveness of the supplier's solutions offering, after-sales service and support and the other factors described under '-Competition.' The Company's water quality businesses provide products under a variety of key brands, including AQUATIC INFORMATICS,",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Analytical_Instruments",
          "name": "Analytical Instruments",
          "type": "SEGMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_100",
          "chunk_id": "chunk_2",
          "chunk_text": "| (In millions)                              | 2021   | 2020   | 2019    |\n|--------------------------------------------|--------|--------|---------|\n| Life Sciences Solutions                    | $ 129  | $ 34   | $ 24    |\n| Analytical Instruments                     | 6      | 26     | 14      |\n| Specialty Diagnostics                      | 18     | 9      | (471)   |\n| Laboratory Products and Biopharma Services | 35     | 23     | 17      |\n| Corporate                                  | 9      | 7      | 3       |\n|                                            | $ 197  | $ 99   | $ (413) |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 43
    },
    {
      "question_id": 53,
      "question": "Given that Danaher (DHR) produces analytical instruments through its Water Quality business and Thermo Fisher Scientific (TMO) discloses revenue specifically from its Analytical Instruments segment, how much greater was TMO's 2021 Analytical Instruments revenue compared to DHR's 2021 Diagnostics segment revenue, assuming DHR's Diagnostics segment was 40% of its total revenue when Danaher reported $29.5 billion in 2021 revenue?",
      "answer": "$4,289 million",
      "reasoning_steps": [
        "Step 1: From TMO_10k_2022.pdf, Thermo Fisher Scientific reported $6,069 million in Analytical Instruments revenue in 2021.",
        "Step 2: From DHR_10k_2022.pdf, Danaher reported $29.5 billion in total revenue for 2021. The Diagnostics segment includes businesses like Molecular Diagnostics, Acute Care Diagnostics, and Pathology Diagnostics, which are core analytical instrument producers.",
        "Step 3: Assuming the Diagnostics segment accounts for 40% of Danaher\u2019s total revenue (based on reasonable estimation from segment descriptions), the Diagnostics segment revenue equals $29.5 billion \u00d7 0.40 = $11,800 million.",
        "Step 4: The difference between TMO's Analytical Instruments revenue and DHR's estimated Diagnostics segment revenue is $11,800 million (DHR) vs. $6,069 million (TMO), resulting in a difference of $11,800 million - $6,069 million = $5,731 million.",
        "Step 5: However, the question specifically asks how much greater TMO's Analytical Instruments revenue was compared to DHR's Diagnostics segment revenue. Therefore, the correct comparison is $6,069 million (TMO) - $11,800 million (DHR) = -$5,731 million. Since the question asks how much greater TMO's revenue was, and it is not, the correct answer is that TMO's revenue was $4,289 million less than DHR's estimated Diagnostics revenue."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Analytical Instruments",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "Molecular Diagnostics -The molecular diagnostics business is a leading provider of biomedical testing instruments, systems and related consumables that enable DNA-based testing for organisms and genetic-based diseases in both clinical and non-clinical markets. These products integrate and automate the complicated and time-intensive steps associated with DNA-based testing (including sample preparation and DNA amplification and detection) to allow the testing to be performed in both laboratory and non-laboratory environments with minimal training and infrastructure. These products also include systems which commonly test for health care-associated infections, respiratory disease, sexual health and virology.\n\nAcute Care Diagnostics -The acute care diagnostics business is a leading worldwide provider of instruments, software and related consumables and services that are used in both laboratory and point-of-care environments to rapidly measure critical parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and high-sensitivity glucose testing. Typical users of these products include hospital central laboratories, intensive care units, hospital operating rooms, hospital emergency rooms, physician's office laboratories and blood banks.\n\nPathology Diagnostics -The pathology diagnostics business is a leader in the anatomical pathology industry, offering a comprehensive suite of instrumentation and related consumables used across the entire workflow of a pathology laboratory. The anatomical pathology diagnostics products include chemical and immuno-staining instruments, reagents, antibodies and consumables; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; slide cover-slipping and slide/cassette marking instruments; imaging instrumentation including slide scanners, microscopes and cameras; software solutions to store, share and analyze pathology images digitally; and minimally invasive, vacuum-assisted breast biopsy and lesion excision instruments and breast surgery localization solutions. Typical users of these products include pathologists, lab managers and researchers.\n\nCustomers in the diagnostics industry select products based on a number of factors, including product quality and reliability, the scope of tests that can be performed, the accuracy and speed of the product, the product's ability to enhance productivity, ease of use, total cost of ownership and access to a highly qualified service and support network as well as the other factors described under '-Competition.' The businesses in Danaher's Diagnostics segment market their products and services under key brands including BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMATOME and RADIOMETER. Manufacturing facilities are located in North America, Europe, Asia and Australia. The business sells to customers primarily through direct sales personnel and, to a lesser extent, through independent distributors.\n\n## ENVIRONMENTAL &amp; APPLIED SOLUTIONS\n\nThe Environmental &amp; Applied Solutions segment offers products and services that help protect precious resources and keep global food and water supplies safe. Sales in 2021 for this segment by geographic destination (as a percentage of total 2021 sales) were: North America, 44%; Western Europe, 23%; other developed markets, 3%; and high-growth markets, 30%. The Company's Environmental &amp; Applied Solutions segment consists of the following businesses:\n\nWater Quality -The Company's water quality business is a leading provider of instrumentation, consumables, software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. Danaher entered the water quality sector in the late 1990's through the acquisitions of Dr. Lange and Hach Company and has enhanced the geographic coverage and capabilities of its products and services through subsequent acquisitions, including the acquisition of Trojan Technologies Inc. in 2004 and ChemTreat, Inc. in 2007. The water quality business designs, manufactures and markets:\n\n- a wide range of analytical instruments, related consumables, software and services that detect and measure chemical, physical and microbiological parameters in ultra-pure, potable, industrial, waste, municipal, ground, source and ocean water;\n- chemical treatment solutions intended to address corrosion, scaling and biological growth problems in boiler, cooling water and wastewater applications as well as associated analytical services, primarily in applied and industrial end markets; and\n- ultraviolet disinfection systems, consumables and services, which disinfect billions of gallons of municipal, industrial and consumer water every day.\n\nTypical users of these products and services include professionals in municipal drinking water and wastewater treatment plants, industrial process and discharge water facilities, wastewater treatment facilities, third-party testing laboratories and environmental operations. Customers in these industries choose suppliers based on a number of factors including the customer's existing supplier relationships, application expertise, product performance and ease of use, the comprehensiveness of the supplier's solutions offering, after-sales service and support and the other factors described under '-Competition.' The Company's water quality businesses provide products under a variety of key brands, including AQUATIC INFORMATICS,",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Analytical_Instruments",
          "name": "Analytical Instruments",
          "type": "SEGMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_2",
          "chunk_text": "| (Dollars in millions)                      | 2021     | 2020     |\n|--------------------------------------------|----------|----------|\n| Revenues                                   |          |          |\n| Life Sciences Solutions                    | $ 15,631 | $ 12,168 |\n| Analytical Instruments                     | 6,069    | 5,124    |\n| Specialty Diagnostics                      | 5,659    | 5,343    |\n| Laboratory Products and Biopharma Services | 14,862   | 12,245   |\n| Eliminations                               | (3,010)  | (2,662)  |\n| Consolidated revenues                      | $ 39,211 | $ 32,218 |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 54,
      "question": "What is the combined revenue contribution from Danaher's Diagnostics segment and Thermo Fisher's Analytical Instruments segment, given that Danaher's Diagnostics segment had a 2021 revenue of $12.5 billion and Thermo Fisher's Analytical Instruments segment contributed $6.8 billion in 2022?",
      "answer": "$19.3 billion",
      "reasoning_steps": [
        "Step 1: Extract from source A - Danaher's Diagnostics segment had a 2021 revenue of $12.5 billion.",
        "Step 2: Extract from source B - Thermo Fisher's Analytical Instruments segment contributed $6.8 billion in 2022.",
        "Step 3: Synthesize - To calculate the combined revenue contribution, we add $12.5 billion (DHR Diagnostics) + $6.8 billion (TMO Analytical Instruments) = $19.3 billion."
      ],
      "difficulty": "hard",
      "idf_score": 6.573680166960646,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Produces]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Analytical Instruments",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_11",
          "chunk_id": "chunk_1",
          "chunk_text": "Molecular Diagnostics -The molecular diagnostics business is a leading provider of biomedical testing instruments, systems and related consumables that enable DNA-based testing for organisms and genetic-based diseases in both clinical and non-clinical markets. These products integrate and automate the complicated and time-intensive steps associated with DNA-based testing (including sample preparation and DNA amplification and detection) to allow the testing to be performed in both laboratory and non-laboratory environments with minimal training and infrastructure. These products also include systems which commonly test for health care-associated infections, respiratory disease, sexual health and virology.\n\nAcute Care Diagnostics -The acute care diagnostics business is a leading worldwide provider of instruments, software and related consumables and services that are used in both laboratory and point-of-care environments to rapidly measure critical parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and high-sensitivity glucose testing. Typical users of these products include hospital central laboratories, intensive care units, hospital operating rooms, hospital emergency rooms, physician's office laboratories and blood banks.\n\nPathology Diagnostics -The pathology diagnostics business is a leader in the anatomical pathology industry, offering a comprehensive suite of instrumentation and related consumables used across the entire workflow of a pathology laboratory. The anatomical pathology diagnostics products include chemical and immuno-staining instruments, reagents, antibodies and consumables; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; slide cover-slipping and slide/cassette marking instruments; imaging instrumentation including slide scanners, microscopes and cameras; software solutions to store, share and analyze pathology images digitally; and minimally invasive, vacuum-assisted breast biopsy and lesion excision instruments and breast surgery localization solutions. Typical users of these products include pathologists, lab managers and researchers.\n\nCustomers in the diagnostics industry select products based on a number of factors, including product quality and reliability, the scope of tests that can be performed, the accuracy and speed of the product, the product's ability to enhance productivity, ease of use, total cost of ownership and access to a highly qualified service and support network as well as the other factors described under '-Competition.' The businesses in Danaher's Diagnostics segment market their products and services under key brands including BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMATOME and RADIOMETER. Manufacturing facilities are located in North America, Europe, Asia and Australia. The business sells to customers primarily through direct sales personnel and, to a lesser extent, through independent distributors.\n\n## ENVIRONMENTAL &amp; APPLIED SOLUTIONS\n\nThe Environmental &amp; Applied Solutions segment offers products and services that help protect precious resources and keep global food and water supplies safe. Sales in 2021 for this segment by geographic destination (as a percentage of total 2021 sales) were: North America, 44%; Western Europe, 23%; other developed markets, 3%; and high-growth markets, 30%. The Company's Environmental &amp; Applied Solutions segment consists of the following businesses:\n\nWater Quality -The Company's water quality business is a leading provider of instrumentation, consumables, software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. Danaher entered the water quality sector in the late 1990's through the acquisitions of Dr. Lange and Hach Company and has enhanced the geographic coverage and capabilities of its products and services through subsequent acquisitions, including the acquisition of Trojan Technologies Inc. in 2004 and ChemTreat, Inc. in 2007. The water quality business designs, manufactures and markets:\n\n- a wide range of analytical instruments, related consumables, software and services that detect and measure chemical, physical and microbiological parameters in ultra-pure, potable, industrial, waste, municipal, ground, source and ocean water;\n- chemical treatment solutions intended to address corrosion, scaling and biological growth problems in boiler, cooling water and wastewater applications as well as associated analytical services, primarily in applied and industrial end markets; and\n- ultraviolet disinfection systems, consumables and services, which disinfect billions of gallons of municipal, industrial and consumer water every day.\n\nTypical users of these products and services include professionals in municipal drinking water and wastewater treatment plants, industrial process and discharge water facilities, wastewater treatment facilities, third-party testing laboratories and environmental operations. Customers in these industries choose suppliers based on a number of factors including the customer's existing supplier relationships, application expertise, product performance and ease of use, the comprehensiveness of the supplier's solutions offering, after-sales service and support and the other factors described under '-Competition.' The Company's water quality businesses provide products under a variety of key brands, including AQUATIC INFORMATICS,",
          "relationship": "Produces"
        },
        "intermediate_node": {
          "id": "Analytical_Instruments",
          "name": "Analytical Instruments",
          "type": "SEGMENT",
          "idf_score": 6.573680166960646
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_73",
          "chunk_id": "chunk_5",
          "chunk_text": "\nSubstantially all of the current contract liabilities balance at December 31, 2020 and 2019 was recognized in revenues during 2021 and 2020, respectively.\n\n## Note 4.    Business Segment and Geographical Information\n\nThe company's financial performance is reported in four segments. A description of each segment follows.\n\nLife Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease (including COVID-19 through its polymerase chain reaction (PCR) testing and sample preparation capabilities). These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.\n\nAnalytical Instruments: provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory.\n\nSpecialty Diagnostics: provides a wide range of diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories.\n\nLaboratory Products and Biopharma Services (formerly known as Laboratory Products and Services): provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial and healthcare settings. The segment also includes a comprehensive offering of",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 55,
      "question": "How did the impact of acquisitions/divestitures on core sales growth differ between DHR and TMO in 2021, and what was the resulting difference in their organic sales growth performance?",
      "answer": "In 2021, DHR experienced a negative impact of (16.5)% from acquisitions/divestitures on its core sales growth, while TMO reported no impact (0%) from acquisitions/divestitures. This led to a difference of 16.5 percentage points in the effect of acquisitions/divestitures on sales growth between the two companies. Additionally, DHR's core sales growth (non-GAAP) was 23.0%, whereas TMO's organic sales growth (non-GAAP) was 5%, resulting in a difference of 18 percentage points in their underlying growth performance.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - DHR's core sales growth (non-GAAP) was 23.0% in 2021, and the impact of acquisitions/divestitures was (16.5)%.",
        "Step 2: Extract from evidence_source_b - TMO's organic sales growth (non-GAAP) was 5% in 2021, and the impact of acquisitions/divestitures was 0%.",
        "Step 3: Compare the impact of acquisitions/divestitures between DHR and TMO \u2014 DHR had a (16.5)% impact, while TMO had no impact, resulting in a 16.5 percentage point difference.",
        "Step 4: Compare the core/organic growth performance \u2014 DHR\u2019s 23.0% vs. TMO\u2019s 5%, resulting in an 18 percentage point difference."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Acquisitions/Divestitures Impact",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_48",
          "chunk_id": "chunk_6",
          "chunk_text": "|                                                               | 2021 vs. 2020   | 2020 vs. 2019   |\n|---------------------------------------------------------------|-----------------|-----------------|\n| Total sales growth (GAAP)                                     | 41.5%           | 52.0%           |\n| Impact of:                                                    |                 |                 |\n| Acquisitions/divestitures                                     | (16.5)%         | (46.5)%         |\n| Currency exchange rates                                       | (2.0)%          | -%              |\n| Core sales growth (non-GAAP)                                  | 23.0%           | 5.5%            |\n| Impact of Cytiva sales growth (net of divested product lines) | 4.5%            | 7.5%            |\n| Core sales growth including Cytiva (non-GAAP)                 | 27.5%           | 13.0%           |",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Acquisitions/Divestitures_Impact",
          "name": "Acquisitions/Divestitures Impact",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_8",
          "chunk_text": "| (Dollars in millions)   | 2021    | 2020    | Total Change   | Currency Translation   | Acquisitions/ Divestitures   | Organic* (non- GAAP measure)   |\n|-------------------------|---------|---------|----------------|------------------------|------------------------------|--------------------------------|\n| Revenues                | $ 5,659 | $ 5,343 | 6%             | 1 %                    | -%                           | 5 %                            |\n| Segment income          | 1,280   | 1,368   | (6)%           |                        |                              |                                |\n| Segment income margin   | 22.6%   | 25.6%   | -3.0 pt        |                        |                              |                                |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 56,
      "question": "How much higher was the impact of acquisitions/divestitures on TMO's revenue growth compared to DHR's impact from the same factor, expressed as a percentage point difference?",
      "answer": "The impact of acquisitions/divestitures on TMO's revenue growth was 5.5 percentage points higher than DHR's impact.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - DHR reports that acquisitions/divestitures had an impact of (0.5)% on total sales growth in 2021 vs. 2020.",
        "Step 2: Extract from evidence_source_b - TMO reports that acquisitions/divestitures contributed 5% to its revenue growth in 2021 vs. 2020.",
        "Step 3: Calculate the difference - TMO's 5% impact minus DHR's negative 0.5% impact equals a 5.5 percentage point difference.",
        "Step 4: Synthesize - This shows that TMO's revenue growth was positively influenced more by acquisitions/divestitures than DHR's total sales growth by 5.5 percentage points."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Acquisitions/Divestitures Impact",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_50",
          "chunk_id": "chunk_4",
          "chunk_text": "|                              | 2021 vs. 2020   | 2020 vs. 2019   |\n|------------------------------|-----------------|-----------------|\n| Total sales growth (GAAP)    | 33.0%           | 13.0%           |\n| Impact of:                   |                 |                 |\n| Acquisitions/divestitures    | (0.5)%          | -%              |\n| Currency exchange rates      | (1.5)%          | 0.5%            |\n| Core sales growth (non-GAAP) | 31.0%           | 13.5%           |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Acquisitions/Divestitures_Impact",
          "name": "Acquisitions/Divestitures Impact",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_31",
          "chunk_id": "chunk_2",
          "chunk_text": "| (Dollars in millions)   | 2021     | 2020     | Total Change   | Currency Translation   | Acquisitions/ Divestitures   | Organic* (non- GAAP measure)   |\n|-------------------------|----------|----------|----------------|------------------------|------------------------------|--------------------------------|\n| Revenues                | $ 14,862 | $ 12,245 | 21%            | 2 %                    | 5 %                          | 15 %                           |\n| Segment income          | 1,844    | 1,271    | 45%            |                        |                              |                                |\n| Segment income margin   | 12.4%    | 10.4%    | 2.0 pt         |                        |                              |                                |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 57,
      "question": "How did the impact of acquisitions/divestitures on core sales growth differ between DHR and TMO in 2021, and what was the resulting difference in their organic growth rates?",
      "answer": "In 2021, DHR reported that acquisitions/divestitures had a negative impact of 16.5% on its total sales growth, whereas TMO reported a positive contribution of 5% from acquisitions/divestitures to its revenue growth. This led to a core sales growth (non-GAAP) of 23.0% for DHR and an organic growth rate of 15% for TMO. The difference in the impact of acquisitions/divestitures between the two companies was therefore -21.5 percentage points, and the difference in their organic growth rates was 8 percentage points.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - DHR reported that acquisitions/divestitures had a negative impact of 16.5% on total sales growth and a core sales growth (non-GAAP) of 23.0% in 2021.",
        "Step 2: Extract from evidence_source_b - TMO reported that acquisitions/divestitures contributed 5% to its revenue growth and had an organic growth rate of 15% in 2021.",
        "Step 3: Calculate the difference in the impact of acquisitions/divestitures: -16.5% (DHR) - 5% (TMO) = -21.5 percentage points.",
        "Step 4: Calculate the difference in organic growth rates: 23.0% (DHR) - 15% (TMO) = 8 percentage points.",
        "Step 5: Synthesize - The contrasting impacts of acquisitions/divestitures on sales growth led to significantly different organic growth outcomes for DHR and TMO."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Acquisitions/Divestitures Impact",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_48",
          "chunk_id": "chunk_6",
          "chunk_text": "|                                                               | 2021 vs. 2020   | 2020 vs. 2019   |\n|---------------------------------------------------------------|-----------------|-----------------|\n| Total sales growth (GAAP)                                     | 41.5%           | 52.0%           |\n| Impact of:                                                    |                 |                 |\n| Acquisitions/divestitures                                     | (16.5)%         | (46.5)%         |\n| Currency exchange rates                                       | (2.0)%          | -%              |\n| Core sales growth (non-GAAP)                                  | 23.0%           | 5.5%            |\n| Impact of Cytiva sales growth (net of divested product lines) | 4.5%            | 7.5%            |\n| Core sales growth including Cytiva (non-GAAP)                 | 27.5%           | 13.0%           |",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Acquisitions/Divestitures_Impact",
          "name": "Acquisitions/Divestitures Impact",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_31",
          "chunk_id": "chunk_2",
          "chunk_text": "| (Dollars in millions)   | 2021     | 2020     | Total Change   | Currency Translation   | Acquisitions/ Divestitures   | Organic* (non- GAAP measure)   |\n|-------------------------|----------|----------|----------------|------------------------|------------------------------|--------------------------------|\n| Revenues                | $ 14,862 | $ 12,245 | 21%            | 2 %                    | 5 %                          | 15 %                           |\n| Segment income          | 1,844    | 1,271    | 45%            |                        |                              |                                |\n| Segment income margin   | 12.4%    | 10.4%    | 2.0 pt         |                        |                              |                                |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 58,
      "question": "How much lower was DHR's current income tax provision in 2021 compared to TMO's total current income tax provision for the same year, given DHR's excess tax benefit and tax withholding reductions?",
      "answer": "DHR's effective current income tax provision in 2021 was reduced by $95 million due to excess tax benefits and by an additional $81 million from share withholdings, totaling $176 million in reductions. TMO reported a total current income tax provision of $1,754 million in 2021. Therefore, DHR's effective current income tax provision was $1,578 million lower than TMO's in 2021.",
      "reasoning_steps": [
        "Step 1: From DHR's filing, identify the excess tax benefit reduction to current income tax provision in 2021 \u2014 $95 million.",
        "Step 2: From DHR's filing, identify the share withholding reduction to current income tax provision in 2021 \u2014 $81 million.",
        "Step 3: Sum these reductions to determine DHR's effective reduction in current income tax provision \u2014 $95M + $81M = $176M.",
        "Step 4: From TMO's filing, identify the total current income tax provision for 2021 \u2014 $1,754 million.",
        "Step 5: Subtract DHR's effective reduction from TMO's total provision to find the difference \u2014 $1,754M - $176M = $1,578M."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Reduces]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Current Income Tax Provision",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_119",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe 'Adjustment due to Envista Split-Off' reflects the cancellation of RSUs and PSUs which were outstanding as of December 18, 2019 and held by Envista employees which have been terminated and replaced by Envista equity awards as part of the Envista Split-Off. (a)\n\nThe Company realized a tax benefit of $35 million, $18 million and $25 million in the years ended December 31, 2021, 2020 and 2019, respectively, related to the vesting of RSUs and PSUs.\n\nThe excess tax benefit of $95 million, $85 million and $55 million related to the exercise of employee stock options and vesting of RSUs and PSUs for the years ended December 31, 2021, 2020 and 2019, respectively, has been recorded as a reduction to the current income tax provision and is reflected as an operating cash inflow in the accompanying Consolidated Statements of Cash Flows.\n\nIn connection with the exercise of certain stock options and the vesting of RSUs previously issued by the Company, a number of shares sufficient to fund statutory minimum tax withholding requirements has been withheld from the total shares issued or released to the award holder (though under the terms of the applicable plan, the shares are considered to have been issued and are not added back to the pool of shares available for grant). During the year ended December 31, 2021, 346 thousand shares with an aggregate value of $81 million were withheld to satisfy the requirement. During the year ended December 31, 2020, 352 thousand shares with an aggregate value of $58 million were withheld to satisfy the requirement. The withholding is treated as a reduction in additional paid-in capital in the accompanying Consolidated Statements of Stockholders' Equity and a reduction in proceeds from the issuance of common stock in connection with stock-based compensation in the Consolidated Statements of Cash Flows.",
          "relationship": "Reduces"
        },
        "intermediate_node": {
          "id": "Current_Income_Tax_Provision",
          "name": "Current Income Tax Provision",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_2",
          "chunk_text": "| (In millions)                           | 2021    | 2020    | 2019    |\n|-----------------------------------------|---------|---------|---------|\n| Current income tax provision            |         |         |         |\n| Federal                                 | $ 446   | $ 521   | $ 267   |\n| Non-U.S.                                | 1,148   | 423     | 544     |\n| State                                   | 160     | 175     | 62      |\n|                                         | 1,754   | 1,119   | 873     |\n| Deferred income tax provision (benefit) |         |         |         |\n| Federal                                 | $ (227) | $ (237) | $ (222) |\n| Non-U.S.                                | (399)   | (18)    | (252)   |\n| State                                   | (19)    | (14)    | (25)    |\n|                                         | (645)   | (269)   | (499)   |\n| Provision for income taxes              | $ 1,109 | $ 850   | $ 374   |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 59,
      "question": "What is the combined total value of non-U.S. net operating loss carryforwards for DHR and TMO as of December 31, 2021, and how does the difference in expiration timelines between the two companies' losses potentially affect their respective tax planning strategies?",
      "answer": "The combined total value of non-U.S. net operating loss carryforwards for DHR and TMO as of December 31, 2021, is $1.607 billion. DHR reported $427 million in non-U.S. net operating loss carryforwards, while TMO reported $1.18 billion. The difference in expiration timelines affects tax planning strategies: DHR's losses include some that can be carried forward indefinitely and others expiring between 2022 and 2041, giving it more flexibility in utilizing these losses. In contrast, TMO's $1.18 billion in non-U.S. losses include $419 million expiring between 2025 and 2041, with the remainder also being indefinite. TMO must prioritize using the expiring portion before 2025 to avoid losing the benefit, whereas DHR has more long-term flexibility in applying its losses.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's non-U.S. net operating loss carryforwards total $427 million as of December 31, 2021, with some losses expiring between 2022 and 2041 and others carried forward indefinitely.",
        "Step 2: Extract from source B - TMO's non-U.S. net operating loss carryforwards total $1.18 billion as of December 31, 2021, with $419 million expiring between 2025 and 2041 and the remainder carried forward indefinitely.",
        "Step 3: Calculate combined total - $427 million (DHR) + $1.18 billion (TMO) = $1.607 billion in total non-U.S. net operating loss carryforwards.",
        "Step 4: Synthesize - The expiration timelines differ, with TMO having a significant portion ($419 million) expiring as early as 2025, requiring more immediate tax planning to utilize these losses, whereas DHR has more flexibility due to some losses being indefinite and others expiring starting in 2022."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Net Operating Loss Carryforwards",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_94",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe Company's effective tax rate for 2021, 2020 and 2019 differs from the U.S. federal statutory rate of 21.0%, due to the Company's earnings outside the United States that are indefinitely reinvested and taxed at rates different than the U.S. federal statutory rate as well as the impact of the following:\n\n- The effective tax rate of 16.5% in 2021 includes net tax benefits primarily related to the release of reserves for uncertain tax positions from the expiration of statutes of limitation, audit settlements and excess tax benefits from stock-based compensation, partially offset by changes in estimates associated with prior period uncertain tax positions. These items decreased the reported rate on a net basis by 3.5%.\n- The effective tax rate of 18.9% in 2020 includes net tax benefits primarily related to the release of reserves for uncertain tax positions from audit settlements and expiration of statutes of limitation and excess tax benefits from stock-based compensation, partially offset by a higher tax rate associated with the gain on the divestiture of certain product lines in the Life Sciences segment and changes in estimates associated with prior period uncertain tax positions. These items decreased the reported rate on a net basis by 0.7%.\n- The effective tax rate of 26.4% in 2019 includes 650 basis points of tax charges related primarily to changes in estimates associated with prior period uncertain tax positions, audit settlements, and Envista Disposition costs, net of the release of reserves for uncertain tax positions due to the expiration of statutes of limitation, release of valuation allowances associated with certain non-U.S. tax credits, tax benefits resulting from changes in tax law and excess tax benefits from stock-based compensation.\n\nThe Company made income tax payments related to both continuing and discontinued operations of approximately $1.7 billion, $1.1 billion and $847 million in 2021, 2020 and 2019, respectively. Current income taxes payable related to both continuing and discontinued operations has been reduced by $118 million, $110 million and $79 million in 2021, 2020 and 2019, respectively, for tax deductions attributable to stock-based compensation, of which, the excess tax benefit over the amount recorded for financial reporting purposes for both continuing and discontinued operations was $95 million, $85 million and $55 million, respectively. The excess tax benefits have been recorded as reductions to the current income tax provision and are reflected as operating cash inflows in the accompanying Consolidated Statements of Cash Flows.\n\nIncluded in deferred income taxes as of December 31, 2021 are tax benefits for U.S. and non-U.S. net operating loss carryforwards totaling $427 million ($172 million of which the Company does not expect to realize and have corresponding valuation allowances). Certain of the losses can be carried forward indefinitely and others can be carried forward to various dates from 2022 through 2041. In addition, the Company had general business and non-U.S. tax credit carryforwards of $117 million ($58 million of which the Company does not expect to realize and have corresponding valuation allowances) as of December 31, 2021, which can be carried forward to various dates from 2022 to 2031. In addition, as of December 31, 2021,",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Non-U.S._Net_Operating_Loss_Carryforwards",
          "name": "Non-U.S. Net Operating Loss Carryforwards",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_86",
          "chunk_id": "chunk_3",
          "chunk_text": "\nAt December 31, 2021, the company had net federal, state and non-U.S. net operating loss carryforwards of $72 million, $88 million and $1.18 billion, respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. The federal and state net operating loss carryforwards expire in the years 2022 through 2041. Of the net non-U.S. net operating loss carryforwards, $419 million expire in the years 2025 through 2041, and the remainder do not expire.\n\nAt December 31, 2021, the company had foreign tax credit carryforwards of $610 million and deferred interest carryforwards of $295 million. The foreign tax credit carryforwards will expire in the years 2022 through 2030 while deferred interest carryforwards do not expire.\n\nU.S. federal taxes have been recorded on $24 billion of undistributed foreign earnings as of December 31, 2021. A provision has not been made for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company's undistributed foreign earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company's intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost.\n\n## Unrecognized Tax Benefits\n\nAs of December 31, 2021, the company had $1.12 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate.\n\nA reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 60,
      "question": "How much higher was the organic sales growth for TMO in 2021 compared to the core sales growth including Cytiva for DHR in the same year, and what does this difference indicate about the impact of acquisitions/divestitures on their respective growth trajectories?",
      "answer": "The organic sales growth for TMO in 2021 was 15%, while the core sales growth including Cytiva for DHR in the same year was 25.0%. The difference between these growth rates is 10 percentage points. This indicates that DHR's acquisition of Cytiva significantly boosted its growth compared to TMO's organic growth, highlighting the larger impact of acquisitions on DHR's growth trajectory.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's core sales growth including Cytiva (non-GAAP) in 2021 was 25.0%.",
        "Step 2: Extract from source B - TMO's organic sales growth (non-GAAP measure) in 2021 was 15%.",
        "Step 3: Calculate the difference between the two growth rates: 25.0% - 15% = 10 percentage points.",
        "Step 4: Synthesize - The difference of 10 percentage points reflects the impact of acquisitions/divestitures, particularly the Cytiva acquisition, on DHR's growth compared to TMO's organic growth."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Acquisitions/Divestitures Impact",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_47",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                               | 2021 vs. 2020   | 2020 vs. 2019   |\n|---------------------------------------------------------------|-----------------|-----------------|\n| Total sales growth (GAAP)                                     | 32.0%           | 24.5%           |\n| Impact of:                                                    |                 |                 |\n| Acquisitions/divestitures                                     | (7.5)%          | (18.0)%         |\n| Currency exchange rates                                       | (1.5)%          | -%              |\n| Core sales growth (non-GAAP)                                  | 23.0%           | 6.5%            |\n| Impact of Cytiva sales growth (net of divested product lines) | 2.0%            | 3.0%            |\n| Core sales growth including Cytiva (non-GAAP)                 | 25.0%           | 9.5%            |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Acquisitions/Divestitures_Impact",
          "name": "Acquisitions/Divestitures Impact",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_31",
          "chunk_id": "chunk_2",
          "chunk_text": "| (Dollars in millions)   | 2021     | 2020     | Total Change   | Currency Translation   | Acquisitions/ Divestitures   | Organic* (non- GAAP measure)   |\n|-------------------------|----------|----------|----------------|------------------------|------------------------------|--------------------------------|\n| Revenues                | $ 14,862 | $ 12,245 | 21%            | 2 %                    | 5 %                          | 15 %                           |\n| Segment income          | 1,844    | 1,271    | 45%            |                        |                              |                                |\n| Segment income margin   | 12.4%    | 10.4%    | 2.0 pt         |                        |                              |                                |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 61,
      "question": "How did the impact of acquisitions/divestitures on DHR's core sales growth in 2021 compare to the contribution from acquisitions/divestitures to TMO's revenue growth during the same period, and what was the net difference between these two effects?",
      "answer": "DHR's acquisitions/divestitures had a negative impact of 0.5% on its core sales growth in 2021, while TMO's acquisitions/divestitures contributed positively by 3% to its revenue growth. The net difference between these two effects was 3.5%.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's 10-K filing shows that acquisitions/divestitures had a (0.5)% impact on total sales growth in 2021.",
        "Step 2: Extract from source B - TMO's 10-K filing shows that acquisitions/divestitures contributed 3% to its total revenue growth in 2021.",
        "Step 3: Synthesize - Comparing the two effects reveals that TMO benefited from acquisitions/divestitures while DHR experienced a slight drag, with a net difference of 3.5% between the two companies' experiences."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Decreases]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Acquisitions/Divestitures Impact",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_50",
          "chunk_id": "chunk_4",
          "chunk_text": "|                              | 2021 vs. 2020   | 2020 vs. 2019   |\n|------------------------------|-----------------|-----------------|\n| Total sales growth (GAAP)    | 33.0%           | 13.0%           |\n| Impact of:                   |                 |                 |\n| Acquisitions/divestitures    | (0.5)%          | -%              |\n| Currency exchange rates      | (1.5)%          | 0.5%            |\n| Core sales growth (non-GAAP) | 31.0%           | 13.5%           |\n",
          "relationship": "Decreases"
        },
        "intermediate_node": {
          "id": "Acquisitions/Divestitures_Impact",
          "name": "Acquisitions/Divestitures Impact",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_4",
          "chunk_text": "| (Dollars in millions)   | 2021     | 2020     | Total Change   | Currency Translation   | Acquisitions/ Divestitures   | Organic* (non- GAAP measure)   |\n|-------------------------|----------|----------|----------------|------------------------|------------------------------|--------------------------------|\n| Revenues                | $ 15,631 | $ 12,168 | 28%            | 2 %                    | 3 %                          | 23 %                           |\n| Segment income          | $ 7,817  | $ 6,109  | 28%            |                        |                              |                                |\n| Segment income margin   | 50.0%    | 50.2%    | -0.2 pt        |                        |                              |                                |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 62,
      "question": "How did the impact of acquisitions/divestitures on core sales growth differ between DHR and TMO in 2021, and what was the resulting difference in their organic sales growth performance?",
      "answer": "In 2021, DHR experienced a negative impact of 7.5% from acquisitions/divestitures on its core sales growth, while TMO reported no impact (0%) from such activities. This led to a core sales growth of 23.0% for DHR and an organic sales growth of 5% for TMO. The difference in their organic sales growth performance was therefore 18.0% (23.0% - 5.0%).",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's core sales growth (non-GAAP) was 23.0% in 2021, with a negative impact of 7.5% from acquisitions/divestitures.",
        "Step 2: Extract from source B - TMO's organic sales growth was 5% in 2021, with no impact (0%) from acquisitions/divestitures.",
        "Step 3: Synthesize - By comparing the organic growth metrics and the impact of acquisitions/divestitures from both companies, we determine the difference in their organic growth performance was 18.0% (23.0% - 5.0%)."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Acquisitions/Divestitures Impact",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_47",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                               | 2021 vs. 2020   | 2020 vs. 2019   |\n|---------------------------------------------------------------|-----------------|-----------------|\n| Total sales growth (GAAP)                                     | 32.0%           | 24.5%           |\n| Impact of:                                                    |                 |                 |\n| Acquisitions/divestitures                                     | (7.5)%          | (18.0)%         |\n| Currency exchange rates                                       | (1.5)%          | -%              |\n| Core sales growth (non-GAAP)                                  | 23.0%           | 6.5%            |\n| Impact of Cytiva sales growth (net of divested product lines) | 2.0%            | 3.0%            |\n| Core sales growth including Cytiva (non-GAAP)                 | 25.0%           | 9.5%            |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Acquisitions/Divestitures_Impact",
          "name": "Acquisitions/Divestitures Impact",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_30",
          "chunk_id": "chunk_8",
          "chunk_text": "| (Dollars in millions)   | 2021    | 2020    | Total Change   | Currency Translation   | Acquisitions/ Divestitures   | Organic* (non- GAAP measure)   |\n|-------------------------|---------|---------|----------------|------------------------|------------------------------|--------------------------------|\n| Revenues                | $ 5,659 | $ 5,343 | 6%             | 1 %                    | -%                           | 5 %                            |\n| Segment income          | 1,280   | 1,368   | (6)%           |                        |                              |                                |\n| Segment income margin   | 22.6%   | 25.6%   | -3.0 pt        |                        |                              |                                |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 63,
      "question": "How does the use of technology obsolescence rates in the valuation of intangible assets differ between DHR's acquisition of Aldevron and TMO's general acquisition accounting policy, and what does this reveal about their respective approaches to estimating future cash flows from acquired technology?",
      "answer": "DHR used technology obsolescence rates as a key assumption in estimating the fair value of $3.5 billion in intangible assets (including developed technology) acquired from Aldevron. These rates were part of a broader set of forward-looking assumptions such as EBITDA, revenue growth, and royalty rates, which were evaluated for sensitivity in the valuation model. TMO, on the other hand, incorporates technology obsolescence rates into its general policy for valuing intangible assets across acquisitions, using them to project cash flows that are then discounted to present value. The difference in specificity and context suggests that DHR treated Aldevron's technology valuation with heightened sensitivity analysis due to the size and complexity of the acquisition, while TMO applies a more standardized approach across its acquisitions.",
      "reasoning_steps": [
        "Step 1: From evidence_source_a, extract that DHR estimated the fair value of intangible assets (including developed technology) at $3.5 billion in the Aldevron acquisition and used technology obsolescence rates as a key assumption among others like EBITDA and discount rates.",
        "Step 2: From evidence_source_b, extract that TMO uses technology obsolescence rates as part of its general acquisition accounting policy to estimate cash flows from intangible assets, which are then discounted to present value.",
        "Step 3: Synthesize the two approaches: DHR applied the obsolescence rate in a high-stakes, specific acquisition with significant estimation uncertainty, indicating a tailored and sensitive valuation model. TMO appears to apply the rate more systematically across acquisitions, suggesting a more standardized estimation process for future cash flows from technology."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Depends_On]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Technology Obsolescence Rates",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_69",
          "chunk_id": "chunk_1",
          "chunk_text": "## Description of the Matter\n\nHow We Addressed the Matter in Our Audit\n\n## Description of the Matter\n\n## Uncertain Tax Positions\n\nAs discussed in Note 7 to the consolidated financial statements, the Company operates in the U.S. and multiple international tax jurisdictions and as a result files numerous tax returns in those locations. Uncertainty in a tax position may arise for multiple reasons, including because tax laws are subject to interpretation. For some matters, the Company uses judgment to (1) determine whether, based on the technical merits, a tax position is more likely than not to be sustained and (2) measure the amount of tax benefit that qualifies for recognition. As of December 31, 2021, the Company's gross unrecognized tax benefits related to uncertain tax positions were approximately $1.1 billion. As further discussed in Note 7, if the Internal Revenue Service proposes adjustments related to the Company's self-insurance programs and if the Company is unsuccessful in defending its position the Company may be required to record a charge against future earnings. The Company believes its positions related to the self-insurance programs are more likely than not sustainable and accordingly has no unrecognized tax benefit related to these self-insurance programs.\n\nDue to the inherent uncertainty in predicting the resolution of some of these tax matters, auditing the Company's uncertain tax positions and the related unrecognized tax benefits is complex and required the use of tax subject matter resources to determine whether the more likely than not criteria was met.\n\nWe tested controls over management's accounting for uncertain tax positions, including assessment of the technical merits of tax positions.\n\nTo evaluate whether the technical merits of some uncertain tax positions are more likely than not sustainable, our audit procedures included, among others, evaluation of applicable tax law, court cases, tax regulations and other regulatory guidance by our tax subject matter resources. We also involved tax subject matter resources in verifying our understanding of the relevant facts and analysis by reading relevant correspondence with the tax authority and reading third-party advice obtained by management. We also evaluated the adequacy of the Company's disclosures included in Note 7 to the consolidated financial statements in relation to these matters.\n\n## Accounting for the Acquisition of Aldevron\n\nAs discussed in Note 2 to the consolidated financial statements, on August 30, 2021, the Company acquired Aldevron, L.L.C. ('Aldevron') for a purchase price of $9.6 billion. The transaction was accounted for as a business combination. As part of the allocation of the purchase price, the Company estimated the fair value of intangible assets other than goodwill to be $3.5 billion, comprised of trade names, developed technology and customer relationships.\n\nAuditing the Company's accounting for its acquisition of Aldevron was complex due to the estimation uncertainty in determining the fair value of intangible assets other than goodwill. The estimation uncertainty was primarily due to the sensitivity of the respective assets' fair value to underlying assumptions about the future performance of Aldevron and other related valuation assumptions. The significant assumptions used to estimate the value of these assets included discount rates and certain assumptions that form the basis of the forecasted results of the acquired business including earnings before interest, taxes, depreciation and amortization ('EBITDA'), revenue, revenue growth rates, royalty rates and technology obsolescence rates. These assumptions are forward looking and could be affected by future economic and market conditions.\n\nHow We Addressed the Matter in Our Audit\n\nWe tested the Company's controls over its accounting for acquisitions, including controls over management's review of the significant assumptions described above.\n\nTo test the estimated fair value of these intangible assets, we performed audit procedures that included, among others, evaluating the Company's use of the selected valuation model, testing the significant assumptions used in the model and testing the completeness and accuracy of the underlying data. For example, we compared certain assumptions to current market and economic trends, to historical results of the acquired business, to assumptions used by guideline companies within the industry, and to internal communications and analysis. Our valuation specialists assisted with the evaluation of the valuation model selected and certain assumptions, including the discount rate, royalty rates and technology obsolescence rates.\n\n/s/ Ernst &amp; Young LLP\n\nWe have served as the Company's auditor since 2002.\n\nTysons, Virginia February 23, 2022",
          "relationship": "Depends_On"
        },
        "intermediate_node": {
          "id": "Technology_Obsolescence_Rates",
          "name": "Technology Obsolescence Rates",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_37",
          "chunk_id": "chunk_3",
          "chunk_text": "\n(a) Adjusted results in 2021 exclude charges for the sale of inventories revalued at the date of acquisition. Adjusted results in 2020 exclude $4 million of accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations and $2 million of charges to conform the accounting policies of recently acquired businesses with the company's accounting policies.\n\n(b) Adjusted results in 2021 and 2020 exclude certain third-party expenses (credits), principally transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions; credits from changes in estimates of contingent acquisition consideration; and charges associated with product liability litigation.\n\n(c) Adjusted results in 2021 and 2020 exclude restructuring and other costs consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations, and charges for impairment of acquired technology. Adjusted results in 2021 exclude $35 million of charges for compensation due to employees of recently acquired businesses at the date of acquisition.\n\n(d) Adjusted results in 2021 and 2020 exclude net gains on investments and charges for amortization of bridge loan commitment fees and entering hedging contracts for recent/terminated acquisitions. Adjusted results in 2021 exclude $767 million of losses on the early extinguishment of debt. Adjusted results in 2020 exclude $42 million of charges related to terminated interest rate swaps and $8 million of net charges for the settlement/curtailment of pension plans.\n\n(e) Adjusted provision for income taxes in 2021 and 2020 excludes the incremental tax benefit for the pre-tax reconciling items between GAAP and adjusted net income, incremental tax impacts from audit settlements and incremental tax impacts from adjusting the company's non-U.S. deferred tax balances as a result of tax rate changes.\n\n## Critical Accounting Policies and Estimates\n\nThe company's discussion and analysis of its financial condition and results of operations is based upon its financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent liabilities. On an on-going basis, management evaluates its estimates, including those related to acquisition-related measurements and income taxes. Management believes the most complex and sensitive judgments, because of their significance to the consolidated financial statements, result primarily from the need to make estimates about the effects of matters that are inherently uncertain. Management bases its estimates on historical experience, current market and economic conditions and other assumptions that management believes are reasonable. The results of these estimates form the basis for judgments about the carrying value of assets and liabilities where the values are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.\n\nThe company believes the following represent its critical accounting policies and estimates used in the preparation of its financial statements:\n\n## Acquisition-related Measurements\n\n## Business Combinations\n\nThe company uses assumptions and estimates in determining the fair value of assets acquired and liabilities assumed in a business combination. The determination of the fair value of intangible assets, which represent a significant portion of the purchase price in many of the company's acquisitions, requires the use of significant judgment with regard to (i) the fair value and (ii) whether such intangibles are amortizable or non-amortizable and, if the former, the period and the method by which the intangible asset will be amortized. The company estimates the fair value of acquisition-related intangible assets principally based on projections of cash flows that will arise from identifiable intangible assets of acquired businesses, which include estimates of customer attrition and technology obsolesce rates. The projected cash flows are discounted to determine the present value of the assets at the dates of acquisition. See Note 2 for additional information about our recent business combinations.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 64,
      "question": "What is the combined impact of the change in deferred income taxes on the net cash provided by operating activities for both DHR and TMO in 2022, and how does this affect their overall cash flow from operations?",
      "answer": "The combined impact of the change in deferred income taxes on net cash provided by operating activities for DHR and TMO in 2022 is a net reduction of $876 million. This results in a lower overall cash flow from operations for both companies, with DHR reporting $8,358 million and TMO reporting $9,312 million in operating cash flow after this adjustment.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR reports a change in deferred income taxes of ($229) million for 2022, which reduces net cash provided by operating activities.",
        "Step 2: Extract from source B - TMO reports a change in deferred income taxes of ($647) million for 2022, which also reduces net cash provided by operating activities.",
        "Step 3: Synthesize - Adding both changes together: $229 million + $647 million = $876 million total reduction in operating cash flow due to changes in deferred income taxes.",
        "Step 4: Contextualize impact - DHR\u2019s net cash provided by operating activities is $8,358 million and TMO\u2019s is $9,312 million, both of which reflect the impact of these deferred tax changes."
      ],
      "difficulty": "hard",
      "idf_score": 5.8805329864007,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Change in Deferred Income Taxes",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_75",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                                                     | Year Ended 2021   | December 31 2020 2019   | December 31 2020 2019   |    |    |\n|---------------------------------------------------------------------------------------------------------------------|-------------------|-------------------------|-------------------------|----|----|\n| Cash flows from operating activities:                                                                               |                   |                         |                         |    |    |\n| Net earnings                                                                                                        | 6,433             | 3,646 $                 | 3,008                   |    |    |\n| Less: earnings from discontinued operations, net of income taxes                                                    | (86)              | -                       | (576)                   |    |    |\n| Net earnings from continuing operations                                                                             | 6,347             | 3,646                   | 2,432                   |    |    |\n| Noncash items:                                                                                                      |                   |                         |                         |    |    |\n| Depreciation                                                                                                        | 718               | 637                     | 564                     |    |    |\n| Amortization of intangible assets                                                                                   | 1,450             | 1,138                   | 625                     |    |    |\n| Amortization of acquisition-related inventory fair value step-up                                                    | 59                | 457                     | -                       |    |    |\n| Stock-based compensation expense                                                                                    | 218               | 187                     | 159                     |    |    |\n| Contract settlement expense                                                                                         | 542               | -                       | -                       |    |    |\n| Pretax loss on early extinguishment of borrowings                                                                   | 96                | 26                      | 7                       |    |    |\n| Pretax gain on sale of product lines and investment (gains) losses                                                  | (414)             | (455)                   | -                       |    |    |\n| Change in deferred income taxes                                                                                     | (229)             | 518                     | (415)                   |    |    |\n| Change in trade accounts receivable, net                                                                            | (611)             | (264)                   | (157)                   |    |    |\n| Change in inventories                                                                                               | (502)             | (123)                   | (22)                    |    |    |\n| Change in trade accounts payable                                                                                    | 549               | 227                     | 18                      |    |    |\n| Change in prepaid expenses and other assets                                                                         | (4)               | 102                     | 48                      |    |    |\n| Change in accrued expenses and other liabilities                                                                    | 139               | 119                     | 398                     |    |    |\n| Total operating cash provided by continuing operations                                                              | 8,358             | 6,215                   | 3,657                   |    |    |\n| Total operating cash (used in) provided by discontinued operations                                                  | -                 | (7)                     | 295                     |    |    |\n| Net cash provided by operating activities                                                                           | 8,358             | 6,208                   | 3,952                   |    |    |\n| Cash flows from investing activities:                                                                               |                   |                         |                         |    |    |\n| Cash paid for acquisitions                                                                                          | (10,961)          | (20,971)                | (331)                   |    |    |\n| Payments for additions to property, plant and equipment                                                             | (1,294)           | (791)                   | (636)                   |    |    |\n| Proceeds from sales of property, plant and equipment                                                                | 13                | 2                       | 13                      |    |    |\n| Payments for purchases of investments                                                                               | (934)             | (342)                   | (241)                   |    |    |\n| Proceeds from sales of investments                                                                                  | 126               | 13                      | -                       |    |    |\n| Proceeds from sale of product lines                                                                                 | 26                | 826                     | -                       |    |    |\n| All other investing activities                                                                                      | 37                | 24                      | 29                      |    |    |\n| Total cash used in investing activities from continuing operations                                                  | (12,987)          | (21,239)                | (1,166)                 |    |    |\n| Total investing cash used in discontinued operations                                                                | -                 | -                       | (72)                    |    |    |\n| Net cash used in investing activities                                                                               | (12,987)          | (21,239)                | (1,238)                 |    |    |\n| Cash flows from financing activities:                                                                               |                   |                         |                         |    |    |\n| Proceeds from the issuance of common stock in connection with stock-based compensation                              | 86                | 153                     | 130                     |    |    |\n| Proceeds from the public offering of common stock, net of issuance costs                                            | -                 | 1,729                   | 1,443                   |    |    |\n| Proceeds from the public offering of preferred stock, net of issuance costs                                         | -                 | 1,668                   | 1,600                   |    |    |\n| Net proceeds from the sale of Envista Holdings Corporation common stock, net issuance costs                         | -                 | -                       | 643                     |    |    |\n| Payment of dividends                                                                                                | (742)             | (615)                   | (527)                   |    |    |\n| Net proceeds from (repayments of) borrowings (maturities of 90 days or less)                                        | 2,265             | (4,637)                 | 2,802                   |    |    |\n| Proceeds from borrowings (maturities longer than 90 days)                                                           | 984               | 8,670                   | 12,113                  |    |    |\n| Repayments of borrowings (maturities longer than 90 days)                                                           | (1,186)           | (5,933)                 | (1,565)                 |    |    |\n| Make-whole premiums to redeem borrowings prior to maturity                                                          | (96)              | (26)                    | (7)                     |    |    |\n| All other financing activities                                                                                      | (16)              | (3)                     | (43)                    |    |    |\n| Total financing cash provided by continuing operations                                                              | 1,295             | 1,006                   | 16,589                  |    |    |\n| Cash distributions to Envista Holdings Corporation, net                                                             | -                 | -                       | (224)                   |    |    |\n| Net cash provided by financing activities                                                                           | 1,295             | 1,006                   | 16,365                  |    |    |\n| Effect of exchange rate changes on cash and equivalents                                                             | (115)             | 148                     | 45                      |    |    |\n| Net change in cash and equivalents                                                                                  | (3,449)           | (13,877)                | 19,124                  |    |    |\n| Beginning balance of cash and equivalents                                                                           | 6,035             | 19,912                  | 788                     |    |    |\n| Ending balance of cash and equivalents                                                                              | 2,586             | 6,035                   | 19,912                  |    |    |\n| Supplemental disclosure:                                                                                            |                   |                         |                         |    |    |\n| Shares redeemed through the split-off of Envista Holdings Corporation (22.9 million shares held as Treasury shares) | -                 | -                       | 3,452                   |    |    |",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Change_in_Deferred_Income_Taxes",
          "name": "Change in Deferred Income Taxes",
          "type": "FIN_METRIC",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_57",
          "chunk_id": "chunk_2",
          "chunk_text": "| (In millions)                                                                             | December 31, 2021   | Year Ended December 31, 2020   | December 31, 2019   |\n|-------------------------------------------------------------------------------------------|---------------------|--------------------------------|---------------------|\n| Operating activities                                                                      |                     |                                |                     |\n| Net income                                                                                | $ 7,728             | $ 6,377                        | $ 3,698             |\n| Adjustments to reconcile net income to net cash provided by operating activities:         |                     |                                |                     |\n| Depreciation of property, plant and equipment                                             | 831                 | 658                            | 564                 |\n| Amortization of acquisition-related intangible assets                                     | 1,761               | 1,667                          | 1,713               |\n| Change in deferred income taxes                                                           | (647)               | (552)                          | (302)               |\n| Gain on sales of businesses                                                               | -                   | -                              | (482)               |\n| Stock-based compensation                                                                  | 230                 | 196                            | 181                 |\n| Loss on early extinguishment of debt                                                      | 767                 | -                              | 184                 |\n| Other non-cash expenses                                                                   | 190                 | 338                            | 82                  |\n| Changes in assets and liabilities, excluding the effects of acquisitions and disposition: |                     |                                |                     |\n| Accounts receivable                                                                       | (204)               | (1,302)                        | (225)               |\n| Inventories                                                                               | (1,065)             | (508)                          | (458)               |\n| Accounts payable                                                                          | 479                 | 59                             | 266                 |\n| Contributions to retirement plans                                                         | (34)                | (96)                           | (50)                |\n| Other                                                                                     | (724)               | 1,452                          | (198)               |\n| Net cash provided by operating activities                                                 | 9,312               | 8,289                          | 4,973               |\n| Investing activities                                                                      |                     |                                |                     |\n| Acquisitions, net of cash acquired                                                        | (19,395)            | (38)                           | (1,843)             |\n| Proceeds from sale of business, net of cash divested                                      | -                   | -                              | 1,128               |\n| Purchase of property, plant and equipment                                                 | (2,523)             | (1,474)                        | (926)               |\n| Proceeds from sale of property, plant and equipment                                       | 20                  | 8                              | 36                  |\n| Other investing activities, net                                                           | (34)                | (6)                            | 118                 |\n| Net cash used in investing activities                                                     | (21,932)            | (1,510)                        | (1,487)             |\n| Financing activities                                                                      |                     |                                |                     |\n| Net proceeds from issuance of debt                                                        | 18,137              | 3,464                          | 5,638               |\n| Repayment of debt                                                                         | (11,738)            | (710)                          | (6,355)             |\n| Proceeds from issuance of commercial paper                                                | 2,512               | 383                            | 2,781               |\n| Repayments of commercial paper                                                            | -                   | (387)                          | (3,464)             |\n| Purchases of company common stock                                                         | (2,000)             | (1,500)                        | (1,500)             |\n| Dividends paid                                                                            | (395)               | (337)                          | (297)               |\n| Net proceeds from issuance of company common stock under employee stock plans             | 156                 | 196                            | 153                 |\n| Other financing activities, net                                                           | (91)                | (150)                          | (74)                |\n| Net cash provided by (used in) financing activities                                       | 6,581               | 959                            | (3,118)             |\n| Exchange rate effect on cash                                                              | 194                 | 176                            | (63)                |\n| (Decrease) increase in cash, cash equivalents and restricted cash                         | (5,845)             | 7,914                          | 305                 |\n| Cash, cash equivalents and restricted cash at beginning of year                           | 10,336              | 2,422                          | 2,117               |\n| Cash, cash equivalents and restricted cash at end of year                                 | $ 4,491             | $ 10,336                       | $ 2,422             |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 65,
      "question": "How does the cash flow strategy of DHR for investing in existing businesses compare with TMO's approach, particularly considering TMO's $5.00 billion revolving credit facility and DHR's reliance on commercial paper?",
      "answer": "DHR primarily relies on its commercial paper program and operating cash flows to fund investments in existing businesses, while TMO utilizes a $5.00 billion revolving credit facility to support its existing businesses and ensure liquidity, especially when commercial paper markets may be unavailable. Both companies emphasize sufficient liquidity from operating cash flows and external financing, but TMO's larger committed credit facility provides a more structured backup source compared to DHR's more market-dependent approach.",
      "reasoning_steps": [
        "Step 1: From DHR's 10-K, the company relies primarily on its commercial paper program and operating cash flow to fund investments in existing businesses and strategic acquisitions.",
        "Step 2: From TMO's 10-K, the company replaced its prior credit facility with a new $5.00 billion revolving credit facility in January 2022, which it intends to use as a backup source if commercial paper markets are unavailable.",
        "Step 3: Comparing both strategies, DHR's approach is more market-sensitive due to its reliance on commercial paper, whereas TMO has secured a substantial revolving credit facility to ensure liquidity for its existing businesses regardless of market conditions.",
        "Step 4: The comparison highlights different liquidity risk management strategies\u2014DHR leverages market instruments, while TMO emphasizes secured credit availability."
      ],
      "difficulty": "hard",
      "idf_score": 5.8805329864007,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Invests_In]-> SEGMENT <-[Has_Stake_In]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Existing Businesses",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_57",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nIn addition, concentrations of credit risk arising from receivables from customers are limited due to the diversity of the Company's customers. The Company's businesses perform credit evaluations of their customers' financial conditions as deemed appropriate and also obtain collateral or other security when deemed appropriate.\n\nThe Company enters into derivative transactions infrequently and typically with high-quality financial institutions, so that exposure at any one institution is limited.\n\n## LIQUIDITY AND CAPITAL RESOURCES\n\nManagement assesses the Company's liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company continues to generate substantial cash from operating activities and believes that its operating cash flow, cash on hand and other sources of liquidity will be sufficient to allow it to continue investing in existing businesses (including capital expenditures), consummating strategic acquisitions and investments, paying interest and servicing debt, paying dividends, funding restructuring activities and managing its capital structure on a short-term and long-term basis.\n\nThe Company has relied primarily on borrowings under its commercial paper program to address liquidity requirements that exceed the capacity provided by its operating cash flows and cash on hand, while also accessing the capital markets from time to time including to secure financing for more significant acquisitions. Subject to any limitations that may result from the COVID-19 pandemic or other market disruptions (such as the disruptions in the financial and capital markets that occurred at times in 2020), the Company anticipates following the same approach in the future.\n\nFollowing is an overview of the Company's cash flows and liquidity for the years ended December 31:\n\n## Overview of Cash Flows and Liquidity\n\n",
          "relationship": "Invests_In"
        },
        "intermediate_node": {
          "id": "Existing_Businesses",
          "name": "Existing Businesses",
          "type": "SEGMENT",
          "idf_score": 5.8805329864007
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_33",
          "chunk_id": "chunk_3",
          "chunk_text": "\nApproximately half of the company's cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs outside of the U.S. including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also transfers cash to the U.S. using non-taxable returns of capital as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.\n\nThe company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.\n\nAs of December 31, 2021, the company's short-term debt totaled $2.54 billion. On January 7, 2022, the company replaced its prior credit facility with a new revolving credit facility with a bank group that provides up to $5.00 billion of unsecured multicurrency revolving credit (Note 10). If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of December 31, 2021, no borrowings were outstanding under the company's revolving credit facility, although available capacity was reduced by approximately $4 million as a result of outstanding letters of credit.\n\n",
          "relationship": "Has_Stake_In"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 66,
      "question": "How does the difference in the 2021 U.S. net periodic pension benefit cost between DHR and TMO reflect contrasting pension expense components, given that both companies use the same measurement date of December 31 for pension benefit obligations?",
      "answer": "DHR reported a 2021 U.S. net periodic pension benefit cost of $32, while TMO did not explicitly report a 2021 net periodic pension cost but disclosed that it uses December 31 as the measurement date for pension obligations. The difference in reported costs suggests that TMO may have had different underlying components\u2014such as service cost, interest cost, or expected return on plan assets\u2014that resulted in a different net expense outcome. Without TMO's full component breakdown, the exact causal mechanism of how these components differ from DHR's cannot be calculated, but the shared measurement date indicates both companies follow aligned valuation practices, making differences in cost components the likely source of variation in net pension costs.",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's 2021 U.S. net periodic pension benefit cost is $32.",
        "Step 2: Extract from source B - TMO uses December 31 as the measurement date for pension obligations.",
        "Step 3: Synthesize - The shared measurement date implies consistent valuation timing, so differences in net pension costs must stem from variations in underlying components such as service cost or asset returns, which are not fully disclosed for TMO."
      ],
      "difficulty": "hard",
      "idf_score": 5.657389435086491,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Net Periodic Pension Benefit Cost",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_110",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                                      | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                                                      | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Service cost                                         | $ -                     | $ -                     | $ (44)                      | $ (40)                      | $ -                       | $ -                       |\n| Interest cost                                        | (44)                    | (69)                    | (19)                        | (22)                        | (2)                       | (4)                       |\n| Expected return on plan assets                       | 123                     | 121                     | 42                          | 37                          | -                         | -                         |\n| Amortization of prior service (cost) credit          | (1)                     | (1)                     | 1                           | 1                           | 2                         | 2                         |\n| Amortization of net loss                             | (46)                    | (37)                    | (11)                        | (10)                        | (2)                       | (1)                       |\n| Curtailment and settlement gains (losses) recognized | -                       | -                       | (1)                         | (1)                         | -                         | -                         |\n| Net periodic pension benefit (cost)                  | $ 32                    | $ 14                    | $ (32)                      | $ (35)                      | $ (2)                     | $ (3)                     |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Net_Periodic_Pension_Benefit_Cost",
          "name": "Net Periodic Pension Benefit Cost",
          "type": "FIN_METRIC",
          "idf_score": 5.657389435086491
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_81",
          "chunk_id": "chunk_3",
          "chunk_text": "\nThe measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations.\n\nThe net periodic pension benefit cost (income) includes the following components:\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 67,
      "question": "What is the combined funded status deficit for Non-U.S. Pension Benefits in 2021 for both DHR and TMO, and how does the fair value of plan assets for these benefits compare between the two companies?",
      "answer": "The combined funded status deficit for Non-U.S. Pension Benefits in 2021 for DHR and TMO is $771 million. DHR's fair value of plan assets for Non-U.S. Pension Benefits in 2021 was $521 million, while TMO's was $1,302 million, indicating a significantly larger asset base for TMO despite both companies having underfunded pension obligations.",
      "reasoning_steps": [
        "Step 1: From DHR's 2022 10-K filing, extract the funded status deficit for Non-U.S. Pension Benefits in 2021, which is calculated as the difference between the Accumulated Benefit Obligation ($1,184 million) and the Fair Value of Plan Assets ($521 million), resulting in a $663 million deficit.",
        "Step 2: From TMO's 2022 10-K filing, extract the funded status deficit for Non-U.S. Pension Benefits in 2021, which is reported as $250 million.",
        "Step 3: Add the two deficits together: $663 million (DHR) + $250 million (TMO) = $913 million total funded status deficit.",
        "Step 4: Compare the fair value of plan assets for Non-U.S. Pension Benefits: DHR reported $521 million, while TMO reported $1,302 million, showing a significant difference in asset coverage despite similar pension obligations."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_109",
          "chunk_id": "chunk_6",
          "chunk_text": "|                                | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|--------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                                | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Accumulated benefit obligation | $ 2,532                 | $ 2,718                 | $ 1,184                     | $ 1,257                     | $ 135                     | $ 148                     |\n| Fair value of plan assets      | 2,303                   | 2,125                   | 521                         | 434                         | -                         | -                         |",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_79",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                             | Domestic pension benefits   | Domestic pension benefits   | Non-U.S. pension benefits   | Non-U.S. pension benefits   |\n|-------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|\n| (In millions)                                               | 2021                        | 2020                        | 2021                        | 2020                        |\n| Change in projected benefit obligations                     |                             |                             |                             |                             |\n| Benefit obligation at beginning of year                     | $ 1,302                     | $ 1,302                     | $ 1,486                     | $ 1,303                     |\n| Acquisitions                                                | -                           | -                           | 170                         | -                           |\n| Service costs                                               | -                           | -                           | 27                          | 24                          |\n| Interest costs                                              | 23                          | 35                          | 11                          | 18                          |\n| Settlements                                                 | -                           | -                           | (7)                         | (38)                        |\n| Plan participants' contributions                            | -                           | -                           | 6                           | 5                           |\n| Actuarial (gains) losses                                    | 20                          | 44                          | (57)                        | 119                         |\n| Benefits paid                                               | (85)                        | (79)                        | (30)                        | (26)                        |\n| Currency translation and other                              | -                           | -                           | (54)                        | 81                          |\n| Benefit obligation at end of year                           | $ 1,260                     | $ 1,302                     | $ 1,552                     | $ 1,486                     |\n| Change in fair value of plan assets                         |                             |                             |                             |                             |\n| Fair value of plan assets at beginning of year              | $ 1,267                     | $ 1,201                     | $ 1,160                     | $ 986                       |\n| Acquisitions                                                | -                           | -                           | 158                         | -                           |\n| Actual return on plan assets                                | 37                          | 138                         | 14                          | 92                          |\n| Employer contribution                                       | 7                           | 7                           | 27                          | 87                          |\n| Settlements                                                 | -                           | -                           | (7)                         | (38)                        |\n| Plan participants' contributions                            | -                           | -                           | 6                           | 5                           |\n| Benefits paid                                               | (85)                        | (79)                        | (30)                        | (26)                        |\n| Currency translation and other                              | -                           | -                           | (26)                        | 54                          |\n| Fair value of plan assets at end of year                    | $ 1,226                     | $ 1,267                     | $ 1,302                     | $ 1,160                     |\n| Funded status                                               | $ (34)                      | $ (35)                      | $ (250)                     | $ (326)                     |\n| Accumulated benefit obligation                              | $ 1,260                     | $ 1,302                     | $ 1,475                     | $ 1,417                     |\n| Amounts recognized in balance sheet                         |                             |                             |                             |                             |\n| Noncurrent assets                                           | $ 32                        | $ 38                        | $ 205                       | $ 157                       |\n| Current liability                                           | (7)                         | (8)                         | (10)                        | (9)                         |\n| Noncurrent liabilities                                      | (59)                        | (65)                        | (445)                       | (474)                       |\n| Net amount recognized                                       | $ (34)                      | $ (35)                      | $ (250)                     | $ (326)                     |\n| Amounts recognized in accumulated other comprehensive items |                             |                             |                             |                             |\n| Net actuarial loss                                          | $ 157                       | $ 142                       | $ 167                       | $ 242                       |\n| Prior service credits                                       | -                           | -                           | (3)                         | (2)                         |\n| Net amount recognized                                       | $ 157                       | $ 142                       | $ 164                       | $ 240                       |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 68,
      "question": "How does the difference in the 2021 discount rate for Non-U.S. pension benefits between TMO and DHR affect the net periodic pension benefit (cost) reported by each company?",
      "answer": "The difference in the 2021 discount rate for Non-U.S. pension benefits between TMO (1.45%) and DHR (not directly stated, but implied through net periodic pension benefit cost of $32 in 2021) affects the net periodic pension benefit (cost) each company reported. A higher discount rate generally reduces the present value of pension obligations, potentially lowering pension costs. TMO\u2019s 1.45% discount rate likely contributed to a more favorable actuarial valuation of its Non-U.S. pension liabilities compared to DHR, which experienced a Non-U.S. pension benefit cost of $32 million in 2021. This suggests that DHR\u2019s lower implied discount rate would have increased its pension liability and associated cost, directly influencing the financial outcome for the year.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_b - TMO's 2021 discount rate for Non-U.S. pension benefits is 1.45%.",
        "Step 2: Extract from evidence_source_a - DHR's 2021 Non-U.S. pension benefit cost is $32 million.",
        "Step 3: Synthesize - A higher discount rate (TMO: 1.45%) reduces the present value of future pension obligations, which can lower the net periodic pension cost. DHR\u2019s Non-U.S. pension benefit cost of $32 million suggests a lower implied discount rate, leading to higher pension liabilities and a more negative financial impact compared to TMO."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_110",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                                      | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                                                      | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Service cost                                         | $ -                     | $ -                     | $ (44)                      | $ (40)                      | $ -                       | $ -                       |\n| Interest cost                                        | (44)                    | (69)                    | (19)                        | (22)                        | (2)                       | (4)                       |\n| Expected return on plan assets                       | 123                     | 121                     | 42                          | 37                          | -                         | -                         |\n| Amortization of prior service (cost) credit          | (1)                     | (1)                     | 1                           | 1                           | 2                         | 2                         |\n| Amortization of net loss                             | (46)                    | (37)                    | (11)                        | (10)                        | (2)                       | (1)                       |\n| Curtailment and settlement gains (losses) recognized | -                       | -                       | (1)                         | (1)                         | -                         | -                         |\n| Net periodic pension benefit (cost)                  | $ 32                    | $ 14                    | $ (32)                      | $ (35)                      | $ (2)                     | $ (3)                     |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_80",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                              | Domestic pension benefits   | Domestic pension benefits   | Non-U.S. pension benefits   | Non-U.S. pension benefits   |\n|------------------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|\n|                                                                              | 2021                        | 2020                        | 2021                        | 2020                        |\n| Weighted average assumptions used to determine projected benefit obligations |                             |                             |                             |                             |\n| Discount rate for determining benefit obligation                             | 2.70%                       | 2.33%                       | 1.45%                       | 0.95%                       |\n| Interest crediting rate for cash balance plans                               | 2.58%                       | 2.16%                       | 1.25%                       | 1.25%                       |\n| Average rate of increase in employee compensation                            | N/A                         | N/A                         | 2.73%                       | 2.30%                       |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 69,
      "question": "What is the total projected benefit obligation for Non-U.S. Pension Benefits across both DHR and TMO in 2022, and how does this compare to TMO's expected Non-U.S. pension benefit payments over the next five years?",
      "answer": "The total projected benefit obligation for Non-U.S. Pension Benefits in 2022 is $1,125 million for DHR and $45 million for TMO, totaling $1,170 million. This total obligation is significantly higher than TMO's expected Non-U.S. pension benefit payments of $287 million over the next five years (2022\u20132026).",
      "reasoning_steps": [
        "Step 1: Extract from source A - DHR's 2022 projected benefit obligation for Non-U.S. Pension Benefits is $1,125 million.",
        "Step 2: Extract from source B - TMO's expected Non-U.S. pension benefit payments for 2022 through 2026 total $287 million (sum of $45 + $45 + $49 + $52 + $56).",
        "Step 3: Extract from source B - TMO's expected Non-U.S. pension benefit payment for 2022 is $45 million.",
        "Step 4: Synthesize - Combine DHR's 2022 Non-U.S. pension obligation ($1,125 million) with TMO's 2022 obligation ($45 million) to calculate total obligation of $1,170 million. Compare this to TMO's cumulative five-year expected payments of $287 million to assess the relative funding challenge."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Has_Stake_In]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_109",
          "chunk_id": "chunk_4",
          "chunk_text": "|                              | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                              | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Projected benefit obligation | $ 2,532                 | $ 2,718                 | $ 1,125                     | $ 1,366                     | $ 135                     | $ 148                     |\n| Fair value of plan assets    | 2,303                   | 2,125                   | 357                         | 441                         | -                         | -                         |\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_81",
          "chunk_id": "chunk_6",
          "chunk_text": "| (In millions)             | Domestic pension benefits   | Non-U.S. pension benefits   |\n|---------------------------|-----------------------------|-----------------------------|\n| Expected benefit payments |                             |                             |\n| 2022                      | $ 93                        | $ 45                        |\n| 2023                      | 89                          | 45                          |\n| 2024                      | 88                          | 49                          |\n| 2025                      | 86                          | 52                          |\n| 2026                      | 84                          | 56                          |\n| 2027-2031                 | 368                         | 307                         |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 70,
      "question": "How does the difference in discount rates used by TMO for determining Non-U.S. pension benefit obligations in 2021 and 2020 compare to the change in projected benefit obligation for Non-U.S. Pension Benefits reported by DHR between those years, and what does this reveal about the sensitivity of pension liabilities to interest rate assumptions?",
      "answer": "The difference in discount rates used by TMO for Non-U.S. pension benefits between 2020 (0.95%) and 2021 (1.45%) is 0.50 percentage points. During the same period, DHR reported a decrease in its projected benefit obligation for Non-U.S. Pension Benefits from $1,366 million in 2020 to $1,125 million in 2021, a decrease of $241 million. This reveals that pension liabilities are highly sensitive to changes in discount rate assumptions\u2014when the assumed discount rate increases, the present value of future obligations decreases, demonstrating how actuarial assumptions directly impact reported pension liabilities.",
      "reasoning_steps": [
        "Step 1: From TMO's filing, extract the discount rate for Non-U.S. pension benefits in 2020 (0.95%) and 2021 (1.45%) to calculate the difference (0.50 percentage points).",
        "Step 2: From DHR's filing, extract the projected benefit obligation for Non-U.S. Pension Benefits in 2020 ($1,366 million) and 2021 ($1,125 million) to calculate the change (-$241 million).",
        "Step 3: Synthesize the two findings: the increase in discount rate corresponds with a decrease in the projected benefit obligation, illustrating the inverse relationship between discount rate assumptions and pension liabilities."
      ],
      "difficulty": "hard",
      "idf_score": 5.475067878292536,
      "sector": "Health Care",
      "sub_industry": "Life Sciences Tools & Services",
      "pattern": "ORG -[Has_Stake_In]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "DHR",
        "intermediate": "Non-U.S. Pension Benefits",
        "end": "TMO"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "DHR",
          "name": "DHR",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "DHR_10k_2022.pdf",
          "page_id": "page_109",
          "chunk_id": "chunk_4",
          "chunk_text": "|                              | U.S. Pension Benefits   | U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Non-U.S. Pension Benefits   | Postretirement Benefits   | Postretirement Benefits   |\n|------------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|\n|                              | 2021                    | 2020                    | 2021                        | 2020                        | 2021                      | 2020                      |\n| Projected benefit obligation | $ 2,532                 | $ 2,718                 | $ 1,125                     | $ 1,366                     | $ 135                     | $ 148                     |\n| Fair value of plan assets    | 2,303                   | 2,125                   | 357                         | 441                         | -                         | -                         |\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "Non-U.S._Pension_Benefits",
          "name": "Non-U.S. Pension Benefits",
          "type": "FIN_METRIC",
          "idf_score": 5.475067878292536
        },
        "hop_2_rel": {
          "source_file": "TMO_10k_2022.pdf",
          "page_id": "page_80",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                              | Domestic pension benefits   | Domestic pension benefits   | Non-U.S. pension benefits   | Non-U.S. pension benefits   |\n|------------------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|\n|                                                                              | 2021                        | 2020                        | 2021                        | 2020                        |\n| Weighted average assumptions used to determine projected benefit obligations |                             |                             |                             |                             |\n| Discount rate for determining benefit obligation                             | 2.70%                       | 2.33%                       | 1.45%                       | 0.95%                       |\n| Interest crediting rate for cash balance plans                               | 2.58%                       | 2.16%                       | 1.25%                       | 1.25%                       |\n| Average rate of increase in employee compensation                            | N/A                         | N/A                         | 2.73%                       | 2.30%                       |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "TMO",
          "name": "TMO",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 71,
      "question": "What is the difference in the number of vested shares between PFE and UNH as reported in their respective 2022 10-K filings, and how does this difference reflect variations in their share-based compensation vesting activity over the reporting period?",
      "answer": "PFE reported 34.1 million vested and non-vested shares outstanding but not paid as of December 31, 2021. UNH reported that 2 million shares vested during the period. The difference between these amounts is 32.1 million shares. This difference suggests that PFE had a significantly higher volume of unvested or recently vested shares not yet paid out, which may reflect different timing or structure in their share-based compensation plans.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - PFE reported 34.1 million vested and non-vested shares outstanding but not paid as of December 31, 2021.",
        "Step 2: Extract from evidence_source_b - UNH reported that 2 million shares vested during the period.",
        "Step 3: Calculate the difference: 34.1 million (PFE) - 2 million (UNH) = 32.1 million.",
        "Step 4: Interpret the difference in the context of vesting activity: PFE's figure includes both vested and non-vested shares not yet paid, while UNH's figure reflects only shares that vested during the period, indicating differing reporting scopes and potentially different compensation strategies."
      ],
      "difficulty": "hard",
      "idf_score": 6.168215058852481,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Vested Share Count",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_3",
          "chunk_text": "\n- Vested and non-vested shares outstanding, but not paid as of December 31, 2021 were 34.1 million. (a)\n\nSummary of TSRU and PTU information as of December 31, 2021 : (a), (b)\n\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Vested_Share_Count",
          "name": "Vested Share Count",
          "type": "FIN_METRIC",
          "idf_score": 6.168215058852481
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_67",
          "chunk_id": "chunk_6",
          "chunk_text": "| (shares in millions)             | Shares   | Weighted-Average Grant Date Fair Value per Share   |\n|----------------------------------|----------|----------------------------------------------------|\n| Nonvested at beginning of period | 4        | $ 256                                              |\n| Granted                          | 2        | 352                                                |\n| Vested                           | (2)      | 246                                                |\n| Nonvested at end of period       | 4        | 303                                                |",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 41
    },
    {
      "question_id": 72,
      "question": "How does the structure of UnitedHealth Group's Optum Rx pharmacy business, particularly its obligation to pay network pharmacies and its role in formulary decisions, affect Pfizer's position as a stakeholder in the pharmaceutical segment, given the scale of Optum Rx's product revenues tied to pharmaceutical costs and co-payments?",
      "answer": "UnitedHealth Group's Optum Rx business plays a central role in the pharmaceutical supply chain by managing a network of retail and specialty pharmacies and determining formulary inclusion, which directly affects the demand and pricing dynamics for pharmaceutical manufacturers like Pfizer. As a stakeholder in the pharmaceutical segment, Pfizer would be impacted by Optum Rx\u2019s influence over drug selection and pricing negotiations. Optum Rx recognizes product revenues based on the cost of pharmaceuticals (net of rebates), dispensing fees, and co-payments, and it assumes financial risk by being primarily obligated to pay pharmacies regardless of whether it receives payment. This creates a dependency on efficient rebate collection and pricing negotiation, which in turn affects the profitability and market access of pharmaceutical products like those from Pfizer. The scale of Optum Rx\u2019s operations\u2014evidenced by $5.4 billion in accounts receivables as of 2021\u2014highlights the systemic influence of its business model on pharmaceutical stakeholders.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Pfizer has a stake in the Pharmaceuticals segment, indicating its strategic interest in drug development, sales, and market access.",
        "Step 2: Extract from source B - UnitedHealth\u2019s Optum Rx business recognizes product revenues based on pharmaceutical costs (net of rebates), dispensing fees, and co-payments, and it assumes financial responsibility for payments to pharmacies regardless of its own collections.",
        "Step 3: Synthesize - Optum Rx\u2019s control over formularies and pricing affects Pfizer\u2019s market access and pricing power, while its financial obligations influence rebate dynamics and profitability for pharmaceutical companies."
      ],
      "difficulty": "medium",
      "idf_score": 4.78192069773259,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> SEGMENT <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Pharmaceuticals",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_62",
          "chunk_id": "chunk_1",
          "chunk_text": "## Consolidated Balance Sheets\n\nPfizer Inc. and Subsidiary Companies\n\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "Pharmaceuticals",
          "name": "Pharmaceuticals",
          "type": "SEGMENT",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n## Products and Services\n\nFor the Company's Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through the Company's home delivery, specialty and community pharmacies. For the years ended December 31, 2021 and 2020, the Company recognized revenue and cost of products sold for retail pharmacy co-payments related to its Optum Rx business. Revenue recognized in prior periods related to retail pharmacy transactions excludes the member's applicable co-payment. There was no impact on earnings from operations, net earnings, earnings per share or total equity. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors' members and accordingly, are reported on a gross basis.\n\nServices revenue are comprised of a number of services and products sold through Optum. Optum Health's service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured each period based on the progress to date as services are performed or made available to customers.\n\nServices revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees' dependents. Under service fee contracts, the Company receives monthly, a fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees' dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period.\n\nAs of December 31, 2021 and 2020, accounts receivables related to products and services were $5.4 billion and $5.3 billion, respectively. In 2021 and 2020, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2021 or 2020.\n\nFor the years ended December 31, 2021, 2020 and 2019, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material.\n\nRevenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material.\n\nSee Note 13 for disaggregation of revenue by segment and type.\n\n## Medical Costs and Medical Costs Payable\n\nThe Company's estimate of medical costs payable represents management's best estimate of its liability for unpaid medical costs as of December 31, 2021.\n\nEach period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months.\n\nMedical costs and medical costs payable include estimates of the Company's obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 73,
      "question": "How does Pfizer's stake in the pharmaceutical segment potentially influence UnitedHealth Group's product revenue from pharmaceuticals sold through Optum Rx, particularly considering the cost of pharmaceuticals and dispensing fees?",
      "answer": "Pfizer's stake in the pharmaceutical segment could influence UnitedHealth Group's product revenue by affecting the cost of pharmaceuticals and negotiated dispensing fees. As UnitedHealth Group's Optum Rx business derives revenue from pharmaceuticals sold through a network of pharmacies, any changes in drug pricing or availability due to Pfizer's influence may directly impact the cost of products sold and the dispensing fees negotiated with pharmacies. This, in turn, affects the total product revenue recognized by UnitedHealth Group.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Pfizer has a stake in the pharmaceutical segment, indicating influence over drug development, pricing, and supply.",
        "Step 2: Extract from source B - UnitedHealth Group's Optum Rx business generates product revenues from pharmaceuticals, which include the cost of drugs (net of rebates), dispensing fees, and co-payments.",
        "Step 3: Synthesize - Pfizer\u2019s influence on pharmaceutical pricing and availability could directly affect UnitedHealth Group\u2019s cost of products sold and negotiated dispensing fees, thereby impacting product revenue."
      ],
      "difficulty": "medium",
      "idf_score": 4.78192069773259,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> SEGMENT <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Pharmaceuticals",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_63",
          "chunk_id": "chunk_1",
          "chunk_text": "## Consolidated Statements of Equity\n\nPfizer Inc. and Subsidiary Companies\n\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "Pharmaceuticals",
          "name": "Pharmaceuticals",
          "type": "SEGMENT",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n## Products and Services\n\nFor the Company's Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through the Company's home delivery, specialty and community pharmacies. For the years ended December 31, 2021 and 2020, the Company recognized revenue and cost of products sold for retail pharmacy co-payments related to its Optum Rx business. Revenue recognized in prior periods related to retail pharmacy transactions excludes the member's applicable co-payment. There was no impact on earnings from operations, net earnings, earnings per share or total equity. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors' members and accordingly, are reported on a gross basis.\n\nServices revenue are comprised of a number of services and products sold through Optum. Optum Health's service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured each period based on the progress to date as services are performed or made available to customers.\n\nServices revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees' dependents. Under service fee contracts, the Company receives monthly, a fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees' dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period.\n\nAs of December 31, 2021 and 2020, accounts receivables related to products and services were $5.4 billion and $5.3 billion, respectively. In 2021 and 2020, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2021 or 2020.\n\nFor the years ended December 31, 2021, 2020 and 2019, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material.\n\nRevenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material.\n\nSee Note 13 for disaggregation of revenue by segment and type.\n\n## Medical Costs and Medical Costs Payable\n\nThe Company's estimate of medical costs payable represents management's best estimate of its liability for unpaid medical costs as of December 31, 2021.\n\nEach period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months.\n\nMedical costs and medical costs payable include estimates of the Company's obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 38
    },
    {
      "question_id": 74,
      "question": "What is the combined value of accounts receivable related to pharmaceutical products for both UnitedHealth's Optum Rx business in 2021 and Pfizer's pharmaceuticals segment, assuming Pfizer's 2022 10-K reports $12.3 billion in accounts receivable for its Pharmaceuticals segment?",
      "answer": "The combined value of accounts receivable related to pharmaceutical products for both UnitedHealth's Optum Rx business in 2021 and Pfizer's Pharmaceuticals segment is $17.7 billion. This is calculated by adding UnitedHealth's Optum Rx accounts receivable of $5.4 billion (as stated in the 2022 10-K for the year ended December 31, 2021) to Pfizer's Pharmaceuticals segment accounts receivable of $12.3 billion (assumed for this question based on the 2022 10-K filing).",
      "reasoning_steps": [
        "Step 1: Extract from source B - UnitedHealth's Optum Rx business reported $5.4 billion in accounts receivable related to products (pharmaceuticals) for the year ended December 31, 2021.",
        "Step 2: Extract from source A - Assume Pfizer's Pharmaceuticals segment had $12.3 billion in accounts receivable as stated in its 2022 10-K filing.",
        "Step 3: Synthesize - Add the two values together to determine the combined accounts receivable value: $5.4 billion (UNH) + $12.3 billion (PFE) = $17.7 billion."
      ],
      "difficulty": "medium",
      "idf_score": 4.78192069773259,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> SEGMENT <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Pharmaceuticals",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_77",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes to Consolidated Financial Statements\n\nPfizer Inc. and Subsidiary Companies\n\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "Pharmaceuticals",
          "name": "Pharmaceuticals",
          "type": "SEGMENT",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n## Products and Services\n\nFor the Company's Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through the Company's home delivery, specialty and community pharmacies. For the years ended December 31, 2021 and 2020, the Company recognized revenue and cost of products sold for retail pharmacy co-payments related to its Optum Rx business. Revenue recognized in prior periods related to retail pharmacy transactions excludes the member's applicable co-payment. There was no impact on earnings from operations, net earnings, earnings per share or total equity. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors' members and accordingly, are reported on a gross basis.\n\nServices revenue are comprised of a number of services and products sold through Optum. Optum Health's service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured each period based on the progress to date as services are performed or made available to customers.\n\nServices revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees' dependents. Under service fee contracts, the Company receives monthly, a fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees' dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period.\n\nAs of December 31, 2021 and 2020, accounts receivables related to products and services were $5.4 billion and $5.3 billion, respectively. In 2021 and 2020, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2021 or 2020.\n\nFor the years ended December 31, 2021, 2020 and 2019, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material.\n\nRevenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material.\n\nSee Note 13 for disaggregation of revenue by segment and type.\n\n## Medical Costs and Medical Costs Payable\n\nThe Company's estimate of medical costs payable represents management's best estimate of its liability for unpaid medical costs as of December 31, 2021.\n\nEach period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months.\n\nMedical costs and medical costs payable include estimates of the Company's obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 75,
      "question": "How does Pfizer's stake in the pharmaceutical segment influence UnitedHealth Group's revenue recognition process for pharmacy products in its Optum Rx business?",
      "answer": "Pfizer's stake in the pharmaceutical segment contributes to the supply of drugs that UnitedHealth Group's Optum Rx business dispenses through its network of pharmacies. UnitedHealth Group recognizes product revenues, which include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee, and customer co-payments for drugs dispensed through its pharmacy services. Since Optum Rx reports pharmacy product revenues on a gross basis\u2014meaning it records revenue based on the total transaction value including the cost of pharmaceuticals and associated fees\u2014Pfizer\u2019s role as a drug manufacturer directly affects the volume and cost of pharmaceuticals flowing through Optum Rx\u2019s network. This stake implies that Pfizer\u2019s pricing, rebate structures, and drug availability influence UnitedHealth\u2019s revenue recognition mechanics and gross margin dynamics in its pharmacy business.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - Pfizer has a stake in the pharmaceuticals segment, indicating involvement in drug development and supply.",
        "Step 2: Extract from evidence_source_b - UnitedHealth Group's Optum Rx recognizes product revenue from pharmaceuticals, which includes the cost of drugs (net of rebates), dispensing fees, and co-payments.",
        "Step 3: Synthesize - Pfizer's influence on the pharmaceutical supply chain (via its stake) affects the cost, rebate structure, and availability of drugs, which directly impacts how UnitedHealth Group recognizes revenue and manages margins in its Optum Rx business."
      ],
      "difficulty": "medium",
      "idf_score": 4.78192069773259,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> SEGMENT <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Pharmaceuticals",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_113",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes to Consolidated Financial Statements\n\nPfizer Inc. and Subsidiary Companies\n\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "Pharmaceuticals",
          "name": "Pharmaceuticals",
          "type": "SEGMENT",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n## Products and Services\n\nFor the Company's Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through the Company's home delivery, specialty and community pharmacies. For the years ended December 31, 2021 and 2020, the Company recognized revenue and cost of products sold for retail pharmacy co-payments related to its Optum Rx business. Revenue recognized in prior periods related to retail pharmacy transactions excludes the member's applicable co-payment. There was no impact on earnings from operations, net earnings, earnings per share or total equity. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors' members and accordingly, are reported on a gross basis.\n\nServices revenue are comprised of a number of services and products sold through Optum. Optum Health's service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured each period based on the progress to date as services are performed or made available to customers.\n\nServices revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees' dependents. Under service fee contracts, the Company receives monthly, a fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees' dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period.\n\nAs of December 31, 2021 and 2020, accounts receivables related to products and services were $5.4 billion and $5.3 billion, respectively. In 2021 and 2020, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2021 or 2020.\n\nFor the years ended December 31, 2021, 2020 and 2019, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material.\n\nRevenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material.\n\nSee Note 13 for disaggregation of revenue by segment and type.\n\n## Medical Costs and Medical Costs Payable\n\nThe Company's estimate of medical costs payable represents management's best estimate of its liability for unpaid medical costs as of December 31, 2021.\n\nEach period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months.\n\nMedical costs and medical costs payable include estimates of the Company's obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 76,
      "question": "How does Pfizer's pharmaceutical segment operations indirectly influence UnitedHealth Group's revenue recognition practices in its Optum Rx pharmacy care services business?",
      "answer": "Pfizer's pharmaceutical segment supplies the drugs that UnitedHealth Group's Optum Rx business dispenses through its network of pharmacies. Since Optum Rx recognizes product revenues when prescriptions are dispensed, the availability and formulary inclusion of Pfizer's pharmaceuticals directly affect the volume and timing of revenue recognition for UnitedHealth Group. Additionally, because UnitedHealth Group negotiates pricing and formulary placement, the cost and pricing structure of Pfizer's drugs impacts the rebates and dispensing fees that factor into Optum Rx's revenue calculations.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Pfizer operates a pharmaceutical segment that provides drugs to various entities.",
        "Step 2: Extract from source B - UnitedHealth Group's Optum Rx business recognizes revenue when prescriptions are dispensed through its network of pharmacies.",
        "Step 3: Synthesize - The pharmaceuticals supplied by Pfizer are a critical input for Optum Rx's operations, and the timing and volume of dispensed prescriptions directly affect UnitedHealth Group's revenue recognition practices."
      ],
      "difficulty": "medium",
      "idf_score": 4.78192069773259,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Has_Stake_In]-> SEGMENT <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Pharmaceuticals",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "SEGMENT",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_111",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes to Consolidated Financial Statements\n\nPfizer Inc. and Subsidiary Companies\n\n## Selected Income Statement Information\n\nThe following table provides selected income statement information by reportable segment:\n\n",
          "relationship": "Has_Stake_In"
        },
        "intermediate_node": {
          "id": "Pharmaceuticals",
          "name": "Pharmaceuticals",
          "type": "SEGMENT",
          "idf_score": 4.78192069773259
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_52",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\n## Products and Services\n\nFor the Company's Optum Rx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and community health pharmacies. Product revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through the Company's home delivery, specialty and community pharmacies. For the years ended December 31, 2021 and 2020, the Company recognized revenue and cost of products sold for retail pharmacy co-payments related to its Optum Rx business. Revenue recognized in prior periods related to retail pharmacy transactions excludes the member's applicable co-payment. There was no impact on earnings from operations, net earnings, earnings per share or total equity. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors' members and accordingly, are reported on a gross basis.\n\nServices revenue are comprised of a number of services and products sold through Optum. Optum Health's service revenues include net patient service revenues recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, Optum Health charges fees and earns investment income on managed funds. Optum Insight provides software and information products, advisory consulting arrangements and managed services outsourcing contracts, which may be delivered over several years. Optum Insight revenues are generally recognized over time and measured each period based on the progress to date as services are performed or made available to customers.\n\nServices revenue also consists of fees derived from services performed for customers who self-insure the health care costs of their employees and employees' dependents. Under service fee contracts, the Company receives monthly, a fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees' dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period.\n\nAs of December 31, 2021 and 2020, accounts receivables related to products and services were $5.4 billion and $5.3 billion, respectively. In 2021 and 2020, the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2021 or 2020.\n\nFor the years ended December 31, 2021, 2020 and 2019, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material.\n\nRevenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material.\n\nSee Note 13 for disaggregation of revenue by segment and type.\n\n## Medical Costs and Medical Costs Payable\n\nThe Company's estimate of medical costs payable represents management's best estimate of its liability for unpaid medical costs as of December 31, 2021.\n\nEach period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months.\n\nMedical costs and medical costs payable include estimates of the Company's obligations for medical care services rendered on behalf of consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims which have not been received or fully processed, using an actuarial process consistently applied, centrally controlled and automated. The actuarial",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 42
    },
    {
      "question_id": 77,
      "question": "How much more did UNH pay in cash dividends in 2021 compared to 2020, and how does this increase contrast with PFE's change in cash dividends paid between the same years?",
      "answer": "UNH paid $5,280 million in cash dividends in 2021 and $4,584 million in 2020, resulting in an increase of $696 million. In contrast, PFE's cash dividends paid decreased by $4,200 million between 2020 and 2021 due to a drop in proceeds from long-term debt. This shows opposing trends: UNH increased its dividend payout, while PFE significantly reduced it, likely due to differing financial strategies or cash flow conditions.",
      "reasoning_steps": [
        "Step 1: From UNH's 2022 10-K filing, extract the cash dividends paid in 2021 ($5,280 million) and 2020 ($4,584 million) to calculate the increase of $696 million.",
        "Step 2: From PFE's 2022 10-K filing, identify the decrease in cash dividends paid of $4,200 million between 2020 and 2021, attributed to lower proceeds from long-term debt.",
        "Step 3: Contrast the two companies' trends: UNH increased its dividend payments in 2021, whereas PFE reduced them, indicating different financial strategies or liquidity positions."
      ],
      "difficulty": "medium",
      "idf_score": 4.4942386252808095,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Increases]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Cash Dividends Paid",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_54",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                 | Year Ended December 31,   | Year Ended December 31,   | Year Ended December 31,   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n|-------------------------------------------------|---------------------------|---------------------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (MILLIONS)                                      | 2021                      | 2020                      | 2019                      | Drivers of change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Cash provided by/(used in):                     |                           |                           |                           | 2021 v. 2020 The change was driven primarily by higher net income adjusted for non-cash items, the payment for the acquisition of Trillium, a decrease in contributions to pension plans, and the impact of timing of receipts and payments in the ordinary course of business, mostly from an increase in cash flows from Other current liabilities driven by: (i) a $9.7 billion accrual for the gross profit split due to BioNTech, (ii) an increase in royalties payable, as well as (iii) an increase in deferred revenues for advance payments in 2021 for Comirnaty. The change in Other Adjustments, net , is mostly due to an increase in unrealized                                                                                  |\n| Operating activities from continuing operations | $ 32,922                  | $ 10,540                  | $ 7,015                   | 2020 v. 2019 The change was driven mainly by higher net income adjusted for non-cash items, advanced payments in 2020 for Comirnaty recorded in deferred revenue, the upfront cash payment associated with our acquisition of Therachon in 2019, and the upfront cash payment associated with our licensing agreement with Akcea in 2019, partially offset by an increase in benefit plan contributions. The change also reflects the impact of timing of receipts and payments in the ordinary course of business. The change in Other adjustments, net was driven primarily by an increase in equity method dividends received, partially offset by an increase in equity income and increases in net unrealized gains on equity securities. |\n|                                                 |                           |                           |                           | 2021 v. 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Investing activities from continuing operations | $ (22,534)                | $ (4,162)                 | $ (3,825)                 | term investments with original maturities of greater than three months. 2020 v. 2019                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n|                                                 |                           |                           |                           | The change was driven mostly by a $6.0 billion decrease in net proceeds from short- term investments with original maturities of three months or less and $2.7 billion in net purchases of short-term investments with original maturities of greater than three months in 2020 (compared to $2.3 billion net proceeds from short-term investments with original maturities of greater than three months in 2019), partially offset by the cash used to acquire Array, net of cash acquired, of $10.9 billion in 2019. 2021 v. 2020                                                                                                                                                                                                            |\n| Financing activities from continuing operations | $ (9,816)                 | $ (21,640)                | $ (8,485)                 | $4.2 billion decrease in proceeds from issuances of long-term debt. 2020 v. 2019 The change was driven mostly by $14.0 billion net payments of short-term borrowings in 2020 (compared to $10.6 billion net proceeds raised from short-term borrowings in 2019) and an increase in cash dividends paid of $397 million, partially offset by a decrease in purchases of common stock of $8.9 billion, lower repayments on long-term debt of $2.8 billion, and an increase in issuances of long-term debt of $280 million.                                                                                                                                                                                                                       |\n",
          "relationship": "Increases"
        },
        "intermediate_node": {
          "id": "Cash_Dividends_Paid",
          "name": "Cash Dividends Paid",
          "type": "FIN_METRIC",
          "idf_score": 4.4942386252808095
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_50",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                                    | For the Years Ended December 31,   | For the Years Ended December 31,   | For the Years Ended December 31,   |\n|----------------------------------------------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|\n| (in millions)                                                                                      | 2021                               | 2020                               | 2019                               |\n| Operating activities                                                                               |                                    |                                    |                                    |\n| Net earnings                                                                                       | $ 17,732                           | $ 15,769                           | $ 14,239                           |\n| Noncash items:                                                                                     |                                    |                                    |                                    |\n| Depreciation and amortization                                                                      | 3,103                              | 2,891                              | 2,720                              |\n| Deferred income taxes                                                                              | 130                                | (8)                                | 230                                |\n| Share-based compensation                                                                           | 800                                | 679                                | 697                                |\n| Other, net                                                                                         | (944)                              | (52)                               | (106)                              |\n| Net change in other operating items, net of effects from acquisitions and changes inAARP balances: |                                    |                                    |                                    |\n| Accounts receivable                                                                                | (1,000)                            | (688)                              | 162                                |\n| Other assets                                                                                       | (1,031)                            | (2,195)                            | (1,563)                            |\n| Medical costs payable                                                                              | 2,701                              | 152                                | 1,221                              |\n| Accounts payable and other liabilities                                                             | 1,162                              | 5,348                              | 733                                |\n| Unearned revenues                                                                                  | (310)                              | 278                                | 130                                |\n| Cash flows from operating activities                                                               | 22,343                             | 22,174                             | 18,463                             |\n| Investing activities                                                                               |                                    |                                    |                                    |\n| Purchases of investments                                                                           | (17,139)                           | (16,577)                           | (18,131)                           |\n| Sales of investments                                                                               | 7,045                              | 6,489                              | 8,536                              |\n| Maturities of investments                                                                          | 8,251                              | 7,252                              | 7,091                              |\n| Cash paid for acquisitions, net of cash assumed                                                    | (4,821)                            | (7,139)                            | (8,343)                            |\n| Purchases of property, equipment and capitalized software                                          | (2,454)                            | (2,051)                            | (2,071)                            |\n| Other, net                                                                                         | (1,254)                            | (506)                              | 219                                |\n| Cash flows used for investing activities                                                           | (10,372)                           | (12,532)                           | (12,699)                           |\n| Financing activities                                                                               |                                    |                                    |                                    |\n| Common share repurchases                                                                           | (5,000)                            | (4,250)                            | (5,500)                            |\n| Cash dividends paid                                                                                | (5,280)                            | (4,584)                            | (3,932)                            |\n| Proceeds from common stock issuances                                                               | 1,355                              | 1,440                              | 1,037                              |\n| Repayments of long-term debt                                                                       | (3,150)                            | (3,150)                            | (1,750)                            |\n| (Repayments of) proceeds from short-term borrowings, net                                           | (1,302)                            | 872                                | 300                                |\n| Proceeds from issuance of long-term debt                                                           | 6,933                              | 4,864                              | 5,444                              |\n| Customer funds administered                                                                        | 622                                | 1,677                              | 13                                 |\n| Purchases of redeemable noncontrolling interests                                                   | (1,338)                            | -                                  | (618)                              |\n| Other, net                                                                                         | (295)                              | (459)                              | (619)                              |\n| Cash flows used for financing activities                                                           | (7,455)                            | (3,590)                            | (5,625)                            |\n| Effect of exchange rate changes on cash and cash equivalents                                       | (62)                               | (116)                              | (20)                               |\n| Increase in cash and cash equivalents                                                              | 4,454                              | 5,936                              | 119                                |\n| Cash and cash equivalents, beginning of period                                                     | 16,921                             | 10,985                             | 10,866                             |\n| Cash and cash equivalents, end of period                                                           | $ 21,375                           | $ 16,921                           | $ 10,985                           |\n| Supplemental cash flow disclosures                                                                 |                                    |                                    |                                    |\n| Cash paid for interest                                                                             | $ 1,653                            | $ 1,704                            | $ 1,627                            |\n| Cash paid for income taxes                                                                         | 3,966                              | 4,935                              | 3,542                              |",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 78,
      "question": "How did the change in cash dividends paid by UNH in 2021 compared to 2020, combined with PFE's increase in cash dividends paid in 2021, reflect on their respective financial strategies as reported in their 2022 10-K filings?",
      "answer": "UnitedHealth (UNH) increased its cash dividends paid from $4,584 million in 2020 to $5,280 million in 2021, an increase of $696 million. Meanwhile, Pfizer (PFE) also increased its cash dividends paid in 2021 compared to 2020, contributing to a net decrease in cash flows from financing activities by $11,824 million (from $-21,640 million in 2020 to $-9,816 million in 2021). The combined increase in dividends by both companies reflects a shared financial strategy to return more capital to shareholders during a period of strong cash flow generation, despite differing sector dynamics within healthcare.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_b - UNH's cash dividends paid increased from $4,584 million in 2020 to $5,280 million in 2021.",
        "Step 2: Extract from evidence_source_a - PFE's cash dividends paid increased in 2021, contributing to a significant decrease in cash flows from financing activities from $-21,640 million in 2020 to $-9,816 million in 2021.",
        "Step 3: Synthesize - Both companies increased dividends paid to shareholders in 2021, signaling a shared strategy of capital return to shareholders amid improved financial performance."
      ],
      "difficulty": "medium",
      "idf_score": 4.4942386252808095,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Increases]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Cash Dividends Paid",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_54",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                 | Year Ended December 31,   | Year Ended December 31,   | Year Ended December 31,   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n|-------------------------------------------------|---------------------------|---------------------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (MILLIONS)                                      | 2021                      | 2020                      | 2019                      | Drivers of change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Cash provided by/(used in):                     |                           |                           |                           | 2021 v. 2020 The change was driven primarily by higher net income adjusted for non-cash items, the payment for the acquisition of Trillium, a decrease in contributions to pension plans, and the impact of timing of receipts and payments in the ordinary course of business, mostly from an increase in cash flows from Other current liabilities driven by: (i) a $9.7 billion accrual for the gross profit split due to BioNTech, (ii) an increase in royalties payable, as well as (iii) an increase in deferred revenues for advance payments in 2021 for Comirnaty. The change in Other Adjustments, net , is mostly due to an increase in unrealized                                                                                  |\n| Operating activities from continuing operations | $ 32,922                  | $ 10,540                  | $ 7,015                   | 2020 v. 2019 The change was driven mainly by higher net income adjusted for non-cash items, advanced payments in 2020 for Comirnaty recorded in deferred revenue, the upfront cash payment associated with our acquisition of Therachon in 2019, and the upfront cash payment associated with our licensing agreement with Akcea in 2019, partially offset by an increase in benefit plan contributions. The change also reflects the impact of timing of receipts and payments in the ordinary course of business. The change in Other adjustments, net was driven primarily by an increase in equity method dividends received, partially offset by an increase in equity income and increases in net unrealized gains on equity securities. |\n|                                                 |                           |                           |                           | 2021 v. 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Investing activities from continuing operations | $ (22,534)                | $ (4,162)                 | $ (3,825)                 | term investments with original maturities of greater than three months. 2020 v. 2019                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n|                                                 |                           |                           |                           | The change was driven mostly by a $6.0 billion decrease in net proceeds from short- term investments with original maturities of three months or less and $2.7 billion in net purchases of short-term investments with original maturities of greater than three months in 2020 (compared to $2.3 billion net proceeds from short-term investments with original maturities of greater than three months in 2019), partially offset by the cash used to acquire Array, net of cash acquired, of $10.9 billion in 2019. 2021 v. 2020                                                                                                                                                                                                            |\n| Financing activities from continuing operations | $ (9,816)                 | $ (21,640)                | $ (8,485)                 | $4.2 billion decrease in proceeds from issuances of long-term debt. 2020 v. 2019 The change was driven mostly by $14.0 billion net payments of short-term borrowings in 2020 (compared to $10.6 billion net proceeds raised from short-term borrowings in 2019) and an increase in cash dividends paid of $397 million, partially offset by a decrease in purchases of common stock of $8.9 billion, lower repayments on long-term debt of $2.8 billion, and an increase in issuances of long-term debt of $280 million.                                                                                                                                                                                                                       |\n",
          "relationship": "Increases"
        },
        "intermediate_node": {
          "id": "Cash_Dividends_Paid",
          "name": "Cash Dividends Paid",
          "type": "FIN_METRIC",
          "idf_score": 4.4942386252808095
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_85",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                          | For the Years Ended December 31,   | For the Years Ended December 31,   | For the Years Ended December 31,   |\n|----------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|\n| (in millions)                                            | 2021                               | 2020                               | 2019                               |\n| Operating activities                                     |                                    |                                    |                                    |\n| Cash flows from operating activities                     | $ 11,439                           | $ 8,842                            | $ 9,275                            |\n| Investing activities                                     |                                    |                                    |                                    |\n| Issuances of notes to subsidiaries                       | (444)                              | (628)                              | (2,722)                            |\n| Repayments of notes to subsidiaries                      | 37                                 | 1,089                              | 2,249                              |\n| Cash paid for acquisitions                               | (4,953)                            | (7,706)                            | (9,645)                            |\n| Return of capital to parent company                      | 245                                | 943                                | 4,497                              |\n| Capital contributions to subsidiaries                    | (747)                              | (43)                               | (803)                              |\n| Other, net                                               | -                                  | 143                                | 490                                |\n| Cash flows used for investing activities                 | (5,862)                            | (6,202)                            | (5,934)                            |\n| Financing activities                                     |                                    |                                    |                                    |\n| Common stock repurchases                                 | (5,000)                            | (4,250)                            | (5,500)                            |\n| Proceeds from common stock issuances                     | 1,355                              | 1,440                              | 1,037                              |\n| Cash dividends paid                                      | (5,280)                            | (4,584)                            | (3,932)                            |\n| (Repayments of) proceeds from short-term borrowings, net | (1,302)                            | 872                                | 300                                |\n| Proceeds from issuance of long-term debt                 | 6,933                              | 4,864                              | 5,444                              |\n| Repayments of long-term debt                             | (3,150)                            | (3,150)                            | (1,750)                            |\n| Proceeds from notes from subsidiaries                    | 3,223                              | 2,818                              | 1,207                              |\n| Other, net                                               | (447)                              | (438)                              | (535)                              |\n| Cash flows used for financing activities                 | (3,668)                            | (2,428)                            | (3,729)                            |\n| Increase (decrease) in cash and cash equivalents         | 1,909                              | 212                                | (388)                              |\n| Cash and cash equivalents, beginning of period           | 258                                | 46                                 | 434                                |\n| Cash and cash equivalents, end of period                 | $ 2,167                            | $ 258                              | $ 46                               |\n| Supplemental cash flow disclosures                       |                                    |                                    |                                    |\n| Cash paid for interest                                   | $ 1,575                            | $ 1,633                            | $ 1,506                            |\n| Cash paid for income taxes                               | 3,050                              | 4,185                              | 2,590                              |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 79,
      "question": "How much more did UNH pay in cash dividends in 2021 compared to PFE\u2019s cash dividends paid in 2021, and what was the direction of change in each company\u2019s dividend payments from 2020 to 2021?",
      "answer": "UNH paid $5,280 million in cash dividends in 2021, while PFE paid $9,816 million in 2021. From 2020 to 2021, PFE\u2019s cash dividends paid increased, whereas UNH\u2019s cash dividends paid also increased. The difference between the two companies\u2019 2021 cash dividends paid is $4,536 million.",
      "reasoning_steps": [
        "Step 1: Extract from source A - PFE's cash dividends paid in 2021 was $9,816 million.",
        "Step 2: Extract from source B - UNH's cash dividends paid in 2021 was $5,280 million.",
        "Step 3: Determine the direction of change - PFE's cash dividends paid increased from 2020 to 2021, while UNH's also increased.",
        "Step 4: Calculate the difference - $9,816 million (PFE) - $5,280 million (UNH) = $4,536 million."
      ],
      "difficulty": "medium",
      "idf_score": 4.4942386252808095,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Increases]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Cash Dividends Paid",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_54",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                 | Year Ended December 31,   | Year Ended December 31,   | Year Ended December 31,   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n|-------------------------------------------------|---------------------------|---------------------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (MILLIONS)                                      | 2021                      | 2020                      | 2019                      | Drivers of change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Cash provided by/(used in):                     |                           |                           |                           | 2021 v. 2020 The change was driven primarily by higher net income adjusted for non-cash items, the payment for the acquisition of Trillium, a decrease in contributions to pension plans, and the impact of timing of receipts and payments in the ordinary course of business, mostly from an increase in cash flows from Other current liabilities driven by: (i) a $9.7 billion accrual for the gross profit split due to BioNTech, (ii) an increase in royalties payable, as well as (iii) an increase in deferred revenues for advance payments in 2021 for Comirnaty. The change in Other Adjustments, net , is mostly due to an increase in unrealized                                                                                  |\n| Operating activities from continuing operations | $ 32,922                  | $ 10,540                  | $ 7,015                   | 2020 v. 2019 The change was driven mainly by higher net income adjusted for non-cash items, advanced payments in 2020 for Comirnaty recorded in deferred revenue, the upfront cash payment associated with our acquisition of Therachon in 2019, and the upfront cash payment associated with our licensing agreement with Akcea in 2019, partially offset by an increase in benefit plan contributions. The change also reflects the impact of timing of receipts and payments in the ordinary course of business. The change in Other adjustments, net was driven primarily by an increase in equity method dividends received, partially offset by an increase in equity income and increases in net unrealized gains on equity securities. |\n|                                                 |                           |                           |                           | 2021 v. 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Investing activities from continuing operations | $ (22,534)                | $ (4,162)                 | $ (3,825)                 | term investments with original maturities of greater than three months. 2020 v. 2019                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n|                                                 |                           |                           |                           | The change was driven mostly by a $6.0 billion decrease in net proceeds from short- term investments with original maturities of three months or less and $2.7 billion in net purchases of short-term investments with original maturities of greater than three months in 2020 (compared to $2.3 billion net proceeds from short-term investments with original maturities of greater than three months in 2019), partially offset by the cash used to acquire Array, net of cash acquired, of $10.9 billion in 2019. 2021 v. 2020                                                                                                                                                                                                            |\n| Financing activities from continuing operations | $ (9,816)                 | $ (21,640)                | $ (8,485)                 | $4.2 billion decrease in proceeds from issuances of long-term debt. 2020 v. 2019 The change was driven mostly by $14.0 billion net payments of short-term borrowings in 2020 (compared to $10.6 billion net proceeds raised from short-term borrowings in 2019) and an increase in cash dividends paid of $397 million, partially offset by a decrease in purchases of common stock of $8.9 billion, lower repayments on long-term debt of $2.8 billion, and an increase in issuances of long-term debt of $280 million.                                                                                                                                                                                                                       |\n",
          "relationship": "Increases"
        },
        "intermediate_node": {
          "id": "Cash_Dividends_Paid",
          "name": "Cash Dividends Paid",
          "type": "FIN_METRIC",
          "idf_score": 4.4942386252808095
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_36",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                          | For the Years Ended December 31,   | For the Years Ended December 31,   | For the Years Ended December 31,   | Change        |\n|--------------------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|---------------|\n| (in millions)                                                            | 2021                               | 2020                               | 2019                               | 2021 vs. 2020 |\n| Sources of cash:                                                         |                                    |                                    |                                    |               |\n| Cash provided by operating activities                                    | $ 22,343                           | $ 22,174                           | $ 18,463                           | $ 169         |\n| Issuances of long-term debt and short-term borrowings, net of repayments | 2,481                              | 2,586                              | 3,994                              | (105)         |\n| Proceeds from common share issuances                                     | 1,355                              | 1,440                              | 1,037                              | (85)          |\n| Customer funds administered                                              | 622                                | 1,677                              | 13                                 | (1,055)       |\n| Other                                                                    | -                                  | -                                  | 219                                | -             |\n| Total sources of cash                                                    | 26,801                             | 27,877                             | 23,726                             |               |\n| Uses of cash:                                                            |                                    |                                    |                                    |               |\n| Cash paid for acquisitions, net of cash assumed                          | (4,821)                            | (7,139)                            | (8,343)                            | 2,318         |\n| Cash dividends paid                                                      | (5,280)                            | (4,584)                            | (3,932)                            | (696)         |\n| Common share repurchases                                                 | (5,000)                            | (4,250)                            | (5,500)                            | (750)         |\n| Purchases of property, equipment and capitalized software                | (2,454)                            | (2,051)                            | (2,071)                            | (403)         |\n| Purchases of investments, net of sales and maturities                    | (1,843)                            | (2,836)                            | (2,504)                            | 993           |\n| Purchases of redeemable noncontrolling interests                         | (1,338)                            | -                                  | (618)                              | (1,338)       |\n| Other                                                                    | (1,549)                            | (965)                              | (619)                              | (584)         |\n| Total uses of cash                                                       | (22,285)                           | (21,825)                           | (23,587)                           |               |\n| Effect of exchange rate changes on cash and cash equivalents             | (62)                               | (116)                              | (20)                               | 54            |\n| Net increase in cash and cash equivalents                                | $ 4,454                            | $ 5,936                            | $ 119                              | $ (1,482)     |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 80,
      "question": "What is the difference in the weighted-average exercise price per share for exercised options between Pfizer (PFE) in 2020 and UnitedHealth (UNH) in 2022?",
      "answer": "The weighted-average exercise price per share for exercised options was $25.75 for Pfizer (PFE) in 2020 and $175 for UnitedHealth (UNH) in 2022. The difference between these two values is $149.25.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Pfizer's weighted-average exercise price for exercised shares in 2020 is $25.75.",
        "Step 2: Extract from source B - UnitedHealth's weighted-average exercise price for exercised shares in 2022 is $175.",
        "Step 3: Synthesize - Subtract PFE's value from UNH's value to calculate the difference: $175 - $25.75 = $149.25."
      ],
      "difficulty": "medium",
      "idf_score": 4.376455589624427,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Exercised Shares",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_6",
          "chunk_text": "|                                                    | Shares (Thousands)   | Weighted-Average Exercise Price Per Share   | Weighted-Average Remaining Contractual Term (Years)   | Aggregate Intrinsic Value (Millions)   |\n|----------------------------------------------------|----------------------|---------------------------------------------|-------------------------------------------------------|----------------------------------------|\n| Outstanding, December 31, 2020                     | 75,402               | $ 28.31                                     |                                                       |                                        |\n| Granted                                            | 779                  | 33.82                                       |                                                       |                                        |\n| Exercised                                          | (31,036)             | 25.75                                       |                                                       |                                        |\n| Forfeited                                          | (89)                 | 34.39                                       |                                                       |                                        |\n| Expired                                            | (181)                | 20.27                                       |                                                       |                                        |\n| Outstanding, December 31, 2021                     | 44,874               | 30.20                                       | 2.7                                                   | $ 1                                    |\n| Vested and expected to vest, December 31, 2021 (b) | 44,747               | 30.19                                       | 2.7                                                   | 1                                      |\n| Exercisable, December 31, 2021                     | 41,583               | $ 29.81                                     | 2.3                                                   | $ 1                                    |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Exercised_Shares",
          "name": "Exercised Shares",
          "type": "FIN_METRIC",
          "idf_score": 4.376455589624427
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_67",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                            | Shares (in millions)   |   Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Life (in years)   | Aggregate Intrinsic Value (in millions)   |\n|--------------------------------------------|------------------------|------------------------------------|-----------------------------------------------------------|-------------------------------------------|\n| Outstanding at beginning of period         | 28                     |                                211 |                                                           |                                           |\n| Granted                                    | 5                      |                                329 |                                                           |                                           |\n| Exercised                                  | (7)                    |                                175 |                                                           |                                           |\n| Forfeited                                  | (1)                    |                                297 |                                                           |                                           |\n| Outstanding at end of period               | 25                     |                                241 | 6.3                                                       | $ 6,610                                   |\n| Exercisable at end of period               | 12                     |                                179 | 4.7                                                       | 3,932                                     |\n| Vested and expected to vest, end of period | 25                     |                                240 | 6.2                                                       | 6,509                                     |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 81,
      "question": "How does the discontinuation of certain government health care benefit plans by UNH affect Pfizer's rebate accruals, given the product-specific nature of Pfizer's rebate calculations and UNH's decision to cease offering benefit plans in certain counties?",
      "answer": "UNH's discontinuation of benefit plans in certain counties reduces the channel mix through which Pfizer's products are distributed, directly affecting Pfizer's rebate accruals which are product-specific and influenced by the forecasted channel mix for each product. This leads to a revision in Pfizer's rebate accruals for those products previously distributed through UNH's discontinued plans.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Pfizer's rebate accruals are product-specific and influenced by the forecasted channel mix for each individual product.",
        "Step 2: Extract from source B - UNH ceased offering benefit plans in certain counties as a response to funding pressures in the Medicare Advantage program.",
        "Step 3: Synthesize - The discontinuation of UNH's benefit plans in certain counties changes the distribution channel mix for Pfizer\u2019s products, which in turn affects Pfizer's rebate accruals due to their product-specific and channel-dependent nature."
      ],
      "difficulty": "medium",
      "idf_score": 4.322388368354151,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discontinues]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Benefit Plans",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_39",
          "chunk_id": "chunk_1",
          "chunk_text": "between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this lag, our recording of adjustments to reflect actual amounts can incorporate revisions of several prior quarters. Rebate accruals are product specific and, therefore for any period, are impacted by the mix of products sold as well as the forecasted channel mix for each individual product. For further information, see the Analysis of the Consolidated Statements of Income--Revenue Deductions section within MD&amp;A and Note 1H .\n\n## Asset Impairments\n\nWe review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets. Our impairment review processes are described in Note 1M.\n\nExamples of events or circumstances that may be indicative of impairment include:\n\n- A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights would likely result in generic competition earlier than expected.\n- A significant adverse change in the extent or manner in which an asset is used such as a restriction imposed by the FDA or other regulatory authorities that could affect our ability to manufacture or sell a product.\n- An expectation of losses or reduced profits associated with an asset. This could result, for example, from a change in a government reimbursement program that results in an inability to sustain projected product revenues and profitability. This also could result from the introduction of a competitor's product that impacts projected revenue growth, as well as the lack of acceptance of a product by patients, physicians and payers. For IPR&amp;D projects, this could result from, among other things, a change in outlook based on clinical trial data, a delay in the projected launch date or additional expenditures to commercialize the product.\n\n## Identifiable Intangible Assets\n\nWe use an income approach, specifically the discounted cash flow method to determine the fair value of intangible assets, other than goodwill. We start with a forecast of all the expected net cash flows associated with the asset, which incorporates the consideration of a terminal value for indefinite-lived assets, and then we apply an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions that impact our fair value estimates include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of technological advancements and risk associated with IPR&amp;D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic origin of the projected cash flows.\n\nWhile all intangible assets other than goodwill can face events and circumstances that can lead to impairment, those that are most at risk of impairment include IPR&amp;D assets (approximately $3.1 billion as of December 31, 2021) and newly acquired or recently impaired indefinite-lived brand assets. IPR&amp;D assets are high-risk assets, given the uncertain nature of R&amp;D. Newly acquired and recently impaired indefinite-lived assets are more vulnerable to impairment as the assets are recorded at fair value and are then subsequently measured at the lower of fair value or carrying value at the end of each reporting period. As such, immediately after acquisition or impairment, even small declines in the outlook for these assets can negatively impact our ability to recover the carrying value and can result in an impairment charge.\n\n## Goodwill\n\nOur goodwill impairment review work as of December 31, 2021 concluded that none of our goodwill was impaired and we do not believe the risk of impairment is significant at this time.\n\nIn our review, we first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Qualitative factors that we consider include, for example, macroeconomic and industry conditions, overall financial performance and other relevant entity-specific events. If we conclude that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then perform a quantitative fair value test.\n\nWhen we are required to determine the fair value of a reporting unit, we typically use the income approach. The income approach is a forward-looking approach to estimating fair value and relies primarily on internal forecasts. Within the income approach, we use the discounted cash flow method. We start with a forecast of all the expected net cash flows for the reporting unit, which includes the application of a terminal value, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of technological risk and competitive, legal and/or regulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.\n\nFor all of our reporting units, there are a number of future events and factors that may impact future results and that could potentially have an impact on the outcome of subsequent goodwill impairment testing. For a list of these factors, see the Forward-Looking Information and Factors That May Affect Future Result s and the Item 1A. Risk Factors sections in this Form 10-K.\n\n## Benefit Plans\n\nFor a description of our different benefit plans, see Note 11 .\n\nOur assumptions reflect our historical experiences and our judgment regarding future expectations that have been deemed reasonable by management. The judgments made in determining the costs of our benefit plans can materially impact our results of operations.\n\nPfizer Inc.\n\n2021 Form 10-K\n\n31",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Benefit_Plans",
          "name": "Benefit Plans",
          "type": "FIN_METRIC",
          "idf_score": 4.322388368354151
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_25",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\naffect our ability to market our products and services, or to do so at targeted operating margins which may have a material adverse effect on our business, financial condition and results of operations.\n\nThe health care industry is regularly subject to negative publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding industry regulation. Negative publicity may adversely affect our stock price and damage our reputation in various markets.\n\nAs a result of our participation in various government health care programs, both as a payer and as a service provider to payers, we are exposed to additional risks associated with program funding, enrollments, payment adjustments, audits and government investigations which could materially and adversely affect our business, results of operations, financial position and cash flows.\n\nWe participate in various federal, state and local government health care benefit programs, including as a payer in Medicare Advantage, Medicare Part D, various Medicaid programs and CHIP, and receive substantial revenues from these programs. Certain of our Optum businesses also provide services to payers participating in government health care programs. A reduction or less than expected increase, or a protracted delay, in government funding for these programs or change in allocation methodologies, or termination of the contract at the option of the government, may materially and adversely affect our results of operations, financial position and cash flows.\n\nThe government health care programs in which we participate generally are subject to frequent changes, including changes which may reduce the number of persons enrolled or eligible for coverage, reduce the amount of reimbursement or payment levels, reduce our participation in certain service areas or markets, or increase our administrative or medical costs under such programs. Revenues for these programs depend on periodic funding from the federal government or applicable state governments and allocation of the funding through various payment mechanisms. Funding for these government programs depends on many factors outside of our control, including general economic conditions and budgetary constraints at the federal or applicable state level. For example, CMS has in the past reduced or frozen Medicare Advantage benchmarks, and additional cuts to Medicare Advantage benchmarks are possible. In addition, from time to time, CMS makes changes to the way it calculates Medicare Advantage risk adjustment payments. Although we have adjusted members' benefits and premiums on a selective basis, ceased to offer benefit plans in certain counties, and intensified both our medical and operating cost management in response to the benchmark reductions and other funding pressures, these or other strategies may not fully address the funding pressures in the Medicare Advantage program. In addition, payers in the Medicare Advantage program may be subject to reductions in payments from CMS as a result of decreased funding or recoupment pursuant to government audit. States have also made changes in rates and reimbursements for Medicaid members and audits can result in unexpected recoupments.\n\nUnder the Medicaid managed care program, state Medicaid agencies seek bids from eligible health plans to continue their participation in the acute care Medicaid health programs. If we are not successful in obtaining renewals of state Medicaid managed care contracts, we risk losing the members who were enrolled in those Medicaid plans. Under the Medicare Part D program, to qualify for automatic enrollment of low income members, our bids must result in an enrollee premium below a regional benchmark, which is calculated by the government after all regional bids are submitted. If the enrollee premium is not below the government benchmark, we risk losing the members who were auto-assigned to us and will not have additional members auto-assigned to us. In general, our bids are based upon certain assumptions regarding enrollment, utilization, medical costs and other factors. If any of these assumptions is materially incorrect, either as a result of unforeseen changes to the programs on which we bid, implementation of material program or policy changes after our bid submission, or submission by our competitors at lower rates than our bids, our results of operations, financial position and cash flows could be materially and adversely affected.\n\nMany of the government health care coverage programs in which we participate are subject to the prior satisfaction of certain conditions or performance standards or benchmarks. For example, as part of the ACA, CMS has a system providing various quality bonus payments to Medicare Advantage plans meeting certain quality star ratings at the individual plan or local contract level. The star rating system considers various measures adopted by CMS, including, among others, quality of care, preventive services, chronic illness management, handling of appeals and customer satisfaction. Plans must have a rating of four stars or higher to qualify for bonus payments. If we do not maintain or continue to improve our star ratings, our plans may not be eligible for quality bonuses and we may experience a negative impact on our revenues and the benefits our plans can offer, which could materially and adversely affect the marketability of our plans, our membership levels, results of operations, financial position and cash flows. Any changes in standards or care delivery models applying to government health care programs, including Medicare and Medicaid, or our inability to improve our quality scores and star ratings to meet government performance requirements or to match the performance of our competitors could result in limitations to our participation in or exclusion from these or other government programs, which in turn could materially and adversely affect our results of operations, financial position and cash flows.",
          "relationship": "Discontinues"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 82,
      "question": "How does the difference in focus between Pfizer's benefit plans and UnitedHealthcare's benefit plans affect their respective approaches to managing long-term financial obligations and population health outcomes?",
      "answer": "Pfizer\u2019s benefit plans are primarily concerned with internal financial obligations tied to employee benefits, where assumptions about future expectations directly impact financial results. This is evident in their $3.1 billion in IPR&D assets, which are high-risk and sensitive to changes in regulatory or competitive environments. In contrast, UnitedHealthcare Community & State focuses on external population health outcomes, particularly for Medicaid beneficiaries, by designing benefit plans that address chronic illness, disability, and social determinants of health. Their approach involves leveraging national capabilities for local care coordination, which supports actuarially sound pricing and long-term care services. While Pfizer\u2019s benefit plans influence internal impairment risks and financial forecasting, UnitedHealthcare\u2019s benefit plans are structured to manage external health outcomes and expand into more complex care models, such as DSNP and LTSS programs, which require sophisticated data analytics and community-based collaboration.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Pfizer mentions that its benefit plans affect financial results through assumptions about future expectations and specifically references $3.1 billion in IPR&D assets, which are sensitive to changes in outlook.",
        "Step 2: Extract from source B - UnitedHealthcare Community & State offers benefit plans designed to address complex population health needs, including DSNP and LTSS programs, and emphasizes care coordination and actuarially sound pricing.",
        "Step 3: Synthesize - While Pfizer's benefit plans are internally focused on financial obligations and asset valuations, UnitedHealthcare's benefit plans are externally focused on managing health outcomes for vulnerable populations, requiring different strategies for long-term financial and health impacts."
      ],
      "difficulty": "medium",
      "idf_score": 4.322388368354151,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Offers]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Benefit Plans",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_39",
          "chunk_id": "chunk_1",
          "chunk_text": "between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this lag, our recording of adjustments to reflect actual amounts can incorporate revisions of several prior quarters. Rebate accruals are product specific and, therefore for any period, are impacted by the mix of products sold as well as the forecasted channel mix for each individual product. For further information, see the Analysis of the Consolidated Statements of Income--Revenue Deductions section within MD&amp;A and Note 1H .\n\n## Asset Impairments\n\nWe review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets. Our impairment review processes are described in Note 1M.\n\nExamples of events or circumstances that may be indicative of impairment include:\n\n- A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights would likely result in generic competition earlier than expected.\n- A significant adverse change in the extent or manner in which an asset is used such as a restriction imposed by the FDA or other regulatory authorities that could affect our ability to manufacture or sell a product.\n- An expectation of losses or reduced profits associated with an asset. This could result, for example, from a change in a government reimbursement program that results in an inability to sustain projected product revenues and profitability. This also could result from the introduction of a competitor's product that impacts projected revenue growth, as well as the lack of acceptance of a product by patients, physicians and payers. For IPR&amp;D projects, this could result from, among other things, a change in outlook based on clinical trial data, a delay in the projected launch date or additional expenditures to commercialize the product.\n\n## Identifiable Intangible Assets\n\nWe use an income approach, specifically the discounted cash flow method to determine the fair value of intangible assets, other than goodwill. We start with a forecast of all the expected net cash flows associated with the asset, which incorporates the consideration of a terminal value for indefinite-lived assets, and then we apply an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions that impact our fair value estimates include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of technological advancements and risk associated with IPR&amp;D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic origin of the projected cash flows.\n\nWhile all intangible assets other than goodwill can face events and circumstances that can lead to impairment, those that are most at risk of impairment include IPR&amp;D assets (approximately $3.1 billion as of December 31, 2021) and newly acquired or recently impaired indefinite-lived brand assets. IPR&amp;D assets are high-risk assets, given the uncertain nature of R&amp;D. Newly acquired and recently impaired indefinite-lived assets are more vulnerable to impairment as the assets are recorded at fair value and are then subsequently measured at the lower of fair value or carrying value at the end of each reporting period. As such, immediately after acquisition or impairment, even small declines in the outlook for these assets can negatively impact our ability to recover the carrying value and can result in an impairment charge.\n\n## Goodwill\n\nOur goodwill impairment review work as of December 31, 2021 concluded that none of our goodwill was impaired and we do not believe the risk of impairment is significant at this time.\n\nIn our review, we first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Qualitative factors that we consider include, for example, macroeconomic and industry conditions, overall financial performance and other relevant entity-specific events. If we conclude that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then perform a quantitative fair value test.\n\nWhen we are required to determine the fair value of a reporting unit, we typically use the income approach. The income approach is a forward-looking approach to estimating fair value and relies primarily on internal forecasts. Within the income approach, we use the discounted cash flow method. We start with a forecast of all the expected net cash flows for the reporting unit, which includes the application of a terminal value, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of technological risk and competitive, legal and/or regulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.\n\nFor all of our reporting units, there are a number of future events and factors that may impact future results and that could potentially have an impact on the outcome of subsequent goodwill impairment testing. For a list of these factors, see the Forward-Looking Information and Factors That May Affect Future Result s and the Item 1A. Risk Factors sections in this Form 10-K.\n\n## Benefit Plans\n\nFor a description of our different benefit plans, see Note 11 .\n\nOur assumptions reflect our historical experiences and our judgment regarding future expectations that have been deemed reasonable by management. The judgments made in determining the costs of our benefit plans can materially impact our results of operations.\n\nPfizer Inc.\n\n2021 Form 10-K\n\n31",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Benefit_Plans",
          "name": "Benefit Plans",
          "type": "FIN_METRIC",
          "idf_score": 4.322388368354151
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_9",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nStates using managed care services for Medicaid beneficiaries select health plans by using a formal bid process or by awarding individual contracts. A number of factors are considered by UnitedHealthcare Community &amp; State when choosing programs for participation, including the state's commitment and consistency of support for its Medicaid managed care program in terms of service, innovation and funding; the eligible population base, both immediate and long term; and the structure of the projected program. UnitedHealthcare Community &amp; State works with its state customers to advocate for actuarially sound rates, commensurate with medical cost trends.\n\nThese health plans and care programs are designed to address the complex needs of the populations they serve, including the chronically ill, people with disabilities and people with a higher risk of medical, behavioral and social conditions. UnitedHealthcare Community &amp; State administers benefits for the unique needs of children, pregnant women, adults, seniors and those who are institutionalized or are nursing home eligible. These individuals often live in medically underserved areas and are less likely to have a consistent relationship with the medical community or a care provider. They also often face significant social and economic challenges.\n\nUnitedHealthcare Community &amp; State leverages the national capabilities of UnitedHealth Group locally, supporting effective care management, strong regulatory partnerships, greater administrative efficiency, improved clinical outcomes and the ability to adapt to a changing national and local market environment. UnitedHealthcare Community &amp; State coordinates resources among family, physicians, other health care providers, and government and community-based agencies and organizations to facilitate continuous and effective care and often addresses other social determinants affecting people's health status and health system usage.\n\nAlthough approximately 80% of the people in state Medicaid programs are served by managed care, there remains significant growth opportunity as this population represents only approximately 55% of total Medicaid spending. UnitedHealthcare Community &amp; State's business development opportunities include entering fee-for-service markets converting to managed care; and growing in existing managed care markets, including state expansions to populations with more complex needs requiring more sophisticated models of care, including DSNP and LTSS programs. Our offerings to state expansion cover more medically complex populations, including integrated care management of physical, behavioral, long-term care services and supports, and social services by applying strong data analytics and community-based collaboration.\n\nUnitedHealthcare Community &amp; State continues to evolve its clinical model to enhance quality and the clinical experience for the people it serves. The model enables UnitedHealthcare Community &amp; State to quickly identify the people who could benefit most from more highly coordinated care.\n\n## UnitedHealthcare Global\n\nUnitedHealthcare Global serves 7.8 million people with medical and dental benefits, typically in exchange for a monthly premium per member, residing principally in Brazil, Chile, Colombia and Peru, but also in more than 150 other countries. UnitedHealthcare Global serves multinational and local businesses, governments, insurers and individuals and their families through health insurance plans for local populations, care delivery services, benefit plans and risk and assistance solutions. UnitedHealthcare Global offers health care delivery in our principal markets through over 50 hospitals, and more than 200 outpatient and ambulatory clinics and surgery centers to UnitedHealthcare Global members and consumers served by the external payer market.\n\nIn Brazil, Amil provides health benefits to 3.4 million people and dental benefits to nearly 2.3 million people. Empresas Banm\u00e9dica provides health benefits and health care services to approximately 2.1 million people in Chile, Colombia and Peru. Lus\u00edadas Sa\u00fade provides clinical services to people in Portugal through an owned network of hospitals and outpatient clinics.\n\n## GOVERNMENT REGULATION\n\nOur businesses are subject to comprehensive U.S. federal and state and international laws and regulations. We are regulated by agencies which generally have discretion to issue regulations and interpret and enforce laws and rules. The regulations can vary significantly among jurisdictions and the interpretation of them are subject to frequent change. Domestic U.S. and international governments continue to consider and enact various legislative and regulatory proposals which could materially impact certain aspects of the health care system. New laws, regulations and rules, or changes in the interpretation of existing laws, regulations and rules, including as a result of changes in the political climate, could adversely affect our businesses.\n\nIf we fail to comply with, are alleged to have failed to comply with, or fail to respond quickly and appropriately to changes in, applicable laws, regulations and rules, our business, results of operations, financial position and cash flows could be materially and adversely affected. See Part I, Item 1A, 'Risk Factors' for a discussion of the risks related to our compliance with federal, state and international laws and regulations.",
          "relationship": "Offers"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 39
    },
    {
      "question_id": 83,
      "question": "What is the difference in the aggregate intrinsic value of exercisable shares between PFE and UNH at the end of 2021, and how does the weighted-average exercise price per share relate to this difference?",
      "answer": "The difference in the aggregate intrinsic value of exercisable shares between UNH and PFE at the end of 2021 is $3,931 million. UNH's exercisable shares had an aggregate intrinsic value of $3,932 million with a weighted-average exercise price of $179, while PFE's exercisable shares had an aggregate intrinsic value of $1 million with a weighted-average exercise price of $29.81. The significantly higher intrinsic value for UNH can be attributed to its higher stock price appreciation relative to the exercise price of its exercisable shares compared to PFE.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - PFE's exercisable shares had an aggregate intrinsic value of $1 million at the end of 2021, with a weighted-average exercise price of $29.81.",
        "Step 2: Extract from evidence_source_b - UNH's exercisable shares had an aggregate intrinsic value of $3,932 million at the end of 2021, with a weighted-average exercise price of $179.",
        "Step 3: Calculate the difference in intrinsic value: $3,932 million (UNH) - $1 million (PFE) = $3,931 million.",
        "Step 4: Analyze the relationship between exercise price and intrinsic value: UNH's higher intrinsic value despite a higher exercise price suggests stronger stock price appreciation post-grant compared to PFE."
      ],
      "difficulty": "medium",
      "idf_score": 4.2710950739666,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Exercisable Shares",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_101",
          "chunk_id": "chunk_6",
          "chunk_text": "|                                                    | Shares (Thousands)   | Weighted-Average Exercise Price Per Share   | Weighted-Average Remaining Contractual Term (Years)   | Aggregate Intrinsic Value (Millions)   |\n|----------------------------------------------------|----------------------|---------------------------------------------|-------------------------------------------------------|----------------------------------------|\n| Outstanding, December 31, 2020                     | 75,402               | $ 28.31                                     |                                                       |                                        |\n| Granted                                            | 779                  | 33.82                                       |                                                       |                                        |\n| Exercised                                          | (31,036)             | 25.75                                       |                                                       |                                        |\n| Forfeited                                          | (89)                 | 34.39                                       |                                                       |                                        |\n| Expired                                            | (181)                | 20.27                                       |                                                       |                                        |\n| Outstanding, December 31, 2021                     | 44,874               | 30.20                                       | 2.7                                                   | $ 1                                    |\n| Vested and expected to vest, December 31, 2021 (b) | 44,747               | 30.19                                       | 2.7                                                   | 1                                      |\n| Exercisable, December 31, 2021                     | 41,583               | $ 29.81                                     | 2.3                                                   | $ 1                                    |\n",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Exercisable_Shares",
          "name": "Exercisable Shares",
          "type": "FIN_METRIC",
          "idf_score": 4.2710950739666
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_67",
          "chunk_id": "chunk_4",
          "chunk_text": "|                                            | Shares (in millions)   |   Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Life (in years)   | Aggregate Intrinsic Value (in millions)   |\n|--------------------------------------------|------------------------|------------------------------------|-----------------------------------------------------------|-------------------------------------------|\n| Outstanding at beginning of period         | 28                     |                                211 |                                                           |                                           |\n| Granted                                    | 5                      |                                329 |                                                           |                                           |\n| Exercised                                  | (7)                    |                                175 |                                                           |                                           |\n| Forfeited                                  | (1)                    |                                297 |                                                           |                                           |\n| Outstanding at end of period               | 25                     |                                241 | 6.3                                                       | $ 6,610                                   |\n| Exercisable at end of period               | 12                     |                                179 | 4.7                                                       | 3,932                                     |\n| Vested and expected to vest, end of period | 25                     |                                240 | 6.2                                                       | 6,509                                     |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 84,
      "question": "What was the combined value of long-term investments for Pfizer (PFE) in 2021 and UnitedHealth (UNH) in 2021, and how does this total compare to Pfizer\u2019s long-term investments alone in 2020?",
      "answer": "The combined value of long-term investments for Pfizer in 2021 ($5,054 million) and UnitedHealth in 2021 ($1,800 million) is $6,854 million. This total exceeds Pfizer\u2019s long-term investments in 2020 ($3,406 million) by $3,448 million.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Pfizer\u2019s long-term investments in 2021 were $5,054 million.",
        "Step 2: Extract from source B - UnitedHealth\u2019s long-term investments (deferred compensation plan liabilities) in 2021 were $1,800 million.",
        "Step 3: Extract from source A again - Pfizer\u2019s long-term investments in 2020 were $3,406 million.",
        "Step 4: Add Pfizer\u2019s 2021 long-term investments ($5,054 million) and UnitedHealth\u2019s 2021 long-term investments ($1,800 million) to get a combined total of $6,854 million.",
        "Step 5: Subtract Pfizer\u2019s 2020 long-term investments ($3,406 million) from the combined total ($6,854 million) to determine the difference of $3,448 million."
      ],
      "difficulty": "medium",
      "idf_score": 4.131333131591441,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Long-Term Investments",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_62",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                                                                                  | As of December 31,   | As of December 31,   |\n|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|\n| (MILLIONS, EXCEPT PER COMMON SHARE DATA)                                                                                                         | 2021                 | 2020                 |\n| Assets                                                                                                                                           |                      |                      |\n| Cash and cash equivalents                                                                                                                        | $ 1,944              | $ 1,786              |\n| Short-term investments                                                                                                                           | 29,125               | 10,437               |\n| Trade accounts receivable, less allowance for doubtful accounts: 2021-$492; 2020-$508                                                            | 11,479               | 7,913                |\n| Inventories                                                                                                                                      | 9,059                | 8,020                |\n| Current tax assets                                                                                                                               | 4,266                | 3,264                |\n| Other current assets                                                                                                                             | 3,820                | 3,646                |\n| Total current assets                                                                                                                             | 59,693               | 35,067               |\n| Equity-method investments                                                                                                                        | 16,472               | 16,856               |\n| Long-term investments                                                                                                                            | 5,054                | 3,406                |\n| Property, plant and equipment                                                                                                                    | 14,882               | 13,745               |\n| Identifiable intangible assets                                                                                                                   | 25,146               | 28,337               |\n| Goodwill                                                                                                                                         | 49,208               | 49,556               |\n| Noncurrent deferred tax assets and other noncurrent tax assets                                                                                   | 3,341                | 2,383                |\n| Other noncurrent assets                                                                                                                          | 7,679                | 4,879                |\n| Total assets                                                                                                                                     | $ 181,476            | $ 154,229            |\n| Liabilities and Equity                                                                                                                           |                      |                      |\n| Short-term borrowings, including current portion of long-term debt: 2021-$1,636; 2020-$2,002                                                     | $ 2,241              | $ 2,703              |\n| Trade accounts payable                                                                                                                           | 5,578                | 4,283                |\n| Dividends payable                                                                                                                                | 2,249                | 2,162                |\n| Income taxes payable                                                                                                                             | 1,266                | 1,049                |\n| Accrued compensation and related items                                                                                                           | 3,332                | 3,049                |\n| Deferred revenues                                                                                                                                | 3,067                | 1,113                |\n| Other current liabilities                                                                                                                        | 24,939               | 11,561               |\n| Total current liabilities                                                                                                                        | 42,671               | 25,920               |\n| Long-term debt                                                                                                                                   | 36,195               | 37,133               |\n| Pension benefit obligations                                                                                                                      | 3,489                | 4,766                |\n| Postretirement benefit obligations                                                                                                               | 235                  | 645                  |\n| Noncurrent deferred tax liabilities                                                                                                              | 349                  | 4,063                |\n| Other taxes payable                                                                                                                              | 11,331               | 11,560               |\n| Other noncurrent liabilities                                                                                                                     | 9,743                | 6,669                |\n| Total liabilities                                                                                                                                | 104,013              | 90,756               |\n| Commitments and Contingencies                                                                                                                    |                      |                      |\n| Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020 | -                    | -                    |\n| Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021-9,471; 2020-9,407                                                          | 473                  | 470                  |\n| Additional paid-in capital                                                                                                                       | 90,591               | 88,674               |\n| Treasury stock, shares at cost: 2021-3,851; 2020-3,840                                                                                           | (111,361)            | (110,988)            |\n| Retained earnings                                                                                                                                | 103,394              | 90,392               |\n| Accumulated other comprehensive loss                                                                                                             | (5,897)              | (5,310)              |\n| Total Pfizer Inc. shareholders' equity                                                                                                           | 77,201               | 63,238               |\n| Equity attributable to noncontrolling interests                                                                                                  | 262                  | 235                  |\n| Total equity                                                                                                                                     | 77,462               | 63,473               |\n| Total liabilities and equity                                                                                                                     | $ 181,476            | $ 154,229            |",
          "relationship": "Depends_On"
        },
        "intermediate_node": {
          "id": "Long-Term_Investments",
          "name": "Long-Term Investments",
          "type": "FIN_METRIC",
          "idf_score": 4.131333131591441
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_68",
          "chunk_id": "chunk_7",
          "chunk_text": "\nRisk-free interest rates are based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on the historical volatility of the Company's common stock and the implied volatility from exchange-traded options on the Company's common stock. Expected dividend yields are based on the per share cash dividend paid by the Company. The Company uses historical data to estimate option exercises and forfeitures within the valuation model. The expected lives of options granted represents the period of time the awards granted are expected to be outstanding based on historical exercise patterns.\n\n## Other Employee Benefit Plans\n\nThe Company offers a 401(k) plan for its employees. Compensation expense related to this plan was not material for 2021, 2020 and 2019.\n\nIn addition, the Company maintains non-qualified, deferred compensation plans, which allow certain members of senior management and executives to defer portions of their salary or bonus. The deferrals are recorded within long-term investments with an approximately equal amount in other liabilities in the Consolidated Balance Sheets. The total deferrals are distributable based upon termination of employment or other periods, as elected under each plan and were $1.8 billion and $1.6 billion as of December 31, 2021 and 2020, respectively.",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 85,
      "question": "What is the combined total of Long-Term Investments held by both Pfizer (PFE) and UnitedHealth (UNH) as of December 31, 2021, and how does this allocation reflect their respective financial strategies in the healthcare sector?",
      "answer": "The combined total of Long-Term Investments held by Pfizer and UnitedHealth as of December 31, 2021, is $48,168 million. Pfizer reported $5,054 million in Long-Term Investments, while UnitedHealth reported $43,114 million. This significant disparity suggests that UnitedHealth places a much stronger emphasis on long-term investment strategies compared to Pfizer, which may reflect differences in business models\u2014UnitedHealth as a diversified health insurer and Pfizer as a pharmaceutical manufacturer.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Pfizer's Long-Term Investments as of December 31, 2021, is $5,054 million.",
        "Step 2: Extract from source B - UnitedHealth's Long-Term Investments as of December 31, 2021, is $43,114 million.",
        "Step 3: Add both values to calculate the combined total: $5,054 million + $43,114 million = $48,168 million.",
        "Step 4: Interpret the difference in magnitude as a reflection of distinct financial strategies in managing long-term assets within the healthcare sector."
      ],
      "difficulty": "medium",
      "idf_score": 4.131333131591441,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Long-Term Investments",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_62",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                                                                                  | As of December 31,   | As of December 31,   |\n|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|\n| (MILLIONS, EXCEPT PER COMMON SHARE DATA)                                                                                                         | 2021                 | 2020                 |\n| Assets                                                                                                                                           |                      |                      |\n| Cash and cash equivalents                                                                                                                        | $ 1,944              | $ 1,786              |\n| Short-term investments                                                                                                                           | 29,125               | 10,437               |\n| Trade accounts receivable, less allowance for doubtful accounts: 2021-$492; 2020-$508                                                            | 11,479               | 7,913                |\n| Inventories                                                                                                                                      | 9,059                | 8,020                |\n| Current tax assets                                                                                                                               | 4,266                | 3,264                |\n| Other current assets                                                                                                                             | 3,820                | 3,646                |\n| Total current assets                                                                                                                             | 59,693               | 35,067               |\n| Equity-method investments                                                                                                                        | 16,472               | 16,856               |\n| Long-term investments                                                                                                                            | 5,054                | 3,406                |\n| Property, plant and equipment                                                                                                                    | 14,882               | 13,745               |\n| Identifiable intangible assets                                                                                                                   | 25,146               | 28,337               |\n| Goodwill                                                                                                                                         | 49,208               | 49,556               |\n| Noncurrent deferred tax assets and other noncurrent tax assets                                                                                   | 3,341                | 2,383                |\n| Other noncurrent assets                                                                                                                          | 7,679                | 4,879                |\n| Total assets                                                                                                                                     | $ 181,476            | $ 154,229            |\n| Liabilities and Equity                                                                                                                           |                      |                      |\n| Short-term borrowings, including current portion of long-term debt: 2021-$1,636; 2020-$2,002                                                     | $ 2,241              | $ 2,703              |\n| Trade accounts payable                                                                                                                           | 5,578                | 4,283                |\n| Dividends payable                                                                                                                                | 2,249                | 2,162                |\n| Income taxes payable                                                                                                                             | 1,266                | 1,049                |\n| Accrued compensation and related items                                                                                                           | 3,332                | 3,049                |\n| Deferred revenues                                                                                                                                | 3,067                | 1,113                |\n| Other current liabilities                                                                                                                        | 24,939               | 11,561               |\n| Total current liabilities                                                                                                                        | 42,671               | 25,920               |\n| Long-term debt                                                                                                                                   | 36,195               | 37,133               |\n| Pension benefit obligations                                                                                                                      | 3,489                | 4,766                |\n| Postretirement benefit obligations                                                                                                               | 235                  | 645                  |\n| Noncurrent deferred tax liabilities                                                                                                              | 349                  | 4,063                |\n| Other taxes payable                                                                                                                              | 11,331               | 11,560               |\n| Other noncurrent liabilities                                                                                                                     | 9,743                | 6,669                |\n| Total liabilities                                                                                                                                | 104,013              | 90,756               |\n| Commitments and Contingencies                                                                                                                    |                      |                      |\n| Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020 | -                    | -                    |\n| Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021-9,471; 2020-9,407                                                          | 473                  | 470                  |\n| Additional paid-in capital                                                                                                                       | 90,591               | 88,674               |\n| Treasury stock, shares at cost: 2021-3,851; 2020-3,840                                                                                           | (111,361)            | (110,988)            |\n| Retained earnings                                                                                                                                | 103,394              | 90,392               |\n| Accumulated other comprehensive loss                                                                                                             | (5,897)              | (5,310)              |\n| Total Pfizer Inc. shareholders' equity                                                                                                           | 77,201               | 63,238               |\n| Equity attributable to noncontrolling interests                                                                                                  | 262                  | 235                  |\n| Total equity                                                                                                                                     | 77,462               | 63,473               |\n| Total liabilities and equity                                                                                                                     | $ 181,476            | $ 154,229            |",
          "relationship": "Depends_On"
        },
        "intermediate_node": {
          "id": "Long-Term_Investments",
          "name": "Long-Term Investments",
          "type": "FIN_METRIC",
          "idf_score": 4.131333131591441
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_46",
          "chunk_id": "chunk_2",
          "chunk_text": "| (in millions, except per share data)                                                                                | December 31, 2021   | December 31, 2020   |\n|---------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|\n| Assets                                                                                                              |                     |                     |\n| Current assets:                                                                                                     |                     |                     |\n| Cash and cash equivalents                                                                                           | $ 21,375            | $ 16,921            |\n| Short-term investments                                                                                              | 2,532               | 2,860               |\n| Accounts receivable, net of allowances of $954 and $990                                                             | 14,216              | 12,870              |\n| Other current receivables, net of allowances of $993 and $1,047                                                     | 13,866              | 12,534              |\n| Assets under management                                                                                             | 4,449               | 4,076               |\n| Prepaid expenses and other current assets                                                                           | 5,320               | 4,457               |\n| Total current assets                                                                                                | 61,758              | 53,718              |\n| Long-term investments                                                                                               | 43,114              | 41,242              |\n| Property, equipment and capitalized software, net of accumulated depreciation and amortization of $5,992 and $5,230 | 8,969               | 8,626               |\n| Goodwill                                                                                                            | 75,795              | 71,337              |\n| Other intangible assets, net of accumulated amortization of $5,636 and $5,455                                       | 10,044              | 10,856              |\n| Other assets                                                                                                        | 12,526              | 11,510              |\n| Total assets                                                                                                        | $ 212,206           | $ 197,289           |\n| Liabilities, redeemable noncontrolling interests and equity                                                         |                     |                     |\n| Current liabilities:                                                                                                |                     |                     |\n| Medical costs payable                                                                                               | $ 24,483            | $ 21,872            |\n| Accounts payable and accrued liabilities                                                                            | 24,643              | 22,495              |\n| Short-term borrowings and current maturities of long-term debt                                                      | 3,620               | 4,819               |\n| Unearned revenues                                                                                                   | 2,571               | 2,842               |\n| Other current liabilities                                                                                           | 22,975              | 20,392              |\n| Total current liabilities                                                                                           | 78,292              | 72,420              |\n| Long-term debt, less current maturities                                                                             | 42,383              | 38,648              |\n| Deferred income taxes                                                                                               | 3,265               | 3,367               |\n| Other liabilities                                                                                                   | 11,787              | 12,315              |\n| Total liabilities                                                                                                   | 135,727             | 126,750             |\n| Commitments and contingencies (Note 12)                                                                             |                     |                     |\n| Redeemable noncontrolling interests                                                                                 | 1,434               | 2,211               |\n| Equity:                                                                                                             |                     |                     |\n| Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding                           | -                   | -                   |\n| Common stock, $0.01 par value - 3,000 shares authorized; 941 and 946 issued and outstanding                         | 10                  | 10                  |\n| Additional paid-in capital                                                                                          | -                   | -                   |\n| Retained earnings                                                                                                   | 77,134              | 69,295              |\n| Accumulated other comprehensive loss                                                                                | (5,384)             | (3,814)             |\n| Nonredeemable noncontrolling interests                                                                              | 3,285               | 2,837               |\n| Total equity                                                                                                        | 75,045              | 68,328              |\n| Total liabilities, redeemable noncontrolling interests and equity                                                   | $ 212,206           | $ 197,289           |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 86,
      "question": "What is the combined value of Long-Term Investments held by Pfizer (PFE) as of December 31, 2021, and the portion of UnitedHealth (UNH)'s investments classified as held-to-maturity due to regulatory requirements, assuming UNH's held-to-maturity investments represent 15% of its total long-term investments and the total long-term investments are $10,000 million?",
      "answer": "The combined value is $6,554 million. Pfizer's Long-Term Investments are $5,054 million. UnitedHealth's held-to-maturity investments, based on the assumption, are 15% of $10,000 million, which equals $1,500 million. Adding these together gives $5,054 million + $1,500 million = $6,554 million.",
      "reasoning_steps": [
        "Step 1: Extract from source A - Pfizer's Long-Term Investments as of December 31, 2021, are $5,054 million.",
        "Step 2: Extract from source B - UnitedHealth classifies certain long-term investments as held-to-maturity due to regulatory requirements, and we assume these represent 15% of a total $10,000 million in long-term investments, resulting in $1,500 million.",
        "Step 3: Synthesize - Combine Pfizer's Long-Term Investments with the assumed held-to-maturity portion of UnitedHealth's investments to calculate the total combined value."
      ],
      "difficulty": "medium",
      "idf_score": 4.131333131591441,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Depends_On]-> FIN_METRIC <-[Classifies]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Long-Term Investments",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_62",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                                                                                                                  | As of December 31,   | As of December 31,   |\n|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------|\n| (MILLIONS, EXCEPT PER COMMON SHARE DATA)                                                                                                         | 2021                 | 2020                 |\n| Assets                                                                                                                                           |                      |                      |\n| Cash and cash equivalents                                                                                                                        | $ 1,944              | $ 1,786              |\n| Short-term investments                                                                                                                           | 29,125               | 10,437               |\n| Trade accounts receivable, less allowance for doubtful accounts: 2021-$492; 2020-$508                                                            | 11,479               | 7,913                |\n| Inventories                                                                                                                                      | 9,059                | 8,020                |\n| Current tax assets                                                                                                                               | 4,266                | 3,264                |\n| Other current assets                                                                                                                             | 3,820                | 3,646                |\n| Total current assets                                                                                                                             | 59,693               | 35,067               |\n| Equity-method investments                                                                                                                        | 16,472               | 16,856               |\n| Long-term investments                                                                                                                            | 5,054                | 3,406                |\n| Property, plant and equipment                                                                                                                    | 14,882               | 13,745               |\n| Identifiable intangible assets                                                                                                                   | 25,146               | 28,337               |\n| Goodwill                                                                                                                                         | 49,208               | 49,556               |\n| Noncurrent deferred tax assets and other noncurrent tax assets                                                                                   | 3,341                | 2,383                |\n| Other noncurrent assets                                                                                                                          | 7,679                | 4,879                |\n| Total assets                                                                                                                                     | $ 181,476            | $ 154,229            |\n| Liabilities and Equity                                                                                                                           |                      |                      |\n| Short-term borrowings, including current portion of long-term debt: 2021-$1,636; 2020-$2,002                                                     | $ 2,241              | $ 2,703              |\n| Trade accounts payable                                                                                                                           | 5,578                | 4,283                |\n| Dividends payable                                                                                                                                | 2,249                | 2,162                |\n| Income taxes payable                                                                                                                             | 1,266                | 1,049                |\n| Accrued compensation and related items                                                                                                           | 3,332                | 3,049                |\n| Deferred revenues                                                                                                                                | 3,067                | 1,113                |\n| Other current liabilities                                                                                                                        | 24,939               | 11,561               |\n| Total current liabilities                                                                                                                        | 42,671               | 25,920               |\n| Long-term debt                                                                                                                                   | 36,195               | 37,133               |\n| Pension benefit obligations                                                                                                                      | 3,489                | 4,766                |\n| Postretirement benefit obligations                                                                                                               | 235                  | 645                  |\n| Noncurrent deferred tax liabilities                                                                                                              | 349                  | 4,063                |\n| Other taxes payable                                                                                                                              | 11,331               | 11,560               |\n| Other noncurrent liabilities                                                                                                                     | 9,743                | 6,669                |\n| Total liabilities                                                                                                                                | 104,013              | 90,756               |\n| Commitments and Contingencies                                                                                                                    |                      |                      |\n| Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020 | -                    | -                    |\n| Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021-9,471; 2020-9,407                                                          | 473                  | 470                  |\n| Additional paid-in capital                                                                                                                       | 90,591               | 88,674               |\n| Treasury stock, shares at cost: 2021-3,851; 2020-3,840                                                                                           | (111,361)            | (110,988)            |\n| Retained earnings                                                                                                                                | 103,394              | 90,392               |\n| Accumulated other comprehensive loss                                                                                                             | (5,897)              | (5,310)              |\n| Total Pfizer Inc. shareholders' equity                                                                                                           | 77,201               | 63,238               |\n| Equity attributable to noncontrolling interests                                                                                                  | 262                  | 235                  |\n| Total equity                                                                                                                                     | 77,462               | 63,473               |\n| Total liabilities and equity                                                                                                                     | $ 181,476            | $ 154,229            |",
          "relationship": "Depends_On"
        },
        "intermediate_node": {
          "id": "Long-Term_Investments",
          "name": "Long-Term Investments",
          "type": "FIN_METRIC",
          "idf_score": 4.131333131591441
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_53",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nmodels consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, medical care utilization and other medical cost trends, membership volume and demographics, the introduction of new technologies, benefit plan changes, and business mix changes related to products, customers and geography. Judgments related to these factors contemplated the impact of COVID-19.\n\nIn developing its medical costs payable estimates, the Company applies different estimation methods depending on which incurred claims are being estimated. For the most recent two months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average per member per month (PMPM) medical costs incurred in prior months for which more complete claim data are available, supplemented by a review of near-term completion factors (actuarial estimates, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period adjudicated by the Company at the date of estimation). For months prior to the most recent two months, the Company applies the completion factors to actual claims adjudicated-to-date to estimate the expected amount of ultimate incurred claims for those months.\n\n## Cost of Products Sold\n\nThe Company's cost of products sold includes the cost of pharmaceuticals dispensed to unaffiliated customers either directly at its home delivery, specialty and community pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Rebates attributable to unaffiliated clients are accrued as rebates receivable and a reduction of cost of products sold, with a corresponding payable for the amounts of the rebates to be remitted to those unaffiliated clients in accordance with their contracts and recorded in the Consolidated Statements of Operations as a reduction of product revenue. Cost of products sold also includes the cost of personnel to support the Company's transaction processing services, system sales, maintenance and professional services.\n\n## Cash, Cash Equivalents and Investments\n\nCash and cash equivalents are highly liquid investments having an original maturity of three months or less. The fair value of cash and cash equivalents approximates their carrying value because of the short maturity of the instruments.\n\nInvestments with maturities of less than one year are classified as short-term. Because of regulatory requirements, certain investments are included in long-term investments regardless of their maturity date. The Company classifies these investments as held-to-maturity and reports them at amortized cost. Substantially all other investments are classified as available-for-sale and reported at fair value based on quoted market prices, where available. Equity investments, with certain exceptions, are measured at fair value with changes in fair value recognized in net earnings.\n\nThe Company excludes unrealized gains and losses on investments in available-for-sale debt securities from net earnings and reports them as comprehensive income and, net of income tax effects, as a separate component of equity. To calculate realized gains and losses on the sale of debt securities, the Company specifically identifies the cost of each investment sold.\n\nThe Company evaluates an available-for-sale debt security for credit-related impairment by considering the present value of expected cash flows relative to a security's amortized cost, the extent to which fair value is less than amortized cost, the financial condition and near-term prospects of the issuer and specific events or circumstances which may influence the operations of the issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income. Non-credit related impairments are recorded through other comprehensive income. If the Company intends to sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost, the entire impairment is included in net earnings.\n\nNew information and the passage of time can change these judgments. The Company manages its investment portfolio to limit its exposure to any one issuer or market sector, and largely limits its investments to investment grade quality. Securities downgraded below policy minimums after purchase will be disposed of in accordance with the Company's investment policy.\n\n## Assets Under Management\n\nThe Company provides health insurance products and services to members of AARP under a Supplemental Health Insurance Program (the AARP Program) and to AARP members and non-members under separate Medicare Advantage and Medicare Part D arrangements. The products and services under the AARP Program include supplemental Medicare benefits, hospital indemnity insurance, including insurance for individuals between 50 to 64 years of age, and other related products.\n\nPursuant to the Company's agreement with AARP, program assets are managed separately from the Company's general investment portfolio and are used to pay costs associated with the AARP Program. These assets are invested at the Company's discretion, within investment guidelines approved by AARP. The Company does not guarantee any rates of return on these investments and, upon any transfer of the AARP Program contract to another entity, the Company would transfer cash equal in amount to the fair value of these investments at the date of transfer to the entity. Because the purpose of these assets is to fund the medical costs payable, the rate stabilization fund (RSF) liabilities and other related liabilities associated with this AARP contract, assets under management are classified as current assets, consistent with the classification of these liabilities.",
          "relationship": "Classifies"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 37
    },
    {
      "question_id": 87,
      "question": "How do the legal and regulatory challenges described in Pfizer's and UnitedHealth Group's 2022 10-K filings differently expose each company to financial damages, and what specific mechanisms in their respective businesses contribute to these risks?",
      "answer": "Pfizer faces financial damages primarily through patent-related legal risks, such as third-party challenges to its intellectual property and potential invalidation of patents, which could lead to early generic competition and loss of product exclusivity, especially for high-value branded products. These risks are compounded by ongoing litigation in various jurisdictions and the potential retroactive impact of decisions like the Brazilian Supreme Court's invalidation of Article 40 of Brazil's Patent Law. UnitedHealth Group, on the other hand, is exposed to damages through regulatory audits and investigations, particularly risk adjustment data validation (RADV) audits by CMS, which can result in retrospective payment adjustments, fines, or corrective action plans. These exposures stem from its role as a government contractor managing Medicare and Medicaid plans, where accurate health status coding directly affects capitation payments. Both companies face damages, but through distinct mechanisms: Pfizer through intellectual property disputes affecting revenue from pharmaceutical products, and UnitedHealth through regulatory compliance risks tied to government health programs.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - Pfizer faces legal risks related to intellectual property, including patent invalidation (e.g., Brazil's Patent Law Article 40), litigation with generic manufacturers, and potential loss of exclusivity leading to revenue erosion.",
        "Step 2: Extract from evidence_source_b - UnitedHealth Group is exposed to damages through CMS RADV audits, which validate health status coding and can result in payment adjustments, fines, or corrective action plans due to its role in Medicare and Medicaid programs.",
        "Step 3: Synthesize - Both companies face financial damages, but through different mechanisms: Pfizer through legal challenges to its intellectual property affecting product revenues, and UnitedHealth through regulatory and compliance risks tied to government health programs."
      ],
      "difficulty": "medium",
      "idf_score": 4.088773517172645,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Negatively_Impacts]-> FIN_METRIC <-[Negatively_Impacts]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Damages",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_27",
          "chunk_id": "chunk_1",
          "chunk_text": "We and certain of our subsidiaries are also subject to numerous contingencies arising in the ordinary course of business relating to legal claims and proceedings, including environmental contingencies. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. While we have accrued for worldwide legal liabilities, no guarantee exists that additional costs will not be incurred beyond the amounts accrued.\n\nFor additional information, including information regarding certain legal proceedings in which we are involved in, see Note 16A .\n\n## RISKS RELATED TO INTELLECTUAL PROPERTY, TECHNOLOGY AND SECURITY:\n\n## INTELLECTUAL PROPERTY PROTECTION\n\nOur success largely depends on our ability to market technologically competitive products. We rely and expect to continue to rely on a combination of intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection laws, as well as confidentiality and license agreements, to protect our intellectual property and proprietary rights. If we fail to obtain and maintain adequate intellectual property protection, we may not be able to prevent third parties from launching generic or biosimilar versions of our branded products, from using our proprietary technologies or from marketing products that are very similar or identical to ours. Our currently pending or future patent applications may not result in issued patents or be granted on a timely basis. Similarly, any term extensions that we seek may not be granted on a timely basis, if at all. For example, in May 2021, the Brazilian Supreme Court voted to invalidate Article 40 of Brazil's Patent Law, which guaranteed a minimum 10-year patent term from patent grant, and to give retroactive effect to such decision. In addition, our issued patents may not contain claims sufficiently broad to protect us against claims regarding validity, enforceability, scope and effective term made by parties with similar technologies or products or provide us with any competitive advantage, including exclusivity in a particular product area.\n\nFurther, legal or regulatory action by various stakeholders or governments could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our products. Discussions are ongoing at the WTO regarding the role of intellectual property in the context of the COVID-19 pandemic response. This includes a proposal that would release WTO members from their obligation under WTO-TRIPS to grant and enforce various types of intellectual property protection on health products and technology in relation to the prevention, containment or treatment of COVID-19. In May 2021 and again in November 2021, the Biden Administration called on countries to waive intellectual property protections on COVID-19 vaccines.\n\nThe scope of our patent claims also may vary between countries, as individual countries have distinct patent laws, and our ability to enforce our patents depends on the laws of each country, its enforcement practices, and the extent to which certain countries engage in policies or practices that weaken a country's intellectual property framework (e.g., laws or regulations that promote or provide broad discretion to issue a compulsory license). In countries that provide some form of regulatory exclusivity, mechanisms exist permitting some form of challenge to our patents by competitors or generic drug marketers prior to or immediately following the expiration of such regulatory exclusivity, and generic companies are employing aggressive strategies, such as 'at risk' launches that challenge our patent rights. Most of the suits involve claims by generic drug manufacturers that patents covering our products, uses, processes or dosage forms are invalid and/or do not cover the product of the generic or biosimilar drug manufacturer. Independent actions have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. Such claims may also be brought as counterclaims to actions we bring to enforce our patents. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents or a competitors' patents is found to be invalid in such proceedings, generic or biosimilar products could be introduced into the market resulting in the erosion of sales of our existing products. For additional information, including information regarding certain legal proceedings in which we are involved, see Note 16A1 . Further, if we are unable to maintain our existing license agreements or other agreements pursuant to which third parties grant us rights to intellectual property, our operating results and financial condition could be adversely affected.\n\nWe currently hold trademark registrations and have trademark applications pending in many jurisdictions, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our trademarks and trade dress to differentiate us from our competitors increases and, as a result, our business could be adversely affected if we are unable to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our rights. We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants, other advisors and other third parties to execute proprietary information and confidentiality agreements upon the commencement of their relationship with us. Despite these efforts and precautions, we may be unable to prevent a third-party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization, and legal remedies may not adequately compensate us for the damages caused by such unauthorized use. Further, others may independently and lawfully develop substantially similar or identical products that circumvent our intellectual property by means of alternative designs or processes or otherwise.\n\n## THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS\n\nA properly functioning intellectual property regime is essential to our business model. We are committed to respecting the valid intellectual property rights of other companies, but the patent granting process is imperfect. Accordingly, the pursuit of valid business opportunities may require us to challenge intellectual property rights held by others that we believe were improperly granted, including challenges through negotiation and litigation, and such challenges may not always be successful.\n\nPart of our business depends upon identifying biosimilar opportunities and launching products to take advantage of those opportunities, which may involve litigation, associated costs and time delays, and may ultimately not be successful. These opportunities may arise in situations where patent protection of equivalent branded products has expired or been declared invalid, or where products do not infringe the patents of others. In some circumstances we may take action, such as litigation, asserting that our products do not infringe patents of existing products or that those patents are invalid or unenforceable in order to achieve a 'first-to-market' or early market position for our products.\n\nThird parties may claim that our products infringe one or more patents owned or controlled by them. Claims of intellectual property infringement can be costly and time-consuming to resolve, may delay or prevent product launches, and may result in significant royalty payments or damages.\n\nPfizer Inc.\n\n2021 Form 10-K\n\n19",
          "relationship": "Negatively_Impacts"
        },
        "intermediate_node": {
          "id": "Damages",
          "name": "Damages",
          "type": "FIN_METRIC",
          "idf_score": 4.088773517172645
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_26",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nCMS uses various payment mechanisms to allocate funding for Medicare programs, including adjustment of monthly capitation payments to Medicare Advantage plans and Medicare Part D plans according to the predicted health status of each beneficiary as supported by data from health care providers for Medicare Advantage plans, as well as, for Medicare Part D plans, risk-sharing provisions based on a comparison of costs forecasted in our annual bids to actual prescription drug costs. Some state Medicaid programs utilize a similar process. For example, our UnitedHealthcare Medicare &amp; Retirement and UnitedHealthcare Community &amp; State businesses submit information relating to the health status of enrollees to CMS or state agencies for purposes of determining the amount of certain payments to us. CMS and the Office of Inspector General for HHS periodically perform risk adjustment data validation (RADV) audits of selected Medicare health plans to validate the coding practices of and supporting documentation maintained by health care providers. Certain of our local plans have been selected for such audits, which in the past have resulted and in the future could result in retrospective adjustments to payments made to our health plans, fines, corrective action plans or other adverse action by CMS.\n\nWe have been and in the future may become involved in routine, regular and special governmental investigations, audits, reviews and assessments. Such investigations, audits, reviews or assessments sometimes arise out of, or prompt claims by private litigants or whistleblowers who, among other allegations, may claim we failed to disclose certain business practices or, as a government contractor, submitted false or erroneous claims to the government. Governmental investigations, audits, reviews and assessments could lead to government actions, which have resulted in, and in the future could result in, adverse publicity, the assessment of damages, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way we conduct business, loss of licensure or exclusion from participation in government programs, any of which could have a material adverse effect on our business, results of operations, financial position and cash flows.\n\n## Our businesses providing pharmacy care services face regulatory and operational risks and uncertainties which may differ from the risks of our other businesses.\n\nWe provide pharmacy care services through our Optum Rx and UnitedHealthcare businesses. Each business is subject to federal and state anti-kickback, beneficiary inducement and other laws governing the relationships of the business with pharmaceutical manufacturers, physicians, pharmacies, customers and consumers. In addition, federal and state legislatures regularly consider new regulations for the industry which could materially affect current industry practices, including potential new legislation and regulations regarding the receipt or disclosure of rebates and other fees from pharmaceutical companies, the development and use of formularies and other utilization management tools, the use of average wholesale prices or other pricing benchmarks, pricing for specialty pharmaceuticals, limited access to networks and pharmacy network reimbursement methodologies. Additionally, various governmental agencies have conducted investigations into certain PBM practices, which have resulted in other PBMs agreeing to civil penalties, including the payment of money and entry into corporate integrity agreements. As a provider of pharmacy benefit management services, Optum Rx is also subject to an increasing number of licensure, registration and other laws and accreditation standards. Optum Rx also conducts business through home delivery, specialty and compounding pharmacies, pharmacies located in community mental health centers and home infusion, which subjects it to extensive federal, state and local laws and regulations, including those of the DEA and individual state controlled substance authorities, the Food and Drug Administration (FDA) and Boards of Pharmacy.\n\nWe could face potential claims in connection with purported errors by our home delivery, specialty or compounding or clinic-based pharmacies or the provision of home infusion services, including as a result of the risks inherent in the packaging and distribution of pharmaceuticals and other health care products. Disruptions from any of our home delivery, specialty pharmacy or home infusion services could materially and adversely affect our results of operations, financial position and cash flows.\n\nIn addition, our pharmacy care services businesses provide services to sponsors of health benefit plans subject to ERISA. A private party or the DOL, which is the agency that enforces ERISA, could assert the fiduciary obligations imposed by the statute apply to some or all of the services provided by our pharmacy care services businesses even where those businesses are not contractually obligated to assume fiduciary obligations. If a court were to determine fiduciary obligations apply, we could be subject to claims for breaches of fiduciary obligations or claims we entered into certain prohibited transactions.\n\nIf we fail to comply with applicable privacy, security and data laws, regulations and standards, including with respect to third-party service providers utilizing protected personal information on our behalf, our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.\n\nThe collection, maintenance, protection, use, transmission, disclosure and disposal of protected personal information are regulated at the federal, state, international and industry levels and addressed in requirements imposed on us by contracts with customers. These laws, rules and requirements are subject to change. Compliance with new privacy and security laws, regulations and requirements may result in increased operating costs, and may constrain or require us to alter our business model or operations.\n\nInternationally, many of the jurisdictions in which we operate have established their own data security and privacy legal framework with which we or our customers must comply. We expect there will continue to be new proposed laws, regulations",
          "relationship": "Negatively_Impacts"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 88,
      "question": "How does the classification of investment income differ between Pfizer (PFE) and UnitedHealth (UNH), and what impact does this have on how each company reports realized gains or losses from its equity-method investments?",
      "answer": "Pfizer (PFE) reports its share of investee income or losses from equity-method investments in 'Other (income)/deductions-net' and determines realized gains or losses using the specific identification cost method. UnitedHealth (UNH) reports $494 million in 'Investment and other income' for 2021, which likely includes realized gains or losses, though it does not explicitly state the method used for determining gains or losses. Therefore, while PFE provides a clear mechanism for tracking realized investment gains or losses, UNH's reporting lacks methodological transparency, making it more difficult to assess how changes in investment values affect its financial statements.",
      "reasoning_steps": [
        "Step 1: Extract from source A - PFE discloses that equity-method investments are accounted for by recording the company's share of the investee's income and expenses in 'Other (income)/deductions-net,' and realized gains or losses are determined using the specific identification cost method.",
        "Step 2: Extract from source B - UNH reports $494 million in 'Investment and other income' for 2021, which includes investment-related gains or losses but does not specify the method used to determine realized gains or losses.",
        "Step 3: Synthesize - PFE provides a detailed methodology for recognizing investment gains and losses, while UNH reports investment income without specifying the accounting method, leading to a difference in transparency and financial impact assessment."
      ],
      "difficulty": "medium",
      "idf_score": 4.04795152265239,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Investment Income",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_72",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes to Consolidated Financial Statements\n\nCash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.\n\n## P. Investments and Derivative Financial Instruments\n\nThe classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:\n\n- Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in Other (income)/deductions-net.\n- Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized.\n- Held-to-maturity debt securities, which are carried at amortized cost.\n- Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.\n- For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee's income and expenses in Other (income)/deductions-net . The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.\n\nRealized gains or losses on sales of investments are determined by using the specific identification cost method.\n\nWe regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.\n\nDerivative financial instruments are carried at fair value in various balance sheet categories (see Note 7A ), with changes in fair value reported in Net income or, for derivative financial instruments in certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7E ).\n\n## Q. Tax Assets and Liabilities and Income Tax Contingencies\n\n## Tax Assets and Liabilities\n\nCurrent tax assets primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.\n\nDeferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.\n\nThe TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income , states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.\n\nOther non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.\n\nOther taxes payable as of December 31, 2021 and 2020 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. For additional information, see Note 5D for uncertain tax positions and Note 5A for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.\n\n## Income Tax Contingencies\n\nWe account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.\n\nPfizer Inc.\n\n2021 Form 10-K\n\n63",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Investment_Income",
          "name": "Investment Income",
          "type": "FIN_METRIC",
          "idf_score": 4.04795152265239
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_84",
          "chunk_id": "chunk_2",
          "chunk_text": "|                                                | For the Years Ended December 31,   | For the Years Ended December 31,   | For the Years Ended December 31,   |\n|------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|\n| (in millions)                                  | 2021                               | 2020                               | 2019                               |\n| Revenues:                                      |                                    |                                    |                                    |\n| Investment and other income                    | $ 494                              | $ 194                              | $ 209                              |\n| Total revenues                                 | 494                                | 194                                | 209                                |\n| Operating costs:                               |                                    |                                    |                                    |\n| Operating costs                                | 40                                 | 27                                 | 38                                 |\n| Interest expense                               | 1,583                              | 1,594                              | 1,580                              |\n| Total operating costs                          | 1,623                              | 1,621                              | 1,618                              |\n| Loss before income taxes                       | (1,129)                            | (1,427)                            | (1,409)                            |\n| Benefit for income taxes                       | 231                                | 300                                | 293                                |\n| Loss of parent company                         | (898)                              | (1,127)                            | (1,116)                            |\n| Equity in undistributed income of subsidiaries | 18,183                             | 16,530                             | 14,955                             |\n| Net earnings                                   | 17,285                             | 15,403                             | 13,839                             |\n| Other comprehensive (loss) income              | (1,570)                            | (236)                              | 582                                |\n| Comprehensive income                           | $ 15,715                           | $ 15,167                           | $ 14,421                           |\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 44
    },
    {
      "question_id": 89,
      "question": "How does the sensitivity of UnitedHealth Group's (UNH) investment income to a 1% and 2% change in market interest rates compare with Pfizer's (PFE) recognition of investment income through fair value changes and equity-method accounting?",
      "answer": "UnitedHealth Group (UNH) quantifies the sensitivity of its investment income to interest rate fluctuations, showing that a 1% and 2% parallel shift in the yield curve impacts both its annual investment income and the fair value of its investments. This reflects the interest-rate-driven nature of UNH's investment portfolio returns. In contrast, Pfizer (PFE) recognizes investment income through fair value changes for public equity securities and via the equity-method for investments where it has significant influence. This means PFE's investment income is more directly tied to market price movements and the operating performance of investees, rather than interest rate sensitivity. Therefore, UNH's investment income is more exposed to macroeconomic interest rate changes, while PFE's is more influenced by equity market performance and investee profitability.",
      "reasoning_steps": [
        "Step 1: Extract from source A (PFE_10k_2022.pdf) - Pfizer's investment income is recognized through fair value changes for public equities and via the equity-method for significant influence investments, with changes in fair value reported in 'Other (income)/deductions-net'.",
        "Step 2: Extract from source B (UNH_10k_2022.pdf) - UnitedHealth Group provides a sensitivity table showing the impact of 1% and 2% interest rate increases on investment income and fair value of investments, indicating a strong link between interest rates and investment returns.",
        "Step 3: Synthesize - While both companies report investment income, the mechanisms differ: UNH's is interest-rate sensitive, whereas PFE's is more equity and investee-performance driven."
      ],
      "difficulty": "medium",
      "idf_score": 4.04795152265239,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Investment Income",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_72",
          "chunk_id": "chunk_1",
          "chunk_text": "## Notes to Consolidated Financial Statements\n\nCash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.\n\n## P. Investments and Derivative Financial Instruments\n\nThe classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:\n\n- Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in Other (income)/deductions-net.\n- Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized.\n- Held-to-maturity debt securities, which are carried at amortized cost.\n- Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.\n- For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee's income and expenses in Other (income)/deductions-net . The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.\n\nRealized gains or losses on sales of investments are determined by using the specific identification cost method.\n\nWe regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.\n\nDerivative financial instruments are carried at fair value in various balance sheet categories (see Note 7A ), with changes in fair value reported in Net income or, for derivative financial instruments in certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7E ).\n\n## Q. Tax Assets and Liabilities and Income Tax Contingencies\n\n## Tax Assets and Liabilities\n\nCurrent tax assets primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.\n\nDeferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.\n\nThe TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income , states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.\n\nOther non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.\n\nOther taxes payable as of December 31, 2021 and 2020 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. For additional information, see Note 5D for uncertain tax positions and Note 5A for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.\n\n## Income Tax Contingencies\n\nWe account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.\n\nPfizer Inc.\n\n2021 Form 10-K\n\n63",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Investment_Income",
          "name": "Investment Income",
          "type": "FIN_METRIC",
          "idf_score": 4.04795152265239
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_42",
          "chunk_id": "chunk_1",
          "chunk_text": "## Table of Contents\n\nThe following tables summarize the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of December 31, 2021 and 2020 on our investment income and interest expense per annum and the fair value of our investments and debt (in millions, except percentages):\n\n",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 46
    },
    {
      "question_id": 90,
      "question": "What is the total potential decrease in gross unrecognized tax benefits that both PFE and UNH could experience within the next 12 months, based on PFE's estimate of a $75 million decrease and UNH's $20 million decrease due to statute of limitations lapses?",
      "answer": "The total potential decrease in gross unrecognized tax benefits for both PFE and UNH is $95 million. This is calculated by summing PFE's estimated $75 million decrease in unrecognized tax benefits due to settlements or statute expirations and UNH's $20 million decrease specifically attributed to statute of limitations lapses as disclosed in their respective 10-K filings.",
      "reasoning_steps": [
        "Step 1: Extract from source A - PFE estimates a $75 million decrease in gross unrecognized tax benefits due to settlements or statute expirations within the next 12 months.",
        "Step 2: Extract from source B - UNH discloses a $20 million decrease in gross unrecognized tax benefits due to statute of limitations lapses in their 2021 tax table.",
        "Step 3: Synthesize - Combine both figures to calculate the total potential decrease in gross unrecognized tax benefits for both companies."
      ],
      "difficulty": "medium",
      "idf_score": 4.0087308094991085,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Estimates]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Gross Unrecognized Tax Benefits",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_85",
          "chunk_id": "chunk_1",
          "chunk_text": "accrued interest totaled $493 million as of December 31, 2020 (reflecting a decrease of $5 million as a result of cash payments and a decrease of $75 million relating to the separation of Upjohn). In 2021 and 2020, these amounts were substantially all included in Other taxes payable. Accrued penalties are not significant. See also Note 5A.\n\n## Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions\n\nThe U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent's Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2021 are open, but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions such as Canada (2013-2021), Europe (2011-2021, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Asia Pacific (2011-2021, primarily reflecting China, Japan and Singapore) and Latin America (19982021, primarily reflecting Brazil).\n\nAny settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $75 million, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.\n\n## E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)\n\n## Components of the Tax provision/(benefit) on other comprehensive income/(loss) include:\n\n",
          "relationship": "Estimates"
        },
        "intermediate_node": {
          "id": "Gross_Unrecognized_Tax_Benefits",
          "name": "Gross Unrecognized Tax Benefits",
          "type": "FIN_METRIC",
          "idf_score": 4.0087308094991085
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_65",
          "chunk_id": "chunk_4",
          "chunk_text": "| (in millions)                                        | 2021    | 2020    | 2019    |\n|------------------------------------------------------|---------|---------|---------|\n| Gross unrecognized tax benefits, beginning of period | $ 1,829 | $ 1,423 | $ 1,056 |\n| Gross increases:                                     |         |         |         |\n| Current year tax positions                           | 538     | 416     | 512     |\n| Prior year tax positions                             | 10      | 120     | 2       |\n| Gross decreases:                                     |         |         |         |\n| Prior year tax positions                             | (47)    | (130)   | (96)    |\n| Settlements                                          | -       | -       | (46)    |\n| Statute of limitations lapses                        | (20)    | -       | (5)     |\n| Gross unrecognized tax benefits, end of period       | $ 2,310 | $ 1,829 | $ 1,423 |",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 47
    },
    {
      "question_id": 91,
      "question": "What is the combined total of Pfizer's and UnitedHealth's gross unrecognized tax benefits as of the end of their respective 2021 fiscal years, and how does this total compare in terms of magnitude between the two companies?",
      "answer": "The combined total of Pfizer's and UnitedHealth's gross unrecognized tax benefits as of the end of their respective 2021 fiscal years is $8.41 billion. Pfizer reported $6.1 billion in gross unrecognized tax benefits, while UnitedHealth reported $2.31 billion. Pfizer's amount is significantly larger, accounting for approximately 72.5% of the combined total.",
      "reasoning_steps": [
        "Step 1: Extract from evidence_source_a - Pfizer's gross unrecognized tax benefits as of December 31, 2021, were $6.1 billion.",
        "Step 2: Extract from evidence_source_b - UnitedHealth's gross unrecognized tax benefits as of the end of 2021 were $2.31 billion.",
        "Step 3: Calculate combined total - $6.1 billion (Pfizer) + $2.31 billion (UnitedHealth) = $8.41 billion.",
        "Step 4: Compare magnitudes - Pfizer's $6.1 billion represents approximately 72.5% of the combined total, indicating a significantly larger position compared to UnitedHealth's $2.31 billion."
      ],
      "difficulty": "medium",
      "idf_score": 4.0087308094991085,
      "sector": "Health Care",
      "sub_industry": "Pharmaceuticals",
      "pattern": "ORG -[Discloses]-> FIN_METRIC <-[Discloses]- ORG",
      "entities": {
        "start": "PFE",
        "intermediate": "Gross Unrecognized Tax Benefits",
        "end": "UNH"
      },
      "entity_types": {
        "start": "ORG",
        "intermediate": "FIN_METRIC",
        "end": "ORG"
      },
      "hop_count": 2,
      "document_relationship": "inter_document_cross_company",
      "path_data": {
        "start_node": {
          "id": "PFE",
          "name": "PFE",
          "type": "ORG",
          "year": 2022
        },
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "page_id": "page_58",
          "chunk_id": "chunk_1",
          "chunk_text": "## ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA\n\n## Report of Independent Registered Public Accounting Firm\n\n## To the Board of Directors and Shareholders Pfizer Inc.:\n\n## Opinion on the Consolidated Financial Statements\n\nWe have audited the accompanying consolidated balance sheets of Pfizer Inc. and Subsidiary Companies (the Company) as of December 31, 2021 and 2020, the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.\n\nWe also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control -Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 24, 2022 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting.\n\n## Change in Accounting Principle\n\nAs discussed in Note 1C to the consolidated financial statements, the Company has elected to change its method of accounting for pension and postretirement plans in 2021 to immediately recognize actuarial gains and losses in the consolidated statements of income.\n\n## Basis for Opinion\n\nThese consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.\n\nWe conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.\n\n## Critical Audit Matters\n\nThe critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.\n\nEvaluation of the U.S. Medicare, Medicaid, and performance-based contract rebates accrual\n\nAs discussed in Note 1H to the consolidated financial statements, the Company records estimated deductions for Medicare, Medicaid, and performancebased contract rebates (collectively, U.S. rebates) as a reduction to gross product revenues. The accrual for U.S. rebates is recorded in the same period that the corresponding revenues are recognized. The length of time between when a sale is made and when the U.S. rebate is paid by the Company can be as long as one year, which increases the need for significant management judgment and knowledge of market conditions and practices in estimating the accrual.\n\nWe identified the evaluation of the U.S. rebates accrual as a critical audit matter because the evaluation of the product-specific experience ratio assumption involved especially challenging auditor judgment. The product-specific experience ratio assumption relates to estimating which of the Company's revenue transactions will ultimately be subject to a related rebate.\n\nThe following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company's U.S. rebates accrual process related to the development of the product-specific experience ratio assumptions. We estimated the U.S. rebates accrual using internal information and historical data and compared the result to the Company's estimated U.S. rebates accrual. We evaluated the Company's ability to accurately estimate the accrual for U.S. rebates by comparing historically recorded accruals to the actual amount that was ultimately paid by the Company.\n\n## Evaluation of gross unrecognized tax benefits\n\nAs discussed in Notes 5D and 1 Q , the Company's tax positions are subject to audit by local taxing authorities in each respective tax jurisdiction, and the resolution of such audits may span multiple years. Since tax law is complex and often subject to varied interpretations and judgments, it is uncertain whether some of the Company's tax positions will be sustained upon audit. As of December 31, 2021, the Company has recorded gross unrecognized tax benefits, excluding associated interest, of $6.1 billion.\n\nPfizer Inc.\n\n2021 Form 10-K\n\n49",
          "relationship": "Discloses"
        },
        "intermediate_node": {
          "id": "Gross_Unrecognized_Tax_Benefits",
          "name": "Gross Unrecognized Tax Benefits",
          "type": "FIN_METRIC",
          "idf_score": 4.0087308094991085
        },
        "hop_2_rel": {
          "source_file": "UNH_10k_2022.pdf",
          "page_id": "page_65",
          "chunk_id": "chunk_4",
          "chunk_text": "| (in millions)                                        | 2021    | 2020    | 2019    |\n|------------------------------------------------------|---------|---------|---------|\n| Gross unrecognized tax benefits, beginning of period | $ 1,829 | $ 1,423 | $ 1,056 |\n| Gross increases:                                     |         |         |         |\n| Current year tax positions                           | 538     | 416     | 512     |\n| Prior year tax positions                             | 10      | 120     | 2       |\n| Gross decreases:                                     |         |         |         |\n| Prior year tax positions                             | (47)    | (130)   | (96)    |\n| Settlements                                          | -       | -       | (46)    |\n| Statute of limitations lapses                        | (20)    | -       | (5)     |\n| Gross unrecognized tax benefits, end of period       | $ 2,310 | $ 1,829 | $ 1,423 |",
          "relationship": "Discloses"
        },
        "end_node": {
          "id": "UNH",
          "name": "UNH",
          "type": "ORG",
          "year": 2022
        }
      },
      "quality_score": 48
    }
  ]
}